{
  "$schema": "https://json-schema.org/draft/2020-12/schema",
  "schemaVersion": "4.0.0",
  "instanceType": "StudyDocument",
  "id": "USDM-DS1062-A-U301F-20251207084231",
  "name": "Protocol Extraction: DS1062-A-U301F",
  "sourceDocument": {
    "documentId": "DOC-178214FA4D58242B",
    "filename": "NCT04656652_Protocol_SAP.pdf",
    "sha256Hash": "178214fa4d58242b67370ab3833766472c10c43fb081c861869700caef41a694",
    "byteSize": 6085497,
    "uploadTimestamp": "2025-12-07T08:42:31.314918",
    "pageCount": 168
  },
  "extractionMetadata": {
    "extractionTimestamp": "2025-12-07T08:42:31.480726",
    "pipelineVersion": "3.1",
    "primaryModel": "gemini-2.5-pro",
    "agentCount": 16,
    "successfulAgents": [
      "study_metadata",
      "arms_design",
      "endpoints_estimands_sap",
      "adverse_events",
      "safety_decision_points",
      "concomitant_medications",
      "biospecimen_handling",
      "laboratory_specifications",
      "informed_consent",
      "pro_specifications",
      "data_management",
      "site_operations_logistics",
      "quality_management",
      "withdrawal_procedures",
      "imaging_central_reading",
      "pkpd_sampling"
    ],
    "failedAgents": [],
    "qualitySummary": {
      "study_metadata": {
        "overallScore": 0.95822695035461,
        "fromCache": true
      },
      "arms_design": {
        "overallScore": 1.0,
        "fromCache": true
      },
      "endpoints_estimands_sap": {
        "overallScore": 1.0,
        "fromCache": true
      },
      "adverse_events": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "safety_decision_points": {
        "overallScore": 0.9937617018967249,
        "fromCache": false
      },
      "concomitant_medications": {
        "overallScore": 0.9800000000000001,
        "fromCache": false
      },
      "biospecimen_handling": {
        "overallScore": 0.8,
        "fromCache": false
      },
      "laboratory_specifications": {
        "overallScore": 0.9782332155477033,
        "fromCache": false
      },
      "informed_consent": {
        "overallScore": 0.7946320346320347,
        "fromCache": false
      },
      "pro_specifications": {
        "overallScore": 0.889247311827957,
        "fromCache": false
      },
      "data_management": {
        "overallScore": 0.9786338797814208,
        "fromCache": false
      },
      "site_operations_logistics": {
        "overallScore": 0.9983870967741936,
        "fromCache": false
      },
      "quality_management": {
        "overallScore": 0.9987546699875468,
        "fromCache": false
      },
      "withdrawal_procedures": {
        "overallScore": 0.9983766233766235,
        "fromCache": false
      },
      "imaging_central_reading": {
        "overallScore": 1.0,
        "fromCache": false
      },
      "pkpd_sampling": {
        "overallScore": 0.9059090909090909,
        "fromCache": false
      }
    },
    "averageQualityScore": 0.954635160942994
  },
  "study": {
    "instanceType": "Study",
    "id": "DS1062-A-U301F",
    "name": "TROPION-LUNG01",
    "officialTitle": "PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)",
    "version": "5.0",
    "provenance": {
      "section_number": null,
      "page_number": 1,
      "text_snippet": "PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS \nDOCETAXEL IN PREVIOUSLY TREATED ADVANCED \nOR METASTATIC NON-SMALL CELL LUNG CANCER \nWITH OR WITHOUT ACTIONABLE GENOMIC \nALTERATIONS (TROPION-LUNG01)\n\nPROTOCOL NUMBER: DS1062-A-U301F\n(TROPION-LUNG01)\n\nVERSION 5.0, Date 09 OCT 2023"
    },
    "studyPhase": {
      "code": "C15602",
      "decode": "Phase 3",
      "codeSystem": "NCI Thesaurus",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS \nDOCETAXEL IN PREVIOUSLY TREATED ADVANCED \nOR METASTATIC NON-SMALL CELL LUNG CANCER"
      }
    },
    "studyType": {
      "code": "C98388",
      "decode": "Interventional",
      "codeSystem": "NCI Thesaurus",
      "codeSystemVersion": "24.03e",
      "provenance": {
        "section_number": "4.1",
        "page_number": 64,
        "text_snippet": "This is a global, multicenter, randomized, active-controlled open-label Phase 3 study designed to \nevaluate the efficacy, safety, and pharmacokinetics (PK) of DS-1062a versus docetaxel in \nsubjects with advanced or metastatic NSCLC with or without actionable genomic alterations"
      }
    },
    "studyIdentifiers": [
      {
        "id": "NCT04656652",
        "scopeId": "clinicaltrials.gov",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "NCT Number: NCT04656652"
        }
      },
      {
        "id": "2020-004643-80",
        "scopeId": "eudract",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "EudraCT NUMBER 2020-004643-80"
        }
      },
      {
        "id": "136626",
        "scopeId": "fda_ind",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "IND 136626"
        }
      }
    ],
    "studyProtocolVersions": [
      {
        "versionNumber": "5.0",
        "versionDate": "2023-10-09",
        "provenance": {
          "section_number": null,
          "page_number": 3,
          "text_snippet": "5.0 09 Oct 2023"
        }
      },
      {
        "versionNumber": "4.0",
        "versionDate": "2022-01-20",
        "provenance": {
          "section_number": null,
          "page_number": 3,
          "text_snippet": "4.0 20 Jan 2022"
        }
      },
      {
        "versionNumber": "3.0",
        "versionDate": "2021-10-01",
        "provenance": {
          "section_number": null,
          "page_number": 3,
          "text_snippet": "3.0 01 Oct 2021"
        }
      },
      {
        "versionNumber": "2.0",
        "versionDate": "2021-03-03",
        "provenance": {
          "section_number": null,
          "page_number": 3,
          "text_snippet": "2.0 03 Mar 2021"
        }
      },
      {
        "versionNumber": "1.0",
        "versionDate": "2020-10-05",
        "provenance": {
          "section_number": null,
          "page_number": 3,
          "text_snippet": "1.0 05 Oct 2020"
        }
      }
    ],
    "studyPopulation": {
      "targetDisease": {
        "name": "Non-Small Cell Lung Cancer",
        "stage": "Stage IIIB, IIIC or Stage IV"
      },
      "ageRange": {
        "minAge": 18,
        "maxAgeNoLimit": true,
        "unit": "years"
      },
      "sex": {
        "allowed": [
          {
            "code": "C20197",
            "decode": "Male",
            "provenance": {
              "section_number": "5.1",
              "page_number": 77,
              "text_snippet": "18. If male, the subject must be surgically sterile or must use a condom in addition to highly \neffective birth control if his partners are of reproductive potential upon enrollment, during the \nTreatment Period, and for at least 4 months after the last dose of DS-1062a or for at least \n6 months after the last dose of docetaxel."
            }
          },
          {
            "code": "C16576",
            "decode": "Female",
            "provenance": {
              "section_number": "5.1",
              "page_number": 77,
              "text_snippet": "17. If the subject is a female of childbearing potential, she must have a negative serum pregnancy \ntest at Screening and must be willing to use highly effective birth control (as detailed in \nSection 10.3.4) upon enrollment, during the Treatment Period, and for at least 7 months, after \nthe last dose of DS-1062a or for at least 6 months after the last dose of docetaxel."
            }
          }
        ]
      },
      "performanceStatus": {
        "scale": "ECOG",
        "allowedValues": [
          0,
          1
        ],
        "provenance": {
          "section_number": "5.1",
          "page_number": 75,
          "text_snippet": "10. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at \nScreening."
        }
      },
      "keyInclusionSummary": {
        "values": [
          "Pathologically documented Stage IIIB, IIIC or Stage IV NSCLC with or without actionable genomic alterations (AGA).",
          "Documentation of radiographic disease progression while on or after receiving the most recent treatment regimen for advanced or metastatic NSCLC.",
          "Subjects without AGA must have received platinum-based chemotherapy and an \u03b1-PD-1/\u03b1-PD-L1 monoclonal antibody.",
          "Subjects with AGA must have been treated with 1 or 2 prior lines of applicable targeted therapy and platinum-based chemotherapy.",
          "Measurable disease based on local imaging assessment using RECIST v1.1.",
          "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.",
          "Adequate bone marrow, hepatic, and renal function."
        ],
        "provenance": {
          "section_number": "5.1",
          "page_number": 22,
          "text_snippet": "Key Inclusion Criteria: \nSubjects eligible for inclusion in the study must meet all inclusion criteria for this study within 28 days before \nrandomization. Below is a list limited to the key inclusion criteria:"
        }
      },
      "keyExclusionSummary": {
        "values": [
          "Spinal cord compression or clinically active central nervous system (CNS) metastases.",
          "Prior treatment with any agent containing a chemotherapeutic agent targeting topoisomerase I, TROP2-targeted therapy, or docetaxel.",
          "Uncontrolled or significant cardiac disease.",
          "History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, or current ILD/pneumonitis.",
          "Clinically severe pulmonary compromise.",
          "History of severe hypersensitivity reactions to DS-1062a or docetaxel."
        ],
        "provenance": {
          "section_number": "5.2",
          "page_number": 24,
          "text_snippet": "Key Exclusion Criteria:\nSubjects meeting any exclusion criteria for this study will be disqualified from entering the study. Below is a list \nlimited to the key exclusion criteria:"
        }
      },
      "provenance": {
        "section_number": "5.1",
        "page_number": 73,
        "text_snippet": "2. Adults \u226518 years (if the legal age of consent is >18 years old, then follow local regulatory \nrequirements23).\n3. Has a life expectancy \u22653 months based on Investigator\u2019s opinion.\n4. Has pathologically documented Stage IIIB, IIIC, or Stage IV NSCLC with or without \nactionable genomic alteration(s) (AGA) at the time of randomization (based on the American \nJoint Committee on Cancer, Eighth Edition) and meets the following criteria for NSCLC:"
      }
    },
    "studyMilestones": {
      "estimatedDurations": {
        "screeningPeriodDays": 28,
        "enrollmentPeriodMonths": 19,
        "treatmentPeriodDescription": "Treatment continues until a subject permanently discontinues DS-1062a or docetaxel due to disease progression, unacceptable toxicity, or other discontinuation criteria.",
        "followUpPeriodMonths": 24,
        "totalStudyDurationMonths": 43
      },
      "provenance": {
        "section_number": "4.1.4",
        "page_number": 69,
        "text_snippet": "Overall Study Duration\nEnrollment is planned to occur over a period of approximately 19 months, with treatment and \nfollow-up (28-day Safety Follow-up and LTSFU) projected to continue for approximately \n24 months after the last subject is randomized. The study will continue until the overall EOS is \nreached for the final analysis in the study. The anticipated total duration of the study is \napproximately 43 months."
      }
    },
    "studyDesignInfo": {
      "designType": "Parallel Assignment",
      "randomization": {
        "isRandomized": true,
        "allocationRatio": "1:1",
        "provenance": {
          "section_number": "4.1.1",
          "page_number": 64,
          "text_snippet": "A total of approximately 590 eligible subjects will be randomized to the DS-1062a arm or \ndocetaxel arm in a 1:1 ratio (295/arm)"
        }
      },
      "blinding": {
        "blindingType": "Open-label",
        "provenance": {
          "section_number": "4.1",
          "page_number": 64,
          "text_snippet": "This is a global, multicenter, randomized, active-controlled open-label Phase 3 study designed to \nevaluate the efficacy, safety, and pharmacokinetics (PK) of DS-1062a versus docetaxel in \nsubjects with advanced or metastatic NSCLC with or without actionable genomic alterations"
        }
      },
      "targetEnrollment": 590,
      "plannedSites": 190,
      "countries": {
        "values": [
          "North America",
          "South America",
          "Europe",
          "Australia",
          "Asia"
        ],
        "provenance": {
          "section_number": "1.1",
          "page_number": 15,
          "text_snippet": "Global study conducted at approximately 190 study sites located predominantly in North America, South \nAmerica, Europe, Australia, and Asia."
        }
      },
      "provenance": {
        "section_number": "1.1",
        "page_number": 15,
        "text_snippet": "Planned Geographical Coverage, Study Sites, and Locations\nGlobal study conducted at approximately 190 study sites located predominantly in North America, South \nAmerica, Europe, Australia, and Asia."
      }
    },
    "therapeuticArea": {
      "value": "Oncology",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS \nDOCETAXEL IN PREVIOUSLY TREATED ADVANCED \nOR METASTATIC NON-SMALL CELL LUNG CANCER"
      }
    },
    "indication": {
      "value": "Advanced or Metastatic Non-Small Cell Lung Cancer",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS \nDOCETAXEL IN PREVIOUSLY TREATED ADVANCED \nOR METASTATIC NON-SMALL CELL LUNG CANCER"
      }
    },
    "sponsorName": {
      "value": "DAIICHI SANKYO, INC.",
      "provenance": {
        "section_number": null,
        "page_number": 1,
        "text_snippet": "DAIICHI SANKYO, INC.\n211 MOUNT AIRY ROAD\nBASKING RIDGE, NEW JERSEY 07920"
      }
    },
    "isPivotal": true,
    "extensionAttributes": [
      {
        "name": "ich_m11_section",
        "value": {
          "sectionNumber": "1.1",
          "title": "Protocol Synopsis"
        }
      }
    ]
  },
  "domainSections": {
    "studyDesign": {
      "moduleId": "arms_design",
      "instanceType": "StudyDesign",
      "data": {
        "id": "DS1062-A-U301F-arms-design",
        "instanceType": "StudyDesign",
        "name": "DS1062-A-U301F Study Design",
        "studyArms": [
          {
            "id": "ARM01",
            "instanceType": "StudyArm",
            "name": "DS-1062a",
            "label": "DS-1062a Arm",
            "description": "DS-1062a (datopotamab deruxtecan) administered at a dose of 6.0 mg/kg as an intravenous infusion once every 3 weeks (Q3W).",
            "armType": {
              "code": "C174266",
              "decode": "Experimental",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 1,
            "plannedSubjects": 295,
            "interventions": [
              {
                "id": "INT01",
                "instanceType": "StudyIntervention",
                "name": "DS-1062a",
                "type": "Drug",
                "role": {
                  "decode": "Investigational"
                },
                "drugClass": "Antibody-Drug Conjugate",
                "dosingRegimen": {
                  "dose": 6,
                  "doseUnit": "mg/kg",
                  "frequency": "Q3W",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "infusionDurationMinutes": 30,
                  "doseCalculationBasis": "Weight-based"
                },
                "isBlinded": false,
                "isPlacebo": false,
                "isComparator": false,
                "biomedicalConcept": {
                  "conceptName": "Datopotamab Deruxtecan",
                  "cdiscCode": "C176324",
                  "domain": "CM"
                },
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 4,
                      "doseUnit": "mg/kg",
                      "provenance": {
                        "section_number": "6.5.1",
                        "page_number": 86,
                        "text_snippet": "Table 6.3: Dose Reduction Levels for DS-1062a\nStarting Dose Dose Reduction 1 Dose Reduction 2 Dose Reduction 3\n6.0 mg/kg 4.0 mg/kg 3.0 mg/kg 2.0 mg/kg"
                      }
                    },
                    {
                      "level": -2,
                      "dose": 3,
                      "doseUnit": "mg/kg",
                      "provenance": {
                        "section_number": "6.5.1",
                        "page_number": 86,
                        "text_snippet": "Table 6.3: Dose Reduction Levels for DS-1062a\nStarting Dose Dose Reduction 1 Dose Reduction 2 Dose Reduction 3\n6.0 mg/kg 4.0 mg/kg 3.0 mg/kg 2.0 mg/kg"
                      }
                    },
                    {
                      "level": -3,
                      "dose": 2,
                      "doseUnit": "mg/kg",
                      "provenance": {
                        "section_number": "6.5.1",
                        "page_number": 86,
                        "text_snippet": "Table 6.3: Dose Reduction Levels for DS-1062a\nStarting Dose Dose Reduction 1 Dose Reduction 2 Dose Reduction 3\n6.0 mg/kg 4.0 mg/kg 3.0 mg/kg 2.0 mg/kg"
                      }
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG01",
                      "condition": "Grade 4 Neutrophil Count Decreased or White Blood Cell Count Decreased",
                      "toxicityGrade": 4,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Resolved to \u2264Grade 2 and >14 days from onset",
                      "provenance": {
                        "section_number": null,
                        "page_number": 89,
                        "text_snippet": "Grade 4 (ANC defined as\n<0.5-0.5 \u00d7109/L; WBC\ndefined as <1.0 \u00d7 109/L)\nDelay dose until resolved to \u2264Grade 2:\n\u2022 If resolved in \u226414 days from day of onset, maintain dose.\n\u2022 If resolved in >14 days from day of onset, reduce dose by 1 level."
                      }
                    },
                    {
                      "id": "TRIG02",
                      "condition": "Grade 3 Febrile Neutropenia",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Until resolved",
                      "provenance": {
                        "section_number": null,
                        "page_number": 89,
                        "text_snippet": "Febrile Neutropenia\nGrade 3 Delay dose until resolved, then reduce dose by 1 level."
                      }
                    },
                    {
                      "id": "TRIG03",
                      "condition": "Grade 1 ILD/pneumonitis",
                      "toxicityGrade": 1,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Resolved to Grade 0 and >28 days from onset",
                      "provenance": {
                        "section_number": null,
                        "page_number": 91,
                        "text_snippet": "For Grade 1 events, DS-1062a can be restarted only if the event is fully\nresolved to Grade 0: b\n\u2022 If resolved in \u226428 days from day of onset, maintain dose\n\u2022 If resolved in >28 days from day of onset, reduce dose by 1 level"
                      }
                    },
                    {
                      "id": "TRIG04",
                      "condition": "Grade 3 Ocular Surface Toxicity",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Resolved to \u2264Grade 1",
                      "provenance": {
                        "section_number": null,
                        "page_number": 93,
                        "text_snippet": "Grade 3 Obtain an ophthalmological assessment. Delay dose until resolved to \u2264\nGrade 1, then reduce dose by 1 level."
                      }
                    },
                    {
                      "id": "TRIG05",
                      "condition": "Grade 3 Nausea/Vomiting (if prophylaxis already optimized)",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Resolved to \u2264Grade 1 or baseline",
                      "provenance": {
                        "section_number": null,
                        "page_number": 95,
                        "text_snippet": "If prophylaxis and supportive medications have ALREADY been\noptimized:\n\u2022 Delay dose until resolved to \u2264 Grade 1 or baseline, and then reduce\ndose by 1 level."
                      }
                    },
                    {
                      "id": "TRIG06",
                      "condition": "Grade 3 Oral Mucositis/Stomatitis (if prophylaxis already optimized)",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Resolved to \u2264Grade 1 or baseline",
                      "provenance": {
                        "section_number": null,
                        "page_number": 96,
                        "text_snippet": "If prophylaxis and supportive medications have ALREADY been\noptimized:\n\u2022 Delay dose until resolved to \u2264 Grade 1 or baseline, then reduce dose\nby 1 level."
                      }
                    },
                    {
                      "id": "TRIG07",
                      "condition": "Grade 3 Diarrhoea (if prophylaxis already optimized)",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Resolved to \u2264Grade 1 or baseline",
                      "provenance": {
                        "section_number": null,
                        "page_number": 96,
                        "text_snippet": "If prophylaxis and supportive medications have ALREADY been\noptimized:\n\u2022 Delay dose until resolved to \u2264 Grade 1 or baseline, then reduce dose\nby 1 level."
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Grade 4 Febrile Neutropenia",
                    "Grade 2, 3, or 4 ILD/pneumonitis",
                    "Grade 4 Ocular Surface Toxicity",
                    "Grade 4 Hepatic Toxicity (AST/ALT or Total Bilirubin)",
                    "Grade 4 Vomiting, Oral Mucositis/Stomatitis, or Diarrhoea",
                    "Dose delay required longer than 12 weeks (84 days) from last infusion"
                  ],
                  "maximumReductions": 3,
                  "provenance": {
                    "section_number": "6.5.1",
                    "page_number": 86,
                    "text_snippet": "Specific criteria for DS-1062a infusion interruptions, dose delays, re-initiation, dose reduction, and/or discontinuation in case of TEAEs that are considered related to the use of DS-1062a by the Investigator are presented in Table 6.4, which is applicable only to TEAEs that are assessed as related to use of DS-1062a by the Investigators."
                  }
                },
                "provenance": {
                  "section_number": "2.1.2",
                  "page_number": 54,
                  "text_snippet": "DS-1062a (datopotamab deruxtecan; Dato-DXd) is an antibody-drug conjugate (ADC) that comprises a recombinant humanized anti TROP2 immunoglobulin 1 monoclonal antibody, MAAP-9001a, which is covalently conjugated to a drug linker, MAAA-1162a, via thioether bonds."
                }
              }
            ],
            "provenance": {
              "section_number": "4.1.1",
              "page_number": 64,
              "text_snippet": "A total of approximately 590 eligible subjects will be randomized to the DS-1062a arm or docetaxel arm in a 1:1 ratio (295/arm), stratified by documented actionable genomic alteration (present versus absent), histology (squamous versus nonsquamous), most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy (yes versus no) and geographical region (United States [US]/Japan/Western Europe versus rest of world [ROW])."
            }
          },
          {
            "id": "ARM02",
            "instanceType": "StudyArm",
            "name": "Docetaxel",
            "label": "Docetaxel Arm",
            "description": "Docetaxel administered as an IV infusion of 75 mg/m\u00b2 over approximately 60 minutes on Day 1 of each 3-week cycle.",
            "armType": {
              "code": "C174267",
              "decode": "Active Comparator",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "allocationRatio": 1,
            "plannedSubjects": 295,
            "interventions": [
              {
                "id": "INT02",
                "instanceType": "StudyIntervention",
                "name": "Docetaxel",
                "type": "Drug",
                "role": {
                  "decode": "Comparator"
                },
                "dosingRegimen": {
                  "dose": 75,
                  "doseUnit": "mg/m\u00b2",
                  "frequency": "Q3W",
                  "route": {
                    "code": "C38276",
                    "decode": "Intravenous",
                    "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                    "codeSystemVersion": "24.03e"
                  },
                  "cycleLengthDays": 21,
                  "infusionDurationMinutes": 60,
                  "doseCalculationBasis": "BSA-based"
                },
                "isBlinded": false,
                "isPlacebo": false,
                "isComparator": true,
                "biomedicalConcept": {
                  "conceptName": "Docetaxel",
                  "cdiscCode": "C1189",
                  "domain": "CM"
                },
                "doseModifications": {
                  "reductionLevels": [
                    {
                      "level": -1,
                      "dose": 55,
                      "doseUnit": "mg/m\u00b2",
                      "provenance": {
                        "section_number": null,
                        "page_number": 98,
                        "text_snippet": "Table 6.5: Dose Reduction Levels for Docetaxel\nStarting Dosea First Dose Reductionb Second Dose Reductionb\n75 mg/m2 55 mg/m2 or Per Investigator Per Investigator"
                      }
                    }
                  ],
                  "modificationTriggers": [
                    {
                      "id": "TRIG08",
                      "condition": "Febrile neutropenia, neutrophils <500 cells/mm3 for >1 week, severe cutaneous reactions, or other Grade 3/4 non-hematological toxicities",
                      "toxicityGrade": 3,
                      "action": "Hold then reduce",
                      "targetLevel": -1,
                      "holdCriteria": "Until resolution of toxicity",
                      "provenance": {
                        "section_number": null,
                        "page_number": 98,
                        "text_snippet": "Subjects dosed initially at 75 mg/m2 who experience either febrile neutropenia, neutrophils\n<500 cells/mm3 for more than 1 week despite growth factor support, severe or cumulative\ncutaneous reactions, or other Grade 3/4 non-hematological toxicities during docetaxel treatment\nshould have treatment withheld until resolution of the toxicity according to the dose delay\naforementioned guidelines. Once the toxicity resolves, docetaxel treatment may resume at\n55 mg/m2 for the remainder of the study."
                      }
                    }
                  ],
                  "permanentDiscontinuationTriggers": [
                    "Grade \u22653 peripheral neuropathy",
                    "Cystoid macular edema (CME)",
                    "Severe hypersensitivity reactions",
                    "Severe cutaneous adverse reactions (e.g., Stevens-Johnson syndrome)",
                    "Dose delay required longer than 4 weeks (28 days)"
                  ],
                  "maximumReductions": 2,
                  "provenance": {
                    "section_number": "6.5.2",
                    "page_number": 97,
                    "text_snippet": "Up to 2 dose reductions will be permitted for subjects receiving docetaxel (Table 6.5). Once the\ndose of docetaxel is reduced, no dose re-escalation will be permitted. After the permitted dose\nreductions, if further toxicity meeting the requirement for dose reduction occurs, the subject will\nbe withdrawn from study treatment."
                  }
                },
                "provenance": {
                  "section_number": "4.1.3.2",
                  "page_number": 68,
                  "text_snippet": "Docetaxel will be administered as an IV infusion of 75 mg/m2 over approximately 60 minutes on\nDay 1 of each 3-week cycle."
                }
              }
            ],
            "provenance": {
              "section_number": "4.1.1",
              "page_number": 64,
              "text_snippet": "A total of approximately 590 eligible subjects will be randomized to the DS-1062a arm or docetaxel arm in a 1:1 ratio (295/arm), stratified by documented actionable genomic alteration (present versus absent), histology (squamous versus nonsquamous), most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy (yes versus no) and geographical region (United States [US]/Japan/Western Europe versus rest of world [ROW])."
            }
          }
        ],
        "studyEpochs": [
          {
            "id": "EPOCH01",
            "instanceType": "StudyEpoch",
            "name": "Screening",
            "description": "Subjects' eligibility will be confirmed. The Screening Period will start on the day of signing the ICF and have a maximum duration of 28 days.",
            "epochType": {
              "code": "C48262",
              "decode": "Screening",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 1,
            "durationDays": 28,
            "provenance": {
              "section_number": "4.1.1",
              "page_number": 65,
              "text_snippet": "The Screening Period will start on the day of signing the ICF and have a maximum\nduration of 28 days. Rescreening is permitted 1 time. During the 28-day Screening\nPeriod, subjects\u2019 eligibility will be confirmed."
            }
          },
          {
            "id": "EPOCH02",
            "instanceType": "StudyEpoch",
            "name": "Treatment",
            "description": "The Treatment Period starts on Cycle 1 Day 1 and continues until a subject permanently discontinues DS-1062a or docetaxel.",
            "epochType": {
              "code": "C101526",
              "decode": "Treatment",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 2,
            "provenance": {
              "section_number": "4.1.1",
              "page_number": 65,
              "text_snippet": "Eligible subjects will be randomized and enter the Treatment Period. The Treatment\nPeriod starts on Cycle 1 Day 1 and continues until a subject permanently discontinues\nDS-1062a or docetaxel."
            }
          },
          {
            "id": "EPOCH03",
            "instanceType": "StudyEpoch",
            "name": "Follow-up",
            "description": "Starts upon permanent discontinuation of study drug. Includes a 28-day safety follow-up and a Long-term Survival Follow-up (LTSFU) every 3 months for survival.",
            "epochType": {
              "code": "C99158",
              "decode": "Follow-up",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "sequenceInStudy": 3,
            "provenance": {
              "section_number": "4.1.1",
              "page_number": 66,
              "text_snippet": "The Follow-up Period will start upon permanent discontinuation of DS-1062a or\ndocetaxel. During the Follow-up Period, subjects will be followed for 28 days\n(+7 days) for safety. After discontinuation of study drug, subjects will then enter the\nLTSFU, during which they will be followed every 3 months for collection of\ninformation on subsequent anticancer treatment and survival, including the cause and\ndate of death."
            }
          }
        ],
        "studyCells": [
          {
            "id": "CELL01",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH01",
            "interventionIds": [],
            "provenance": {
              "section_number": "1.2",
              "page_number": 29,
              "text_snippet": "Figure 1.1: Study Level Flow Diagram"
            }
          },
          {
            "id": "CELL02",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH01",
            "interventionIds": [],
            "provenance": {
              "section_number": "1.2",
              "page_number": 29,
              "text_snippet": "Figure 1.1: Study Level Flow Diagram"
            }
          },
          {
            "id": "CELL03",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH02",
            "interventionIds": [
              "INT01"
            ],
            "provenance": {
              "section_number": "1.2",
              "page_number": 29,
              "text_snippet": "Figure 1.1: Study Level Flow Diagram"
            }
          },
          {
            "id": "CELL04",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH02",
            "interventionIds": [
              "INT02"
            ],
            "provenance": {
              "section_number": "1.2",
              "page_number": 29,
              "text_snippet": "Figure 1.1: Study Level Flow Diagram"
            }
          },
          {
            "id": "CELL05",
            "instanceType": "StudyCell",
            "armId": "ARM01",
            "epochId": "EPOCH03",
            "interventionIds": [],
            "provenance": {
              "section_number": "1.2",
              "page_number": 29,
              "text_snippet": "Figure 1.1: Study Level Flow Diagram"
            }
          },
          {
            "id": "CELL06",
            "instanceType": "StudyCell",
            "armId": "ARM02",
            "epochId": "EPOCH03",
            "interventionIds": [],
            "provenance": {
              "section_number": "1.2",
              "page_number": 29,
              "text_snippet": "Figure 1.1: Study Level Flow Diagram"
            }
          }
        ],
        "designMetadata": {
          "id": "DESIGN01",
          "designType": {
            "code": "C82639",
            "decode": "Parallel",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "24.03e"
          },
          "isRandomized": true,
          "allocationRatio": "1:1",
          "randomizationDetails": {
            "randomization_method": "IRT",
            "provenance": {
              "section_number": "6.3",
              "page_number": 85,
              "text_snippet": "Randomization will be managed through an IRT for subjects meeting all eligibility criteria. The\nsystem will assign a unique randomization number and dose group for that subject. The\ninstructions on how to use the system will be provided in the IRT Manual."
            }
          },
          "blindingType": "Open-label",
          "whoIsBlinded": [],
          "isPlaceboControlled": false,
          "isActiveControlled": true,
          "stratificationFactors": [
            {
              "id": "STRAT01",
              "name": "Documented actionable genomic alteration",
              "levels": [
                "present",
                "absent"
              ],
              "is_irt_stratification": true,
              "is_analysis_stratification": true,
              "provenance": {
                "section_number": "4.1.1",
                "page_number": 64,
                "text_snippet": "stratified by documented actionable genomic alteration\n(present versus absent)"
              }
            },
            {
              "id": "STRAT02",
              "name": "Histology",
              "levels": [
                "squamous",
                "nonsquamous"
              ],
              "is_irt_stratification": true,
              "is_analysis_stratification": true,
              "provenance": {
                "section_number": "4.1.1",
                "page_number": 64,
                "text_snippet": "histology (squamous versus nonsquamous)"
              }
            },
            {
              "id": "STRAT03",
              "name": "Most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy",
              "levels": [
                "yes",
                "no"
              ],
              "is_irt_stratification": true,
              "is_analysis_stratification": true,
              "provenance": {
                "section_number": "4.1.1",
                "page_number": 64,
                "text_snippet": "most immediate prior\ntherapy included anti-PD-1/anti-PD-L1 immunotherapy (yes versus no)"
              }
            },
            {
              "id": "STRAT04",
              "name": "Geographical region",
              "levels": [
                "US/Japan/Western Europe",
                "ROW"
              ],
              "is_irt_stratification": true,
              "is_analysis_stratification": true,
              "provenance": {
                "section_number": "4.1.1",
                "page_number": 64,
                "text_snippet": "geographical region\n(United States [US]/Japan/Western Europe versus rest of world [ROW])"
              }
            }
          ],
          "provenance": {
            "section_number": "4.1",
            "page_number": 64,
            "text_snippet": "This is a global, multicenter, randomized, active-controlled open-label Phase 3 study designed to\nevaluate the efficacy, safety, and pharmacokinetics (PK) of DS-1062a versus docetaxel in\nsubjects with advanced or metastatic NSCLC with or without actionable genomic alterations"
          }
        },
        "provenance": {
          "section_number": "4.1",
          "page_number": 64,
          "text_snippet": "This is a global, multicenter, randomized, active-controlled open-label Phase 3 study designed to evaluate the efficacy, safety, and pharmacokinetics (PK) of DS-1062a versus docetaxel in subjects with advanced or metastatic NSCLC with or without actionable genomic alterations (ie, alterations in genes with approved therapies, such as EGFR, ALK, ROS1, NTRK, BRAF, MET exon 14 skipping or RET)."
        }
      }
    },
    "endpointsEstimandsSAP": {
      "moduleId": "endpoints_estimands_sap",
      "instanceType": "EndpointsEstimandsSAP",
      "data": {
        "id": "DS1062-A-U301F-endpoints-estimands-sap",
        "instanceType": "EndpointsEstimandsSAP",
        "name": "DS1062-A-U301F Endpoints, Estimands & SAP",
        "documentType": "protocol",
        "protocol_endpoints": {
          "objectives": [
            {
              "id": "objective-001",
              "instanceType": "Objective",
              "name": "Primary Efficacy Objective",
              "text": "To compare the efficacy of DS-1062a with that of docetaxel, as measured by PFS and OS, for subjects with NSCLC with or without actionable genomic alterations.",
              "level": {
                "code": "C85826",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-001",
                "endpoint-002"
              ],
              "provenance": {
                "section_number": "1.1",
                "page_number": 16,
                "text_snippet": "To compare the efficacy of DS-1062a with that of docetaxel, as measured by PFS and OS, for subjects with NSCLC with or without actionable genomic alterations"
              }
            },
            {
              "id": "objective-002",
              "instanceType": "Objective",
              "name": "Secondary Efficacy Objective",
              "text": "To further evaluate the efficacy of DS-1062a compared with docetaxel.",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-003",
                "endpoint-004",
                "endpoint-005",
                "endpoint-006",
                "endpoint-007",
                "endpoint-008"
              ],
              "provenance": {
                "section_number": "1.1",
                "page_number": 16,
                "text_snippet": "To further evaluate the efficacy of DS-1062a compared with docetaxel"
              }
            },
            {
              "id": "objective-003",
              "instanceType": "Objective",
              "name": "Secondary Safety Objective",
              "text": "To further evaluate the safety of DS-1062a compared with docetaxel.",
              "level": {
                "code": "C49657",
                "decode": "Safety",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-009"
              ],
              "provenance": {
                "section_number": "1.1",
                "page_number": 17,
                "text_snippet": "To further evaluate the safety of DS-1062a compared with docetaxel"
              }
            },
            {
              "id": "objective-004",
              "instanceType": "Objective",
              "name": "Secondary PK Objective",
              "text": "To assess the PK of DS-1062a.",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-010"
              ],
              "provenance": {
                "section_number": "1.1",
                "page_number": 18,
                "text_snippet": "To assess the PK of DS-1062a"
              }
            },
            {
              "id": "objective-005",
              "instanceType": "Objective",
              "name": "Secondary Immunogenicity Objective",
              "text": "To assess the immunogenicity of DS-1062a.",
              "level": {
                "code": "C85827",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-011"
              ],
              "provenance": {
                "section_number": "1.1",
                "page_number": 18,
                "text_snippet": "To assess the immunogenicity of DS-1062a"
              }
            },
            {
              "id": "objective-006",
              "instanceType": "Objective",
              "name": "Exploratory PFS2 Objective",
              "text": "To evaluate PFS2 for DS-1062a compared with that of docetaxel.",
              "level": {
                "code": "C174265",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-012"
              ],
              "provenance": {
                "section_number": "1.1",
                "page_number": 18,
                "text_snippet": "To evaluate PFS2 for DS-1062a compared with that of docetaxel"
              }
            },
            {
              "id": "objective-007",
              "instanceType": "Objective",
              "name": "Exploratory Biomarker Objective",
              "text": "To evaluate biomarkers that may associate with the clinical benefit from DS-1062a.",
              "level": {
                "code": "C174265",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-013"
              ],
              "provenance": {
                "section_number": "1.1",
                "page_number": 18,
                "text_snippet": "To evaluate biomarkers that may associate with the clinical benefit from DS-1062a"
              }
            },
            {
              "id": "objective-008",
              "instanceType": "Objective",
              "name": "Exploratory PRO Objective",
              "text": "To evaluate PRO endpoints for DS-1062a compared with that of docetaxel.",
              "level": {
                "code": "C174265",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "endpoint_ids": [
                "endpoint-014"
              ],
              "provenance": {
                "section_number": "1.1",
                "page_number": 19,
                "text_snippet": "To evaluate PRO endpoints for DS-1062a compared with that of docetaxel."
              }
            }
          ],
          "endpoints": [
            {
              "id": "endpoint-001",
              "instanceType": "Endpoint",
              "name": "PFS by BICR",
              "label": "Primary Efficacy Endpoint",
              "text": "Progression-Free Survival (PFS) defined as the time from randomization to the earlier of the dates of the first radiographic disease progression or death due to any cause.",
              "purpose": "To assess the effect of treatment on disease progression or death.",
              "level": {
                "code": "C98747",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST v1.1",
              "assessor": "BICR",
              "assessment_timepoints_weeks": [
                6,
                12,
                18,
                24
              ],
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 16,
                "text_snippet": "PFS is defined as the time from randomization to the earlier of the dates of the first radiographic disease progression or death due to any cause."
              }
            },
            {
              "id": "endpoint-002",
              "instanceType": "Endpoint",
              "name": "OS",
              "label": "Primary Efficacy Endpoint",
              "text": "Overall Survival (OS) defined as the time from randomization to death due to any cause.",
              "purpose": "To assess the effect of treatment on survival.",
              "level": {
                "code": "C98747",
                "decode": "Primary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Survival follow-up",
              "assessor": "Investigator",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 16,
                "text_snippet": "OS is defined as the time from randomization to death due to any cause."
              }
            },
            {
              "id": "endpoint-003",
              "instanceType": "Endpoint",
              "name": "PFS by Investigator",
              "label": "Secondary Efficacy Endpoint",
              "text": "PFS as assessed by Investigator per RECIST v1.1.",
              "purpose": "To further evaluate the effect of treatment on disease progression or death.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST v1.1",
              "assessor": "Investigator",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 16,
                "text_snippet": "Title: PFS\nDescription: PFS as assessed by Investigator per RECIST v1.1."
              }
            },
            {
              "id": "endpoint-004",
              "instanceType": "Endpoint",
              "name": "ORR by BICR and Investigator",
              "label": "Secondary Efficacy Endpoint",
              "text": "Overall Response Rate (ORR) defined as the proportion of subjects who achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR).",
              "purpose": "To assess tumor response.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST v1.1",
              "assessor": "BICR and Investigator",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 16,
                "text_snippet": "ORR is defined as the proportion of subjects who achieved a BOR of CR or PR."
              }
            },
            {
              "id": "endpoint-005",
              "instanceType": "Endpoint",
              "name": "DoR by BICR and Investigator",
              "label": "Secondary Efficacy Endpoint",
              "text": "Duration of Response (DoR) defined as the time from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of radiographic disease progression or death due to any cause, whichever occurs first.",
              "purpose": "To assess the durability of tumor response.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST v1.1",
              "assessor": "BICR and Investigator",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 16,
                "text_snippet": "DoR is defined as the time from the date of the first documentation of objective response (CR or PR) to the date of the first radiographic disease progression or death due to any cause, whichever occurs first."
              }
            },
            {
              "id": "endpoint-006",
              "instanceType": "Endpoint",
              "name": "DCR by BICR and Investigator",
              "label": "Secondary Efficacy Endpoint",
              "text": "Disease Control Rate (DCR) defined as the proportion of subjects who achieved a BOR of CR, PR, or Stable Disease (SD).",
              "purpose": "To assess disease control.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST v1.1",
              "assessor": "BICR and Investigator",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 17,
                "text_snippet": "DCR is defined as the proportion of subjects who achieved a BOR of CR, PR, or SD."
              }
            },
            {
              "id": "endpoint-007",
              "instanceType": "Endpoint",
              "name": "TTR by BICR and Investigator",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time to Response (TTR) defined as the time from randomization to the date of the first documentation of objective response (CR or PR) in responding subjects.",
              "purpose": "To assess the time to onset of tumor response.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "RECIST v1.1",
              "assessor": "BICR and Investigator",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 17,
                "text_snippet": "TTR is defined as the time from randomization to the date of the first documentation of objective response (CR or PR) in responding subjects."
              }
            },
            {
              "id": "endpoint-008",
              "instanceType": "Endpoint",
              "name": "TTD",
              "label": "Secondary Efficacy Endpoint",
              "text": "Time to Deterioration (TTD) in any of the 3 symptoms, chest pain, cough, or dyspnea.",
              "purpose": "To assess time to symptom deterioration.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "EORTC-QLQ-LC13",
              "assessor": "Patient",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 17,
                "text_snippet": "Title: TTD\nDescription: TTD in any of the 3 symptoms, chest pain, cough, or dyspnea."
              }
            },
            {
              "id": "endpoint-009",
              "instanceType": "Endpoint",
              "name": "Safety Parameters",
              "label": "Safety Endpoint",
              "text": "Incidence of TEAEs, SAEs, AESIs, and changes in laboratory parameters, vital signs, ECGs, and ophthalmologic findings.",
              "purpose": "To evaluate the safety and tolerability of the study treatments.",
              "level": {
                "code": "C49656",
                "decode": "Safety",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25463",
                "decode": "Count Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "NCI-CTCAE v5.0",
              "assessor": "Investigator",
              "analysis_population_id": "population-002",
              "provenance": {
                "section_number": "1.1",
                "page_number": 17,
                "text_snippet": "TEAEs, SAEs, AESIs, ECOG PS, vital sign measurements, standard clinical laboratory parameters (hematology, serum chemistry, and urinalysis), ECG parameters, ECHO/MUGA scan findings, and ophthalmologic findings."
              }
            },
            {
              "id": "endpoint-010",
              "instanceType": "Endpoint",
              "name": "PK Parameters",
              "label": "Secondary Endpoint",
              "text": "Plasma concentrations and PK parameters of DS-1062a, total anti-TROP2 antibody, and MAAA-1181a (Cmax, AUClast, AUCtau).",
              "purpose": "To characterize the pharmacokinetic profile of DS-1062a.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Non-compartmental analysis of concentration time data",
              "assessor": "Bioanalytical Laboratory",
              "analysis_population_id": "population-004",
              "provenance": {
                "section_number": "1.1",
                "page_number": 18,
                "text_snippet": "Plasma concentrations and PK parameters of DS-1062a, total anti-TROP2 antibody, and MAAA-1181a in the full PK sampling cohort."
              }
            },
            {
              "id": "endpoint-011",
              "instanceType": "Endpoint",
              "name": "Immunogenicity",
              "label": "Secondary Endpoint",
              "text": "Antidrug antibody (ADA) prevalence and incidence.",
              "purpose": "To assess the immunogenicity of DS-1062a.",
              "level": {
                "code": "C98748",
                "decode": "Secondary",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C82583",
                "decode": "Binary Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Validated ADA assay",
              "assessor": "Bioanalytical Laboratory",
              "analysis_population_id": "population-002",
              "provenance": {
                "section_number": "1.1",
                "page_number": 18,
                "text_snippet": "ADA prevalence: the proportion of subjects who are ADA positive at any point in time (at baseline and post-baseline).\nADA incidence: the proportion of subjects having treatment-emergent ADA."
              }
            },
            {
              "id": "endpoint-012",
              "instanceType": "Endpoint",
              "name": "PFS2",
              "label": "Exploratory Endpoint",
              "text": "Second Progression-Free Survival (PFS2) as assessed by local standard clinical practice.",
              "purpose": "To evaluate time to second progression or death.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25208",
                "decode": "Time-to-Event Endpoint",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Local standard clinical practice",
              "assessor": "Investigator",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 18,
                "text_snippet": "Title: PFS2\nDescription: PFS2 as assessed by local standard clinical practice"
              }
            },
            {
              "id": "endpoint-013",
              "instanceType": "Endpoint",
              "name": "Biomarkers",
              "label": "Exploratory Endpoint",
              "text": "Tumor TROP2 expression and other biomarkers including genomic alterations, gene expression, and protein expression.",
              "purpose": "To explore potential predictive and prognostic biomarkers.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "Central laboratory analysis",
              "assessor": "Central Laboratory",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 18,
                "text_snippet": "Tumor TROP2 expression (central laboratory analysis)\nOther biomarkers including genomic alterations, gene expression, protein expression, and pharmacogenomics may be measured in tumor and blood samples."
              }
            },
            {
              "id": "endpoint-014",
              "instanceType": "Endpoint",
              "name": "PRO Endpoints",
              "label": "Exploratory Endpoint",
              "text": "Change from baseline in EORTC-QLQ-C30, EORTC-QLQ-LC13, EQ-5D-5L, and PRO-CTCAE scores.",
              "purpose": "To evaluate the impact of treatment on patient-reported outcomes and quality of life.",
              "level": {
                "code": "C174264",
                "decode": "Exploratory",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "outcome_type": {
                "code": "C25513",
                "decode": "Continuous Variable",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "assessment_method": "EORTC-QLQ-C30, EORTC-QLQ-LC13, EQ-5D-5L, PRO-CTCAE",
              "assessor": "Patient",
              "analysis_population_id": "population-001",
              "provenance": {
                "section_number": "1.1",
                "page_number": 19,
                "text_snippet": "Title: Patient-reported Outcomes\n\u2022 Change from baseline in QLQ-C30 functioning scales.\n\u2022 Change from baseline in global health (QLQ-C30 question No. 29).\n\u2022 Change from baseline in quality of life (QLQ-C30 question No. 30).\n\u2022 Change from baseline in overall health status (EQ-5D Visual Analog Scale).\n\u2022 Summary statistics (ie, frequency distributions) for each PRO-CTCAE."
              }
            }
          ],
          "estimands": [
            {
              "id": "estimand-001",
              "instanceType": "Estimand",
              "name": "Primary Estimand for PFS",
              "text": "Treatment effect on Progression-Free Survival comparing DS-1062a vs Docetaxel in the Full Analysis Set.",
              "endpoint_id": "endpoint-001",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "DS-1062a 6.0 mg/kg IV once every 3 weeks"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98389",
                    "decode": "Active Comparator Arm"
                  },
                  "description": "Docetaxel 75 mg/m2 IV once every 3 weeks"
                },
                "provenance": {
                  "section_number": "4.1.3",
                  "page_number": 67,
                  "text_snippet": "DS-1062a will be administered as an intravenous (IV) infusion once Q3W on Day 1 of 21-day cycles at a dose of 6.0 mg/kg... Docetaxel will be administered as an IV infusion of 75 mg/m2 over approximately 60 minutes on Day 1 of each 3-week cycle."
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "Full Analysis Set (all randomized subjects)",
                "provenance": {
                  "section_number": "9.4",
                  "page_number": 128,
                  "text_snippet": "The Full Analysis Set (FAS) will include all subjects who have been randomized to the study. Following the Intent-to-Treat principle, subjects will be analyzed according to the treatment and strata they have been assigned to during the randomization process. FAS will be the primary analysis set for all efficacy analysis."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-001",
                "description": "Time from randomization to the earlier of radiographic disease progression per RECIST v1.1 by BICR or death from any cause.",
                "provenance": {
                  "section_number": "9.5.1.1",
                  "page_number": 128,
                  "text_snippet": "PFS is defined as the time from randomization to the earlier of the dates of the first radiographic disease progression or death due to any cause."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-001",
                  "name": "Discontinuation of study treatment",
                  "description": "Subject discontinues assigned study treatment for reasons other than disease progression or death (e.g., toxicity, withdrawal of consent).",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "To assess the effect of the treatment strategy regardless of adherence. Subjects are followed for disease progression and survival after treatment discontinuation.",
                  "provenance": {
                    "section_number": "4.1.1",
                    "page_number": 66,
                    "text_snippet": "Subjects who discontinue treatment without radiographic disease progression or start new anticancer therapy without radiographic disease progression will continue to undergo tumor assessments every 6 weeks (\u00b17 days) until radiographic disease progression as assessed by Investigator, death, lost to follow-up, or withdrawal of consent."
                  }
                },
                {
                  "id": "ice-002",
                  "name": "Initiation of new anti-cancer therapy",
                  "description": "Subject starts a new, non-protocol specified anti-cancer therapy before documented progression.",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "To assess the effect of the initial treatment strategy. Subjects are followed for disease progression and survival after initiation of new therapy.",
                  "provenance": {
                    "section_number": "4.1.1",
                    "page_number": 66,
                    "text_snippet": "Subjects who discontinue treatment without radiographic disease progression or start new anticancer therapy without radiographic disease progression will continue to undergo tumor assessments every 6 weeks (\u00b17 days) until radiographic disease progression as assessed by Investigator, death, lost to follow-up, or withdrawal of consent."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [
                "sens-001"
              ],
              "provenance": {
                "section_number": "9.5.1.1",
                "page_number": 128,
                "text_snippet": "The primary efficacy analysis of PFS and OS will compare the DS-1062a and docetaxel arms, using a stratified log-rank test stratified by the randomization stratification factors."
              }
            },
            {
              "id": "estimand-002",
              "instanceType": "Estimand",
              "name": "Primary Estimand for OS",
              "text": "Treatment effect on Overall Survival comparing DS-1062a vs Docetaxel in the Full Analysis Set.",
              "endpoint_id": "endpoint-002",
              "treatment": {
                "experimental_arm": {
                  "arm_type": {
                    "code": "C98388",
                    "decode": "Experimental Arm"
                  },
                  "description": "DS-1062a 6.0 mg/kg IV once every 3 weeks"
                },
                "comparator_arm": {
                  "arm_type": {
                    "code": "C98389",
                    "decode": "Active Comparator Arm"
                  },
                  "description": "Docetaxel 75 mg/m2 IV once every 3 weeks"
                },
                "provenance": {
                  "section_number": "4.1.3",
                  "page_number": 67,
                  "text_snippet": "DS-1062a will be administered as an intravenous (IV) infusion once Q3W on Day 1 of 21-day cycles at a dose of 6.0 mg/kg... Docetaxel will be administered as an IV infusion of 75 mg/m2 over approximately 60 minutes on Day 1 of each 3-week cycle."
                }
              },
              "population": {
                "analysis_population_id": "population-001",
                "description": "Full Analysis Set (all randomized subjects)",
                "provenance": {
                  "section_number": "9.4",
                  "page_number": 128,
                  "text_snippet": "The Full Analysis Set (FAS) will include all subjects who have been randomized to the study. Following the Intent-to-Treat principle, subjects will be analyzed according to the treatment and strata they have been assigned to during the randomization process. FAS will be the primary analysis set for all efficacy analysis."
                }
              },
              "variable": {
                "endpoint_id": "endpoint-002",
                "description": "Time from randomization to death from any cause.",
                "provenance": {
                  "section_number": "9.5.1.1",
                  "page_number": 128,
                  "text_snippet": "OS is defined as the time from randomization to death due to any cause."
                }
              },
              "intercurrent_events": [
                {
                  "id": "ice-003",
                  "name": "Discontinuation of study treatment and/or initiation of subsequent therapy",
                  "description": "Any event occurring after randomization, such as treatment discontinuation or initiation of subsequent anti-cancer therapies.",
                  "strategy": {
                    "code": "C178899",
                    "decode": "Treatment Policy Strategy"
                  },
                  "strategy_rationale": "To assess the overall effect of the treatment strategy on survival, which inherently includes effects of subsequent therapies.",
                  "provenance": {
                    "section_number": "8.3",
                    "page_number": 111,
                    "text_snippet": "All subjects should be followed for survival at least every 3 months after discontinuing study drug until EOS (see Table 1.2). Survival monitoring will continue until the end of the study."
                  }
                }
              ],
              "summary_measure": {
                "code": "C16859",
                "decode": "Hazard Ratio"
              },
              "sensitivity_analysis_ids": [
                "sens-001"
              ],
              "provenance": {
                "section_number": "9.5.1.1",
                "page_number": 128,
                "text_snippet": "The primary efficacy analysis of PFS and OS will compare the DS-1062a and docetaxel arms, using a stratified log-rank test stratified by the randomization stratification factors."
              }
            }
          ],
          "analysis_populations": [
            {
              "id": "population-001",
              "instanceType": "AnalysisPopulation",
              "name": "Full Analysis Set",
              "label": "FAS",
              "text": "All subjects who have been randomized to the study. Subjects will be analyzed according to the treatment and strata they have been assigned to during the randomization process.",
              "population_type": {
                "code": "C71105",
                "decode": "Full Analysis Set"
              },
              "inclusion_criteria": [
                "All randomized subjects"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-004",
                "endpoint-005",
                "endpoint-006",
                "endpoint-007",
                "endpoint-008",
                "endpoint-012",
                "endpoint-013",
                "endpoint-014"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 128,
                "text_snippet": "The Full Analysis Set (FAS) will include all subjects who have been randomized to the study. Following the Intent-to-Treat principle, subjects will be analyzed according to the treatment and strata they have been assigned to during the randomization process. FAS will be the primary analysis set for all efficacy analysis."
              }
            },
            {
              "id": "population-002",
              "instanceType": "AnalysisPopulation",
              "name": "Safety Analysis Set",
              "label": "Safety",
              "text": "All randomized subjects who received at least 1 dose of study drug. Subjects will be analyzed according to the study treatment received.",
              "population_type": {
                "code": "C115932",
                "decode": "Safety Population"
              },
              "inclusion_criteria": [
                "All randomized subjects who received at least 1 dose of study drug"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-009",
                "endpoint-011"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 127,
                "text_snippet": "The Safety Analysis Set will include all randomized subjects who received at least 1 dose of study drug. Subjects will be analyzed according to the study treatment received, where treatment received is the randomized study drug if the subject took at least 1 dose of the randomized study drug; otherwise, the first treatment received will be used."
              }
            },
            {
              "id": "population-003",
              "instanceType": "AnalysisPopulation",
              "name": "Per-protocol Analysis Set",
              "label": "PPS",
              "text": "All subjects in the Full Analysis Set who did not have major protocol violations.",
              "population_type": {
                "code": "C70927",
                "decode": "Per-Protocol Population"
              },
              "inclusion_criteria": [
                "Member of the Full Analysis Set",
                "No major protocol violations"
              ],
              "exclusion_criteria": [
                "Presence of major protocol violations"
              ],
              "is_primary_for_endpoints": [],
              "is_sensitivity_for_endpoints": [
                "endpoint-001",
                "endpoint-002"
              ],
              "provenance": {
                "section_number": "9.4",
                "page_number": 128,
                "text_snippet": "The Per-protocol Analysis Set (PPS) will include all subjects in FAS who did not have major protocol violations. Details about the major protocol deviations will be specified in the SAP."
              }
            },
            {
              "id": "population-004",
              "instanceType": "AnalysisPopulation",
              "name": "PK Analysis Set",
              "label": "PK",
              "text": "All subjects in the Safety Analysis Set who had at least 1 PK sample with measurable plasma concentration of DS-1062a, total anti-TROP2 antibody, or MAAA-1181a.",
              "population_type": {
                "code": "C93001",
                "decode": "Modified Intent-to-Treat Population"
              },
              "inclusion_criteria": [
                "Member of the Safety Analysis Set",
                "At least 1 PK sample with measurable plasma concentration"
              ],
              "exclusion_criteria": [],
              "is_primary_for_endpoints": [
                "endpoint-010"
              ],
              "is_sensitivity_for_endpoints": [],
              "provenance": {
                "section_number": "9.4",
                "page_number": 128,
                "text_snippet": "The PK Analysis Set will include all subjects in the Safety Analysis Set who had at least 1 PK sample with measurable plasma concentration of DS-1062a, total anti-TROP2 antibody, or MAAA-1181a."
              }
            }
          ],
          "provenance": {
            "section_number": "3",
            "page_number": 59,
            "text_snippet": "3. OBJECTIVES, OUTCOME MEASURES, AND ENDPOINTS"
          }
        },
        "sap_analyses": {
          "sensitivity_analyses": [
            {
              "id": "sens-001",
              "instanceType": "SensitivityAnalysis",
              "name": "Per-Protocol Sensitivity Analysis",
              "description": "Primary analyses for PFS and OS repeated on the Per-Protocol population.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173329",
                "decode": "Sensitivity Analysis"
              },
              "purpose": "To assess the robustness of the primary efficacy results by excluding subjects with major protocol violations.",
              "analysis_population_id": "population-003",
              "statistical_model": "Same as primary analysis (stratified log-rank test and stratified Cox model).",
              "provenance": {
                "section_number": "9.4",
                "page_number": 128,
                "text_snippet": "The Per-protocol Analysis Set (PPS) will include all subjects in FAS who did not have major protocol violations. Details about the major protocol deviations will be specified in the SAP."
              }
            },
            {
              "id": "sens-002",
              "instanceType": "SensitivityAnalysis",
              "name": "Investigator-Assessed PFS Analysis",
              "description": "Analysis of Progression-Free Survival as assessed by the Investigator.",
              "target_estimand_id": "estimand-001",
              "analysis_type": {
                "code": "C173330",
                "decode": "Supplementary Analysis"
              },
              "purpose": "To supplement the primary BICR-assessed PFS analysis and evaluate consistency of results based on investigator assessment.",
              "analysis_population_id": "population-001",
              "statistical_model": "Analyzed in a similar manner as PFS by BICR (stratified log-rank test and stratified Cox model).",
              "provenance": {
                "section_number": "9.5.1.2",
                "page_number": 129,
                "text_snippet": "PFS as assessed by Investigator will be analyzed in a similar manner as PFS by BICR."
              }
            }
          ],
          "statistical_methods": [
            {
              "id": "method-001",
              "instanceType": "StatisticalMethod",
              "name": "Primary Analysis of PFS and OS",
              "description": "Comparison of PFS and OS between treatment arms using a stratified log-rank test.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002"
              ],
              "model_type": "Log-rank test",
              "stratification_factors": [
                "documented actionable genomic alteration (present versus absent)",
                "histology (squamous versus nonsquamous)",
                "most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy (yes versus no)",
                "geographical region (US/Japan/Western Europe versus ROW)"
              ],
              "alpha": 0.05,
              "provenance": {
                "section_number": "9.5.1.1",
                "page_number": 128,
                "text_snippet": "The primary efficacy analysis of PFS and OS will compare the DS-1062a and docetaxel arms, using a stratified log-rank test stratified by the randomization stratification factors."
              }
            },
            {
              "id": "method-002",
              "instanceType": "StatisticalMethod",
              "name": "Hazard Ratio Estimation for PFS and OS",
              "description": "Estimation of the hazard ratio and its confidence interval using a stratified Cox proportional hazards model.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002"
              ],
              "model_type": "Cox Proportional Hazards Model",
              "stratification_factors": [
                "documented actionable genomic alteration (present versus absent)",
                "histology (squamous versus nonsquamous)",
                "most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy (yes versus no)",
                "geographical region (US/Japan/Western Europe versus ROW)"
              ],
              "provenance": {
                "section_number": "9.5.1.1",
                "page_number": 129,
                "text_snippet": "The stratified cox regression model, stratified by the randomization stratification factors, will be fitted to estimate the hazard ratio of PFS and OS between the treatment versus the control arm (docetaxel) and the corresponding CI."
              }
            },
            {
              "id": "method-003",
              "instanceType": "StatisticalMethod",
              "name": "Survival Curve Estimation",
              "description": "Summarization and graphical presentation of time-to-event endpoints using the Kaplan-Meier method.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-003",
                "endpoint-005",
                "endpoint-007",
                "endpoint-008",
                "endpoint-012"
              ],
              "model_type": "Kaplan-Meier",
              "provenance": {
                "section_number": "9.5.1.1",
                "page_number": 128,
                "text_snippet": "PFS and OS will be summarized and graphically presented using the Kaplan-Meier method by treatment arm with median and corresponding confidence interval (CI) for the median using the Brookmeyer and Crowley method."
              }
            },
            {
              "id": "method-004",
              "instanceType": "StatisticalMethod",
              "name": "Analysis of ORR and DCR",
              "description": "Estimation of the response rate and its 2-sided 95% exact confidence interval.",
              "for_endpoint_ids": [
                "endpoint-004",
                "endpoint-006"
              ],
              "model_type": "Clopper-Pearson",
              "provenance": {
                "section_number": "9.5.1.2",
                "page_number": 129,
                "text_snippet": "The estimate of ORR and its 2-sided 95% exact (Clopper-Pearson26) CI will be provided by treatment arm."
              }
            },
            {
              "id": "method-005",
              "instanceType": "StatisticalMethod",
              "name": "Safety Analysis",
              "description": "Descriptive statistics will be used to summarize safety data, presented in tabular format by treatment arm.",
              "for_endpoint_ids": [
                "endpoint-009"
              ],
              "model_type": "Descriptive Statistics",
              "provenance": {
                "section_number": "9.5.2",
                "page_number": 131,
                "text_snippet": "Safety analyses in general will be descriptive and will be presented in tabular format with the appropriate summary statistics. Safety analyses will be performed using the Safety Analysis Set and subjects will be analyzed according to their actual treatment received."
              }
            }
          ],
          "subgroup_analyses": [
            {
              "id": "subgroup-001",
              "instanceType": "SubgroupAnalysis",
              "name": "Actionable Genomic Alteration Subgroup",
              "description": "Analysis of PFS, OS, ORR, and DoR by presence of actionable genomic alterations.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-004",
                "endpoint-005"
              ],
              "subgroup_variable": "Actionable Genomic Alteration (AGA) status",
              "categories": [
                {
                  "name": "Present",
                  "definition": "Subjects with documented AGA"
                },
                {
                  "name": "Absent",
                  "definition": "Subjects without documented AGA"
                }
              ],
              "provenance": {
                "section_number": "9.5.1.2",
                "page_number": 129,
                "text_snippet": "Subgroup analyses will be conducted for PFS, OS, ORR, and DoR based on randomization period (before and after protocol version 4.0 to include subjects with actionable genomic alterations) as well as by presence of actionable genomic alterations (present versus absent)."
              }
            },
            {
              "id": "subgroup-002",
              "instanceType": "SubgroupAnalysis",
              "name": "Histology Subgroup",
              "description": "Analysis of PFS and OS by tumor histology.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002"
              ],
              "subgroup_variable": "Histology",
              "categories": [
                {
                  "name": "Squamous",
                  "definition": "Subjects with squamous NSCLC"
                },
                {
                  "name": "Nonsquamous",
                  "definition": "Subjects with nonsquamous NSCLC"
                }
              ],
              "provenance": {
                "section_number": "4.1.1",
                "page_number": 64,
                "text_snippet": "...stratified by documented actionable genomic alteration (present versus absent), histology (squamous versus nonsquamous)..."
              }
            },
            {
              "id": "subgroup-003",
              "instanceType": "SubgroupAnalysis",
              "name": "Prior Immunotherapy Subgroup",
              "description": "Analysis of PFS and OS by whether most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002"
              ],
              "subgroup_variable": "Prior anti-PD-1/PD-L1 therapy",
              "categories": [
                {
                  "name": "Yes",
                  "definition": "Prior therapy included anti-PD-1/PD-L1"
                },
                {
                  "name": "No",
                  "definition": "Prior therapy did not include anti-PD-1/PD-L1"
                }
              ],
              "provenance": {
                "section_number": "4.1.1",
                "page_number": 64,
                "text_snippet": "...most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy (yes versus no)..."
              }
            },
            {
              "id": "subgroup-004",
              "instanceType": "SubgroupAnalysis",
              "name": "Geographical Region Subgroup",
              "description": "Analysis of PFS and OS by geographical region.",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002"
              ],
              "subgroup_variable": "Geographical Region",
              "categories": [
                {
                  "name": "US/Japan/Western Europe",
                  "definition": "Subjects from US, Japan, or Western Europe"
                },
                {
                  "name": "Rest of World (ROW)",
                  "definition": "Subjects from other regions"
                }
              ],
              "provenance": {
                "section_number": "4.1.1",
                "page_number": 64,
                "text_snippet": "...and geographical region (United States [US]/Japan/Western Europe versus rest of world [ROW])."
              }
            },
            {
              "id": "subgroup-005",
              "instanceType": "SubgroupAnalysis",
              "name": "Randomization Period Subgroup",
              "description": "Analysis of PFS, OS, ORR, and DoR based on randomization period (before and after protocol version 4.0).",
              "for_endpoint_ids": [
                "endpoint-001",
                "endpoint-002",
                "endpoint-004",
                "endpoint-005"
              ],
              "subgroup_variable": "Randomization Period",
              "categories": [
                {
                  "name": "Before Protocol v4.0",
                  "definition": "Subjects randomized before protocol version 4.0"
                },
                {
                  "name": "After Protocol v4.0",
                  "definition": "Subjects randomized on or after protocol version 4.0"
                }
              ],
              "provenance": {
                "section_number": "9.5.1.2",
                "page_number": 129,
                "text_snippet": "Subgroup analyses will be conducted for PFS, OS, ORR, and DoR based on randomization period (before and after protocol version 4.0 to include subjects with actionable genomic alterations)..."
              }
            }
          ],
          "multiplicity_adjustment": {
            "method": "Graphical Approach with Alpha Rollover",
            "description": "The overall type I error rate is controlled at 2-sided 0.05. PFS is tested first at alpha=0.008. OS is tested at alpha=0.042. If the test for PFS is statistically significant, its alpha is rolled over to the test for OS, for a total alpha of 0.05 for OS. An interim analysis for OS will be performed at the time of the primary PFS analysis, with stopping boundaries determined by a Lan-DeMets procedure with an O'Brien-Fleming function.",
            "alpha_allocation": "PFS: 0.008 (2-sided); OS: 0.042 (2-sided)",
            "gatekeeping_strategy": "Parallel gatekeeping with alpha splitting and rollover between the two independent primary endpoints, PFS and OS.",
            "provenance": {
              "section_number": "9.5.1.4",
              "page_number": 130,
              "text_snippet": "The overall type I error rate is controlled at 2-sided 0.05 for the entire study. PFS will be tested under 2-sided alpha of 0.008, and OS will be tested under 2-sided alpha of 0.042. Alpha is subject to rollover between PFS and OS. For example, the overall alpha for OS will be 2-sided 0.05 if PFS is positive, and 2-sided 0.042 if PFS is negative. A graphic presentation of the testing process and alpha splitting is shown below."
            }
          },
          "missing_data_handling": {
            "primary_method": "Censoring",
            "method_description": "For time-to-event endpoints (PFS, OS, DoR, etc.), data from subjects who have not had an event by the data cutoff date or are lost to follow-up will be censored at the last date they were known to be event-free. For other endpoints, missing data will generally not be imputed.",
            "assumptions": [
              "Censoring is non-informative."
            ],
            "provenance": {
              "section_number": "9.1",
              "page_number": 126,
              "text_snippet": "In general, missing data will not be imputed for the purpose of data analysis, unless otherwise specified."
            }
          },
          "provenance": {
            "section_number": "9",
            "page_number": 126,
            "text_snippet": "9. STATISTICAL CONSIDERATIONS"
          }
        },
        "extraction_statistics": {
          "objectives_count": 8,
          "endpoints_count": 14,
          "estimands_count": 2,
          "populations_count": 4,
          "sensitivity_analyses_count": 2,
          "statistical_methods_count": 5,
          "subgroup_analyses_count": 5,
          "has_multiplicity_adjustment": true,
          "has_missing_data_strategy": true
        },
        "provenance": {
          "section_number": "1",
          "page_number": 1,
          "text_snippet": "CLINICAL STUDY PROTOCOL\nPHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)"
        }
      }
    },
    "adverseEvents": {
      "moduleId": "adverse_events",
      "instanceType": "AdverseEvents",
      "data": {
        "id": "DS1062-A-U301F-adverse-events",
        "instanceType": "AdverseEvents",
        "name": "DS1062-A-U301F Adverse Events",
        "ae_definitions": {
          "ae_definition": "An AE is any untoward medical occurrence in a subject administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.",
          "teae_definition": "A TEAE is defined as an AE with a start or worsening date on or after the start date of study treatment until 35 days (ie, 28 days +7 days) since date of last dose of study treatment (ie, on-treatment period).",
          "collection_start": "signing the ICF",
          "collection_end": "28 days (+7 days) after the last dose of study medication",
          "collection_end_days": 35,
          "pre_existing_condition_handling": "Exacerbation of a pre-existing medical condition and symptom after the first dose of DS-1062a or docetaxel including increase in severity of the symptom will be recorded as an AE on the Adverse Event eCRF, unless it is a condition of NSCLC.",
          "provenance": {
            "section_number": "10.5.1",
            "page_number": 152,
            "text_snippet": "An AE is any untoward medical occurrence in a subject administered a pharmaceutical product and that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product."
          }
        },
        "sae_criteria": {
          "sae_definition": "An SAE is any untoward medical occurrence that at any dose:",
          "criteria": [
            {
              "id": "sae-001",
              "criterion_type": {
                "code": "C48275",
                "decode": "Death",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Results in death",
              "exclusions": [],
              "provenance": {
                "section_number": "10.5.2",
                "page_number": 153,
                "text_snippet": "Results in death"
              }
            },
            {
              "id": "sae-002",
              "criterion_type": {
                "code": "C82569",
                "decode": "Life Threatening",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Is life-threatening. The term \u2018life-threatening\u2019 in the definition of \u2018serious\u2019 refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.",
              "exclusions": [],
              "provenance": {
                "section_number": "10.5.2",
                "page_number": 153,
                "text_snippet": "Is life-threatening\n\u2212 The term \u2018life-threatening\u2019 in the definition of \u2018serious\u2019 refers to an event in which the subject was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe"
              }
            },
            {
              "id": "sae-003",
              "criterion_type": {
                "code": "C83052",
                "decode": "Hospitalization Required",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Requires inpatient hospitalization or prolongation of existing hospitalization.",
              "exclusions": [
                "Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline or for administration of anticancer therapy after discontinuation of study drug is not considered an AE."
              ],
              "provenance": {
                "section_number": "10.5.2",
                "page_number": 153,
                "text_snippet": "Requires inpatient hospitalization or prolongation of existing hospitalization"
              }
            },
            {
              "id": "sae-004",
              "criterion_type": {
                "code": "C83053",
                "decode": "Prolonged Hospitalization",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Requires inpatient hospitalization or prolongation of existing hospitalization.",
              "exclusions": [],
              "provenance": {
                "section_number": "10.5.2",
                "page_number": 153,
                "text_snippet": "Requires inpatient hospitalization or prolongation of existing hospitalization"
              }
            },
            {
              "id": "sae-005",
              "criterion_type": {
                "code": "C82577",
                "decode": "Disability",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Results in persistent or significant disability/incapacity. The term disability means a substantial disruption of a person\u2019s ability to conduct normal life functions.",
              "exclusions": [],
              "provenance": {
                "section_number": "10.5.2",
                "page_number": 154,
                "text_snippet": "Results in persistent or significant disability/incapacity\n\u2212 The term disability means a substantial disruption of a person\u2019s ability to conduct normal life functions."
              }
            },
            {
              "id": "sae-006",
              "criterion_type": {
                "code": "C82579",
                "decode": "Congenital Anomaly",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Is a congenital anomaly/birth defect",
              "exclusions": [],
              "provenance": {
                "section_number": "10.5.2",
                "page_number": 154,
                "text_snippet": "Is a congenital anomaly/birth defect"
              }
            },
            {
              "id": "sae-007",
              "criterion_type": {
                "code": "C84265",
                "decode": "Medically Important",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "Is an important medical event. Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.",
              "exclusions": [],
              "provenance": {
                "section_number": "10.5.2",
                "page_number": 154,
                "text_snippet": "Is an important medical event\n\u2022 Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious."
              }
            }
          ],
          "provenance": {
            "section_number": "10.5.2",
            "page_number": 153,
            "text_snippet": "An SAE is any untoward medical occurrence that at any dose:"
          }
        },
        "grading_system": {
          "system_name": "NCI-CTCAE",
          "system_version": "v5.0",
          "grade_definitions": [
            {
              "grade": 1,
              "label": "Mild AE",
              "definition": "Mild AE"
            },
            {
              "grade": 2,
              "label": "Moderate AE",
              "definition": "Moderate AE"
            },
            {
              "grade": 3,
              "label": "Severe AE",
              "definition": "Severe AE"
            },
            {
              "grade": 4,
              "label": "Life-threatening",
              "definition": "Life-threatening consequences; urgent intervention indicated"
            },
            {
              "grade": 5,
              "label": "Death",
              "definition": "Death related to AE"
            }
          ],
          "provenance": {
            "section_number": "10.5.3",
            "page_number": 154,
            "text_snippet": "The severity of AEs will be graded using NCI-CTCAE v5.0. For each episode, the highest severity grade attained should be reported."
          }
        },
        "causality_assessment": {
          "method_description": "The Investigator should assess causal relationship between an AE and the study drug based on his/her clinical judgment.",
          "categories": [
            {
              "id": "causality-001",
              "category_type": {
                "code": "C53258",
                "decode": "Related",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "The AE follows a reasonable temporal sequence from study drug administration and cannot be reasonably explained by the subject\u2019s clinical state or other factors (eg, disease under study, concurrent diseases, and concomitant medications). OR The AE follows a reasonable temporal sequence from study drug administration and is a known reaction to the drug under study (or its chemical group) or is predicted by known pharmacology."
            },
            {
              "id": "causality-002",
              "category_type": {
                "code": "C53257",
                "decode": "Not Related",
                "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
                "codeSystemVersion": "24.03e"
              },
              "definition": "The AE does not follow a reasonable sequence from study drug administration or can be reasonably explained by the subject\u2019s clinical state or other factors (eg, disease under study, concurrent diseases, and concomitant medications)."
            }
          ],
          "provenance": {
            "section_number": "10.5.4",
            "page_number": 155,
            "text_snippet": "The Investigator should assess causal relationship between an AE and the study drug based on his/her clinical judgment and the following definitions. The causality assessment must be made based on the available information and can be updated as new information becomes available."
          }
        },
        "coding_dictionary": {
          "dictionary_name": "MedDRA",
          "dictionary_version": null,
          "provenance": {
            "section_number": "9.5.2",
            "page_number": 131,
            "text_snippet": "AEs will be coded using MedDRA and graded using NCI-CTCAE v5.0."
          }
        },
        "reporting_procedures": {
          "routine_ae_reporting": {
            "timeline_hours": null,
            "timeline_description": "All non-serious AEs occurring after the subject has taken the first dose of DS-1062a or docetaxel until 28 days (+7 days) after the last dose will be recorded on the AE eCRF.",
            "method": "eCRF"
          },
          "sae_reporting": {
            "initial_report_hours": 24,
            "followup_report_days": null,
            "recipients": [
              "Sponsor",
              "CRO"
            ],
            "method": "eCRF or Serious Adverse Event Report Form via fax/email if eCRF is unavailable."
          },
          "susar_reporting": null,
          "pregnancy_reporting": {
            "timeline_hours": 24,
            "outcome_tracking": true,
            "partner_pregnancy": true
          },
          "expedited_reporting_criteria": [
            "SAEs",
            "Hepatic events (both serious and non-serious) that meet potential Hy\u2019s Law criteria",
            "All potential ILD/pneumonitis cases (both serious and non-serious)",
            "Grade \u2265 3 IRR events",
            "Grade \u2265 3 ocular surface toxicity events",
            "Grade \u2265 2 keratitis events (including keratitis, punctate keratitis, and ulcerative keratitis)"
          ],
          "unblinding_procedures": null,
          "provenance": {
            "section_number": "8.4.1.1",
            "page_number": 113,
            "text_snippet": "The following types of events should be reported by the Investigator in the electronic data capture (EDC) within 24 hours of awareness:\n\u2022 SAEs (Section 10.5.2).\n\u2022 Hepatic events (both serious and non-serious) that meet potential Hy\u2019s Law criteria (as defined in Section 8.4.1.3). A targeted questionnaire is built within the eCRF to collect relevant additional information for these potential cases.\n\u2022 All potential ILD/pneumonitis cases should be reported within 24 hours, including both serious"
          }
        },
        "aesi_list": [
          {
            "id": "aesi-001",
            "aesi_name": "Interstitial Lung Disease/Pneumonitis",
            "meddra_pt": null,
            "rationale": "Considered an important identified risk based on a comprehensive cumulative review of the available safety data from the clinical development program, as well as the results of potential ILD/pneumonitis cases reviewed by the independent ILD AC, available data from recent epidemiology/literature, biological plausibility, and safety information from drugs with a similar monoclonal antibody and/or payload as DS-1062a.",
            "special_monitoring": "Evaluations should include: High-resolution CT, Pulmonologist consultation, Bronchoscopy and BAL if clinically indicated and feasible, Pulmonary function tests (including FVC and CO diffusing capacity) and pulse oximetry (SpO2), Clinical laboratory tests (arterial blood gases if clinically indicated, blood culture, blood cell count, differential white blood cell count, C-reactive protein, and a COVID-19 test), and one blood sample collection for PK analysis. Additional relevant information is collected through eCRF targeted questionnaires (TQs).",
            "expedited_reporting": true,
            "provenance": {
              "section_number": "8.4.1.2",
              "page_number": 115,
              "text_snippet": "Interstitial Lung Disease/Pneumonitis\nILD/pneumonitis is considered an important identified risk based on a comprehensive cumulative review of the available safety data from the clinical development program, as well as the results of potential ILD/pneumonitis cases reviewed by the independent ILD AC, available data from recent epidemiology/literature, biological plausibility, and safety information from drugs with a similar monoclonal antibody and/or payload as DS-1062a."
            }
          },
          {
            "id": "aesi-002",
            "aesi_name": "Infusion-related Reaction",
            "meddra_pt": null,
            "rationale": "IRR is an identified risk.",
            "special_monitoring": "A targeted questionnaire for \u2265 Grade 3 IRR will be available as an eCRF to collect relevant additional information for these potential cases.",
            "expedited_reporting": true,
            "provenance": {
              "section_number": "8.4.1.2",
              "page_number": 116,
              "text_snippet": "Infusion-related Reaction\nIRR is an identified risk. A Grade 3 IRR was reported and was assessed by an external consultant as anaphylaxis. A targeted questionnaire for \u2265 Grade 3 IRR will be available as an eCRF to collect relevant additional information for these potential cases. All Grade \u22653 events of infusion-related reaction, regardless of seriousness, must be reported in the eCRF within 24 hours."
            }
          },
          {
            "id": "aesi-003",
            "aesi_name": "Oral Mucositis/Stomatitis",
            "meddra_pt": null,
            "rationale": "Considered as identified risks and AESIs associated with DS-1062a treatment.",
            "special_monitoring": "Additional relevant information regarding these AESIs regardless of seriousness will be collected through eCRF targeted questionnaires.",
            "expedited_reporting": false,
            "provenance": {
              "section_number": "8.4.1.2",
              "page_number": 117,
              "text_snippet": "Oral Mucositis/Stomatitis\nOral mucositis/stomatitis AEs are considered as identified risks and AESIs associated with DS-1062a treatment."
            }
          },
          {
            "id": "aesi-004",
            "aesi_name": "Mucosal Inflammation Other Than Oral Mucositis/Stomatitis",
            "meddra_pt": null,
            "rationale": "The category of \u201cmucosal inflammation other than oral mucositis/stomatitis\u201d is also an identified risk and an AESI.",
            "special_monitoring": "Additional relevant information regarding these AESIs regardless of seriousness will be collected through eCRF targeted questionnaires.",
            "expedited_reporting": false,
            "provenance": {
              "section_number": "8.4.1.2",
              "page_number": 117,
              "text_snippet": "Mucosal Inflammation Other Than Oral Mucositis/Stomatitis\nMucosal inflammation AEs are considered as identified risks associated with DS-1062a treatment. The category of \u201cmucosal inflammation other than oral mucositis/stomatitis\u201d is also an identified risk and an AESI."
            }
          },
          {
            "id": "aesi-005",
            "aesi_name": "Ocular Surface Toxicity",
            "meddra_pt": "dry eye, keratitis",
            "rationale": "Ocular surface toxicity (eg, dry eye, keratitis) is considered an AESI associated with DS-1062a. Dry eye is considered as an identified risk and keratitis as a potential risk within this AESI.",
            "special_monitoring": "Additional relevant information regarding these AESIs regardless of seriousness will be collected through eCRF targeted questionnaires.",
            "expedited_reporting": true,
            "provenance": {
              "section_number": "8.4.1.2",
              "page_number": 117,
              "text_snippet": "Ocular Surface Toxicity\nOcular surface toxicity (eg, dry eye, keratitis) is considered an AESI associated with DS-1062a. Dry eye is considered as an identified risk and keratitis as a potential risk within this AESI. Subjects should be advised to use artificial tears daily and to avoid the use of contact lenses."
            }
          }
        ],
        "dlt_criteria": {
          "has_dlt_criteria": false,
          "provenance": {
            "section_number": "2.2",
            "page_number": 55,
            "text_snippet": "Clinical data are available from the ongoing Phase 1 first-in-human study, DS1062-A-J101, evaluating escalating doses of DS-1062a (0.27 mg/kg to 10.0 mg/kg) in unselected subjects with advanced NSCLC relapsed or refractory to standard of care therapy. As described in the IB, dose-limiting toxicities occurred in 3 subjects..."
          }
        },
        "safety_committees": [
          {
            "id": "safety-committee-001",
            "committee_name": "Interstitial Lung Disease Adjudication Committee",
            "committee_type": {
              "code": "C93496",
              "decode": "Adjudication Committee",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "responsibilities": [
              "Adjudicate all cases of potential ILD/pneumonitis on an ongoing basis.",
              "Review ongoing cases of ILD/pneumonitis to make the final determination of ILD/pneumonitis diagnoses to guide Sponsor decisions regarding trial suspension or trial discontinuation and to provide assessment of ILD/pneumonitis prevalence at the end of the study."
            ],
            "provenance": {
              "section_number": "10.1.5",
              "page_number": 137,
              "text_snippet": "Interstitial Lung Disease Adjudication Committee\nAn external ILD AC will be used for this study. Details on the membership, responsibilities, and working procedures of the external ILD AC will be described in its own charter, provided as a separate document. The ILD AC will adjudicate all cases of potential ILD/pneumonitis on an ongoing basis."
            }
          },
          {
            "id": "safety-committee-002",
            "committee_name": "Data Monitoring Committee",
            "committee_type": {
              "code": "C93494",
              "decode": "Data Monitoring Committee",
              "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
              "codeSystemVersion": "24.03e"
            },
            "responsibilities": [
              "Protect the rights, safety, and well-being of subjects who will be participating in this study by monitoring the progress and results.",
              "Periodically review unblinded safety data in this study.",
              "May recommend modification of the study protocol or study based on pre-specified rules described in the DMC charter."
            ],
            "provenance": {
              "section_number": "10.1.5",
              "page_number": 138,
              "text_snippet": "Data Monitoring Committee\nAn independent data monitoring committee (DMC) will be created to further protect the rights, safety, and well-being of subjects who will be participating in this study by monitoring the progress and results. The DMC will comprise qualified physicians and scientists who are not Investigators in the study and not otherwise directly associated with the Sponsor.\nThe DMC will periodically review unblinded safety data in this study."
            }
          }
        ],
        "extraction_statistics": {
          "aesi_count": 5,
          "dlt_criteria_count": 0,
          "sae_criteria_count": 7,
          "has_grading_system": true,
          "has_causality_assessment": true,
          "has_dlt_criteria": false
        },
        "provenance": {
          "section_number": "8.4",
          "page_number": 111,
          "text_snippet": "8.4. Safety Assessments"
        }
      }
    },
    "safetyDecisionPoints": {
      "moduleId": "safety_decision_points",
      "instanceType": "SafetyDecisionPoints",
      "data": {
        "id": "DS1062-A-U301F-safety-decision-points",
        "instanceType": "SafetyDecisionPoints",
        "name": "DS1062-A-U301F Safety Decision Points",
        "discovered_categories": [
          {
            "category_id": "cat-001",
            "category_name": "Infusion-Related Reaction",
            "category_description": "Adverse events related to the infusion of the study drug.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 88,
              "text_snippet": "Table 6.4: Dose Modifications for Non-hematologic and Hematologic Toxicity Related to DS-1062a\nInfusion-Related Reaction"
            }
          },
          {
            "category_id": "cat-002",
            "category_name": "Hematologic Toxicity",
            "category_description": "Adverse events related to blood cell counts.",
            "parameters_count": 5,
            "provenance": {
              "section_number": null,
              "page_number": 89,
              "text_snippet": "Hematologic Toxicity"
            }
          },
          {
            "category_id": "cat-003",
            "category_name": "Pulmonary Toxicity",
            "category_description": "Adverse events related to lung function and structure.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 90,
              "text_snippet": "Pulmonary Toxicity"
            }
          },
          {
            "category_id": "cat-004",
            "category_name": "Ocular Toxicity",
            "category_description": "Adverse events related to the eyes and vision.",
            "parameters_count": 1,
            "provenance": {
              "section_number": null,
              "page_number": 93,
              "text_snippet": "Ocular Surface Toxicity\n(eg, dry eye, decreased or blurred vision, photophobia, keratitis, corneal ulcer)"
            }
          },
          {
            "category_id": "cat-005",
            "category_name": "Hepatic Toxicity",
            "category_description": "Adverse events related to liver function.",
            "parameters_count": 3,
            "provenance": {
              "section_number": null,
              "page_number": 93,
              "text_snippet": "Hepatic Toxicity"
            }
          },
          {
            "category_id": "cat-006",
            "category_name": "Gastrointestinal Toxicity",
            "category_description": "Adverse events related to the digestive system.",
            "parameters_count": 3,
            "provenance": {
              "section_number": null,
              "page_number": 95,
              "text_snippet": "Gastrointestinal"
            }
          },
          {
            "category_id": "cat-007",
            "category_name": "General Toxicity",
            "category_description": "General rules for laboratory and non-laboratory adverse events not otherwise specified.",
            "parameters_count": 2,
            "provenance": {
              "section_number": null,
              "page_number": 96,
              "text_snippet": "Other Laboratory Adverse Events\nOther Non-laboratory Adverse Events"
            }
          },
          {
            "category_id": "cat-008",
            "category_name": "Infectious Disease",
            "category_description": "Dose modifications related to COVID-19 infection.",
            "parameters_count": 1,
            "provenance": {
              "section_number": "10.7",
              "page_number": 157,
              "text_snippet": "Appendix 8: Instructions Related to Coronavirus Disease 2019 (COVID-19)"
            }
          },
          {
            "category_id": "cat-009",
            "category_name": "Neurologic Toxicity",
            "category_description": "Adverse events related to the nervous system.",
            "parameters_count": 1,
            "provenance": {
              "section_number": "6.5.2",
              "page_number": 98,
              "text_snippet": "Subjects who develop \u2265Grade 3 peripheral neuropathy should have docetaxel treatment discontinued entirely."
            }
          }
        ],
        "decision_points": [
          {
            "id": "dp-001",
            "parameter_name": "Infusion-Related Reaction (IRR)",
            "parameter_category": "Infusion-Related Reaction",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-001-r1",
                "rule_type": "dose_modify",
                "rule_description": "Reduce infusion rate for Grade 1 IRR.",
                "conditions": {
                  "grade": "1",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "modify_infusion",
                    "action_description": "Reduce infusion rate by 50%."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 88,
                  "text_snippet": "Grade 1: If any signs or symptoms of infusion-related reaction (such as fever and chills, with and without nausea/vomiting, pain, headache, dizziness, dyspnea, Grade 1 or 2 hypotension) is observed during administration, the infusion rate should be reduced by 50% of the initial infusion rate and subjects should be closely monitored."
                }
              },
              {
                "rule_id": "dp-001-r2",
                "rule_type": "dose_hold",
                "rule_description": "Interrupt infusion for Grade 2 IRR.",
                "conditions": {
                  "grade": "2",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_infusion",
                    "action_description": "Interrupt infusion. Restart at 50% reduced rate if event resolves to Grade 1."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": null,
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 88,
                  "text_snippet": "Grade 2: Administration of DS-1062a should be interrupted briefly. Symptomatic treatment should be started.\nIf the event resolves or improves to Grade 1, infusion can be restarted at a 50% reduced infusion rate (ie, 180 minutes for a 90- minute infusion and 60 minutes for a 30-minute infusion)."
                }
              },
              {
                "rule_id": "dp-001-r3",
                "rule_type": "dose_discontinue",
                "rule_description": "Stop infusion for Grade 3 IRR and consider permanent discontinuation.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_infusion",
                    "action_description": "Stop infusion immediately for the cycle. If IRR does not resolve within the same day, or recurs, permanently discontinue DS-1062a."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 89,
                  "text_snippet": "Grade 3: Administration of DS-1062a should be stopped immediately for that cycle and initiate treatment of the IRR symptoms.\nIf the IRR does not resolve within the same day, recurrence of symptoms occurs following initial improvement, or hospitalization is necessary for clinical sequelae, then permanently discontinue DS-1062a."
                }
              },
              {
                "rule_id": "dp-001-r4",
                "rule_type": "dose_discontinue",
                "rule_description": "Permanently discontinue for Grade 4 IRR.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue DS-1062a immediately and permanently."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 89,
                  "text_snippet": "Grade 4: Administration of DS-1062a must be discontinued immediately and permanently."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "Close observation for at least 1-hour post-infusion (can be shortened to 30 mins after 2 cycles without IRR).",
              "method": "Clinical observation"
            },
            "provenance": {
              "section_number": null,
              "page_number": 88,
              "text_snippet": "Infusion-Related Reaction\nPremedication is required prior to any dose of DS-1062a and must include antihistamines and acetaminophen with or without glucocorticoids. Subjects should remain at the site for at least 1-hour post infusion of DS-1062a for close observation for possible allergic reaction.\nIf a subject doesn\u2019t experience any IRR during or after the first 2 cycles, the post-infusion observation period can be shortened to at least 30 minutes for subsequent cycles."
            }
          },
          {
            "id": "dp-002",
            "parameter_name": "Neutrophil/White Blood Cell Count",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-002-r1",
                "rule_type": "dose_hold",
                "rule_description": "Delay dose for Grade 3 neutropenia/leukopenia.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": "<1.0-0.5 x 10^9/L",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264Grade 2, then maintain dose."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 2",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 89,
                  "text_snippet": "Grade 3 (ANC defined as <1.0-0.5 \u00d7 10^9/L; WBC defined as <2.0-1.0 \u00d710^9/L): Delay dose until resolved to \u2264Grade 2, then maintain dose."
                }
              },
              {
                "rule_id": "dp-002-r2",
                "rule_type": "dose_hold_reduce",
                "rule_description": "Delay dose for Grade 4 neutropenia/leukopenia with potential reduction.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": "<0.5 x 10^9/L",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264Grade 2. If resolved in \u226414 days, maintain dose. If resolved in >14 days, reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 2",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 89,
                  "text_snippet": "Grade 4 (ANC defined as <0.5-0.5 \u00d710^9/L; WBC defined as <1.0 \u00d7 10^9/L): Delay dose until resolved to \u2264Grade 2:\nIf resolved in \u226414 days from day of onset, maintain dose.\nIf resolved in >14 days from day of onset, reduce dose by 1 level."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 89,
              "text_snippet": "Neutrophil Count Decreased and/or White Blood Cell Count Decreased"
            }
          },
          {
            "id": "dp-003",
            "parameter_name": "Febrile Neutropenia",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-003-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and reduce dose for Grade 3 febrile neutropenia.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved, then reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "Resolved",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 89,
                  "text_snippet": "Grade 3: Delay dose until resolved, then reduce dose by 1 level."
                }
              },
              {
                "rule_id": "dp-003-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4 febrile neutropenia.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 89,
                  "text_snippet": "Grade 4: Discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 89,
              "text_snippet": "Febrile Neutropenia"
            }
          },
          {
            "id": "dp-004",
            "parameter_name": "Lymphocyte Count",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-004-r1",
                "rule_type": "dose_hold_reduce",
                "rule_description": "Delay dose for Grade 4 lymphopenia with potential reduction.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264Grade 2. If resolved in \u226414 days, maintain dose. If resolved in >14 days, reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 2",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 90,
                  "text_snippet": "Grade 4: Delay dose until resolved to \u2264Grade 2:\nIf resolved in \u226414 days from day of onset, maintain dose.\nIf resolved in >14 days from day of onset, reduce dose by 1 level."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 90,
              "text_snippet": "Lymphocyte Count Decreased"
            }
          },
          {
            "id": "dp-005",
            "parameter_name": "Anaemia",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-005-r1",
                "rule_type": "dose_hold",
                "rule_description": "Delay dose for Grade 3 anaemia.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264Grade 2, then maintain dose."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 2",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 90,
                  "text_snippet": "Grade 3: Delay dose until resolved to \u2264Grade 2, then maintain dose."
                }
              },
              {
                "rule_id": "dp-005-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and reduce dose for Grade 4 anaemia.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264Grade 2, then reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 2",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 90,
                  "text_snippet": "Grade 4: Delay dose until resolved to \u2264Grade 2, then reduce dose by 1 level."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 90,
              "text_snippet": "Anaemia"
            }
          },
          {
            "id": "dp-006",
            "parameter_name": "Platelet Count",
            "parameter_category": "Hematologic Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-006-r1",
                "rule_type": "dose_hold_reduce",
                "rule_description": "Delay dose for Grade 3 thrombocytopenia with potential reduction.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264Grade 1. If resolved in \u22647 days, maintain dose. If resolved in >7 days, reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 1",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 90,
                  "text_snippet": "Grade 3: Delay dose until resolved to \u2264Grade 1:\nIf resolved in \u22647 days from day of onset, maintain dose.\nIf resolved in >7 days from day of onset, reduce dose by 1 level."
                }
              },
              {
                "rule_id": "dp-006-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and reduce dose for Grade 4 thrombocytopenia.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264Grade 1, then reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 1",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 90,
                  "text_snippet": "Grade 4: Delay dose until resolved to \u2264Grade 1, then reduce dose by 1 level."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 90,
              "text_snippet": "Platelet Count Decreased"
            }
          },
          {
            "id": "dp-007",
            "parameter_name": "Interstitial Lung Disease (ILD)/Pneumonitis",
            "parameter_category": "Pulmonary Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-007-r1",
                "rule_type": "dose_hold",
                "rule_description": "Delay treatment if ILD/pneumonitis is suspected.",
                "conditions": {
                  "grade": "Suspected",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay treatment with DS-1062a pending further evaluations."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 90,
                  "text_snippet": "If the AE is suspected to be ILD/pneumonitis, treatment with DS-1062a should be delayed pending further evaluations."
                }
              },
              {
                "rule_id": "dp-007-r2",
                "rule_type": "dose_hold_reduce",
                "rule_description": "Delay dose for Grade 1 ILD/pneumonitis with potential reduction.",
                "conditions": {
                  "grade": "1",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose. Restart only if fully resolved to Grade 0. If resolved \u226428 days, maintain dose. If resolved >28 days, reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "Grade 0",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 91,
                  "text_snippet": "Grade 1: The administration of DS-1062a must be delayed for any ILD/pneumonitis events regardless of grade.\nFor Grade 1 events, DS-1062a can be restarted only if the event is fully resolved to Grade 0:\nIf resolved in \u226428 days from day of onset, maintain dose\nIf resolved in >28 days from day of onset, reduce dose by 1 level"
                }
              },
              {
                "rule_id": "dp-007-r3",
                "rule_type": "dose_discontinue",
                "rule_description": "Permanently discontinue for Grade 2 or higher ILD/pneumonitis.",
                "conditions": {
                  "grade": ">=2",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Permanently discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 92,
                  "text_snippet": "Grade 2: Permanently discontinue subject from study treatment.\nGrade 3 and 4: Permanently discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "Upon suspicion (new/worsening pulmonary symptoms).",
              "method": "High-resolution CT, Pulmonologist consultation, PFTs, SpO2."
            },
            "provenance": {
              "section_number": null,
              "page_number": 90,
              "text_snippet": "Pulmonary Toxicity\nIf a subject develops radiographic changes potentially consistent with ILD/pneumonitis or develops an acute onset of new or worsening pulmonary or other related signs/symptoms such as dyspnea, cough or fever, rule out ILD/pneumonitis."
            }
          },
          {
            "id": "dp-008",
            "parameter_name": "Ocular Surface Toxicity",
            "parameter_category": "Ocular Toxicity",
            "measurement_type": "Corneal Toxicity Severity Grading Scale",
            "decision_rules": [
              {
                "rule_id": "dp-008-r1",
                "rule_type": "monitoring_increase",
                "rule_description": "Consider assessment for Grade 1.",
                "conditions": {
                  "grade": "1",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "monitoring_increase",
                    "action_description": "Consider obtaining an ophthalmological assessment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 93,
                  "text_snippet": "Grade 1: Consider obtaining an ophthalmological assessment."
                }
              },
              {
                "rule_id": "dp-008-r2",
                "rule_type": "dose_hold",
                "rule_description": "Delay dose for Grade 2.",
                "conditions": {
                  "grade": "2",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Obtain ophthalmological assessment. Delay dose until resolved to \u2264 Grade 1, then maintain dose."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264 Grade 1",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 93,
                  "text_snippet": "Grade 2: Obtain an ophthalmological assessment. Delay dose until resolved to \u2264 Grade 1, then maintain dose."
                }
              },
              {
                "rule_id": "dp-008-r3",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and reduce dose for Grade 3.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Obtain ophthalmological assessment. Delay dose until resolved to \u2264 Grade 1, then reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264 Grade 1",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 93,
                  "text_snippet": "Grade 3: Obtain an ophthalmological assessment. Delay dose until resolved to \u2264 Grade 1, then reduce dose by 1 level."
                }
              },
              {
                "rule_id": "dp-008-r4",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Obtain an urgent ophthalmological assessment. Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 93,
                  "text_snippet": "Grade 4: Obtain an urgent ophthalmological assessment. Discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "At screening, EOT, and as clinically indicated for symptoms.",
              "method": "Ophthalmological assessment including visual acuity, slit lamp, fundoscopy."
            },
            "provenance": {
              "section_number": "8.4.4",
              "page_number": 120,
              "text_snippet": "Ophthalmologic assessments (OAs) including visual acuity testing, slit lamp examination, intraocular pressure measurement, fundoscopy, and fluorescein staining will be performed at screening, as clinically indicated, and at the end of treatment (EOT) visit by an ophthalmologist, or if unavailable, another licensed eye care provider."
            }
          },
          {
            "id": "dp-009",
            "parameter_name": "AST/ALT with Total Bilirubin (Hy's Law)",
            "parameter_category": "Hepatic Toxicity",
            "measurement_type": "ULN",
            "decision_rules": [
              {
                "rule_id": "dp-009-r1",
                "rule_type": "dose_discontinue",
                "rule_description": "Permanently discontinue if drug-induced liver injury cannot be ruled out.",
                "conditions": {
                  "grade": null,
                  "anc_threshold": "AST/ALT \u22653.0 x ULN with simultaneous total bilirubin >2.0 x ULN",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay study medication until drug-induced liver injury can be ruled out. If it cannot be ruled out, permanently discontinue study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 93,
                  "text_snippet": "AST/ALT \u22653.0 \u00d7 ULN with simultaneous total bilirubin >2.0 \u00d7 ULN: Delay study medication until drug-induced liver injury can be ruled out. If drug-induced liver injury cannot be ruled out from diagnostic workup, permanently discontinue study treatment."
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "Monitor AST/ALT and total bilirubin twice weekly until resolution or return to baseline.",
              "method": "Blood chemistry"
            },
            "provenance": {
              "section_number": null,
              "page_number": 93,
              "text_snippet": "AST or ALT with Simultaneous Total Bilirubin Increased"
            }
          },
          {
            "id": "dp-010",
            "parameter_name": "AST or ALT",
            "parameter_category": "Hepatic Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade / ULN",
            "decision_rules": [
              {
                "rule_id": "dp-010-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and reduce dose for Grade 3 AST/ALT elevation.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": ">5.0 \u2013 20.0 x ULN",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264Grade 1 (or baseline), then reduce by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 1 or baseline",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 94,
                  "text_snippet": "Grade 3 (>5.0 \u2013 20.0 \u00d7 ULN...): Repeat testing within 3 days. Delay dose until resolved to \u2264Grade 1 if baseline \u22643 \u00d7 ULN, otherwise delay dose until resolved to \u2264baseline, then reduce by 1 level."
                }
              },
              {
                "rule_id": "dp-010-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4 AST/ALT elevation.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": ">20.0 x ULN",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 94,
                  "text_snippet": "Grade 4 (>20.0 \u00d7 ULN...): Discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 94,
              "text_snippet": "AST or ALT"
            }
          },
          {
            "id": "dp-011",
            "parameter_name": "Total Bilirubin",
            "parameter_category": "Hepatic Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade / ULN",
            "decision_rules": [
              {
                "rule_id": "dp-011-r1",
                "rule_type": "dose_hold_reduce",
                "rule_description": "Delay dose for Grade 2 bilirubin elevation with potential reduction.",
                "conditions": {
                  "grade": "2",
                  "anc_threshold": ">1.5 \u2013 3.0 x ULN",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "If no Gilbert's/liver mets, delay dose until \u2264Grade 1. If resolved \u22647 days, maintain dose. If >7 days, reduce by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 1",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 94,
                  "text_snippet": "Grade 2 (>1.5 \u2013 3.0 \u00d7 ULN...): If no documented Gilbert\u2019s syndrome or liver metastases at baseline, delay dose until resolved to \u2264Grade 1:\nIf resolved in \u22647 days from day of onset, maintain dose.\nIf resolved in >7 days from day of onset, reduce dose by 1 level."
                }
              },
              {
                "rule_id": "dp-011-r2",
                "rule_type": "dose_reduce_discontinue",
                "rule_description": "Delay dose for Grade 3 bilirubin elevation with potential discontinuation.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": ">3.0 \u2013 10.0 x ULN",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose. If resolved in \u22647 days, reduce dose by 1 level. If resolved in >7 days, discontinue DS-1062a."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264Grade 1 or \u2264Grade 2 depending on baseline",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 95,
                  "text_snippet": "Grade 3 (>3.0 \u2013 10.0 \u00d7 ULN...): If no documented Gilbert\u2019s syndrome or liver metastases at baseline, repeat testing within 3 days. Delay dose until resolved to \u2264Grade 1:\nIf resolved in \u22647 days from day of onset, reduce dose by 1 level.\nIf resolved in >7 days from day of onset, discontinue DS-1062a."
                }
              },
              {
                "rule_id": "dp-011-r3",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4 bilirubin elevation.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": ">10.0 x ULN",
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 95,
                  "text_snippet": "Grade 4 (>10.0 \u00d7 ULN...): Discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 94,
              "text_snippet": "Total Bilirubin"
            }
          },
          {
            "id": "dp-012",
            "parameter_name": "Nausea/Vomiting",
            "parameter_category": "Gastrointestinal Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-012-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and potentially reduce dose for Grade 3 Nausea/Vomiting.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "If prophylaxis not optimized, delay dose, optimize, and maintain dose. If already optimized, delay dose until \u2264 Grade 1 and reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264 Grade 1 or baseline",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 95,
                  "text_snippet": "Grade 3: If prophylaxis and supportive medications have NOT YET been optimized: Delay dose until resolved to \u2264 Grade 1 or baseline, optimize medications, and then maintain dose.\nIf prophylaxis and supportive medications have ALREADY been optimized: Delay dose until resolved to \u2264 Grade 1 or baseline, and then reduce dose by 1 level."
                }
              },
              {
                "rule_id": "dp-012-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4 Vomiting.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 95,
                  "text_snippet": "Grade 4 Vomiting: Discontinue subject from study treatment"
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 95,
              "text_snippet": "Nausea/Vomiting"
            }
          },
          {
            "id": "dp-013",
            "parameter_name": "Oral Mucositis/Stomatitis",
            "parameter_category": "Gastrointestinal Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-013-r1",
                "rule_type": "dose_hold_reduce",
                "rule_description": "Consider dose delay or reduction for Grade 2.",
                "conditions": {
                  "grade": "2",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "dose_modify",
                    "action_description": "Consider a dose delay or reduction if clinically indicated."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 2: Consider a dose delay or reduction if clinically indicated."
                }
              },
              {
                "rule_id": "dp-013-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and potentially reduce dose for Grade 3.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "If prophylaxis not optimized, delay dose, optimize, and maintain dose. If already optimized, delay dose until \u2264 Grade 1 and reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264 Grade 1 or baseline",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 3: If prophylaxis and supportive medications have NOT YET been optimized: Delay dose until resolved to \u2264 Grade 1 or baseline, optimize medications, and then maintain dose.\nIf prophylaxis and supportive medications have ALREADY been optimized: Delay dose until resolved to \u2264 Grade 1 or baseline, then reduce dose by 1 level."
                }
              },
              {
                "rule_id": "dp-013-r3",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 4: Discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 95,
              "text_snippet": "Oral Mucositis/Stomatitis"
            }
          },
          {
            "id": "dp-014",
            "parameter_name": "Diarrhoea",
            "parameter_category": "Gastrointestinal Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-014-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and potentially reduce dose for Grade 3.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "If prophylaxis not optimized, delay dose, optimize, and maintain dose. If already optimized, delay dose until \u2264 Grade 1 and reduce dose by 1 level."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264 Grade 1 or baseline",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 3: If prophylaxis and supportive medications per institutional guidelines have NOT YET been optimized: Delay dose until resolved to \u2264 Grade 1 or baseline, optimize medications, and then maintain dose.\nIf prophylaxis and supportive medications have ALREADY been optimized: Delay dose until resolved to \u2264 Grade 1 or baseline, then reduce dose by 1 level."
                }
              },
              {
                "rule_id": "dp-014-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 4: Discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 96,
              "text_snippet": "Diarrhoea"
            }
          },
          {
            "id": "dp-015",
            "parameter_name": "Other Laboratory Adverse Events",
            "parameter_category": "General Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-015-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and reduce dose for Grade 3.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264 Grade 1 or baseline level and then reduce dose by 1 level, if determined to be clinically significant."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264 Grade 1 or baseline",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 3: Delay dose until resolved to \u2264 Grade 1 or baseline level and then reduce dose by 1 level, if determined by the investigator to be clinically significant."
                }
              },
              {
                "rule_id": "dp-015-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 4: Discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 96,
              "text_snippet": "Other Laboratory Adverse Events"
            }
          },
          {
            "id": "dp-016",
            "parameter_name": "Other Non-laboratory Adverse Events",
            "parameter_category": "General Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-016-r1",
                "rule_type": "dose_reduce",
                "rule_description": "Delay and reduce dose for Grade 3.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "hold_dose",
                    "action_description": "Delay dose until resolved to \u2264 Grade 1 or baseline level and then reduce dose by 1 level, if determined to be clinically significant."
                  }
                ],
                "recovery_criteria": {
                  "anc_required": "\u2264 Grade 1 or baseline",
                  "timeframe": null
                },
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 3: Delay dose until resolved to \u2264 Grade 1 or baseline level and then reduce dose by 1 level, if determined by the investigator to be clinically significant."
                }
              },
              {
                "rule_id": "dp-016-r2",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue subject from study treatment."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": null,
                  "page_number": 96,
                  "text_snippet": "Grade 4: Discontinue subject from study treatment."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": null,
              "page_number": 96,
              "text_snippet": "Other Non-laboratory Adverse Events"
            }
          },
          {
            "id": "dp-017",
            "parameter_name": "COVID-19 Infection",
            "parameter_category": "Infectious Disease",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-017-r1",
                "rule_type": "dose_resume",
                "rule_description": "Resume at same dose for Grade 1.",
                "conditions": {
                  "grade": "1",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "resume_dose",
                    "action_description": "Resume study drug at the same dose."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "10.7",
                  "page_number": 157,
                  "text_snippet": "Grade 1: Resume study drug at the same dose"
                }
              },
              {
                "rule_id": "dp-017-r2",
                "rule_type": "dose_reduce",
                "rule_description": "Resume or reduce dose for Grade 2 based on CT findings.",
                "conditions": {
                  "grade": "2",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "dose_modify",
                    "action_description": "Resume study drug at the same dose if chest CT findings are completely resolved. Reduce by 1 dose level if chest CT findings are nearly resolved."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "10.7",
                  "page_number": 157,
                  "text_snippet": "Grade 2: Resume study drug at the same dose if chest CT findings are completely resolved\nReduce by 1 dose level if chest CT findings are nearly resolved"
                }
              },
              {
                "rule_id": "dp-017-r3",
                "rule_type": "dose_reduce_discontinue",
                "rule_description": "Reduce or discontinue for Grade 3 based on CT findings.",
                "conditions": {
                  "grade": "3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "dose_modify",
                    "action_description": "Reduce by 1 dose level if chest CT findings are completely resolved. Discontinue study drug if chest CT findings are not completely resolved."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "10.7",
                  "page_number": 157,
                  "text_snippet": "Grade 3: Reduce by 1 dose level if chest CT findings are completely resolved\nDiscontinue study drug if chest CT findings are not completely resolved"
                }
              },
              {
                "rule_id": "dp-017-r4",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue for Grade 4.",
                "conditions": {
                  "grade": "4",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Discontinue study drug."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "10.7",
                  "page_number": 157,
                  "text_snippet": "Grade 4: Discontinue study drug"
                }
              }
            ],
            "monitoring_requirements": {
              "frequency": "Closely monitor signs/symptoms after resuming DS-1062a, with phone calls every 3 days for the first week, then weekly for a total of 6 weeks.",
              "method": "Clinical observation and phone calls"
            },
            "provenance": {
              "section_number": "10.7",
              "page_number": 157,
              "text_snippet": "Table 10.7: COVID-19 Dose Modification Criteria"
            }
          },
          {
            "id": "dp-018",
            "parameter_name": "Peripheral Neuropathy (Docetaxel)",
            "parameter_category": "Neurologic Toxicity",
            "measurement_type": "NCI-CTCAE v5.0 Grade",
            "decision_rules": [
              {
                "rule_id": "dp-018-r1",
                "rule_type": "dose_discontinue",
                "rule_description": "Discontinue docetaxel for Grade 3 or higher peripheral neuropathy.",
                "conditions": {
                  "grade": ">=3",
                  "anc_threshold": null,
                  "duration": null
                },
                "actions": [
                  {
                    "action_type": "discontinue_drug",
                    "action_description": "Docetaxel treatment should be discontinued entirely."
                  }
                ],
                "recovery_criteria": null,
                "provenance": {
                  "section_number": "6.5.2",
                  "page_number": 98,
                  "text_snippet": "Subjects who develop \u2265Grade 3 peripheral neuropathy should have docetaxel treatment discontinued entirely."
                }
              }
            ],
            "monitoring_requirements": null,
            "provenance": {
              "section_number": "6.5.2",
              "page_number": 98,
              "text_snippet": "Subjects who develop \u2265Grade 3 peripheral neuropathy should have docetaxel treatment discontinued entirely."
            }
          }
        ],
        "stopping_rules_summary": {
          "total_permanent_stopping_conditions": 11,
          "stopping_conditions": [
            {
              "condition_id": "stop-001",
              "condition_type": "individual_subject",
              "description": "Dose delay for DS-1062a or docetaxel longer than allowed.",
              "trigger_threshold": "Dose delay > 12 weeks (84 days) for DS-1062a; > 4 weeks (28 days) for docetaxel.",
              "action": "Permanent discontinuation from study drug.",
              "provenance": {
                "section_number": "6.5.1",
                "page_number": 86,
                "text_snippet": "If a subject is assessed as requiring a dose delay longer than 12 weeks or 84 days from last infusion, the subject must discontinue treatment with DS-1062a."
              }
            },
            {
              "condition_id": "stop-002",
              "condition_type": "individual_subject",
              "description": "Grade 4 Infusion-Related Reaction (IRR).",
              "trigger_threshold": "Occurrence of Grade 4 IRR.",
              "action": "Permanent discontinuation of DS-1062a.",
              "provenance": {
                "section_number": null,
                "page_number": 89,
                "text_snippet": "Grade 4: Administration of DS-1062a must be discontinued immediately and permanently."
              }
            },
            {
              "condition_id": "stop-003",
              "condition_type": "individual_subject",
              "description": "Recurrent or non-resolving Grade 3 Infusion-Related Reaction (IRR).",
              "trigger_threshold": "IRR does not resolve within the same day, or recurs after initial improvement.",
              "action": "Permanent discontinuation of DS-1062a.",
              "provenance": {
                "section_number": null,
                "page_number": 89,
                "text_snippet": "If the IRR does not resolve within the same day, recurrence of symptoms occurs following initial improvement, or hospitalization is necessary for clinical sequelae, then permanently discontinue DS-1062a."
              }
            },
            {
              "condition_id": "stop-004",
              "condition_type": "individual_subject",
              "description": "Grade 4 Febrile Neutropenia.",
              "trigger_threshold": "Occurrence of Grade 4 Febrile Neutropenia.",
              "action": "Permanent discontinuation from study treatment.",
              "provenance": {
                "section_number": null,
                "page_number": 89,
                "text_snippet": "Febrile Neutropenia\nGrade 4: Discontinue subject from study treatment."
              }
            },
            {
              "condition_id": "stop-005",
              "condition_type": "individual_subject",
              "description": "Grade 1 ILD/Pneumonitis not resolved within 84 days.",
              "trigger_threshold": "Failure to resolve to Grade 0 within 84 days from last infusion.",
              "action": "Permanent discontinuation of DS-1062a.",
              "provenance": {
                "section_number": null,
                "page_number": 91,
                "text_snippet": "However, if the Grade 1 ILD/pneumonitis has not resolved within 84 days from the last infusion, the drug should be permanently discontinued."
              }
            },
            {
              "condition_id": "stop-006",
              "condition_type": "individual_subject",
              "description": "Grade 2 or higher ILD/Pneumonitis.",
              "trigger_threshold": "Occurrence of Grade \u22652 ILD/Pneumonitis.",
              "action": "Permanent discontinuation of DS-1062a.",
              "provenance": {
                "section_number": null,
                "page_number": 92,
                "text_snippet": "Grade 2: Permanently discontinue subject from study treatment.\nGrade 3 and 4: Permanently discontinue subject from study treatment."
              }
            },
            {
              "condition_id": "stop-007",
              "condition_type": "individual_subject",
              "description": "Grade 4 Ocular Surface Toxicity (Corneal Perforation).",
              "trigger_threshold": "Occurrence of Grade 4 Ocular Surface Toxicity.",
              "action": "Permanent discontinuation from study treatment.",
              "provenance": {
                "section_number": null,
                "page_number": 93,
                "text_snippet": "Grade 4 = Corneal perforation\nGrade 4: Obtain an urgent ophthalmological assessment. Discontinue subject from study treatment."
              }
            },
            {
              "condition_id": "stop-008",
              "condition_type": "individual_subject",
              "description": "Suspected drug-induced liver injury (Hy's Law).",
              "trigger_threshold": "AST/ALT \u22653x ULN and Total Bilirubin >2x ULN, where DILI cannot be ruled out.",
              "action": "Permanent discontinuation from study treatment.",
              "provenance": {
                "section_number": null,
                "page_number": 93,
                "text_snippet": "If drug-induced liver injury cannot be ruled out from diagnostic workup, permanently discontinue study treatment."
              }
            },
            {
              "condition_id": "stop-009",
              "condition_type": "individual_subject",
              "description": "Grade 4 elevation of AST/ALT, Total Bilirubin, Vomiting, Oral Mucositis, Diarrhoea, or other lab/non-lab AEs.",
              "trigger_threshold": "Occurrence of any Grade 4 toxicity listed.",
              "action": "Permanent discontinuation from study treatment.",
              "provenance": {
                "section_number": null,
                "page_number": 94,
                "text_snippet": "Grade 4 (>20.0 \u00d7 ULN if baseline was normal; >20.0 \u00d7 baseline if baseline was abnormal): Discontinue subject from study treatment."
              }
            },
            {
              "condition_id": "stop-010",
              "condition_type": "individual_subject",
              "description": "Grade 3 Total Bilirubin that does not resolve within 7 days.",
              "trigger_threshold": "Resolution takes >7 days from onset.",
              "action": "Permanent discontinuation of DS-1062a.",
              "provenance": {
                "section_number": null,
                "page_number": 95,
                "text_snippet": "If resolved in >7 days from day of onset, discontinue DS-1062a."
              }
            },
            {
              "condition_id": "stop-011",
              "condition_type": "individual_subject",
              "description": "Grade 3 or higher peripheral neuropathy with docetaxel.",
              "trigger_threshold": "Occurrence of Grade \u22653 peripheral neuropathy.",
              "action": "Permanent discontinuation of docetaxel.",
              "provenance": {
                "section_number": "6.5.2",
                "page_number": 98,
                "text_snippet": "Subjects who develop \u2265Grade 3 peripheral neuropathy should have docetaxel treatment discontinued entirely."
              }
            }
          ],
          "provenance": {
            "section_number": "6.5",
            "page_number": 85,
            "text_snippet": "6.5. Guidelines for Dose Modification"
          }
        },
        "dose_modification_levels": {
          "DS-1062a": {
            "has_defined_levels": true,
            "levels": [
              {
                "level_id": "dose-0",
                "level_name": "Starting Dose",
                "dose_percentage": 100,
                "absolute_dose": "6.0 mg/kg",
                "provenance": {
                  "section_number": "6.5.1",
                  "page_number": 86,
                  "text_snippet": "Starting Dose: 6.0 mg/kg"
                }
              },
              {
                "level_id": "dose-1",
                "level_name": "First Reduction",
                "dose_percentage": 66.7,
                "absolute_dose": "4.0 mg/kg",
                "provenance": {
                  "section_number": "6.5.1",
                  "page_number": 86,
                  "text_snippet": "Dose Reduction 1: 4.0 mg/kg"
                }
              },
              {
                "level_id": "dose-2",
                "level_name": "Second Reduction",
                "dose_percentage": 50,
                "absolute_dose": "3.0 mg/kg",
                "provenance": {
                  "section_number": "6.5.1",
                  "page_number": 86,
                  "text_snippet": "Dose Reduction 2: 3.0 mg/kg"
                }
              },
              {
                "level_id": "dose-3",
                "level_name": "Third Reduction",
                "dose_percentage": 33.3,
                "absolute_dose": "2.0 mg/kg",
                "provenance": {
                  "section_number": "6.5.1",
                  "page_number": 86,
                  "text_snippet": "Dose Reduction 3: 2.0 mg/kg"
                }
              }
            ],
            "minimum_dose": "2.0 mg/kg",
            "re_escalation_allowed": false,
            "re_escalation_criteria": "No dose re-escalation is permitted.",
            "provenance": {
              "section_number": "6.5.1",
              "page_number": 86,
              "text_snippet": "Once the dose of DS-1062a is reduced, no dose re-escalation will be permitted."
            }
          },
          "Docetaxel": {
            "has_defined_levels": true,
            "levels": [
              {
                "level_id": "dose-0",
                "level_name": "Starting Dose",
                "dose_percentage": 100,
                "absolute_dose": "75 mg/m\u00b2",
                "provenance": {
                  "section_number": "6.5.2",
                  "page_number": 98,
                  "text_snippet": "Starting Dose: 75 mg/m^2"
                }
              },
              {
                "level_id": "dose-1",
                "level_name": "First Reduction",
                "dose_percentage": 73.3,
                "absolute_dose": "55 mg/m\u00b2 or Per Investigator",
                "provenance": {
                  "section_number": "6.5.2",
                  "page_number": 98,
                  "text_snippet": "First Dose Reduction: 55 mg/m^2 or Per Investigator"
                }
              },
              {
                "level_id": "dose-2",
                "level_name": "Second Reduction",
                "dose_percentage": null,
                "absolute_dose": "Per Investigator",
                "provenance": {
                  "section_number": "6.5.2",
                  "page_number": 98,
                  "text_snippet": "Second Dose Reduction: Per Investigator"
                }
              }
            ],
            "minimum_dose": "Per Investigator",
            "re_escalation_allowed": false,
            "re_escalation_criteria": "No dose re-escalation will be permitted.",
            "provenance": {
              "section_number": "6.5.2",
              "page_number": 97,
              "text_snippet": "Once the dose of docetaxel is reduced, no dose re-escalation will be permitted."
            }
          },
          "provenance": {
            "section_number": "6.5",
            "page_number": 85,
            "text_snippet": "6.5. Guidelines for Dose Modification"
          }
        },
        "organ_specific_adjustments": [
          {
            "id": "organ-001",
            "organ_system": "Hepatic",
            "organ_system_detail": "Liver function impairment (DS-1062a)",
            "adjustment_trigger": "Grade 3 AST/ALT elevation (>5.0 x ULN)",
            "adjustment_action": "Delay dose until resolution to \u2264Grade 1 or baseline, then reduce dose by 1 level.",
            "monitoring_requirements": "Repeat testing within 3 days.",
            "provenance": {
              "section_number": null,
              "page_number": 94,
              "text_snippet": "Grade 3 (>5.0 \u2013 20.0 \u00d7 ULN...): Repeat testing within 3 days. Delay dose until resolved to \u2264Grade 1 if baseline \u22643 \u00d7 ULN, otherwise delay dose until resolved to \u2264baseline, then reduce by 1 level."
            }
          },
          {
            "id": "organ-002",
            "organ_system": "Hepatic",
            "organ_system_detail": "Liver function impairment (DS-1062a)",
            "adjustment_trigger": "Grade 3 Total Bilirubin elevation (>3.0 x ULN)",
            "adjustment_action": "Delay dose. If resolves \u22647 days, reduce by 1 level. If >7 days, discontinue.",
            "monitoring_requirements": "Repeat testing within 3 days.",
            "provenance": {
              "section_number": null,
              "page_number": 95,
              "text_snippet": "Grade 3 (>3.0 \u2013 10.0 \u00d7 ULN...): If no documented Gilbert\u2019s syndrome or liver metastases at baseline, repeat testing within 3 days. Delay dose until resolved to \u2264Grade 1:\nIf resolved in \u22647 days from day of onset, reduce dose by 1 level.\nIf resolved in >7 days from day of onset, discontinue DS-1062a."
            }
          },
          {
            "id": "organ-003",
            "organ_system": "Pulmonary",
            "organ_system_detail": "Interstitial Lung Disease/Pneumonitis (DS-1062a)",
            "adjustment_trigger": "Grade 1 ILD/Pneumonitis",
            "adjustment_action": "Delay dose. If resolves >28 days, reduce dose by 1 level. If does not resolve in 84 days, discontinue.",
            "monitoring_requirements": "High-resolution CT and clinical follow-up.",
            "provenance": {
              "section_number": null,
              "page_number": 91,
              "text_snippet": "For Grade 1 events, DS-1062a can be restarted only if the event is fully resolved to Grade 0:\nIf resolved in \u226428 days from day of onset, maintain dose\nIf resolved in >28 days from day of onset, reduce dose by 1 level\nHowever, if the Grade 1 ILD/pneumonitis has not resolved within 84 days from the last infusion, the drug should be permanently discontinued."
            }
          },
          {
            "id": "organ-004",
            "organ_system": "Hepatic",
            "organ_system_detail": "Liver function impairment (Docetaxel)",
            "adjustment_trigger": "Elevated bilirubin or transaminases.",
            "adjustment_action": "Delay dose. Resume at 55 mg/m\u00b2 after resolution. Permanently discontinue for concurrent Grade 2 AST/ALT > 3xULN and total bilirubin > 2xULN.",
            "monitoring_requirements": "Per local label and institutional guidance.",
            "provenance": {
              "section_number": "6.5.2",
              "page_number": 98,
              "text_snippet": "Once the toxicity resolves, docetaxel treatment may resume at 55 mg/m2 for the remainder of the study... Subjects with concurrent Grade 2 AST/ALT > 3 \u00d7 ULN AND total bilirubin >2 \u00d7 ULN should have treatment permanently discontinued."
            }
          }
        ],
        "extraction_statistics": {
          "decision_points_count": 18,
          "stopping_rules_count": 11,
          "organ_adjustments_count": 4,
          "dose_levels_count": 7,
          "categories_count": 9
        },
        "provenance": {
          "section_number": "6.5",
          "page_number": 85,
          "text_snippet": "6.5. Guidelines for Dose Modification\nAll dose modifications (ie, infusion interruptions, dose delays, re-initiation, dose reduction, and/or treatment discontinuation) should be based on the worst preceding toxicity NCI-CTCAE v5.0. Possible exceptions to the dose modification criteria may be allowed on a case-by-case basis after discussion and agreement between the Investigator and Sponsor."
        }
      }
    },
    "concomitantMedications": {
      "moduleId": "concomitant_medications",
      "instanceType": "ConcomitantMedications",
      "data": {
        "id": "DS1062-A-U301F-concomitant-medications",
        "instanceType": "ConcomitantMedicationRestrictions",
        "name": "DS1062-A-U301F Concomitant Medication Restrictions",
        "description": "Medication restrictions and requirements for DS1062-A-U301F",
        "prohibited_medications": [
          {
            "id": "proh-001",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Other anticancer therapies",
            "specific_drugs": [
              "cytotoxic agents",
              "targeted agents",
              "immunotherapy",
              "antibody therapy",
              "retinoid",
              "transplant",
              "anticancer hormonal treatment"
            ],
            "prohibition_reason": {
              "decode": "efficacy_interference"
            },
            "prohibition_reason_detail": "Prohibited to avoid confounding efficacy and safety assessments.",
            "prohibition_period": {
              "decode": "treatment_period"
            },
            "prohibition_period_detail": "Prohibited during the treatment period.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 99,
              "text_snippet": "Other anticancer therapy, including cytotoxic, targeted agents, immunotherapy, antibody, retinoid, transplant, or anticancer hormonal treatment (concurrent use of hormones for noncancer-related conditions [eg, insulin for diabetes and hormone replacement therapy] is acceptable)."
            }
          },
          {
            "id": "proh-002",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Other investigational therapeutic agents",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "study_design"
            },
            "prohibition_reason_detail": "Participation in other investigational studies is not allowed.",
            "prohibition_period": {
              "decode": "treatment_period"
            },
            "prohibition_period_detail": "Prohibited during the treatment period.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 99,
              "text_snippet": "Other investigational therapeutic agents."
            }
          },
          {
            "id": "proh-003",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Radiotherapy to the thorax",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "safety"
            },
            "prohibition_reason_detail": "Prohibited during the treatment period to avoid overlapping toxicities.",
            "prohibition_period": {
              "decode": "treatment_period"
            },
            "prohibition_period_detail": "Prohibited during the treatment period.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 99,
              "text_snippet": "Radiotherapy to the thorax"
            }
          },
          {
            "id": "proh-004",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Antimalarials",
            "specific_drugs": [
              "chloroquine",
              "hydroxychloroquine"
            ],
            "prohibition_reason": {
              "decode": "drug_interaction"
            },
            "prohibition_reason_detail": "Concomitant treatment is not allowed during the study treatment.",
            "prohibition_period": {
              "decode": "treatment_period"
            },
            "prohibition_period_detail": "Prohibited during the study treatment period.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "Concomitant treatment with chloroquine or hydroxychloroquine is not allowed during the study treatment."
            }
          },
          {
            "id": "proh-005",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Topoisomerase I targeting agents",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "contraindicated"
            },
            "prohibition_reason_detail": "Prior treatment with any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I is an exclusion criterion.",
            "prohibition_period": {
              "decode": "entire_study"
            },
            "prohibition_period_detail": "Exclusion criterion based on prior treatment history.",
            "provenance": {
              "section_number": "5.2",
              "page_number": 78,
              "text_snippet": "Had prior treatment with: \na. Any agent, including an ADC, containing a chemotherapeutic agent targeting topoisomerase I."
            }
          },
          {
            "id": "proh-006",
            "instanceType": "ProhibitedMedication",
            "medication_class": "TROP2-targeted therapy",
            "specific_drugs": [],
            "prohibition_reason": {
              "decode": "contraindicated"
            },
            "prohibition_reason_detail": "Prior treatment with TROP2-targeted therapy is an exclusion criterion.",
            "prohibition_period": {
              "decode": "entire_study"
            },
            "prohibition_period_detail": "Exclusion criterion based on prior treatment history.",
            "provenance": {
              "section_number": "5.2",
              "page_number": 78,
              "text_snippet": "Had prior treatment with: ... b. TROP2-targeted therapy."
            }
          },
          {
            "id": "proh-007",
            "instanceType": "ProhibitedMedication",
            "medication_class": "Taxanes",
            "specific_drugs": [
              "docetaxel"
            ],
            "prohibition_reason": {
              "decode": "study_design"
            },
            "prohibition_reason_detail": "Prior treatment with docetaxel is an exclusion criterion as it is the comparator arm.",
            "prohibition_period": {
              "decode": "entire_study"
            },
            "prohibition_period_detail": "Exclusion criterion based on prior treatment history.",
            "provenance": {
              "section_number": "5.2",
              "page_number": 78,
              "text_snippet": "Had prior treatment with: ... c. Docetaxel."
            }
          }
        ],
        "restricted_medications": [
          {
            "id": "rest-001",
            "instanceType": "RestrictedMedication",
            "medication_class": "Systemic Corticosteroids",
            "specific_drugs": [
              "prednisone"
            ],
            "restriction_type": {
              "decode": "dose_limit"
            },
            "conditions": {
              "max_dose": "10mg/day prednisone equivalent",
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": "Chronic use >10mg/day is prohibited. Higher doses are permitted for managing Adverse Events."
            },
            "rationale": "To avoid potential interference with study drug efficacy or safety.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "Concomitant use of chronic systemic (IV or oral) corticosteroids or other immunosuppressive medications > 10 mg/day of prednisone or equivalent, except for managing AEs; inhaled steroids, intra-articular steroid injections, and other topical steroid formulations are permitted in this study."
            }
          },
          {
            "id": "rest-002",
            "instanceType": "RestrictedMedication",
            "medication_class": "Radiotherapy",
            "specific_drugs": [],
            "restriction_type": {
              "decode": "conditional_use"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": "Must not delay treatment for more than the maximum time specified in the dose modification section.",
              "clinical_scenario": "Allowed for palliative radiation to known metastatic sites as long as it does not affect assessment of response."
            },
            "rationale": "To allow for palliative care while minimizing impact on efficacy assessment.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 99,
              "text_snippet": "Radiotherapy (except for palliative radiation to known metastatic sites as long as it does not affect assessment of response or delay treatment for more than the maximum time specified in the dose modification section [see Section 6.5])."
            }
          },
          {
            "id": "rest-003",
            "instanceType": "RestrictedMedication",
            "medication_class": "Bone-modifying agents",
            "specific_drugs": [
              "bisphosphonates",
              "RANKL-targeting agents"
            ],
            "restriction_type": {
              "decode": "timing_restriction"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": "Allowed if initiated at least 4 weeks prior to baseline tumor assessment. Not allowed to be initiated during study treatment unless for treatment of AEs or SAEs."
            },
            "rationale": "To ensure stability of bone disease assessment at baseline.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 101,
              "text_snippet": "The use of approved bone-modifying agents (eg, bisphosphonates or receptor activator of nuclear factor kappa B ligand [RANKL]-targeting agents) to treat or control bone disease is allowed on study if a subject had initiated treatment with such agents at least 4 weeks prior to baseline tumor assessment."
            }
          },
          {
            "id": "rest-004",
            "instanceType": "RestrictedMedication",
            "medication_class": "Tobacco Products",
            "specific_drugs": [
              "tobacco",
              "e-cigarettes",
              "vaping"
            ],
            "restriction_type": {
              "decode": "avoid_if_possible"
            },
            "conditions": {
              "max_dose": null,
              "approval_required_from": "not_specified",
              "monitoring_requirements": null,
              "timing_restriction": null,
              "clinical_scenario": "Use is strongly discouraged but not prohibited."
            },
            "rationale": "General health recommendation.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "The use of tobacco products, e-cigarettes and vaping is strongly discouraged but not prohibited."
            }
          }
        ],
        "required_medications": [
          {
            "id": "req-001",
            "instanceType": "RequiredMedication",
            "medication_name": null,
            "medication_class": "Antihistamine",
            "requirement_type": {
              "decode": "premedication"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "not_specified"
              },
              "frequency": "Prior to any dose of DS-1062a"
            },
            "timing": {
              "relative_to": "DS-1062a infusion",
              "time_before_minutes": null,
              "timing_description": "Required prior to any dose of DS-1062a."
            },
            "purpose": "Prevention of infusion-related reactions for DS-1062a.",
            "alternatives": [],
            "provenance": {
              "section_number": "6.2.1",
              "page_number": 83,
              "text_snippet": "Premedication is required prior to any dose of DS-1062a and must include antihistamines and acetaminophen, with or without glucocorticoids."
            }
          },
          {
            "id": "req-002",
            "instanceType": "RequiredMedication",
            "medication_name": "acetaminophen",
            "medication_class": "Analgesic",
            "requirement_type": {
              "decode": "premedication"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "not_specified"
              },
              "frequency": "Prior to any dose of DS-1062a"
            },
            "timing": {
              "relative_to": "DS-1062a infusion",
              "time_before_minutes": null,
              "timing_description": "Required prior to any dose of DS-1062a."
            },
            "purpose": "Prevention of infusion-related reactions for DS-1062a.",
            "alternatives": [],
            "provenance": {
              "section_number": "6.2.1",
              "page_number": 83,
              "text_snippet": "Premedication is required prior to any dose of DS-1062a and must include antihistamines and acetaminophen, with or without glucocorticoids."
            }
          },
          {
            "id": "req-003",
            "instanceType": "RequiredMedication",
            "medication_name": "dexamethasone",
            "medication_class": "Corticosteroid",
            "requirement_type": {
              "decode": "premedication"
            },
            "dosing": {
              "dose": "16mg",
              "route": {
                "decode": "PO"
              },
              "frequency": "Per day (e.g., 8.0 mg twice a day) for 3 days"
            },
            "timing": {
              "relative_to": "docetaxel infusion",
              "time_before_minutes": null,
              "timing_description": "Starting 1 day prior to docetaxel administration."
            },
            "purpose": "To reduce the incidence and severity of fluid retention and hypersensitivity reactions for docetaxel.",
            "alternatives": [],
            "provenance": {
              "section_number": "6.1.2",
              "page_number": 82,
              "text_snippet": "Subjects should be premedicated with oral corticosteroids, such as dexamethasone 16.0 mg per day (for example, 8.0 mg twice a day) for 3 days starting 1 day prior to docetaxel administration, in order to reduce the incidence and severity of fluid retention as well as the severity of hypersensitivity reactions."
            }
          },
          {
            "id": "req-004",
            "instanceType": "RequiredMedication",
            "medication_name": null,
            "medication_class": "Anti-emetic agents",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "not_specified"
              },
              "frequency": "As needed"
            },
            "timing": {
              "relative_to": "DS-1062a infusion",
              "time_before_minutes": null,
              "timing_description": "Highly recommended prior to infusion of DS-1062a and on subsequent days as needed."
            },
            "purpose": "Prophylaxis of nausea and vomiting for DS-1062a.",
            "alternatives": [
              "5-hydroxytryptamine 3 (5-HT3) antagonists",
              "neurokinin-1 (NK-1) receptor antagonists",
              "steroids (e.g., dexamethasone)"
            ],
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "Based on the currently available clinical safety data, it is highly recommended that subjects receive prophylactic anti-emetic agents prior to infusion of DS-1062a and on subsequent days as needed. Anti-emetics such as 5-hydroxytryptamine 3 antagonists (5-HT3), neurokinin-1 (NK-1) receptor antagonists, and steroids (eg, dexamethasone) should be considered and administered in accordance with the prescribing information or institutional guidelines."
            }
          },
          {
            "id": "req-005",
            "instanceType": "RequiredMedication",
            "medication_name": null,
            "medication_class": "Oral care mouth rinse",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "topical"
              },
              "frequency": "4 to 6 times a day"
            },
            "timing": {
              "relative_to": "study treatment",
              "time_before_minutes": null,
              "timing_description": "Initiate before study intervention and maintain throughout the study."
            },
            "purpose": "Prevention of oral mucositis/stomatitis for DS-1062a.",
            "alternatives": [
              "nonalcoholic, bicarbonate-containing mouthwash",
              "dexamethasone oral solution 0.1 mg/mL"
            ],
            "provenance": {
              "section_number": "6.2.1",
              "page_number": 83,
              "text_snippet": "For prevention of oral mucositis/stomatitis, subjects are advised to initiate a daily oral care protocol (OCP) before study intervention initiation and maintain it throughout the study. An OCP should include daily inert, bland mouth rinses (eg, with a nonalcoholic, bicarbonate-containing mouthwash 4 to 6 times a day), although other prophylaxis regimens (eg, dexamethasone oral solution 0.1 mg/mL 10 mL 3 to 4 times daily swish for 1 minute to 2 minutes then spit out, as well as cryotherapy"
            }
          },
          {
            "id": "req-006",
            "instanceType": "RequiredMedication",
            "medication_name": "artificial tears",
            "medication_class": "Ophthalmic lubricant",
            "requirement_type": {
              "decode": "prophylaxis"
            },
            "dosing": {
              "dose": null,
              "route": {
                "decode": "topical"
              },
              "frequency": "4 times per day (preventative), up to 8 times per day as needed"
            },
            "timing": {
              "relative_to": "study treatment",
              "time_before_minutes": null,
              "timing_description": "Starting on the day of the first DS-1062a dose."
            },
            "purpose": "Prevention of ocular surface toxicity for DS-1062a.",
            "alternatives": [],
            "provenance": {
              "section_number": null,
              "page_number": 41,
              "text_snippet": "Note: For prevention of ocular surface toxicity, it should be strongly recommended that subjects avoid the use of contact lenses starting on the day of the first DS-1062a dose and to use artificial tears (preferably preservative-free) 4 times per day as preventative measure and up to 8 times per day as clinically needed."
            }
          }
        ],
        "rescue_medications": [
          {
            "id": "resc-001",
            "instanceType": "RescueMedication",
            "medication_name": "doxepin",
            "medication_class": "Topical analgesic",
            "indication": "Pain management for oral mucositis/stomatitis",
            "dosing_instructions": "doxepin 0.5%",
            "documentation_required": true,
            "impact_on_endpoints": null,
            "provenance": {
              "section_number": "6.5.1",
              "page_number": 95,
              "text_snippet": "Provide adequate pain management (eg, doxepin 0.5%, viscous lidocaine 2%)."
            }
          },
          {
            "id": "resc-002",
            "instanceType": "RescueMedication",
            "medication_name": "lidocaine",
            "medication_class": "Topical anesthetic",
            "indication": "Pain management for oral mucositis/stomatitis",
            "dosing_instructions": "viscous lidocaine 2%",
            "documentation_required": true,
            "impact_on_endpoints": null,
            "provenance": {
              "section_number": "6.5.1",
              "page_number": 95,
              "text_snippet": "Provide adequate pain management (eg, doxepin 0.5%, viscous lidocaine 2%)."
            }
          },
          {
            "id": "resc-003",
            "instanceType": "RescueMedication",
            "medication_name": "nystatin",
            "medication_class": "Topical antifungal",
            "indication": "Management of oral mucositis/stomatitis",
            "dosing_instructions": "Oral suspension, as per clinician preference.",
            "documentation_required": true,
            "impact_on_endpoints": null,
            "provenance": {
              "section_number": "6.5.1",
              "page_number": 95,
              "text_snippet": "May consider oral nystatin suspension or other topical antifungal agents at least 15 minutes after the steroid-containing mouthwash according to clinician preference based on institutional/local guidelines."
            }
          }
        ],
        "washout_requirements": [
          {
            "id": "wash-001",
            "instanceType": "WashoutRequirement",
            "medication_class": "Major surgery",
            "specific_drugs": [],
            "washout_duration_days": 21,
            "washout_description": "\u22653 weeks before randomization",
            "rationale": "To allow for adequate recovery from surgery.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.1",
              "page_number": 76,
              "text_snippet": "Major surgery \u22653 weeks"
            }
          },
          {
            "id": "wash-002",
            "instanceType": "WashoutRequirement",
            "medication_class": "Radiation therapy to chest",
            "specific_drugs": [],
            "washout_duration_days": 28,
            "washout_description": "\u22654 weeks before randomization",
            "rationale": "To allow for recovery from radiation-induced toxicity.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.1",
              "page_number": 76,
              "text_snippet": "Radiation therapy including palliative radiation to chest \u22654 weeks"
            }
          },
          {
            "id": "wash-003",
            "instanceType": "WashoutRequirement",
            "medication_class": "Palliative radiation therapy (non-chest)",
            "specific_drugs": [],
            "washout_duration_days": 14,
            "washout_description": "\u22652 weeks before randomization",
            "rationale": "To allow for recovery from radiation-induced toxicity.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.1",
              "page_number": 76,
              "text_snippet": "\u22652 weeks (palliative radiation therapy to other areas [ie, limited field and 10 or fewer days or fractions] including whole brain radiotherapy)"
            }
          },
          {
            "id": "wash-004",
            "instanceType": "WashoutRequirement",
            "medication_class": "Anticancer chemotherapy",
            "specific_drugs": [],
            "washout_duration_days": 14,
            "washout_description": "\u22652 weeks or 5 times the terminal elimination half-life, whichever is longer, before randomization.",
            "rationale": "To ensure clearance of prior therapies and prevent overlapping toxicities.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.1",
              "page_number": 76,
              "text_snippet": "Anticancer chemotherapy (Immunotherapy [non-antibody-based therapy]), retinoid therapy\n\n\u22652 weeks or 5 times the t1/2 of the chemotherapeutic agent, whichever is longer"
            }
          },
          {
            "id": "wash-005",
            "instanceType": "WashoutRequirement",
            "medication_class": "Nitrosoureas or Mitomycin C",
            "specific_drugs": [
              "mitomycin C"
            ],
            "washout_duration_days": 42,
            "washout_description": "\u22656 weeks before randomization",
            "rationale": "Longer washout required due to delayed myelosuppression.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.1",
              "page_number": 76,
              "text_snippet": "\u22656 weeks for nitrosoureas or mitomycin C"
            }
          },
          {
            "id": "wash-006",
            "instanceType": "WashoutRequirement",
            "medication_class": "Tyrosine kinase inhibitors",
            "specific_drugs": [],
            "washout_duration_days": 7,
            "washout_description": "\u22651 week before randomization",
            "rationale": "To ensure clearance of prior therapy.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.1",
              "page_number": 76,
              "text_snippet": "\u22651 week for tyrosine kinase inhibitors approved for the treatment of NSCLC-baseline computed tomography (CT) scan should be completed after discontinuation of tyrosine kinase inhibitors."
            }
          },
          {
            "id": "wash-007",
            "instanceType": "WashoutRequirement",
            "medication_class": "Antibody-based anticancer therapy",
            "specific_drugs": [],
            "washout_duration_days": 28,
            "washout_description": "\u22654 weeks before randomization",
            "rationale": "To ensure clearance of prior biologic therapy.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.1",
              "page_number": 77,
              "text_snippet": "Antibody-based anticancer therapy \u22654 weeks"
            }
          },
          {
            "id": "wash-008",
            "instanceType": "WashoutRequirement",
            "medication_class": "Antimalarials",
            "specific_drugs": [
              "chloroquine",
              "hydroxychloroquine"
            ],
            "washout_duration_days": 15,
            "washout_description": ">14 days before randomization",
            "rationale": "To ensure clearance of prior therapy.",
            "applies_to": {
              "decode": "randomization"
            },
            "provenance": {
              "section_number": "5.1",
              "page_number": 77,
              "text_snippet": "Chloroquine/Hydroxychloroquine >14 days"
            }
          }
        ],
        "drug_interactions": [
          {
            "id": "int-001",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "CYP3A4_inhibitor"
            },
            "severity": {
              "decode": "strong"
            },
            "affected_drugs": [],
            "clinical_effect": "May increase docetaxel exposure and risk of toxicity.",
            "management": {
              "decode": "avoid_if_possible"
            },
            "management_detail": "Should be avoided. If concomitant use cannot be avoided, close clinical surveillance is warranted, and a dose-adjustment of docetaxel may be suitable.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "The concomitant use of docetaxel with strong cytochrome P450 (CYP) 3A4 inhibitors should be avoided. If the concomitant use of a strong CYP3A4 inhibitor cannot be avoided, a close clinical surveillance is warranted, and a dose-adjustment of docetaxel may be suitable during the treatment with the strong CYP3A4 inhibitor."
            }
          },
          {
            "id": "int-002",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "CYP3A_inhibitor"
            },
            "severity": {
              "decode": "not_specified"
            },
            "affected_drugs": [],
            "clinical_effect": "Potential to alter exposure of DS-1062a.",
            "management": {
              "decode": "monitoring"
            },
            "management_detail": "Subjects should be closely monitored when DS-1062a is concomitantly used with drugs that inhibit CYP3A.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "Subjects should be closely monitored when DS-1062a is concomitantly used with drugs that inhibit CYP3A, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, multidrug and toxin extrusion transporter (MATE) 2-K, P-glycoprotein, breast cancer resistance protein (BCRP), and multidrug resistance-associated protein (MRP) 1."
            }
          },
          {
            "id": "int-003",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "OATP_inhibitor"
            },
            "severity": {
              "decode": "not_specified"
            },
            "affected_drugs": [],
            "clinical_effect": "Potential to alter exposure of DS-1062a.",
            "management": {
              "decode": "monitoring"
            },
            "management_detail": "Subjects should be closely monitored when DS-1062a is concomitantly used with drugs that inhibit OATP1B1 and OATP1B3.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "Subjects should be closely monitored when DS-1062a is concomitantly used with drugs that inhibit CYP3A, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, multidrug and toxin extrusion transporter (MATE) 2-K, P-glycoprotein, breast cancer resistance protein (BCRP), and multidrug resistance-associated protein (MRP) 1."
            }
          },
          {
            "id": "int-004",
            "instanceType": "DrugInteraction",
            "interaction_type": {
              "decode": "other"
            },
            "severity": {
              "decode": "not_specified"
            },
            "affected_drugs": [],
            "clinical_effect": "Potential to alter exposure of DS-1062a.",
            "management": {
              "decode": "monitoring"
            },
            "management_detail": "Subjects should be closely monitored when DS-1062a is concomitantly used with drugs that inhibit MATE2-K, P-glycoprotein, BCRP, and MRP1.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "Subjects should be closely monitored when DS-1062a is concomitantly used with drugs that inhibit CYP3A, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, multidrug and toxin extrusion transporter (MATE) 2-K, P-glycoprotein, breast cancer resistance protein (BCRP), and multidrug resistance-associated protein (MRP) 1."
            }
          }
        ],
        "allowed_medications": [
          {
            "id": "allow-001",
            "instanceType": "AllowedMedication",
            "medication_class": "Hormones for noncancer-related conditions",
            "specific_drugs": [
              "insulin",
              "hormone replacement therapy"
            ],
            "notes": "Concurrent use is acceptable.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 99,
              "text_snippet": "Other anticancer therapy... (concurrent use of hormones for noncancer-related conditions [eg, insulin for diabetes and hormone replacement therapy] is acceptable)."
            }
          },
          {
            "id": "allow-002",
            "instanceType": "AllowedMedication",
            "medication_class": "Hematopoietic growth factors",
            "specific_drugs": [
              "G-CSF",
              "erythropoietin"
            ],
            "notes": "May be used for prophylaxis or treatment based on clinical judgment of the Investigator, particularly for subjects receiving docetaxel.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "Hematopoietic growth factors may be used for prophylaxis or treatment based on the clinical judgment of the Investigator.\n\u2212 Subjects receiving docetaxel may receive growth factors (including G-CSF and erythropoietin) at the discretion of the Investigator."
            }
          },
          {
            "id": "allow-003",
            "instanceType": "AllowedMedication",
            "medication_class": "Local or replacement steroids",
            "specific_drugs": [],
            "notes": "Inhaled intranasal, intraocular, intra-articular or topical steroids and adrenal replacement steroid doses are permitted in the absence of active autoimmune disease.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 101,
              "text_snippet": "Inhaled intranasal, intraocular, intra-articular or topical steroids and adrenal replacement steroid doses are permitted in the absence of active autoimmune disease."
            }
          },
          {
            "id": "allow-004",
            "instanceType": "AllowedMedication",
            "medication_class": "Corticosteroid mouthwash",
            "specific_drugs": [],
            "notes": "Permitted to prevent and manage certain AEs.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 100,
              "text_snippet": "Corticosteroid mouthwash formulations are permitted to prevent and manage certain AEs."
            }
          },
          {
            "id": "allow-005",
            "instanceType": "AllowedMedication",
            "medication_class": "Bronchodilators",
            "specific_drugs": [
              "albuterol"
            ],
            "notes": "Permitted for intermittent use in subjects with bronchopulmonary disorders.",
            "provenance": {
              "section_number": "6.6",
              "page_number": 101,
              "text_snippet": "Subjects with bronchopulmonary disorders who require intermittent use of bronchodilators (eg, albuterol) will be included in this study."
            }
          }
        ],
        "vaccine_policy": {
          "instanceType": "VaccinePolicy",
          "live_vaccines_prohibited": true,
          "live_vaccine_washout_days": 30,
          "inactivated_vaccines_allowed": true,
          "covid_vaccine_policy": null,
          "specific_restrictions": [
            "Live vaccines are not recommended during the study, except for emergency use per Investigator's discretion.",
            "For Czech Republic: Subject must not be vaccinated with a live vaccine within 30 days before, during the Treatment Period, and for 90 days after the last dose of DS-1062a or docetaxel."
          ],
          "provenance": {
            "section_number": "6.6",
            "page_number": 100,
            "text_snippet": "Live vaccines are not recommended during the study, except for emergency use per Investigator\u2019s discretion. In Czech Republic only, please see Section 10.9.1 for text applicable to sites in Czech Republic."
          }
        },
        "herbal_supplements_policy": {
          "instanceType": "HerbalSupplementsPolicy",
          "prohibited_supplements": [],
          "rationale": "Concomitant use of dietary supplements and alternative/complementary treatments is discouraged, but not prohibited.",
          "provenance": {
            "section_number": "6.6",
            "page_number": 100,
            "text_snippet": "Concomitant use of dietary supplements, medications not prescribed by the Investigator, and alternative/complementary treatments is discouraged, but not prohibited."
          }
        },
        "provenance": {
          "section_number": "6.6",
          "page_number": 99,
          "text_snippet": "6.6. Prior and Concomitant Medications"
        }
      }
    },
    "biospecimenHandling": {
      "moduleId": "biospecimen_handling",
      "instanceType": "BiospecimenHandling",
      "data": {
        "discovered_specimen_types": [
          {
            "specimen_id": "SPEC-001",
            "specimen_name": "Tumor Biopsy",
            "specimen_category": "tissue",
            "specimen_subtype": "tumor_biopsy",
            "purpose": "biomarker",
            "purpose_description": "TROP2 testing, biomarker analysis",
            "provenance": {
              "section_number": "8.1",
              "page_number": 106,
              "text_snippet": "Qualifying Tumor Tissue Specimen\nA pre-treatment biopsy procedure to collect fresh tumor tissue from the primary or metastatic lesions performed after termination of the most recent anticancer treatment is required for all subjects. Alternatively, tumor tissue previously retrieved from a biopsy procedure performed within 2 years prior to the subject signing the informed consent that has a minimum of 10 \u00d7 4 micron sections or a tissue block equivalent of 10 \u00d7 4 micron sections...may be"
            }
          },
          {
            "specimen_id": "SPEC-002",
            "specimen_name": "Pharmacogenomics Blood Sample",
            "specimen_category": "blood",
            "specimen_subtype": "whole_blood",
            "purpose": "pharmacogenomics",
            "purpose_description": "Analysis of genes involved in absorption, metabolism, elimination, safety, and efficacy of the study drug.",
            "provenance": {
              "section_number": "8.6.5",
              "page_number": 124,
              "text_snippet": "Pharmacogenomic (Inherited Genetic) Analysis\nA single blood sample for pharmacogenetic analysis will be collected from each subject. The pharmacogenomic blood sample will be scheduled for Cycle 1 Day 1 pre-dose (see Table 1.1) but may be collected at any time after the first dose of DS-1062a."
            }
          },
          {
            "specimen_id": "SPEC-003",
            "specimen_name": "Blood sample for cfDNA",
            "specimen_category": "blood",
            "specimen_subtype": "whole_blood",
            "purpose": "biomarker",
            "purpose_description": "To assess changes in tumor mutations or other genomic alterations in response to treatment.",
            "provenance": {
              "section_number": "8.6.1",
              "page_number": 123,
              "text_snippet": "Cell-free DNA from blood samples collected during the study to assess changes in tumor mutations or other genomic alterations in response to treatment will be analyzed with the intent of monitoring the biological or antitumor impact of treatment with DS-1062a or control therapy, docetaxel."
            }
          },
          {
            "specimen_id": "SPEC-004",
            "specimen_name": "Blood sample for predictive liquid biopsy",
            "specimen_category": "blood",
            "specimen_subtype": "whole_blood",
            "purpose": "biomarker",
            "purpose_description": "To identify subjects who are likely to derive clinical benefit.",
            "provenance": {
              "section_number": "8.6.1",
              "page_number": 123,
              "text_snippet": "A blood sample will be collected at the time point specified in the Schedules of Events to serve as a liquid biopsy to identify subjects who are likely to derive clinical benefit (Table 1.1)."
            }
          },
          {
            "specimen_id": "SPEC-005",
            "specimen_name": "Blood sample for WES/WGS control",
            "specimen_category": "blood",
            "specimen_subtype": "whole_blood",
            "purpose": "genomics",
            "purpose_description": "Control for whole exome sequence/whole genome sequence tissue analysis.",
            "provenance": {
              "section_number": "8.6.1",
              "page_number": 123,
              "text_snippet": "A whole blood sample will be collected at the time point specified at Cycle 1 Day 1 to serve as a control for whole exome sequence/whole genome sequence tissue analysis."
            }
          },
          {
            "specimen_id": "SPEC-006",
            "specimen_name": "Plasma sample for ILD biomarkers",
            "specimen_category": "blood",
            "specimen_subtype": "plasma",
            "purpose": "biomarker",
            "purpose_description": "To assess biomarkers predictive of ILD.",
            "provenance": {
              "section_number": "8.6.1",
              "page_number": 123,
              "text_snippet": "Plasma and serum will be collected at the time points specified in the Schedules of Events (Table 1.1 and Table 1.2) and at the time of suspected ILD onset. Samples may be analyzed to assess biomarkers predictive of ILD."
            }
          },
          {
            "specimen_id": "SPEC-007",
            "specimen_name": "Serum sample for ILD biomarkers",
            "specimen_category": "blood",
            "specimen_subtype": "serum",
            "purpose": "biomarker",
            "purpose_description": "To assess biomarkers predictive of ILD.",
            "provenance": {
              "section_number": "8.6.1",
              "page_number": 123,
              "text_snippet": "Plasma and serum will be collected at the time points specified in the Schedules of Events (Table 1.1 and Table 1.2) and at the time of suspected ILD onset. Samples may be analyzed to assess biomarkers predictive of ILD."
            }
          },
          {
            "specimen_id": "SPEC-008",
            "specimen_name": "PK Blood Samples",
            "specimen_category": "blood",
            "specimen_subtype": null,
            "purpose": "pk",
            "purpose_description": "Pharmacokinetic analyses of DS-1062a.",
            "provenance": {
              "section_number": "8.5",
              "page_number": 121,
              "text_snippet": "Blood samples for PK analyses of DS-1062a will be obtained from subjects receiving DS-1062a based on the Schedules of Events (Table 1.1 and Table 1.2) at time points outlined in Table 8.1."
            }
          },
          {
            "specimen_id": "SPEC-009",
            "specimen_name": "ADA Sample",
            "specimen_category": "blood",
            "specimen_subtype": "plasma",
            "purpose": "immunogenicity",
            "purpose_description": "Plasma antidrug antibody (ADA) analyses.",
            "provenance": {
              "section_number": "8.6.6",
              "page_number": 125,
              "text_snippet": "Blood samples for plasma antidrug antibody (ADA) analyses will be collected from subjects receiving DS-1062a at the time points specified in the Schedules of Events (Table 1.1 and Table 1.2)."
            }
          }
        ],
        "collection_containers": [],
        "collection_schedule": [
          {
            "schedule_id": "COL-001",
            "specimen_ref": "SPEC-001",
            "timepoint_name": "Screening",
            "timepoint_type": "screening",
            "relative_time": null,
            "collection_window": {
              "value": 28,
              "unit": "days",
              "description": "During the Screening Period"
            },
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 35,
              "text_snippet": "Biomarker Samples | Tumor Biopsy Sample (Archival or freshly Obtained during Screening) | SCR X"
            }
          },
          {
            "schedule_id": "COL-002",
            "specimen_ref": "SPEC-002",
            "timepoint_name": "C1D1 pre-dose",
            "timepoint_type": "treatment_initiation",
            "relative_time": "C1D1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 35,
              "text_snippet": "Biomarker Samples | Pharmacogenomics Blood Sample | SCR X | Comments: Scheduled for C1D1 pre-dose but may be collected at any time after the first dose of DS-1062a or docetaxel."
            }
          },
          {
            "schedule_id": "COL-003",
            "specimen_ref": "SPEC-003",
            "timepoint_name": "C1D1 pre-dose",
            "timepoint_type": "treatment_initiation",
            "relative_time": "C1D1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 35,
              "text_snippet": "Biomarker Samples | Blood sample for cfDNA | SCR X"
            }
          },
          {
            "schedule_id": "COL-004",
            "specimen_ref": "SPEC-003",
            "timepoint_name": "C2D1 pre-dose",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C2D1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 35,
              "text_snippet": "Biomarker Samples | Blood sample for cfDNA | Cycle 2 BI X"
            }
          },
          {
            "schedule_id": "COL-005",
            "specimen_ref": "SPEC-003",
            "timepoint_name": "C3D1 pre-dose",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C3D1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 35,
              "text_snippet": "Biomarker Samples | Blood sample for cfDNA | Cycle 3 BI X"
            }
          },
          {
            "schedule_id": "COL-006",
            "specimen_ref": "SPEC-003",
            "timepoint_name": "C4D1 and subsequent cycles pre-dose",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C4D1, C9D1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.2",
              "page_number": 45,
              "text_snippet": "Biomarker Sample | Blood Sample for cfDNA | Before infusion at C5D1 and C9D1 only"
            }
          },
          {
            "schedule_id": "COL-007",
            "specimen_ref": "SPEC-004",
            "timepoint_name": "Screening",
            "timepoint_type": "screening",
            "relative_time": null,
            "collection_window": {
              "value": 28,
              "unit": "days",
              "description": "During the Screening Period"
            },
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 35,
              "text_snippet": "Biomarker Samples | Blood sample for predictive liquid biopsy | SCR X"
            }
          },
          {
            "schedule_id": "COL-008",
            "specimen_ref": "SPEC-005",
            "timepoint_name": "Screening",
            "timepoint_type": "screening",
            "relative_time": null,
            "collection_window": {
              "value": 28,
              "unit": "days",
              "description": "During the Screening Period"
            },
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 35,
              "text_snippet": "Biomarker Samples | Blood sample for WES/WGS control | SCR X"
            }
          },
          {
            "schedule_id": "COL-009",
            "specimen_ref": "SPEC-006",
            "timepoint_name": "Suspected ILD onset",
            "timepoint_type": "unscheduled",
            "relative_time": null,
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.2",
              "page_number": 45,
              "text_snippet": "Plasma for ILD Biomarkers | Additional sample should be collected at time of suspected ILD onset."
            }
          },
          {
            "schedule_id": "COL-010",
            "specimen_ref": "SPEC-007",
            "timepoint_name": "Suspected ILD onset",
            "timepoint_type": "unscheduled",
            "relative_time": null,
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.2",
              "page_number": 45,
              "text_snippet": "Serum for ILD Biomarkers | Additional sample should be collected at time of suspected ILD onset."
            }
          },
          {
            "schedule_id": "COL-011",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Sparse PK, C1D1",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C1D1",
            "collection_window": null,
            "number_of_samples": 2,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 38,
              "text_snippet": "PK Blood Samples of DS-1062a | Sparse PK Sampling | C1 BI X, C1 EOI X"
            }
          },
          {
            "schedule_id": "COL-012",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Sparse PK, C2D1",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C2D1",
            "collection_window": null,
            "number_of_samples": 2,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 38,
              "text_snippet": "PK Blood Samples of DS-1062a | Sparse PK Sampling | C2 BI X, C2 EOI Xa"
            }
          },
          {
            "schedule_id": "COL-013",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Sparse PK, C3D1",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C3D1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 38,
              "text_snippet": "PK Blood Samples of DS-1062a | Sparse PK Sampling | C3 BI X"
            }
          },
          {
            "schedule_id": "COL-014",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Sparse PK, C4D1 and subsequent cycles",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C4D1, C6D1, C8D1",
            "collection_window": null,
            "number_of_samples": 2,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.2",
              "page_number": 49,
              "text_snippet": "PK Blood Samples of DS-1062a | Sparse PK Sampling | C4, C6, and C8 only. No PK sampling after C8."
            }
          },
          {
            "schedule_id": "COL-015",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Full PK, C1D1",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C1D1",
            "collection_window": null,
            "number_of_samples": 5,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 38,
              "text_snippet": "PK Blood Samples of DS-1062a | Full PK Sampling | C1 BI X, C1 EOI Xb"
            }
          },
          {
            "schedule_id": "COL-016",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Full PK, C1D2, D4, D8, D15",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C1D2, C1D4, C1D8, C1D15",
            "collection_window": {
              "value": 1,
              "unit": "day",
              "description": "\u00b11 day for D4, D8, D15; \u00b12 hours for D2"
            },
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 8.1",
              "page_number": 122,
              "text_snippet": "Full Sampling Pharmacokinetic Cohort... Days 2, 4, 8, 15 | 24 hours (\u00b12 hours) after Day 1 infusion start, 3 days (\u00b11 day) after Day 1 infusion start, 7 days (\u00b11 day) after Day 1 infusion start, 14 days (\u00b11 day) after Day 1 infusion start"
            }
          },
          {
            "schedule_id": "COL-017",
            "specimen_ref": "SPEC-008",
            "timepoint_name": "Full PK, C2D1, C3D1, C4D1, C6D1, C8D1",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C2D1, C3D1, C4D1, C6D1, C8D1",
            "collection_window": null,
            "number_of_samples": 2,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 8.1",
              "page_number": 122,
              "text_snippet": "Cycles 2, 3, 4, 6, 8 | Day 1 (\u00b1 2) | Pre-dose: Within 8 hours before infusion, Post-dose: Within 1 hour after end of infusion"
            }
          },
          {
            "schedule_id": "COL-018",
            "specimen_ref": "SPEC-009",
            "timepoint_name": "C1D1 pre-dose",
            "timepoint_type": "treatment_initiation",
            "relative_time": "C1D1",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 34,
              "text_snippet": "Immunogenicity | ADA Sample | SCR Xf"
            }
          },
          {
            "schedule_id": "COL-019",
            "specimen_ref": "SPEC-009",
            "timepoint_name": "C1D15",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C1D15",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 34,
              "text_snippet": "Immunogenicity | ADA Sample | C1 Day 15 X"
            }
          },
          {
            "schedule_id": "COL-020",
            "specimen_ref": "SPEC-009",
            "timepoint_name": "C2D15",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C2D15",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 34,
              "text_snippet": "Immunogenicity | ADA Sample | C2 Day 15 X"
            }
          },
          {
            "schedule_id": "COL-021",
            "specimen_ref": "SPEC-009",
            "timepoint_name": "C3D15",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C3D15",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.1",
              "page_number": 34,
              "text_snippet": "Immunogenicity | ADA Sample | C3 Day 15 X"
            }
          },
          {
            "schedule_id": "COL-022",
            "specimen_ref": "SPEC-009",
            "timepoint_name": "C4D1 and subsequent cycles",
            "timepoint_type": "treatment_cycle",
            "relative_time": "C4D1, C6D1, C8D1, C12D1, etc.",
            "collection_window": null,
            "number_of_samples": 1,
            "fasting_required": null,
            "provenance": {
              "section_number": "Table 1.2",
              "page_number": 45,
              "text_snippet": "ADA Sample | Xg | Comments: g Every 2 cycles from C4 to C8 (ie, C4, C6, and C8) then every 4 cycles from C8 to EOT (ie, C8, C12, C16, etc.)"
            }
          }
        ],
        "processing_requirements": [
          {
            "process_id": "PROC-001",
            "specimen_ref": "SPEC-001",
            "process_name": "Fixation and Embedding",
            "process_description": "Tissue samples to be formalin-fixed and paraffin-embedded (FFPE).",
            "provenance": {
              "section_number": "8.1",
              "page_number": 106,
              "text_snippet": "collection during the Screening Period using Sponsor-provided neutral-buffered formalin in kits is preferred to standardize tissue fixation for subsequent analysis. Previously collected tissue samples from surgery, endoscopy, or core needle biopsy already collected and formalin-fixed paraffin-embedded may be used."
            }
          },
          {
            "process_id": "PROC-002",
            "specimen_ref": [
              "SPEC-002",
              "SPEC-003",
              "SPEC-004",
              "SPEC-005",
              "SPEC-006",
              "SPEC-007",
              "SPEC-008",
              "SPEC-009"
            ],
            "process_name": "Standard Processing",
            "process_description": "Processing as per Laboratory Manual.",
            "provenance": {
              "section_number": "8.6.2",
              "page_number": 123,
              "text_snippet": "Biomarker samples will be shipped to a central laboratory. Sample collection, preparation, handling, storage, and shipping instructions are provided in the Laboratory Manual."
            }
          }
        ],
        "storage_requirements": [
          {
            "storage_id": "STOR-001",
            "specimen_ref": "SPEC-002",
            "storage_duration": {
              "value": 15,
              "unit": "years",
              "description": "Maximum of 15 years after the finalization of the CSR."
            },
            "storage_temperature": null,
            "provenance": {
              "section_number": "8.6.5.1",
              "page_number": 125,
              "text_snippet": "Banked DNA samples will be stored for a maximum of 15 years after the finalization of the CSR for this protocol. These specimens will be kept for pharmacogenetic analysis in case new genomic or genetic information is obtained in the future..."
            }
          },
          {
            "storage_id": "STOR-002",
            "specimen_ref": [
              "SPEC-001",
              "SPEC-003",
              "SPEC-004",
              "SPEC-005",
              "SPEC-006",
              "SPEC-007",
              "SPEC-008",
              "SPEC-009"
            ],
            "storage_duration": {
              "value": 15,
              "unit": "years",
              "description": "Maximum of 15 years (or according to local regulations) after the finalization of the CSR."
            },
            "storage_temperature": null,
            "provenance": {
              "section_number": "8.6.3",
              "page_number": 124,
              "text_snippet": "If the subject agrees, remaining samples (tumor, blood or other specimen obtained during the study) may be stored for a maximum of 15 years (or according to local regulations) after the finalization of the clinical study report (CSR) for the study at a facility selected by the Sponsor to enable further analysis..."
            }
          }
        ],
        "shipping_requirements": [
          {
            "shipping_id": "SHIP-001",
            "specimen_ref": [
              "SPEC-001",
              "SPEC-002",
              "SPEC-003",
              "SPEC-004",
              "SPEC-005",
              "SPEC-006",
              "SPEC-007",
              "SPEC-008",
              "SPEC-009"
            ],
            "destination": "Central Laboratory",
            "shipping_conditions": "As per Laboratory Manual.",
            "provenance": {
              "section_number": "8.6.2",
              "page_number": 123,
              "text_snippet": "Biomarker samples will be shipped to a central laboratory. Sample collection, preparation, handling, storage, and shipping instructions are provided in the Laboratory Manual."
            }
          }
        ],
        "central_laboratory": {
          "lab_name": null,
          "lab_contact": null,
          "provenance": {
            "section_number": "8.6.2",
            "page_number": 123,
            "text_snippet": "Biomarker samples will be shipped to a central laboratory. Sample collection, preparation, handling, storage, and shipping instructions are provided in the Laboratory Manual."
          }
        },
        "kit_specifications": {
          "kit_description": "Sponsor-provided neutral-buffered formalin in kits for tumor tissue fixation.",
          "provenance": {
            "section_number": "8.1",
            "page_number": 106,
            "text_snippet": "Although baseline fresh biopsies taken from metastatic lesions prior to the date of subject informed consent are acceptable, collection during the Screening Period using Sponsor-provided neutral-buffered formalin in kits is preferred to standardize tissue fixation for subsequent analysis."
          }
        },
        "quality_requirements": null,
        "regulatory_requirements": {
          "informed_consent_required": true,
          "irb_approval_required": true,
          "other_requirements": "Unless restricted by local/site policies or country-specific regulations, blood and tissue collections for exploratory biomarker and pharmacogenomic analyses must be followed.",
          "provenance": {
            "section_number": "8.6",
            "page_number": 122,
            "text_snippet": "Note: Unless restricted by local/site policies or country-specific regulations, blood and tissue collections for exploratory biomarker and pharmacogenomic analyses as described below must be followed, and any deviations from the protocol should be reported as protocol deviations."
          }
        },
        "volume_summary": null,
        "id": "biospecimen-handling-001",
        "instanceType": "BiospecimenHandling",
        "name": "DS1062-A-U301F Biospecimen Handling"
      }
    },
    "laboratorySpecifications": {
      "moduleId": "laboratory_specifications",
      "instanceType": "LaboratorySpecifications",
      "data": {
        "id": "LS-001",
        "instanceType": "LaboratorySpecifications",
        "name": "Laboratory Specifications for DS1062-A-U301F",
        "description": "Protocol-discovered laboratory testing requirements for the TROPION-LUNG01 study.",
        "central_laboratory": {
          "vendor_name": "Not specified, but central laboratories are used for PK, biomarker, ECG, and imaging assessments.",
          "accreditations": null,
          "data_transfer_method": null,
          "provenance": {
            "section_number": "8.3",
            "page_number": 110,
            "text_snippet": "BICR Radiographic Tumor Assessment \nRadiographic imaging scans will be sent to a central imaging vendor for BICR assessment."
          }
        },
        "discovered_panels": [
          {
            "panel_id": "PNL-001",
            "panel_name": "Hematology",
            "panel_code": null,
            "panel_description": "Standard hematology panel including complete blood count with differential.",
            "panel_category": "hematology",
            "test_count": 11,
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: hemoglobin, hematocrit, platelet count, red blood cell count, WBC count, differential WBC count..."
            }
          },
          {
            "panel_id": "PNL-002",
            "panel_name": "Blood Chemistry",
            "panel_code": null,
            "panel_description": "Comprehensive serum chemistry panel to assess organ function and metabolic status.",
            "panel_category": "chemistry",
            "test_count": 18,
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: albumin, ALT, ALP, AST, bilirubin (total), BUN, Urea, calcium, chloride, creatinine..."
            }
          },
          {
            "panel_id": "PNL-003",
            "panel_name": "Coagulation",
            "panel_code": null,
            "panel_description": "Panel to assess blood clotting function.",
            "panel_category": "coagulation",
            "test_count": 2,
            "provenance": {
              "section_number": "10.2",
              "page_number": 142,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Coagulation\nAnalytes: prothrombin time INR, partial thromboplastin time and/or activated partial thromboplastin time"
            }
          },
          {
            "panel_id": "PNL-004",
            "panel_name": "Urinalysis",
            "panel_code": null,
            "panel_description": "Abbreviated urinalysis with microscopic analysis if indicated.",
            "panel_category": "urinalysis",
            "test_count": 11,
            "provenance": {
              "section_number": "10.2",
              "page_number": 142,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Urinalysis (abbreviated)\nAnalytes: bilirubin, protein, glucose, nitrites, blood, white blood cells, pH..."
            }
          },
          {
            "panel_id": "PNL-005",
            "panel_name": "Hepatitis Panel",
            "panel_code": null,
            "panel_description": "Screening for Hepatitis B and C viruses.",
            "panel_category": "immunology",
            "test_count": 4,
            "provenance": {
              "section_number": "5.2",
              "page_number": 79,
              "text_snippet": "14. Has an active or uncontrolled hepatitis B and/or hepatitis C infection, is positive for hepatitis B or C virus based on the evaluation of results of tests for hepatitis B (hepatitis B surface antigen [HBsAg], anti-hepatitis B surface antibody [anti-HBs], anti-hepatitis B core antibody [anti-HBc], or hepatitis B virus [HBV] DNA), and/or hepatitis C infection (as per hepatitis C virus [HCV] RNA) within 28 days of randomization."
            }
          }
        ],
        "laboratory_tests": [
          {
            "test_id": "LAB-001",
            "test_name": "hemoglobin",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: hemoglobin"
            }
          },
          {
            "test_id": "LAB-002",
            "test_name": "hematocrit",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: hematocrit"
            }
          },
          {
            "test_id": "LAB-003",
            "test_name": "platelet count",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: platelet count"
            }
          },
          {
            "test_id": "LAB-004",
            "test_name": "red blood cell count",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: red blood cell count"
            }
          },
          {
            "test_id": "LAB-005",
            "test_name": "WBC count",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: WBC count"
            }
          },
          {
            "test_id": "LAB-006",
            "test_name": "basophils",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: differential WBC count: basophils"
            }
          },
          {
            "test_id": "LAB-007",
            "test_name": "eosinophils",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: differential WBC count: eosinophils"
            }
          },
          {
            "test_id": "LAB-008",
            "test_name": "lymphocytes",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: differential WBC count: lymphocytes"
            }
          },
          {
            "test_id": "LAB-009",
            "test_name": "monocytes",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: differential WBC count: monocytes"
            }
          },
          {
            "test_id": "LAB-010",
            "test_name": "neutrophils",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Hematology\nAnalytes: differential WBC count: neutrophils"
            }
          },
          {
            "test_id": "LAB-011",
            "test_name": "absolute neutrophil count",
            "panel_ref": "PNL-001",
            "specimen_type": "whole_blood",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "3. Absolute neutrophil count \u22651500/mm3 (granulocyte-colony stimulating factor [G-CSF] administration is not allowed within 1 week prior to Screening assessment)."
            }
          },
          {
            "test_id": "LAB-012",
            "test_name": "albumin",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: albumin"
            }
          },
          {
            "test_id": "LAB-013",
            "test_name": "ALT",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: ALT"
            }
          },
          {
            "test_id": "LAB-014",
            "test_name": "ALP",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: ALP"
            }
          },
          {
            "test_id": "LAB-015",
            "test_name": "AST",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: AST"
            }
          },
          {
            "test_id": "LAB-016",
            "test_name": "bilirubin (total)",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: bilirubin (total)"
            }
          },
          {
            "test_id": "LAB-017",
            "test_name": "BUN",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: BUN"
            }
          },
          {
            "test_id": "LAB-018",
            "test_name": "Urea",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: Urea (if BUN is not available)"
            }
          },
          {
            "test_id": "LAB-019",
            "test_name": "calcium",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: calcium"
            }
          },
          {
            "test_id": "LAB-020",
            "test_name": "chloride",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: chloride"
            }
          },
          {
            "test_id": "LAB-021",
            "test_name": "creatinine",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: creatinine"
            }
          },
          {
            "test_id": "LAB-022",
            "test_name": "cholesterol (total)",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: cholesterol (total)"
            }
          },
          {
            "test_id": "LAB-023",
            "test_name": "creatine phosphokinase",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: creatine phosphokinase"
            }
          },
          {
            "test_id": "LAB-024",
            "test_name": "lactate dehydrogenase",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: lactate dehydrogenase"
            }
          },
          {
            "test_id": "LAB-025",
            "test_name": "magnesium",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: magnesium"
            }
          },
          {
            "test_id": "LAB-026",
            "test_name": "potassium",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: potassium"
            }
          },
          {
            "test_id": "LAB-027",
            "test_name": "protein (total)",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: protein (total)"
            }
          },
          {
            "test_id": "LAB-028",
            "test_name": "sodium",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: sodium"
            }
          },
          {
            "test_id": "LAB-029",
            "test_name": "uric acid",
            "panel_ref": "PNL-002",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 141,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Blood Chemistry\nAnalytes: uric acid"
            }
          },
          {
            "test_id": "LAB-030",
            "test_name": "prothrombin time INR",
            "panel_ref": "PNL-003",
            "specimen_type": "plasma",
            "provenance": {
              "section_number": "10.2",
              "page_number": 142,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Coagulation\nAnalytes: prothrombin time INR"
            }
          },
          {
            "test_id": "LAB-031",
            "test_name": "partial thromboplastin time / activated partial thromboplastin time",
            "panel_ref": "PNL-003",
            "specimen_type": "plasma",
            "provenance": {
              "section_number": "10.2",
              "page_number": 142,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Coagulation\nAnalytes: partial thromboplastin time and/or activated partial thromboplastin time"
            }
          },
          {
            "test_id": "LAB-032",
            "test_name": "Urinalysis Dipstick",
            "panel_ref": "PNL-004",
            "specimen_type": "urine",
            "provenance": {
              "section_number": "10.2",
              "page_number": 142,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Urinalysis (abbreviated)\nAnalytes: bilirubin, protein, glucose, nitrites, blood, white blood cells, pH, specific gravity, color, clarity"
            }
          },
          {
            "test_id": "LAB-033",
            "test_name": "Urine Microscopic Analysis",
            "panel_ref": "PNL-004",
            "specimen_type": "urine",
            "clinical_significance": "To be performed if clinically indicated or based on significant abnormal findings from the urine dipstick.",
            "provenance": {
              "section_number": "10.2",
              "page_number": 142,
              "text_snippet": "microscopic analyses: to be performed if clinically indicated or based on significant abnormal findings from the urine dipstick"
            }
          },
          {
            "test_id": "LAB-034",
            "test_name": "Pregnancy Test",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "10.2",
              "page_number": 142,
              "text_snippet": "Table 10.1: Clinical Laboratory Tests\nTest: Pregnancy test (serum or urine)"
            }
          },
          {
            "test_id": "LAB-035",
            "test_name": "HIV Antibody Test",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "8.1",
              "page_number": 107,
              "text_snippet": "Human Immunodeficiency Virus Antibody Test\nPerform an HIV antibody test as required by local regulations or independent Institutional Review Board (IRB)/Ethics Committee (EC)."
            }
          },
          {
            "test_id": "LAB-036",
            "test_name": "Hepatitis B surface antigen (HBsAg)",
            "panel_ref": "PNL-005",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "8.1",
              "page_number": 107,
              "text_snippet": "Hepatitis Screening\nHbsAg and HCV antibody testing must be performed prior to enrollment..."
            }
          },
          {
            "test_id": "LAB-037",
            "test_name": "anti-hepatitis B surface antibody (anti-HBs)",
            "panel_ref": "PNL-005",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "5.2",
              "page_number": 79,
              "text_snippet": "...tests for hepatitis B (hepatitis B surface antigen [HBsAg], anti-hepatitis B surface antibody [anti-HBs], anti-hepatitis B core antibody [anti-HBc]..."
            }
          },
          {
            "test_id": "LAB-038",
            "test_name": "anti-hepatitis B core antibody (anti-HBc)",
            "panel_ref": "PNL-005",
            "specimen_type": "serum",
            "provenance": {
              "section_number": "5.2",
              "page_number": 79,
              "text_snippet": "...tests for hepatitis B (hepatitis B surface antigen [HBsAg], anti-hepatitis B surface antibody [anti-HBs], anti-hepatitis B core antibody [anti-HBc]..."
            }
          },
          {
            "test_id": "LAB-039",
            "test_name": "Hepatitis C virus (HCV) RNA",
            "panel_ref": "PNL-005",
            "specimen_type": "serum",
            "clinical_significance": "To be tested if HCV antibody is positive.",
            "provenance": {
              "section_number": "8.1",
              "page_number": 107,
              "text_snippet": "HbsAg and HCV antibody testing must be performed prior to enrollment (if HCV antibody is positive, test HCV RNA)."
            }
          },
          {
            "test_id": "LAB-040",
            "test_name": "COVID-19 Test",
            "specimen_type": "serum",
            "special_handling": "Serum samples will be collected prior to study drug infusion, shipped to a central laboratory, and stored there until the tests become available.",
            "provenance": {
              "section_number": "10.7",
              "page_number": 158,
              "text_snippet": "Serum samples will be used for COVID-19 testing from each subject who provides consent, unless prohibited by local restrictions. Samples will be collected prior to the study drug infusion, shipped to a central laboratory, and stored there until the tests become available."
            }
          }
        ],
        "testing_schedule": [
          {
            "schedule_id": "SCH-001",
            "test_or_panel_ref": "PNL-001",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Up to 28 days prior to randomization"
              },
              {
                "timepoint_name": "Cycle 1-3, Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72h before infusion"
              },
              {
                "timepoint_name": "Cycle 4+, Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72h before infusion"
              },
              {
                "timepoint_name": "End of Treatment",
                "timepoint_type": "follow_up"
              },
              {
                "timepoint_name": "28-Day Safety Follow-up",
                "timepoint_type": "follow_up"
              }
            ],
            "frequency": "At screening, prior to each cycle, at EOT, and at 28-day safety follow-up.",
            "provenance": {
              "section_number": "1.3",
              "page_number": 32,
              "text_snippet": "Table 1.1: Schedule of Events for Screening and Cycles 1 through 3 of the Treatment Period. Assessment: Hematology. SCR: X, Cycle 1-3 Day 1: X."
            }
          },
          {
            "schedule_id": "SCH-002",
            "test_or_panel_ref": "PNL-002",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "window": "Up to 28 days prior to randomization"
              },
              {
                "timepoint_name": "Cycle 1-3, Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72h before infusion"
              },
              {
                "timepoint_name": "Cycle 4+, Day 1",
                "timepoint_type": "treatment",
                "window": "Within 72h before infusion"
              },
              {
                "timepoint_name": "End of Treatment",
                "timepoint_type": "follow_up"
              },
              {
                "timepoint_name": "28-Day Safety Follow-up",
                "timepoint_type": "follow_up"
              }
            ],
            "frequency": "At screening, prior to each cycle, at EOT, and at 28-day safety follow-up.",
            "provenance": {
              "section_number": "1.3",
              "page_number": 32,
              "text_snippet": "Table 1.1: Schedule of Events for Screening and Cycles 1 through 3 of the Treatment Period. Assessment: Clinical Chemistry. SCR: X, Cycle 1-3 Day 1: X."
            }
          },
          {
            "schedule_id": "SCH-003",
            "test_or_panel_ref": "PNL-003",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening"
              }
            ],
            "frequency": "At Screening only.",
            "provenance": {
              "section_number": "1.3",
              "page_number": 32,
              "text_snippet": "Table 1.1: Schedule of Events for Screening and Cycles 1 through 3 of the Treatment Period. Assessment: Coagulation. SCR: X."
            }
          },
          {
            "schedule_id": "SCH-004",
            "test_or_panel_ref": "PNL-004",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening"
              },
              {
                "timepoint_name": "During Treatment",
                "timepoint_type": "treatment",
                "conditions": "As clinically indicated"
              }
            ],
            "frequency": "At Screening and as clinically indicated during treatment.",
            "provenance": {
              "section_number": "1.3",
              "page_number": 32,
              "text_snippet": "Table 1.1: Schedule of Events for Screening and Cycles 1 through 3 of the Treatment Period. Assessment: Urinalysis. SCR: X. Cycles 1-3: As clinically indicated."
            }
          },
          {
            "schedule_id": "SCH-005",
            "test_or_panel_ref": "LAB-034",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening"
              },
              {
                "timepoint_name": "Each Cycle",
                "timepoint_type": "treatment",
                "window": "Within 72h before infusion"
              },
              {
                "timepoint_name": "End of Treatment",
                "timepoint_type": "follow_up"
              },
              {
                "timepoint_name": "28-Day Safety Follow-up",
                "timepoint_type": "follow_up"
              }
            ],
            "frequency": "At screening, before each cycle, at EOT, and at 28-day safety follow-up for female subjects of childbearing potential.",
            "provenance": {
              "section_number": "8.4.2",
              "page_number": 119,
              "text_snippet": "Repeat pregnancy tests (urine or serum per institutional guidelines) must be performed 72 hours before infusion at each cycle, at the EOT visit, and at the 28-Day Safety Follow-up visit."
            }
          },
          {
            "schedule_id": "SCH-006",
            "test_or_panel_ref": "LAB-035",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening",
                "conditions": "If required by local regulations or IRB/EC."
              }
            ],
            "frequency": "At Screening, if required.",
            "provenance": {
              "section_number": "1.3",
              "page_number": 33,
              "text_snippet": "Table 1.1: Schedule of Events... Assessment: HIV Ab Test. SCR: X. Comments: If required by local regulations or IRB/EC, subject should be tested for HIV prior to randomization."
            }
          },
          {
            "schedule_id": "SCH-007",
            "test_or_panel_ref": "PNL-005",
            "timepoints": [
              {
                "timepoint_name": "Screening",
                "timepoint_type": "screening"
              }
            ],
            "frequency": "At Screening.",
            "provenance": {
              "section_number": "1.3",
              "page_number": 33,
              "text_snippet": "Table 1.1: Schedule of Events... Assessment: HBsAg, HCV Ab (if HCV Ab is positive, test HCV-RNA). SCR: X."
            }
          },
          {
            "schedule_id": "SCH-008",
            "test_or_panel_ref": "LAB-040",
            "timepoints": [
              {
                "timepoint_name": "Cycle 1 Day 1",
                "timepoint_type": "treatment"
              },
              {
                "timepoint_name": "Every 3 cycles thereafter",
                "timepoint_type": "treatment"
              }
            ],
            "frequency": "Collected prior to DS-1062a or docetaxel infusion on Cycle 1 Day 1 and every 3 cycles thereafter.",
            "provenance": {
              "section_number": "1.2",
              "page_number": 44,
              "text_snippet": "Table 1.2: Schedule of Events... Assessment: COVID-19 Sample. Comments: Unless prohibited by local restrictions, if subject provides consent, serum samples should be collected prior to DS-1062a or docetaxel infusion. Sample on Cycle 1 Day 1 and every 3 cycles thereafter."
            }
          }
        ],
        "sample_collection_requirements": {
          "fasting_requirements": "Not specified for routine safety labs.",
          "timing_requirements": "Safety labs to be collected within 72 hours before infusion at each cycle.",
          "processing_requirements": "To be performed by local laboratory for safety tests. Central lab processing for PK and biomarkers as per Laboratory Manual.",
          "storage_requirements": "As per Laboratory Manual for central lab samples.",
          "shipping_requirements": "As per Laboratory Manual for central lab samples.",
          "provenance": {
            "section_number": "1.3",
            "page_number": 32,
            "text_snippet": "Comments for Hematology and Clinical Chemistry: Screening data may be used as C1D1 data if obtained within 72 h of administration of DS-1062a or docetaxel. Within 72 h before administration of DS-1062a or docetaxel."
          }
        },
        "lab_based_dose_modifications": [
          {
            "modification_id": "MOD-001",
            "parameter_name": "Neutrophil Count / White Blood Cell Count",
            "trigger_condition": "Grade 3 (ANC <1.0-0.5 \u00d7 10^9/L; WBC <2.0-1.0 \u00d710^9/L)",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 2, then maintain dose.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 89,
              "text_snippet": "Grade 3 (ANC defined as <1.0-0.5 \u00d7 10^9/L; WBC defined as <2.0-1.0 \u00d710^9/L): Delay dose until resolved to \u2264Grade 2, then maintain dose."
            }
          },
          {
            "modification_id": "MOD-002",
            "parameter_name": "Neutrophil Count / White Blood Cell Count",
            "trigger_condition": "Grade 4 (ANC <0.5 \u00d710^9/L; WBC <1.0 \u00d7 10^9/L) resolving in \u226414 days",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 2, then maintain dose.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 89,
              "text_snippet": "Grade 4... Delay dose until resolved to \u2264Grade 2: If resolved in \u226414 days from day of onset, maintain dose."
            }
          },
          {
            "modification_id": "MOD-003",
            "parameter_name": "Neutrophil Count / White Blood Cell Count",
            "trigger_condition": "Grade 4 (ANC <0.5 \u00d710^9/L; WBC <1.0 \u00d7 10^9/L) resolving in >14 days",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 2, then reduce dose by 1 level.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 89,
              "text_snippet": "Grade 4... Delay dose until resolved to \u2264Grade 2: ... If resolved in >14 days from day of onset, reduce dose by 1 level."
            }
          },
          {
            "modification_id": "MOD-004",
            "parameter_name": "Febrile Neutropenia",
            "trigger_condition": "Grade 3",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved, then reduce dose by 1 level.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 89,
              "text_snippet": "Febrile Neutropenia Grade 3: Delay dose until resolved, then reduce dose by 1 level."
            }
          },
          {
            "modification_id": "MOD-005",
            "parameter_name": "Febrile Neutropenia",
            "trigger_condition": "Grade 4",
            "required_action": "dose_discontinue",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 89,
              "text_snippet": "Febrile Neutropenia Grade 4: Discontinue subject from study treatment."
            }
          },
          {
            "modification_id": "MOD-006",
            "parameter_name": "Lymphocyte Count",
            "trigger_condition": "Grade 4 resolving in >14 days",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 2, then reduce dose by 1 level.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 90,
              "text_snippet": "Lymphocyte Count Decreased Grade 4: Delay dose until resolved to \u2264Grade 2: ... If resolved in >14 days from day of onset, reduce dose by 1 level."
            }
          },
          {
            "modification_id": "MOD-007",
            "parameter_name": "Anaemia",
            "trigger_condition": "Grade 3",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 2, then maintain dose.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 90,
              "text_snippet": "Anaemia Grade 3: Delay dose until resolved to \u2264Grade 2, then maintain dose."
            }
          },
          {
            "modification_id": "MOD-008",
            "parameter_name": "Anaemia",
            "trigger_condition": "Grade 4",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 2, then reduce dose by 1 level.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 90,
              "text_snippet": "Anaemia Grade 4: Delay dose until resolved to \u2264Grade 2, then reduce dose by 1 level."
            }
          },
          {
            "modification_id": "MOD-009",
            "parameter_name": "Platelet Count",
            "trigger_condition": "Grade 3 resolving in >7 days",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 1, then reduce dose by 1 level.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 90,
              "text_snippet": "Platelet Count Decreased Grade 3: Delay dose until resolved to \u2264Grade 1: ... If resolved in >7 days from day of onset, reduce dose by 1 level."
            }
          },
          {
            "modification_id": "MOD-010",
            "parameter_name": "Platelet Count",
            "trigger_condition": "Grade 4",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 1, then reduce dose by 1 level.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 90,
              "text_snippet": "Platelet Count Decreased Grade 4: Delay dose until resolved to \u2264Grade 1, then reduce dose by 1 level."
            }
          },
          {
            "modification_id": "MOD-011",
            "parameter_name": "AST/ALT and Total Bilirubin (Hy's Law)",
            "trigger_condition": "AST/ALT \u22653.0 \u00d7 ULN with simultaneous total bilirubin >2.0 \u00d7 ULN",
            "required_action": "dose_discontinue",
            "recovery_criteria": "Permanently discontinue study treatment if drug-induced liver injury cannot be ruled out.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 93,
              "text_snippet": "AST/ALT \u22653.0 \u00d7 ULN with simultaneous total bilirubin >2.0 \u00d7 ULN: ... If drug-induced liver injury cannot be ruled out from diagnostic workup, permanently discontinue study treatment."
            }
          },
          {
            "modification_id": "MOD-012",
            "parameter_name": "AST or ALT",
            "trigger_condition": "Grade 3 (>5.0 \u2013 20.0 \u00d7 ULN)",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 1 if baseline \u22643 \u00d7 ULN, otherwise delay dose until resolved to \u2264baseline, then reduce by 1 level.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 94,
              "text_snippet": "Grade 3 (>5.0 \u2013 20.0 \u00d7 ULN...): Repeat testing within 3 days. Delay dose until resolved to \u2264Grade 1 if baseline \u22643 \u00d7 ULN, otherwise delay dose until resolved to \u2264baseline, then reduce by 1 level."
            }
          },
          {
            "modification_id": "MOD-013",
            "parameter_name": "AST or ALT",
            "trigger_condition": "Grade 4 (>20.0 \u00d7 ULN)",
            "required_action": "dose_discontinue",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 94,
              "text_snippet": "Grade 4 (>20.0 \u00d7 ULN...): Discontinue subject from study treatment."
            }
          },
          {
            "modification_id": "MOD-014",
            "parameter_name": "Total Bilirubin",
            "trigger_condition": "Grade 2 (>1.5 \u2013 3.0 \u00d7 ULN) without Gilbert's/liver mets, resolving in >7 days",
            "required_action": "dose_hold",
            "recovery_criteria": "Delay dose until resolved to \u2264Grade 1, then reduce dose by 1 level.",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 94,
              "text_snippet": "Grade 2 (>1.5 \u2013 3.0 \u00d7 ULN...): If no documented Gilbert\u2019s syndrome or liver metastases at baseline, delay dose until resolved to \u2264Grade 1: ... If resolved in >7 days from day of onset, reduce dose by 1 level."
            }
          },
          {
            "modification_id": "MOD-015",
            "parameter_name": "Total Bilirubin",
            "trigger_condition": "Grade 3 (>3.0 \u2013 10.0 \u00d7 ULN) without Gilbert's/liver mets, resolving in >7 days",
            "required_action": "dose_discontinue",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 95,
              "text_snippet": "Grade 3 (>3.0 \u2013 10.0 \u00d7 ULN...): If no documented Gilbert\u2019s syndrome or liver metastases at baseline... If resolved in >7 days from day of onset, discontinue DS-1062a."
            }
          },
          {
            "modification_id": "MOD-016",
            "parameter_name": "Total Bilirubin",
            "trigger_condition": "Grade 4 (>10.0 \u00d7 ULN)",
            "required_action": "dose_discontinue",
            "provenance": {
              "section_number": "Table 6.4",
              "page_number": 95,
              "text_snippet": "Grade 4 (>10.0 \u00d7 ULN...): Discontinue subject from study treatment."
            }
          }
        ],
        "eligibility_lab_criteria": [
          {
            "criteria_id": "ELIG-001",
            "criteria_type": "inclusion",
            "parameter_name": "Platelet count",
            "condition": "Platelet count \u2265100,000/mm\u00b3 (platelet transfusion is not allowed within 1 week prior to Screening assessment)",
            "operator": "gte",
            "threshold_value": 100000,
            "threshold_unit": "/mm^3",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "1. Platelet count \u2265100,000/mm3 (platelet transfusion is not allowed within 1 week prior to Screening assessment)"
            }
          },
          {
            "criteria_id": "ELIG-002",
            "criteria_type": "inclusion",
            "parameter_name": "Hemoglobin",
            "condition": "Hemoglobin \u22659.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to Screening assessment)",
            "operator": "gte",
            "threshold_value": 9.0,
            "threshold_unit": "g/dL",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "2. Hemoglobin \u22659.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to Screening assessment)"
            }
          },
          {
            "criteria_id": "ELIG-003",
            "criteria_type": "inclusion",
            "parameter_name": "Absolute neutrophil count",
            "condition": "Absolute neutrophil count \u22651500/mm\u00b3 (G-CSF administration is not allowed within 1 week prior to Screening assessment)",
            "operator": "gte",
            "threshold_value": 1500,
            "threshold_unit": "/mm^3",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "3. Absolute neutrophil count \u22651500/mm3 (granulocyte-colony stimulating factor [G-CSF] administration is not allowed within 1 week prior to Screening assessment)."
            }
          },
          {
            "criteria_id": "ELIG-004",
            "criteria_type": "inclusion",
            "parameter_name": "AST and ALT",
            "condition": "AST and ALT \u22642.5 \u00d7 ULN (or AST and ALT \u22645.0 \u00d7 ULN if transferase elevation is due to liver metastases)",
            "operator": "lte",
            "threshold_value": 2.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \u22642.5 \u00d7 upper limit of normal (ULN) or AST and ALT \u22645.0 \u00d7 ULN if transferase elevation is due to liver metastases) AND"
            }
          },
          {
            "criteria_id": "ELIG-005",
            "criteria_type": "inclusion",
            "parameter_name": "Total bilirubin",
            "condition": "Total bilirubin \u22641.5 \u00d7 ULN (or <3.0 \u00d7 ULN in the presence of documented Gilbert\u2019s syndrome or liver metastases at baseline)",
            "operator": "lte",
            "threshold_value": 1.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "2. Total bilirubin \u22641.5 \u00d7 ULN (or <3.0 \u00d7 ULN in the presence of documented Gilbert\u2019s syndrome [unconjugated hyperbilirubinemia] or liver metastases at baseline)."
            }
          },
          {
            "criteria_id": "ELIG-006",
            "criteria_type": "inclusion",
            "parameter_name": "Creatinine clearance",
            "condition": "Creatinine clearance \u226530 mL/min as calculated using the Cockcroft-Gault equation.",
            "operator": "gte",
            "threshold_value": 30,
            "threshold_unit": "mL/min",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "1. Creatinine clearance \u226530 mL/min as calculated using the Cockcroft-Gault equation."
            }
          },
          {
            "criteria_id": "ELIG-007",
            "criteria_type": "inclusion",
            "parameter_name": "LVEF",
            "condition": "Has left ventricular ejection fraction (LVEF) \u226550% by either ECHO or MUGA scan within 28 days before randomization.",
            "operator": "gte",
            "threshold_value": 50,
            "threshold_unit": "%",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "Has left ventricular ejection fraction (LVEF) \u226550% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before randomization."
            }
          },
          {
            "criteria_id": "ELIG-008",
            "criteria_type": "inclusion",
            "parameter_name": "Coagulation",
            "condition": "Adequate blood clotting function defined as INR/prothrombin time and either partial thromboplastin or activated partial thromboplastin time \u22641.5 \u00d7 ULN.",
            "operator": "lte",
            "threshold_value": 1.5,
            "threshold_unit": "xULN",
            "provenance": {
              "section_number": "5.1",
              "page_number": 24,
              "text_snippet": "Has adequate blood clotting function defined as international normalized ratio/prothrombin time and either partial thromboplastin or activated partial thromboplastin time \u22641.5 \u00d7 ULN."
            }
          },
          {
            "criteria_id": "ELIG-009",
            "criteria_type": "exclusion",
            "parameter_name": "Mean QTcF",
            "condition": "Mean QT interval corrected for heart rate using Fridericia\u2019s formula (QTcF) prolongation >470 msec",
            "operator": "gt",
            "threshold_value": 470,
            "threshold_unit": "msec",
            "provenance": {
              "section_number": "5.2",
              "page_number": 25,
              "text_snippet": "1. Mean QT interval corrected for heart rate using Fridericia\u2019s formula (QTcF) prolongation >470 msec (based on the average of Screening triplicate 12-lead electrocardiogram [ECG] determinations)."
            }
          },
          {
            "criteria_id": "ELIG-010",
            "criteria_type": "exclusion",
            "parameter_name": "LVEF",
            "condition": "LVEF <50% by ECHO or MUGA scan within 28 days before randomization.",
            "operator": "lt",
            "threshold_value": 50,
            "threshold_unit": "%",
            "provenance": {
              "section_number": "5.2",
              "page_number": 25,
              "text_snippet": "5. LVEF <50% by ECHO or MUGA scan within 28 days before randomization."
            }
          },
          {
            "criteria_id": "ELIG-011",
            "criteria_type": "exclusion",
            "parameter_name": "Hepatitis B or C",
            "condition": "Has an active or uncontrolled hepatitis B and/or hepatitis C infection.",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "provenance": {
              "section_number": "5.2",
              "page_number": 79,
              "text_snippet": "14. Has an active or uncontrolled hepatitis B and/or hepatitis C infection, is positive for hepatitis B or C virus..."
            }
          },
          {
            "criteria_id": "ELIG-012",
            "criteria_type": "exclusion",
            "parameter_name": "HIV",
            "condition": "Has known human immunodeficiency virus (HIV) infection that is not well controlled (defined as detectable viral RNA load, CD4+ counts/levels <=250, history of AIDS-defining opportunistic infection within 12 months, or not stable on anti-HIV retroviral medications).",
            "operator": null,
            "threshold_value": null,
            "threshold_unit": null,
            "provenance": {
              "section_number": "5.2",
              "page_number": 79,
              "text_snippet": "13. Has known human immunodeficiency virus (HIV) infection that is not well controlled. All the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load, CD4+ counts/levels >250, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on same anti-HIV retroviral medications."
            }
          }
        ],
        "critical_value_reporting": {
          "notification_timeline": "Not explicitly defined, but certain events like SAEs and potential Hy's Law require reporting within 24 hours of awareness.",
          "notification_recipients": [
            "Sponsor"
          ],
          "documentation_requirements": "Events to be reported in the electronic data capture (EDC) system.",
          "critical_value_list": [],
          "provenance": {
            "section_number": "8.4.1.1",
            "page_number": 113,
            "text_snippet": "The following types of events should be reported by the Investigator in the electronic data capture (EDC) within 24 hours of awareness: SAEs, Hepatic events... that meet potential Hy\u2019s Law criteria, All potential ILD/pneumonitis cases..."
          }
        },
        "abnormal_result_grading": {
          "grading_system": "NCI-CTCAE",
          "grading_version": "v5.0",
          "clinically_significant_threshold": "Any abnormal laboratory value considered clinically significant by the Investigator should be recorded on the AE page of the eCRF.",
          "ae_reporting_threshold": "Grade 3 or 4",
          "provenance": {
            "section_number": "8.4.3",
            "page_number": 119,
            "text_snippet": "All laboratory values must be appraised by the Investigator as to clinical significance... All abnormal laboratory values considered clinically significant by the Investigator should be recorded on the AE page of the eCRF... Abnormal laboratory values (NCI-CTCAE Grade 3 or 4) occurring during the clinical study will be followed..."
          }
        },
        "pregnancy_testing": {
          "required": true,
          "applicable_population": "Female subjects of childbearing potential.",
          "test_type": "serum, urine",
          "timing": "At Screening (serum), within 72 hours before Cycle 1 Day 1, within 72 hours before each subsequent cycle, at EOT, and at the 28-Day Safety Follow-up visit.",
          "sensitivity": "Not specified.",
          "action_if_positive": "A positive urine pregnancy test must immediately be confirmed using a serum test.",
          "provenance": {
            "section_number": "8.4.2",
            "page_number": 118,
            "text_snippet": "For women of childbearing potential... document the results of a negative serum pregnancy test. ... Within 72 hours before Cycle 1 Day 1, a pregnancy test (urine/serum per institutional procedures) must be done for all female subjects of childbearing potential... Repeat pregnancy tests... must be performed 72 hours before infusion at each cycle, at the EOT visit, and at the 28-Day Safety Follow-up visit. A positive urine pregnancy test must immediately be confirmed using a serum test."
          }
        },
        "pharmacokinetic_samples": {
          "pk_sampling_required": true,
          "analytes": [
            "DS-1062a ADC",
            "total anti-TROP2 antibody",
            "MAAA-1181a"
          ],
          "sample_type": "blood",
          "timepoints_description": "Samples collected for two cohorts: Full PK (~20 subjects) and Sparse PK (all other subjects). For Full PK cohort, Cycle 1 includes pre-dose, and post-dose at 30min, 3h, 5h, 7h, 24h, 3d, 7d, 14d. Sparse PK cohort has a reduced schedule. Subsequent cycles have pre-dose and post-dose samples. A sample is also collected upon suspicion of ILD/pneumonitis.",
          "volume_per_sample": "Not specified.",
          "processing_requirements": "To be detailed in the Laboratory Manual.",
          "provenance": {
            "section_number": "8.5",
            "page_number": 121,
            "text_snippet": "Blood samples for PK analyses of DS-1062a will be obtained from subjects receiving DS-1062a based on the Schedules of Events (Table 1.1 and Table 1.2) at time points outlined in Table 8.1. In addition, a blood sample for PK will be collected as soon as ILD/pneumonitis is suspected in a subject. ... Plasma concentration-time profiles of the 3 analytes (DS-1062a ADC, total anti-TROP2 antibody, and MAAA-1181a) will be established from blood PK samples..."
          }
        },
        "biomarker_samples": {
          "biomarker_sampling_required": true,
          "biomarkers": [
            {
              "name": "Cell-free DNA (cfDNA)",
              "purpose": "Assess changes in tumor mutations or other genomic alterations in response to treatment.",
              "sample_type": "blood",
              "timing": "Specified in Schedule of Events.",
              "provenance": {
                "section_number": "8.6.1",
                "page_number": 123,
                "text_snippet": "Cell-free DNA from blood samples collected during the study to assess changes in tumor mutations or other genomic alterations in response to treatment will be analyzed..."
              }
            },
            {
              "name": "ILD predictive biomarkers",
              "purpose": "Assess biomarkers predictive of ILD.",
              "sample_type": "plasma, serum",
              "timing": "Specified in Schedule of Events and at time of suspected ILD onset.",
              "provenance": {
                "section_number": "8.6.1",
                "page_number": 123,
                "text_snippet": "Plasma and serum will be collected at the time points specified in the Schedules of Events (Table 1.1 and Table 1.2) and at the time of suspected ILD onset. Samples may be analyzed to assess biomarkers predictive of ILD."
              }
            },
            {
              "name": "Liquid biopsy",
              "purpose": "Identify subjects who are likely to derive clinical benefit.",
              "sample_type": "blood",
              "timing": "Specified in Schedule of Events.",
              "provenance": {
                "section_number": "8.6.1",
                "page_number": 123,
                "text_snippet": "A blood sample will be collected at the time point specified in the Schedules of Events to serve as a liquid biopsy to identify subjects who are likely to derive clinical benefit (Table 1.1)."
              }
            },
            {
              "name": "Whole exome/genome sequence control",
              "purpose": "Serve as a control for tissue analysis.",
              "sample_type": "whole_blood",
              "timing": "Cycle 1 Day 1.",
              "provenance": {
                "section_number": "8.6.1",
                "page_number": 123,
                "text_snippet": "A whole blood sample will be collected at the time point specified at Cycle 1 Day 1 to serve as a control for whole exome sequence/whole genome sequence tissue analysis."
              }
            },
            {
              "name": "Tumor tissue biomarkers",
              "purpose": "Investigate the effect of DS-1062a at the molecular and cellular level.",
              "sample_type": "tumor_tissue",
              "timing": "Pre-treatment biopsy required.",
              "provenance": {
                "section_number": "8.6.2",
                "page_number": 123,
                "text_snippet": "Exploratory Biomarker Assessments in Tumor Tissues\nBiomarker analyses will be used to investigate the effect of DS-1062a at the molecular and cellular level..."
              }
            },
            {
              "name": "Pharmacogenomic (inherited genetic) analysis",
              "purpose": "Analyze genes involved in absorption, metabolism, elimination, safety, and efficacy.",
              "sample_type": "blood",
              "timing": "Scheduled for Cycle 1 Day 1 pre-dose but may be collected any time after first dose.",
              "provenance": {
                "section_number": "8.6.5",
                "page_number": 124,
                "text_snippet": "A single blood sample for pharmacogenetic analysis will be collected from each subject. The pharmacogenomic blood sample will be scheduled for Cycle 1 Day 1 pre-dose (see Table 1.1) but may be collected at any time after the first dose of DS-1062a."
              }
            },
            {
              "name": "Antidrug antibody (ADA)",
              "purpose": "Assess immunogenicity.",
              "sample_type": "plasma",
              "timing": "Specified in Schedule of Events.",
              "provenance": {
                "section_number": "8.6.6",
                "page_number": 125,
                "text_snippet": "Immunogenicity\nBlood samples for plasma antidrug antibody (ADA) analyses will be collected from subjects receiving DS-1062a at the time points specified in the Schedules of Events (Table 1.1 and Table 1.2)."
              }
            },
            {
              "name": "TROP2 expression",
              "purpose": "Measure TROP2 expression levels via immunohistochemistry.",
              "sample_type": "tumor_tissue",
              "timing": "Pre-treatment biopsy.",
              "provenance": {
                "section_number": "8.6.4",
                "page_number": 124,
                "text_snippet": "TROP2 Immunohistochemistry Analysis\nTROP2 expression levels may be measured using an immunohistochemistry assay on all tumor biopsy samples collected during this study."
              }
            }
          ],
          "optional_consent_required": true,
          "provenance": {
            "section_number": "8.6",
            "page_number": 122,
            "text_snippet": "8.6. Biomarker and Pharmacodynamic Assessments\nNote: Unless restricted by local/site policies or country-specific regulations, blood and tissue collections for exploratory biomarker and pharmacogenomic analyses as described below must be followed..."
          }
        },
        "local_lab_requirements": {
          "local_lab_allowed": true,
          "allowed_tests": [
            "Hematology",
            "Blood Chemistry",
            "Coagulation",
            "Urinalysis",
            "Pregnancy tests"
          ],
          "certification_requirements": "Not specified.",
          "provenance": {
            "section_number": "10.2",
            "page_number": 141,
            "text_snippet": "The clinical laboratory tests listed in Table 10.1 are to be performed by local laboratory in this study."
          }
        },
        "extraction_statistics": {
          "total_panels_discovered": 5,
          "total_tests_discovered": 40,
          "total_schedule_entries": 8,
          "dose_modification_rules": 16,
          "eligibility_criteria_count": 12,
          "critical_values_defined": 0
        },
        "provenance": {
          "section_number": "8.4.3",
          "page_number": 119,
          "text_snippet": "8.4.3. Clinical Laboratory Evaluations\nClinical laboratory tests including hematology, blood chemistry, and pregnancy tests will be performed as per the Schedules of Events by the local laboratory (Table 1.1 and Table 1.2)."
        }
      }
    },
    "informedConsent": {
      "moduleId": "informed_consent",
      "instanceType": "InformedConsentElements",
      "data": {
        "id": "DS1062-A-U301F-informed-consent",
        "instanceType": "InformedConsentElements",
        "name": "DS1062-A-U301F Informed Consent Elements",
        "description": "ICF content elements for DS1062-A-U301F",
        "study_overview": {
          "study_purpose": "To compare the efficacy and safety of DS-1062a versus docetaxel in subjects with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations, and to demonstrate superiority in terms of either progression-free survival (PFS) or overall survival (OS).",
          "study_duration_for_participant": "Participation involves a Screening Period (up to 28 days), a Treatment Period which continues until disease progression or other discontinuation criteria are met, a 28-day Safety Follow-up period, and a Long-Term Survival Follow-up period where survival status is collected every 3 months until the end of the study.",
          "number_of_visits": null,
          "total_time_commitment": null,
          "number_of_participants": "Approximately 590 eligible subjects will be randomized globally.",
          "study_locations": "The study will be conducted at approximately 190 study sites located in North America, South America, Europe, Australia, and Asia.",
          "provenance": {
            "section_number": "1.1",
            "page_number": 15,
            "text_snippet": "Protocol Title\nPhase 3 Randomized Study Of DS-1062a Versus Docetaxel In Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-Lung01)"
          }
        },
        "study_procedures": {
          "screening_procedures": [
            {
              "procedure_id": "PROC-001",
              "procedure_name": "Informed Consent",
              "description": "Signing the Informed Consent Form (ICF) before any study-specific procedures.",
              "frequency": "Once at the beginning of the Screening Period.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 30,
                "text_snippet": "A signed and dated ICF must be obtained before any study-specific procedures or assessments are initiated."
              }
            },
            {
              "procedure_id": "PROC-002",
              "procedure_name": "Medical History and Demographics Review",
              "description": "Collection of demographic information and review of medical and NSCLC history.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 30,
                "text_snippet": "Assessment: Demographics and Eligibility. Procedures: Demographics, Medical History, NSCLC History. SCR: X"
              }
            },
            {
              "procedure_id": "PROC-003",
              "procedure_name": "Physical Examination",
              "description": "A complete physical examination including height and weight.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 31,
                "text_snippet": "Assessment: Safety. Procedures: Physical Examination and ECOG PS, Height, Weight. SCR: X"
              }
            },
            {
              "procedure_id": "PROC-004",
              "procedure_name": "Vital Signs and Pulse Oximetry (SpO2)",
              "description": "Measurement of temperature, blood pressure, pulse, respiratory rate, and blood oxygen saturation.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 30,
                "text_snippet": "Assessment: Safety. Procedures: Vital Signs, SpO2. SCR: X"
              }
            },
            {
              "procedure_id": "PROC-005",
              "procedure_name": "ECOG Performance Status",
              "description": "Assessment of your ability to perform daily activities.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 31,
                "text_snippet": "Assessment: Safety. Procedure: Physical Examination and ECOG PS. SCR: X"
              }
            },
            {
              "procedure_id": "PROC-006",
              "procedure_name": "Ophthalmologic (Eye) Assessment",
              "description": "Includes visual acuity testing, slit lamp examination, intraocular pressure measurement, fundoscopy, and fluorescein staining.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 31,
                "text_snippet": "Procedure: Ophthalmologic Assessment. SCR: X. Comments: Includes a visual acuity test, intraocular pressure test, slit lamp examination, fundoscopy, and fluorescein staining."
              }
            },
            {
              "procedure_id": "PROC-007",
              "procedure_name": "Electrocardiogram (ECG)",
              "description": "Measurement of the electrical activity of the heart. Performed in triplicate.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 31,
                "text_snippet": "Procedure: 12-Lead ECG. SCR: Xd. Comments: d Within 7 days before randomization. Screening only, taken in triplicate in close succession, no more than 5 min apart, and after at least 5 min of quiet rest in the supine position."
              }
            },
            {
              "procedure_id": "PROC-008",
              "procedure_name": "Cardiac Imaging (ECHO or MUGA scan)",
              "description": "Assessment of heart function, specifically the left ventricular ejection fraction (LVEF).",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 32,
                "text_snippet": "Procedure: ECHO or MUGA (LVEF). SCR: Xe. Comments: e Within 28 days before randomization."
              }
            },
            {
              "procedure_id": "PROC-009",
              "procedure_name": "Blood Tests",
              "description": "Blood samples for hematology, clinical chemistry, and coagulation tests.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 32,
                "text_snippet": "Assessment: Laboratory Assessments. Procedures: Hematology, Clinical Chemistry, Coagulation. SCR: X"
              }
            },
            {
              "procedure_id": "PROC-010",
              "procedure_name": "Urinalysis",
              "description": "Collection of a urine sample for testing.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 32,
                "text_snippet": "Procedure: Urinalysis. SCR: X"
              }
            },
            {
              "procedure_id": "PROC-011",
              "procedure_name": "Pregnancy Test",
              "description": "A serum pregnancy test is required for all female subjects of childbearing potential.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 33,
                "text_snippet": "Procedure: Pregnancy Test. SCR: Xf. Comments: f A negative serum pregnancy test during Screening is required (within 28 days prior to randomization) for all female subjects of childbearing potential."
              }
            },
            {
              "procedure_id": "PROC-012",
              "procedure_name": "Infectious Disease Screening",
              "description": "Testing for HIV, Hepatitis B (HBsAg, anti-HBs, anti-HBc), and Hepatitis C (HCV Ab, HCV-RNA if positive).",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 33,
                "text_snippet": "Procedures: HIV Ab Test; HBsAg, HCV Ab (if HCV Ab is positive, test HCV-RNA). SCR: X"
              }
            },
            {
              "procedure_id": "PROC-013",
              "procedure_name": "Tumor Biopsy",
              "description": "A pre-treatment tumor biopsy procedure is required. Alternatively, a previously collected tumor tissue sample from within the last 2 years may be used.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "5.1",
                "page_number": 75,
                "text_snippet": "7. Must undergo a pre-treatment tumor biopsy procedure. OR If available, tumor tissue previously retrieved from a biopsy procedure performed within 2 years prior to the subject signing informed consent... may be substituted for the pre-treatment biopsy procedure during Screening."
              }
            },
            {
              "procedure_id": "PROC-014",
              "procedure_name": "Biomarker Blood Samples",
              "description": "Collection of blood samples for pharmacogenomic analysis, cell-free DNA (cfDNA), predictive liquid biopsy, WES/WGS control, and ILD biomarkers.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 35,
                "text_snippet": "Procedures: Pharmacogenomics Blood Sample; Blood sample for cfDNA; Blood sample for predictive liquid biopsy; Blood sample for WES/WGS control; Plasma sample for ILD biomarkers; Serum sample for ILD biomarkers. SCR: X"
              }
            },
            {
              "procedure_id": "PROC-015",
              "procedure_name": "Tumor Imaging",
              "description": "CT or MRI scans of the chest, abdomen, and brain. A bone scan is also required if bone metastases are present or suspected.",
              "frequency": "Once during Screening.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 36,
                "text_snippet": "Procedures: CT/MRI of the chest, abdomen, and any other sites of disease; CT/MRI of Brain. SCR: X"
              }
            },
            {
              "procedure_id": "PROC-016",
              "procedure_name": "Patient-Reported Outcome (PRO) Questionnaires",
              "description": "Completion of questionnaires about quality of life and symptoms (EORTC-QLQ-C30, EORTC-QLQ-LC13, EQ-5D-5L, PRO-CTCAE).",
              "frequency": "Once during Screening (at baseline).",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 39,
                "text_snippet": "Procedures: EORTC-QLQ-C30; EORTC-QLQ-LC13; EQ-5D-5L; PRO-CTCAE. SCR: X. Comments: Collected at clinical site at baseline."
              }
            }
          ],
          "treatment_procedures": [
            {
              "procedure_id": "PROC-017",
              "procedure_name": "Randomization",
              "description": "Assignment by chance (like a coin toss) to receive either DS-1062a or docetaxel.",
              "frequency": "Once, after all screening procedures are complete.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "8.2",
                "page_number": 108,
                "text_snippet": "After all Screening procedures are performed, results of Screening tests are available (ie, between the Screening visit and randomization), and subjects are confirmed to meet all eligibility criteria, eligible subjects will be randomized in a 1:1 ratio to DS-1062a 6.0 mg/kg or the control treatment, docetaxel 75 mg/m2."
              }
            },
            {
              "procedure_id": "PROC-018",
              "procedure_name": "Study Drug Administration",
              "description": "Intravenous (IV) infusion of either DS-1062a or docetaxel on Day 1 of each 21-day cycle.",
              "frequency": "Every 3 weeks.",
              "duration": "Approximately 30-90 minutes for DS-1062a; approximately 60 minutes for docetaxel.",
              "is_optional": false,
              "provenance": {
                "section_number": "6.1.1",
                "page_number": 81,
                "text_snippet": "Dosing Instructions/Regimen: One IV infusion every 3 weeks on Day 1 of each 21-day cycle."
              }
            },
            {
              "procedure_id": "PROC-019",
              "procedure_name": "Post-infusion Observation",
              "description": "Monitoring for allergic reactions for at least 30-60 minutes after DS-1062a infusion.",
              "frequency": "After each DS-1062a infusion.",
              "duration": "30-60 minutes.",
              "is_optional": false,
              "provenance": {
                "section_number": "6.1.1",
                "page_number": 81,
                "text_snippet": "Subjects should remain at the site for at least 1-hour post infusion of DS-1062a for close observation for possible allergic reaction. If a subject doesn\u2019t experience any IRR during or after the first 2 cycles, the post-infusion observation period can be shortened to at least 30 minutes for subsequent cycles."
              }
            },
            {
              "procedure_id": "PROC-020",
              "procedure_name": "Ongoing Safety Assessments",
              "description": "Includes physical exams, vital signs, pulse oximetry, ECOG PS, and laboratory tests (hematology, chemistry).",
              "frequency": "At the beginning of each treatment cycle.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 30,
                "text_snippet": "The Schedule of Events table shows Vital Signs, Physical Examination, ECOG PS, Hematology, and Clinical Chemistry are performed at BI (Before Infusion) of each cycle."
              }
            },
            {
              "procedure_id": "PROC-021",
              "procedure_name": "Ongoing Tumor Imaging",
              "description": "CT or MRI scans to assess tumor response.",
              "frequency": "Every 6 weeks.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 36,
                "text_snippet": "Every 6 weeks (\u00b17 days) from randomization until radiographic disease progression as assessed by Investigator, death, lost to follow-up, or withdrawal of consent (regardless of discontinuing study treatment or starting new anticancer therapy)."
              }
            },
            {
              "procedure_id": "PROC-022",
              "procedure_name": "Pharmacokinetic (PK) Blood Samples",
              "description": "Blood draws to measure the amount of study drug in the body. A subset of participants will have more frequent draws.",
              "frequency": "At specified time points during Cycles 1-8.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 38,
                "text_snippet": "Assessment: PK Blood Samples of DS-1062a. Procedures: Sparse PK Sampling, Full PK Sampling. Performed at various timepoints in Cycles 1, 2, and 3."
              }
            },
            {
              "procedure_id": "PROC-023",
              "procedure_name": "Immunogenicity (ADA) Blood Samples",
              "description": "Blood draws to check if the body is making antibodies against DS-1062a.",
              "frequency": "At specified time points for subjects receiving DS-1062a.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 34,
                "text_snippet": "Assessment: Immunogenicity (only in subjects receiving DS-1062a). Procedure: ADA Sample. Performed at BI of Cycle 1, Day 8 of Cycle 1, BI of Cycle 2, etc."
              }
            },
            {
              "procedure_id": "PROC-024",
              "procedure_name": "Ongoing PRO Questionnaires",
              "description": "Completion of questionnaires about quality of life and symptoms.",
              "frequency": "At specified time points during treatment.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 39,
                "text_snippet": "Assessment: PRO Assessments. Procedures: EORTC-QLQ-C30, EORTC-QLQ-LC13, EQ-5D-5L. Collected from home or at the study site on Day 15 (\u00b11 day) of Cycles 1 to 5 and odd cycles thereafter until PD or EOT, whichever comes first."
              }
            },
            {
              "procedure_id": "PROC-025",
              "procedure_name": "Ongoing Pregnancy Tests",
              "description": "Urine or serum pregnancy tests for female subjects of childbearing potential.",
              "frequency": "Before each treatment cycle.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.3",
                "page_number": 33,
                "text_snippet": "For subsequent treatment cycles, repeat pregnancy test (urine/serum per institutional guidelines) within 72 h BI at each cycle, at EOT, and at the 28-Day Safety Follow-up visit."
              }
            }
          ],
          "follow_up_procedures": [
            {
              "procedure_id": "PROC-026",
              "procedure_name": "End of Treatment (EOT) Visit",
              "description": "A final set of assessments after the last dose of study drug, including physical exam, vital signs, labs, ECG, and ophthalmic assessment.",
              "frequency": "Once, approximately 28 days after the last dose.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.2",
                "page_number": 42,
                "text_snippet": "Table 1.2: Schedule of Events for Cycle 4 and Subsequent Cycles of the Treatment Period, End of Treatment, and Follow-up Period. The EOT column lists assessments including Vital Signs, Physical Examination, Weight, Ophthalmologic Assessment, etc."
              }
            },
            {
              "procedure_id": "PROC-027",
              "procedure_name": "Safety Follow-up",
              "description": "Monitoring for adverse events for 28 days after the last dose of study drug.",
              "frequency": "During the 28 days after the last dose.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.1",
                "page_number": 103,
                "text_snippet": "A safety follow-up evaluation should be performed approximately 28 days (+7 days) after the last dose of study drug as described in the Schedule of Events (Table 1.2)."
              }
            },
            {
              "procedure_id": "PROC-028",
              "procedure_name": "Long-Term Survival Follow-up",
              "description": "Contact (e.g., by phone) to check on your health status and any new cancer treatments you may have started.",
              "frequency": "Every 3 months until the end of the study.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "1.2",
                "page_number": 42,
                "text_snippet": "Follow-up: Long-Term Survival Follow-up (Every 3 Months)"
              }
            },
            {
              "procedure_id": "PROC-029",
              "procedure_name": "Post-Treatment Tumor Assessments",
              "description": "For subjects who stop treatment without their cancer progressing, tumor imaging will continue.",
              "frequency": "Every 6 weeks until disease progression is documented.",
              "duration": null,
              "is_optional": false,
              "provenance": {
                "section_number": "7.1",
                "page_number": 102,
                "text_snippet": "Subjects who discontinue study treatment for reasons other than radiographic disease progression will continue to undergo tumor assessments every 6 weeks during the Follow-up Period until radiographic disease progression as assessed by Investigator, death, lost to follow up, or withdrawal of consent."
              }
            }
          ],
          "optional_procedures": [
            {
              "procedure_id": "PROC-030",
              "procedure_name": "Pharmacogenomic (Inherited Genetic) Testing",
              "description": "A single blood sample will be collected to analyze genes that may be involved in how your body processes the study drug or in drug-related side effects.",
              "frequency": "Once, at Cycle 1 Day 1 (or any time after).",
              "duration": null,
              "is_optional": true,
              "provenance": {
                "section_number": "8.6.5",
                "page_number": 124,
                "text_snippet": "A single blood sample for pharmacogenetic analysis will be collected from each subject. The pharmacogenomic blood sample will be scheduled for Cycle 1 Day 1 pre-dose (see Table 1.1) but may be collected at any time after the first dose of DS-1062a."
              }
            },
            {
              "procedure_id": "PROC-031",
              "procedure_name": "Biobanking of Samples",
              "description": "Remaining blood and/or tumor tissue samples may be stored for up to 15 years for future research on cancer and other diseases.",
              "frequency": "N/A",
              "duration": null,
              "is_optional": true,
              "provenance": {
                "section_number": "8.6.3",
                "page_number": 124,
                "text_snippet": "If the subject agrees, remaining samples (tumor, blood or other specimen obtained during the study) may be stored for a maximum of 15 years (or according to local regulations) after the finalization of the clinical study report (CSR) for the study at a facility selected by the Sponsor to enable further analysis..."
              }
            }
          ],
          "provenance": {
            "section_number": "1.3",
            "page_number": 30,
            "text_snippet": "Table 1.1: Schedule of Events for Screening and Cycles 1 through 3 of the Treatment Period"
          }
        },
        "risks": {
          "known_risks": [
            {
              "risk_id": "RISK-001",
              "risk_description": "Interstitial Lung Disease (ILD)/Pneumonitis (inflammation of the lungs)",
              "severity": "severe, life-threatening, fatal",
              "frequency": "uncommon",
              "management": "Requires immediate medical attention, steroid treatment, and may require permanent discontinuation of the study drug. An autopsy may be encouraged in fatal cases.",
              "provenance": {
                "section_number": "8.4.1.2",
                "page_number": 115,
                "text_snippet": "Interstitial Lung Disease/Pneumonitis\nILD/pneumonitis is considered an important identified risk based on a comprehensive cumulative review of the available safety data from the clinical development program..."
              }
            },
            {
              "risk_id": "RISK-002",
              "risk_description": "Infusion-Related Reactions (IRR)",
              "severity": "mild, moderate, severe",
              "frequency": "common",
              "management": "Pre-medication is given to reduce risk. Infusion may be slowed, interrupted, or stopped. Additional medications may be given.",
              "provenance": {
                "section_number": "8.4.1.2",
                "page_number": 116,
                "text_snippet": "Infusion-related Reaction\nIRR is an identified risk. A Grade 3 IRR was reported and was assessed by an external consultant as anaphylaxis."
              }
            },
            {
              "risk_id": "RISK-003",
              "risk_description": "Oral Mucositis/Stomatitis (mouth sores or inflammation)",
              "severity": "mild, moderate, severe",
              "frequency": "very_common",
              "management": "An oral care protocol including special mouth rinses is recommended. Dose modification may be required.",
              "provenance": {
                "section_number": "8.4.1.2",
                "page_number": 117,
                "text_snippet": "Oral Mucositis/Stomatitis\nOral mucositis/stomatitis AEs are considered as identified risks and AESIs associated with DS-1062a treatment."
              }
            },
            {
              "risk_id": "RISK-004",
              "risk_description": "Nausea and Vomiting",
              "severity": "mild, moderate, severe",
              "frequency": "very_common",
              "management": "Anti-nausea medications will be provided. Dose modification may be required for severe cases.",
              "provenance": {
                "section_number": "2.2",
                "page_number": 55,
                "text_snippet": "The most frequent (\u226520% of subjects) TEAEs across all doses, all grades, regardless of dose and causality were: nausea (47%), stomatitis (39%), fatigue (34%), alopecia (34%), decreased appetite (25%), vomiting (23%), and constipation (21%)."
              }
            },
            {
              "risk_id": "RISK-005",
              "risk_description": "Fatigue (tiredness)",
              "severity": "mild, moderate, severe",
              "frequency": "very_common",
              "management": "Rest and supportive care. Dose modification may be required.",
              "provenance": {
                "section_number": "2.3",
                "page_number": 57,
                "text_snippet": "Other identified risks include IRR, fatigue, anaemia, stomatitis/mucosal inflammation, diarrhoea, nausea, decreased appetite, alopecia, vomiting, dry eye, and rash/rash maculopapular."
              }
            },
            {
              "risk_id": "RISK-006",
              "risk_description": "Alopecia (hair loss)",
              "severity": "mild, moderate",
              "frequency": "very_common",
              "management": "Supportive care.",
              "provenance": {
                "section_number": "2.2",
                "page_number": 55,
                "text_snippet": "The most frequent (\u226520% of subjects) TEAEs across all doses, all grades, regardless of dose and causality were: nausea (47%), stomatitis (39%), fatigue (34%), alopecia (34%)..."
              }
            },
            {
              "risk_id": "RISK-007",
              "risk_description": "Decreased Appetite",
              "severity": "mild, moderate, severe",
              "frequency": "very_common",
              "management": "Nutritional support. Dose modification may be required.",
              "provenance": {
                "section_number": "2.2",
                "page_number": 55,
                "text_snippet": "The most frequent (\u226520% of subjects) TEAEs across all doses, all grades, regardless of dose and causality were: ...decreased appetite (25%)..."
              }
            },
            {
              "risk_id": "RISK-008",
              "risk_description": "Anemia (low red blood cells)",
              "severity": "mild, moderate, severe",
              "frequency": "common",
              "management": "Monitoring of blood counts. May require blood transfusion or dose modification.",
              "provenance": {
                "section_number": "2.3",
                "page_number": 57,
                "text_snippet": "Other identified risks include IRR, fatigue, anaemia, stomatitis/mucosal inflammation, diarrhoea, nausea, decreased appetite, alopecia, vomiting, dry eye, and rash/rash maculopapular."
              }
            },
            {
              "risk_id": "RISK-009",
              "risk_description": "Diarrhea",
              "severity": "mild, moderate, severe",
              "frequency": "common",
              "management": "Anti-diarrhea medication and hydration. Dose modification may be required for severe cases.",
              "provenance": {
                "section_number": "2.3",
                "page_number": 57,
                "text_snippet": "Other identified risks include IRR, fatigue, anaemia, stomatitis/mucosal inflammation, diarrhoea, nausea, decreased appetite, alopecia, vomiting, dry eye, and rash/rash maculopapular."
              }
            },
            {
              "risk_id": "RISK-010",
              "risk_description": "Ocular Surface Toxicity (eye problems, e.g., dry eye, blurred vision)",
              "severity": "mild, moderate, severe",
              "frequency": "common",
              "management": "Use of preservative-free artificial tears is recommended. Avoidance of contact lenses. May require ophthalmologist consultation and dose modification.",
              "provenance": {
                "section_number": "8.4.1.2",
                "page_number": 117,
                "text_snippet": "Ocular Surface Toxicity\nOcular surface toxicity (eg, dry eye, keratitis) is considered an AESI associated with DS-1062a. Dry eye is considered as an identified risk and keratitis as a potential risk within this AESI."
              }
            },
            {
              "risk_id": "RISK-011",
              "risk_description": "Rash",
              "severity": "mild, moderate, severe",
              "frequency": "common",
              "management": "Topical or oral medications. Dose modification may be required.",
              "provenance": {
                "section_number": "2.3",
                "page_number": 57,
                "text_snippet": "Other identified risks include IRR, fatigue, anaemia, stomatitis/mucosal inflammation, diarrhoea, nausea, decreased appetite, alopecia, vomiting, dry eye, and rash/rash maculopapular."
              }
            },
            {
              "risk_id": "RISK-012",
              "risk_description": "Decreased white blood cell and platelet counts",
              "severity": "mild, moderate, severe, life-threatening",
              "frequency": "common",
              "management": "Monitoring of blood counts. May require dose delay, dose reduction, or growth factor support.",
              "provenance": {
                "section_number": "6.4",
                "page_number": 89,
                "text_snippet": "Hematologic Toxicity\nNeutrophil Count Decreased and/or White Blood Cell Count Decreased"
              }
            },
            {
              "risk_id": "RISK-013",
              "risk_description": "Increased liver enzymes",
              "severity": "mild, moderate, severe",
              "frequency": "common",
              "management": "Monitoring of blood tests. May require dose delay or reduction.",
              "provenance": {
                "section_number": "2.3",
                "page_number": 57,
                "text_snippet": "The potential risks include keratitis, skin pigmentation, AST increased, ALT increased, and constipation."
              }
            }
          ],
          "potential_risks": [
            "Keratitis (inflammation of the cornea)",
            "Changes in skin pigmentation",
            "Constipation"
          ],
          "reproductive_risks": "The study drugs can cause harm to an unborn baby or a baby who is breastfeeding. Female participants must not be pregnant or breastfeeding and must use highly effective contraception. Male participants must also use contraception to prevent pregnancy in their partners. Donation of eggs or sperm is not permitted during the study and for a period after.",
          "unknown_risks_statement": "Because DS-1062a is an investigational drug, there may be other risks that are currently unknown.",
          "risk_mitigation_measures": "You will be monitored closely for side effects. The study protocol includes specific guidelines for managing side effects, including dose delays, dose reductions, or stopping treatment. Premedication is required before infusions to reduce the risk of infusion reactions. An oral care protocol is recommended to prevent mouth sores. Use of artificial tears is recommended to prevent eye problems.",
          "provenance": {
            "section_number": "2.3",
            "page_number": 57,
            "text_snippet": "Benefit and Risk Assessment\nBased on cumulative review of safety data, important identified risks for DS-1062a are ILD/pneumonitis. Other identified risks include IRR, fatigue, anaemia, stomatitis/mucosal inflammation, diarrhoea, nausea, decreased appetite, alopecia, vomiting, dry eye, and rash/rash maculopapular. The potential risks include keratitis, skin pigmentation, AST increased, ALT increased, and constipation."
          }
        },
        "benefits": {
          "potential_benefits": [
            "The study treatment may help to control or shrink your cancer, but this is not guaranteed."
          ],
          "no_benefit_statement": "There is no guarantee that you will receive any direct medical benefit from participating in this study. Your condition may stay the same, or it may worsen.",
          "societal_benefits": "The information learned from this study may help future patients with non-small cell lung cancer and may help doctors better understand this disease and its treatment.",
          "provenance": {
            "section_number": "2.3",
            "page_number": 57,
            "text_snippet": "Benefit and Risk Assessment\nA total of 208 subjects have been treated with DS-1062a in the ongoing DS1062-A-J101 Phase 1 study. Data from this study show efficacy across dose groups with tumor responses observed at starting doses of 4.0-, 6.0-, and 8.0-mg/kg and an acceptable and manageable toxicity profile."
          }
        },
        "alternatives": {
          "alternative_treatments": [
            {
              "treatment_name": "Standard of Care Therapy",
              "description": "Treatment with other approved cancer drugs, such as docetaxel (which is also the control drug in this study) or other chemotherapy agents."
            },
            {
              "treatment_name": "Other Clinical Trials",
              "description": "Participation in a different research study, if you are eligible."
            },
            {
              "treatment_name": "Best Supportive Care",
              "description": "Care focused on managing symptoms and improving quality of life without specific anti-cancer treatment."
            }
          ],
          "no_treatment_option": true,
          "standard_of_care_description": "For patients whose NSCLC has progressed after prior therapies, docetaxel monotherapy is a widely used treatment. Other options may include different chemotherapy drugs or participation in other clinical trials.",
          "provenance": {
            "section_number": "2.1.2",
            "page_number": 54,
            "text_snippet": "Docetaxel monotherapy remains perhaps the most widely used treatment for patients whose NSCLC has progressed after platinum-based chemotherapy and immune checkpoint inhibitors (in the case of NSCLC without AGA), or targeted therapies (in the case of NSCLC with AGA), consistent with NCCN guidelines."
          }
        },
        "compensation_costs": {
          "participant_compensation": null,
          "payment_schedule": null,
          "travel_reimbursement": null,
          "participant_costs": [],
          "covered_costs": [
            "The investigational drug (DS-1062a) or the comparator drug (docetaxel).",
            "Study-related procedures, tests, and assessments that are performed for research purposes only."
          ],
          "injury_compensation": "The Sponsor provides insurance to make available compensation in case of a study-related injury. The details of this will be described in the informed consent form.",
          "provenance": {
            "section_number": "10.1.7",
            "page_number": 139,
            "text_snippet": "Reimbursement, Indemnity, and Insurance\nThe Sponsor provides insurance for study subjects to make available compensation in case of study-related injury."
          }
        },
        "confidentiality": {
          "data_protection_statement": "Your personal and medical information collected for this study will be kept confidential in accordance with applicable laws. Your identity will not be publicly disclosed.",
          "who_has_access": [
            "The study staff at the research site.",
            "Sponsor representatives (Daiichi Sankyo)",
            "Regulatory authorities (e.g., FDA)",
            "Institutional Review Board (IRB) or Ethics Committee (EC)",
            "Data Monitoring Committee (DMC)"
          ],
          "hipaa_authorization": true,
          "data_retention_period": "At least 2 years after the last marketing approval in an ICH region.",
          "international_data_transfer": true,
          "data_sharing": "De-identified data from this study may be shared with or used by third parties, including commercial partners and other researchers, for future research.",
          "provenance": {
            "section_number": "10.1.3",
            "page_number": 136,
            "text_snippet": "The Investigators and the Sponsor will preserve the confidentiality of all subjects taking part in the study, in accordance with GCP and local regulations... In compliance with ICH GCP Guidelines, it is required that the Investigator and institution permit authorized representatives of the company, of the regulatory agency(s), and the independent IRB/EC direct access to review the subject\u2019s original medical records for verification of study-related procedures and data."
          }
        },
        "voluntary_participation": {
          "voluntary_statement": "Your participation in this study is completely voluntary. You can choose not to participate or to leave the study at any time.",
          "withdrawal_rights": "You may withdraw from the study at any time for any reason, without penalty or loss of benefits to which you are otherwise entitled. Your decision will not affect your future medical care.",
          "withdrawal_consequences": "If you decide to leave the study, the study doctor will discuss your options for future medical care. You may be asked to complete an End of Treatment visit for safety reasons.",
          "data_after_withdrawal": "The Sponsor may retain and continue to use any data collected before your withdrawal of consent.",
          "provenance": {
            "section_number": "7.2",
            "page_number": 104,
            "text_snippet": "Subject Withdrawal/Discontinuation from the Study\nSubjects may discontinue from the study for any of the following reasons: ... Withdrawal by subject (discontinuation from the study)"
          }
        },
        "special_consents": {
          "genetic_testing": {
            "required": false,
            "description": "A blood sample will be collected for pharmacogenomic (inherited genetic) analysis to study genes involved in how your body processes the study drug or in drug-related side effects. A separate consent may be required.",
            "opt_out_allowed": true,
            "future_use": true,
            "results_disclosure": "Results from this research will not be disclosed to you or your doctor.",
            "provenance": {
              "section_number": "8.6.5",
              "page_number": 124,
              "text_snippet": "Pharmacogenomic (Inherited Genetic) Analysis\nA single blood sample for pharmacogenetic analysis will be collected from each subject."
            }
          },
          "biobanking": {
            "required": false,
            "storage_duration": "Up to 15 years after the finalization of the clinical study report.",
            "future_research_use": true,
            "commercialization_statement": "Research using your samples may lead to the development of new diagnostic tests or treatments, but you will not receive any financial benefit from this.",
            "destruction_option": true,
            "provenance": {
              "section_number": "8.6.5.1",
              "page_number": 125,
              "text_snippet": "Banking of Specimens for Inherited Genetic Analysis... Banked DNA samples will be stored for a maximum of 15 years after the finalization of the CSR for this protocol."
            }
          },
          "photography_recording": null,
          "provenance": {
            "section_number": "8.6",
            "page_number": 122,
            "text_snippet": "8.6. Biomarker and Pharmacodynamic Assessments"
          }
        },
        "contacts": {
          "study_questions_contact": "You should contact the Investigator or study site staff for any questions about the study.",
          "rights_questions_contact": "You should contact the Institutional Review Board (IRB) or Ethics Committee (EC) for questions about your rights as a research participant.",
          "emergency_contact": null,
          "twenty_four_hour_contact": "A local SAE Hotline number will be provided to the study site for reporting serious adverse events.",
          "provenance": {
            "section_number": "8.4.1.1",
            "page_number": 114,
            "text_snippet": "Sites should call the local SAE Hotline (see the Investigator site file provided to the sites) or the study monitor for any questions on SAE reporting."
          }
        },
        "reproductive_requirements": {
          "pregnancy_testing_required": true,
          "contraception_requirements": "Females of childbearing potential must have a negative pregnancy test before starting the study and must agree to use a highly effective method of birth control.",
          "contraception_duration": "For females: during the study and for at least 7 months after the last dose of DS-1062a or 6 months after docetaxel. For males: during the study and for at least 4 months after the last dose of DS-1062a or 6 months after docetaxel.",
          "pregnancy_reporting": "You must immediately inform the study doctor if you or your partner becomes pregnant during the study or within the specified time after the last dose.",
          "breastfeeding_restrictions": "You must not breastfeed during the study and for at least 7 months after the last dose of DS-1062a or 6 months after docetaxel.",
          "male_requirements": "Male participants must be surgically sterile or use a condom and ensure their female partner uses highly effective contraception. They must not freeze or donate sperm during the study and for a specified period after.",
          "provenance": {
            "section_number": "5.1",
            "page_number": 77,
            "text_snippet": "17. If the subject is a female of childbearing potential, she must have a negative serum pregnancy test at Screening and must be willing to use highly effective birth control (as detailed in Section 10.3.4) upon enrollment, during the Treatment Period, and for at least 7 months, after the last dose of DS-1062a or for at least 6 months after the last dose of docetaxel."
          }
        },
        "extraction_statistics": {
          "has_risks": true,
          "has_benefits": true,
          "has_alternatives": true,
          "has_compensation": true,
          "has_genetic_consent": true,
          "has_biobanking": true,
          "risk_count": 13,
          "procedure_count": 31
        },
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "CLINICAL STUDY PROTOCOL\nPHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)"
        }
      }
    },
    "proSpecifications": {
      "moduleId": "pro_specifications",
      "instanceType": "PROSpecifications",
      "data": {
        "id": "DS1062-A-U301F-pro-specifications",
        "instanceType": "PROSpecifications",
        "name": "DS1062-A-U301F PRO Specifications",
        "description": "PRO/COA specifications for DS1062-A-U301F (TROPION-LUNG01)",
        "pro_instruments": [
          {
            "instrument_id": "PRO-001",
            "instrument_name": "European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30",
            "instrument_abbreviation": "EORTC-QLQ-C30",
            "instrument_type": "disease_specific",
            "instrument_version": null,
            "copyright_holder": "EORTC",
            "license_required": true,
            "administration": {
              "mode": "electronic",
              "device_type": "patient_smartphone",
              "completion_location": "either",
              "language_versions": [],
              "estimated_completion_time": null,
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "PROs will be collected electronically on site at baseline and at home thereafter. Subjects will be able to use apps on their own smartphones or personal electronic devices to access the electronic PRO questionnaires."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-001",
                  "timepoint_name": "Baseline",
                  "visit_reference": "Screening",
                  "window_before_days": 28,
                  "window_after_days": 0,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-002",
                  "timepoint_name": "During Treatment (Odd Cycles)",
                  "visit_reference": "Day 15 of Cycles 1, 3, 5 and odd cycles thereafter",
                  "window_before_days": 1,
                  "window_after_days": 1,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-003",
                  "timepoint_name": "End of Treatment",
                  "visit_reference": "EOT",
                  "window_before_days": 0,
                  "window_after_days": 7,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-004",
                  "timepoint_name": "Long-Term Follow-Up",
                  "visit_reference": "EOT +90 days",
                  "window_before_days": 7,
                  "window_after_days": 7,
                  "is_required": true
                }
              ],
              "recall_period": null,
              "completion_window_hours": null,
              "provenance": {
                "section_number": "1.3",
                "page_number": 51,
                "text_snippet": "EORTC-QLQ-C30: X at Day 15 of C4, then collected on odd number cycles thereafter (5, 7, 9, etc.)... Collected from home or at the study site at C4 and then every odd number cycle on Day 15 (\u00b11 day) until PD or EOT and then once more at EOT +90 days over a window of 14 days (ie, \u00b17 days from EOT +90 days)."
              }
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Functioning scales",
                  "domain_description": null,
                  "items_included": [],
                  "score_range": null,
                  "higher_is_better": null
                },
                {
                  "domain_name": "Global health status",
                  "domain_description": null,
                  "items_included": [
                    "29"
                  ],
                  "score_range": null,
                  "higher_is_better": null
                },
                {
                  "domain_name": "Quality of life",
                  "domain_description": null,
                  "items_included": [
                    "30"
                  ],
                  "score_range": null,
                  "higher_is_better": null
                }
              ],
              "total_score_available": false,
              "scoring_algorithm": "To be scored according to the corresponding scoring manual.",
              "mcid": null,
              "responder_definition": null,
              "provenance": {
                "section_number": null,
                "page_number": 19,
                "text_snippet": "To evaluate PRO endpoints for DS-1062a compared with that of docetaxel. Title: Patient-reported Outcomes. \u2022 Change from baseline in QLQ-C30 functioning scales. \u2022 Change from baseline in global health (QLQ-C30 question No. 29). \u2022 Change from baseline in quality of life (QLQ-C30 question No. 30)."
              }
            },
            "missing_data": null,
            "training_requirements": null,
            "provenance": {
              "section_number": "8.2",
              "page_number": 108,
              "text_snippet": "The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)"
            }
          },
          {
            "instrument_id": "PRO-002",
            "instrument_name": "European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13",
            "instrument_abbreviation": "EORTC-QLQ-LC13",
            "instrument_type": "disease_specific",
            "instrument_version": null,
            "copyright_holder": "EORTC",
            "license_required": true,
            "administration": {
              "mode": "electronic",
              "device_type": "patient_smartphone",
              "completion_location": "either",
              "language_versions": [],
              "estimated_completion_time": null,
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "PROs will be collected electronically on site at baseline and at home thereafter. Subjects will be able to use apps on their own smartphones or personal electronic devices to access the electronic PRO questionnaires."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-005",
                  "timepoint_name": "Baseline",
                  "visit_reference": "Screening",
                  "window_before_days": 28,
                  "window_after_days": 0,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-006",
                  "timepoint_name": "During Treatment (All Cycles)",
                  "visit_reference": "Day 15 of each cycle",
                  "window_before_days": 1,
                  "window_after_days": 1,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-007",
                  "timepoint_name": "End of Treatment",
                  "visit_reference": "EOT",
                  "window_before_days": 0,
                  "window_after_days": 7,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-008",
                  "timepoint_name": "Long-Term Follow-Up",
                  "visit_reference": "EOT +90 days",
                  "window_before_days": 7,
                  "window_after_days": 7,
                  "is_required": true
                }
              ],
              "recall_period": null,
              "completion_window_hours": null,
              "provenance": {
                "section_number": "1.3",
                "page_number": 51,
                "text_snippet": "EORTC-QLQ-LC13: X at Day 15 of every cycle... Collected from home or at the study site at every cycle on Day 15 (\u00b11 day) until PD or EOT and then once more at EOT +90 days over a window of 14 days (ie, \u00b17 days from EOT +90 days)."
              }
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Time to Deterioration (TTD)",
                  "domain_description": "TTD in any of the 3 symptoms, chest pain, cough, or dyspnea.",
                  "items_included": [],
                  "score_range": null,
                  "higher_is_better": false
                }
              ],
              "total_score_available": false,
              "scoring_algorithm": "To be scored according to the corresponding scoring manual. Questions 36 and 37 will not be administered.",
              "mcid": "\u226510-point increase from randomization",
              "responder_definition": "An increase of \u226510 points in severity in the linearly transformed scale, which is subsequently confirmed by a second increase of \u226510 points for the same symptom at the next scheduled assessment, or death within 21 days of the first \u226510-point increase.",
              "provenance": {
                "section_number": null,
                "page_number": 17,
                "text_snippet": "Title: TTD\nDescription: TTD in any of the 3 symptoms, chest pain, cough, or dyspnea.\n...The TTD is defined as the time from randomization to first onset of a \u226510-point increase in cough, chest pain, or dyspnea, confirmed by a second \u226510-point increase from randomization in the same symptom at the next scheduled assessment, or confirmed by death within 21 days of the first \u226510-point increase from randomization."
              }
            },
            "missing_data": null,
            "training_requirements": null,
            "provenance": {
              "section_number": "8.2",
              "page_number": 108,
              "text_snippet": "The EORTC Quality of Life Questionnaire Lung Cancer-13 (EORTC-QLQ-LC13; except questions 36 and 37)"
            }
          },
          {
            "instrument_id": "PRO-003",
            "instrument_name": "EuroQol Questionnaire 5 Dimensions 5 Levels",
            "instrument_abbreviation": "EQ-5D-5L",
            "instrument_type": "utility",
            "instrument_version": null,
            "copyright_holder": "EuroQol Group",
            "license_required": true,
            "administration": {
              "mode": "electronic",
              "device_type": "patient_smartphone",
              "completion_location": "either",
              "language_versions": [],
              "estimated_completion_time": null,
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "PROs will be collected electronically on site at baseline and at home thereafter. Subjects will be able to use apps on their own smartphones or personal electronic devices to access the electronic PRO questionnaires."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-009",
                  "timepoint_name": "Baseline",
                  "visit_reference": "Screening",
                  "window_before_days": 28,
                  "window_after_days": 0,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-010",
                  "timepoint_name": "During Treatment (Odd Cycles)",
                  "visit_reference": "Day 15 of Cycles 1, 3, 5 and odd cycles thereafter",
                  "window_before_days": 1,
                  "window_after_days": 1,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-011",
                  "timepoint_name": "End of Treatment",
                  "visit_reference": "EOT",
                  "window_before_days": 0,
                  "window_after_days": 7,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-012",
                  "timepoint_name": "Long-Term Follow-Up",
                  "visit_reference": "EOT +90 days",
                  "window_before_days": 7,
                  "window_after_days": 7,
                  "is_required": true
                }
              ],
              "recall_period": null,
              "completion_window_hours": null,
              "provenance": {
                "section_number": "1.3",
                "page_number": 51,
                "text_snippet": "EQ-5D-5L: X at Day 15 of C4, then collected on odd number cycles thereafter (5, 7, 9, etc.)... Collected from home or at the study site at C4 and then every odd number cycle on Day 15 (\u00b11 day) until PD or EOT and then once more at EOT +90 days over a window of 14 days (ie, \u00b17 days from EOT +90 days)."
              }
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Overall health status",
                  "domain_description": "Visual Analog Scale (VAS)",
                  "items_included": [
                    "VAS"
                  ],
                  "score_range": null,
                  "higher_is_better": true
                }
              ],
              "total_score_available": false,
              "scoring_algorithm": "To be scored according to the corresponding scoring manual.",
              "mcid": null,
              "responder_definition": null,
              "provenance": {
                "section_number": null,
                "page_number": 19,
                "text_snippet": "\u2022 Change from baseline in overall health status (EQ-5D Visual Analog Scale)."
              }
            },
            "missing_data": null,
            "training_requirements": null,
            "provenance": {
              "section_number": "8.2",
              "page_number": 108,
              "text_snippet": "The EuroQol Questionnaire- 5 dimensions-5 levels (EQ-5D-5L)"
            }
          },
          {
            "instrument_id": "PRO-004",
            "instrument_name": "Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events",
            "instrument_abbreviation": "PRO-CTCAE",
            "instrument_type": "symptom",
            "instrument_version": null,
            "copyright_holder": "NCI",
            "license_required": false,
            "administration": {
              "mode": "electronic",
              "device_type": "patient_smartphone",
              "completion_location": "either",
              "language_versions": [],
              "estimated_completion_time": null,
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "PROs will be collected electronically on site at baseline and at home thereafter. Subjects will be able to use apps on their own smartphones or personal electronic devices to access the electronic PRO questionnaires."
              }
            },
            "schedule": {
              "assessment_timepoints": [
                {
                  "timepoint_id": "TP-013",
                  "timepoint_name": "Baseline",
                  "visit_reference": "Screening",
                  "window_before_days": 28,
                  "window_after_days": 0,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-014",
                  "timepoint_name": "During Treatment (Cycles 1-10)",
                  "visit_reference": "Day 1, Day 8, and Day 15 (\u00b11 day) of Cycles 1-10",
                  "window_before_days": 0,
                  "window_after_days": 0,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-015",
                  "timepoint_name": "End of Treatment",
                  "visit_reference": "EOT",
                  "window_before_days": 0,
                  "window_after_days": 7,
                  "is_required": true
                },
                {
                  "timepoint_id": "TP-016",
                  "timepoint_name": "Safety Follow-Up",
                  "visit_reference": "28-Day Safety Follow-up",
                  "window_before_days": 0,
                  "window_after_days": 7,
                  "is_required": true
                }
              ],
              "recall_period": null,
              "completion_window_hours": 24,
              "provenance": {
                "section_number": "1.3",
                "page_number": 52,
                "text_snippet": "PRO-CTCAE 1-3; 24; 28-29; 51, 74: X at Days 1, 8, and 15 of Cycles 4-10... Collected from home at every cycle within a 24-hour window on Day 1 and Day 8, and Day 15 (\u00b11 day) until PD or EOT, or up to C10, whichever comes first."
              }
            },
            "scoring": {
              "domains": [
                {
                  "domain_name": "Specific AEs",
                  "domain_description": "Impact of specific AEs on quality of life.",
                  "items_included": [
                    "1",
                    "2",
                    "3",
                    "24",
                    "28",
                    "29",
                    "51",
                    "74"
                  ],
                  "score_range": null,
                  "higher_is_better": false
                }
              ],
              "total_score_available": false,
              "scoring_algorithm": "To be scored according to the corresponding scoring manual. Analysis will be summary statistics (ie, frequency distributions).",
              "mcid": null,
              "responder_definition": null,
              "provenance": {
                "section_number": null,
                "page_number": 19,
                "text_snippet": "\u2022 Summary statistics (ie, frequency distributions) for each PRO-CTCAE."
              }
            },
            "missing_data": null,
            "training_requirements": null,
            "provenance": {
              "section_number": "8.2",
              "page_number": 108,
              "text_snippet": "The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 1-3; 24; 28-29; 51; 74"
            }
          }
        ],
        "epro_system": {
          "vendor_name": null,
          "platform_name": null,
          "integration_with_edc": null,
          "data_transfer_frequency": null,
          "alert_triggers": [],
          "reminder_schedule": null,
          "offline_capability": null,
          "device_requirements": {
            "device_type": "byod",
            "minimum_os_version": null,
            "app_name": null,
            "provenance": {
              "section_number": "8.5",
              "page_number": 121,
              "text_snippet": "Subjects will be able to use apps on their own smartphones or personal electronic devices to access the electronic PRO questionnaires."
            }
          },
          "compliance_alert_threshold": null,
          "provenance": {
            "section_number": "8.5",
            "page_number": 121,
            "text_snippet": "PROs will be directly reported by the subject. PROs will be collected electronically on site at baseline and at home thereafter. Subjects will be able to use apps on their own smartphones or personal electronic devices to access the electronic PRO questionnaires. Paper PRO questionnaires may be made available under special circumstances to be approved by the Sponsor. However, electronic PROs are the preferred method."
          }
        },
        "clinro_instruments": [
          {
            "instrument_id": "CLINRO-001",
            "instrument_name": "Eastern Cooperative Oncology Group Performance Status",
            "instrument_abbreviation": "ECOG PS",
            "assessor": "investigator",
            "training_certification_required": false,
            "inter_rater_reliability_requirements": null,
            "schedule": [
              "Screening",
              "Day 1 of each cycle",
              "End of Treatment",
              "28-Day Safety Follow-up"
            ],
            "provenance": {
              "section_number": "8.4.4",
              "page_number": 120,
              "text_snippet": "ECOG Performance Status\nAssess and record the subject\u2019s ECOG PS as per the Schedules of Events (Table 1.1 and Table 1.2)."
            }
          },
          {
            "instrument_id": "CLINRO-002",
            "instrument_name": "Response Evaluation Criteria in Solid Tumors version 1.1",
            "instrument_abbreviation": "RECIST v1.1",
            "assessor": "investigator",
            "training_certification_required": false,
            "inter_rater_reliability_requirements": null,
            "schedule": [
              "Screening (Baseline)",
              "Every 6 weeks (\u00b17 days) until disease progression"
            ],
            "provenance": {
              "section_number": "8.3",
              "page_number": 109,
              "text_snippet": "Radiographic tumor assessments will include all known or suspected sites of disease, as per RECIST v1.1 (Section 10.4)."
            }
          },
          {
            "instrument_id": "CLINRO-003",
            "instrument_name": "National Cancer Institute - Common Terminology Criteria for Adverse Events v5.0",
            "instrument_abbreviation": "NCI-CTCAE v5.0",
            "assessor": "investigator",
            "training_certification_required": false,
            "inter_rater_reliability_requirements": null,
            "schedule": [
              "Ongoing throughout study for adverse event assessment"
            ],
            "provenance": {
              "section_number": "10.5.3",
              "page_number": 154,
              "text_snippet": "Grade Assessment\nThe severity of AEs will be graded using NCI-CTCAE v5.0. For each episode, the highest severity grade attained should be reported."
            }
          }
        ],
        "obsro_instruments": [],
        "perfo_instruments": [],
        "daily_diary": null,
        "analysis_specifications": {
          "primary_pro_endpoint": null,
          "secondary_pro_endpoints": [
            "Time to deterioration (TTD) in any of the 3 symptoms, chest pain, cough, or dyspnea from EORTC-QLQ-LC13"
          ],
          "exploratory_pro_endpoints": [
            "Change from baseline in QLQ-C30 functioning scales",
            "Change from baseline in global health (QLQ-C30 question No. 29)",
            "Change from baseline in quality of life (QLQ-C30 question No. 30)",
            "Change from baseline in overall health status (EQ-5D Visual Analog Scale)",
            "Summary statistics for each PRO-CTCAE item"
          ],
          "analysis_population": "Full Analysis Set (FAS) without a missing baseline PRO score and at least 1 post-baseline score.",
          "statistical_methods": [
            "Kaplan-Meier method will be used to estimate the distribution of TTD.",
            "A stratified log-rank test will be used to compare TTD between treatment arms.",
            "Descriptive analysis will be conducted on PRO scores."
          ],
          "sensitivity_analyses": [],
          "responder_analysis_planned": true,
          "time_to_event_analysis_planned": true,
          "provenance": {
            "section_number": "9.5.1.2.1",
            "page_number": 129,
            "text_snippet": "Patient-Reported Outcomes\nPRO assessments in the study will include EORTC-QLQ-C30, EORTC-QLQ-LC13 (except questions 36 and 37), EQ-5D-5L, and PRO-CTCAE (1-3; 24; 28-29; 51; 74).\nTime to deterioration (TTD) in any of the 3 symptoms, cough, chest pain, or dyspnea is defined as the time from randomization to the first clinically meaningful symptom deterioration in any of the 3 symptoms, cough, chest pain, or dyspnea."
          }
        },
        "extraction_statistics": {
          "pro_instrument_count": 4,
          "clinro_count": 3,
          "obsro_count": 0,
          "perfo_count": 0,
          "has_epro": true,
          "has_daily_diary": false
        },
        "provenance": {
          "section_number": "8.2",
          "page_number": 108,
          "text_snippet": "Patient-reported Outcomes\nPatient-reported outcome (PRO) assessments will include:\n\u2022 The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)\n\u2022 The EORTC Quality of Life Questionnaire Lung Cancer-13 (EORTC-QLQ-LC13; except questions 36 and 37)\n\u2022 The EuroQol Questionnaire- 5 dimensions-5 levels (EQ-5D-5L)\n\u2022 The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 1-3; 24; 28-29; 51; 74"
        }
      }
    },
    "dataManagement": {
      "moduleId": "data_management",
      "instanceType": "DataManagement",
      "data": {
        "id": "DS1062-A-U301F-data-management",
        "instanceType": "DataManagementPlan",
        "name": "DS1062-A-U301F Data Management Plan",
        "edc_specifications": {
          "instanceType": "EDCSpecifications",
          "vendor_name": null,
          "system_capabilities": [
            "randomization",
            "ePRO",
            "audit_trail",
            "electronic_signature",
            "central_lab_integration",
            "IWRS_integration"
          ],
          "integration_systems": [
            {
              "id": "integration-001",
              "system_type": "IWRS",
              "vendor_name": null,
              "transfer_frequency": "real_time",
              "transfer_method": "API",
              "provenance": {
                "section_number": "8.2",
                "page_number": 108,
                "text_snippet": "Randomization will be performed by an IRT. Randomization will be stratified by documented actionable genomic alteration (present versus absent), histology (squamous versus nonsquamous), most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy (yes versus no) and geographical region (US/Japan/Western Europe versus ROW)."
              }
            },
            {
              "id": "integration-002",
              "system_type": "central_lab",
              "vendor_name": null,
              "transfer_frequency": "at_milestones",
              "transfer_method": "SFTP",
              "provenance": {
                "section_number": "10.1.4",
                "page_number": 137,
                "text_snippet": "Data received from external sources such as central laboratories will be reconciled to the clinical database."
              }
            },
            {
              "id": "integration-003",
              "system_type": "imaging_vendor",
              "vendor_name": null,
              "transfer_frequency": "per_visit",
              "transfer_method": "DICOM",
              "provenance": {
                "section_number": "8.3",
                "page_number": 110,
                "text_snippet": "BICR Radiographic Tumor Assessment \nRadiographic imaging scans will be sent to a central imaging vendor for BICR assessment. Sites will send subject scans to the central imaging vendor after each tumor assessment visit."
              }
            },
            {
              "id": "integration-004",
              "system_type": "ePRO",
              "vendor_name": null,
              "transfer_frequency": "real_time",
              "transfer_method": "API",
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "PROs will be directly reported by the subject. PROs will be collected electronically on site at baseline and at home thereafter. Subjects will be able to use apps on their own smartphones or personal electronic devices to access the electronic PRO questionnaires."
              }
            }
          ],
          "language_requirements": [],
          "crf_modules": [
            {
              "id": "crf-001",
              "module_name": "Demographics",
              "forms": [
                "Demographics"
              ],
              "visit_schedule": [
                "Screening"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 30,
                "text_snippet": "Assessment: Demographics and Eligibility, Demographics. SCR: X. Comments: Includes: birth date, age at Screening, sex, race, ethnicity, country"
              }
            },
            {
              "id": "crf-002",
              "module_name": "Eligibility",
              "forms": [
                "Inclusion Criteria",
                "Exclusion Criteria"
              ],
              "visit_schedule": [
                "Screening"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 30,
                "text_snippet": "Assessment: Demographics and Eligibility, Inclusion/Exclusion Criteria. SCR: X. Comments: See Section 5 and Section 8.1."
              }
            },
            {
              "id": "crf-003",
              "module_name": "Adverse Events",
              "forms": [
                "Adverse Event Log",
                "Serious Adverse Event Log"
              ],
              "visit_schedule": [
                "All"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 39,
                "text_snippet": "Assessment: AEs, Non-serious AEs, SAEs. Comments: All non-serious AEs occurring after the subject has taken the first dose of study drug until 35 days after the last dose of study drug will be recorded in the Adverse Event section of the eCRF."
              }
            },
            {
              "id": "crf-004",
              "module_name": "Study Drug Administration",
              "forms": [
                "DS-1062a Administration",
                "Docetaxel Administration"
              ],
              "visit_schedule": [
                "Treatment Cycles"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 37,
                "text_snippet": "Assessment: Study Drug, Administration of DS-1062a. Cycle 1, Day 1: X. Cycle 2, Day 1: X. Cycle 3, Day 1: X."
              }
            },
            {
              "id": "crf-005",
              "module_name": "Tumor Assessments",
              "forms": [
                "Target Lesions",
                "Non-Target Lesions",
                "New Lesions",
                "Overall Response"
              ],
              "visit_schedule": [
                "Baseline",
                "Treatment Cycles",
                "Follow-up"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 36,
                "text_snippet": "Assessment: Tumor Response and Lung Disease Assessment. Comments: Every 6 weeks (\u00b17 days) from randomization until radiographic disease progression as assessed by Investigator, death, lost to follow-up, or withdrawal of consent (regardless of discontinuing study treatment or starting new anticancer therapy)."
              }
            },
            {
              "id": "crf-006",
              "module_name": "Vital Signs",
              "forms": [
                "Vital Signs"
              ],
              "visit_schedule": [
                "All"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 30,
                "text_snippet": "Assessment: Safety, Vital Signs. SCR: Xb,c. Cycle 1, Day 1: X. Cycle 2, Day 1: X. Cycle 3, Day 1: X."
              }
            },
            {
              "id": "crf-007",
              "module_name": "Laboratory Assessments",
              "forms": [
                "Hematology",
                "Clinical Chemistry"
              ],
              "visit_schedule": [
                "Screening",
                "Treatment Cycles"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 32,
                "text_snippet": "Assessment: Laboratory Assessments, Hematology, Clinical Chemistry. SCR: Xb,d. Cycle 1, Day 1: X. Cycle 2, Day 1: X. Cycle 3, Day 1: X."
              }
            },
            {
              "id": "crf-008",
              "module_name": "Concomitant Medications",
              "forms": [
                "Concomitant Medication Log"
              ],
              "visit_schedule": [
                "All"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "6.6",
                "page_number": 99,
                "text_snippet": "Therapies used from the time the subject signs the ICF for study participation to the 28-Day Follow-up visit (+7 days) after the last administration of DS-1062a will be recorded in the eCRF. Prophylactic therapies (including any required premedication), prior therapies, and all concomitant therapies will be recorded in the eCRF."
              }
            },
            {
              "id": "crf-009",
              "module_name": "Patient Reported Outcomes",
              "forms": [
                "EORTC-QLQ-C30",
                "EORTC-QLQ-LC13",
                "EQ-5D-5L",
                "PRO-CTCAE"
              ],
              "visit_schedule": [
                "Baseline",
                "Treatment Cycles"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 39,
                "text_snippet": "Assessment: PRO Assessments, EORTC-QLQ-C30, EORTC-QLQ-LC13, EQ-5D-5L, PRO-CTCAE."
              }
            },
            {
              "id": "crf-010",
              "module_name": "End of Treatment",
              "forms": [
                "End of Treatment"
              ],
              "visit_schedule": [
                "EOT"
              ],
              "is_repeating": false,
              "provenance": {
                "section_number": "Table 1.2",
                "page_number": 42,
                "text_snippet": "Table 1.2: Schedule of Events for Cycle 4 and Subsequent Cycles of the Treatment Period, End of Treatment, and Follow-up Period"
              }
            },
            {
              "id": "crf-011",
              "module_name": "Survival Follow-up",
              "forms": [
                "Survival Status"
              ],
              "visit_schedule": [
                "Follow-up"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1.2",
                "page_number": 51,
                "text_snippet": "Assessment: OS, Survival FU. Long-Term Survival Follow-up (Every 3 Months): X. Comments: In cases where subject withdraws consent and refuses to undergo any further study procedures, subjects will be asked to be followed for long-term survival only (eg, study personnel contacting the subject by telephone)."
              }
            },
            {
              "id": "crf-012",
              "module_name": "ECG Assessment",
              "forms": [
                "ECG Results"
              ],
              "visit_schedule": [
                "Screening",
                "Treatment Cycles"
              ],
              "is_repeating": true,
              "provenance": {
                "section_number": "Table 1.1",
                "page_number": 31,
                "text_snippet": "Assessment: Safety, 12-Lead ECG. SCR: Xd. Cycle 1, Day 1: X. Cycle 2, Day 1: X. Cycle 3, Day 1: X."
              }
            }
          ],
          "provenance": {
            "section_number": "10.1.4",
            "page_number": 137,
            "text_snippet": "Data Collection\nAn eCRF must be completed for each subject who signs an ICF and undergoes any Screening procedure. If a subject is not treated, the reason must be recorded on the eCRF. All data collected during the study will be recorded in this individual, subject-specific eCRF. Instructions will be provided for the completion of the eCRF and any corrections made will be automatically documented via an \u201caudit trail.\u201d"
          }
        },
        "data_standards": {
          "instanceType": "DataStandards",
          "sdtm_version": null,
          "sdtm_ig_version": null,
          "adam_version": null,
          "controlled_terminology": {
            "cdisc_ct_version": null,
            "meddra_version": null,
            "whodrug_version": null,
            "snomed_version": null
          },
          "define_xml_required": null,
          "define_xml_version": null,
          "adrg_required": null,
          "sdrg_required": null,
          "provenance": {
            "section_number": "10.1.4",
            "page_number": 137,
            "text_snippet": "All AEs will be coded using MedDRA. SAEs in the clinical database will be reconciled with the safety database.\nAll concomitant medications and prior cancer therapies will be coded using the World Health Organization Drug Reference Dictionary."
          }
        },
        "data_quality": {
          "instanceType": "DataQuality",
          "edit_checks": {
            "standard_checks": [
              "range_checks",
              "consistency_checks",
              "required_fields",
              "date_logic"
            ],
            "protocol_specific_checks": [],
            "auto_query_enabled": true,
            "provenance": {
              "section_number": "10.1.4",
              "page_number": 137,
              "text_snippet": "Data will be vetted both electronically by programmed data rules within the application and manually. Queries generated by rules and raised by reviewers will be generated within the EDC application. During this review, subject data will be checked for consistency, completeness and any apparent discrepancies."
            }
          },
          "sdv_strategy": {
            "approach": null,
            "sdv_percentage": null,
            "critical_data_points": [],
            "sdv_timing": null
          },
          "query_management": {
            "resolution_target_days": null,
            "escalation_threshold_days": null,
            "auto_query_triggers": []
          },
          "data_review": {
            "medical_review_frequency": null,
            "statistical_review_frequency": null,
            "data_review_committee": true,
            "provenance": {
              "section_number": "10.1.5",
              "page_number": 137,
              "text_snippet": "Committees\nInterstitial Lung Disease Adjudication Committee\nAn external ILD AC will be used for this study."
            }
          }
        },
        "database_management": {
          "instanceType": "DatabaseManagement",
          "database_design": {
            "external_data_sources": [
              "central_lab",
              "imaging",
              "ePRO",
              "ECG"
            ],
            "calculated_fields": [
              "Creatinine Clearance",
              "BSA"
            ],
            "derived_variables": [
              "Progression-Free Survival (PFS)",
              "Overall Survival (OS)",
              "Duration of Response (DoR)",
              "Best Overall Response (BOR)"
            ],
            "provenance": {
              "section_number": "3.1",
              "page_number": 59,
              "text_snippet": "Table 3.1: Description of Objectives, Outcome Measures, and Endpoints"
            }
          },
          "interim_locks": [
            {
              "id": "lock-001",
              "lock_name": "OS Interim Analysis",
              "trigger": "At the time of primary PFS analysis, when approximately 293 deaths have occurred.",
              "scope": "partial",
              "provenance": {
                "section_number": "9.6",
                "page_number": 133,
                "text_snippet": "OS will also be analyzed at the primary analysis of PFS (OS IA). ... It is projected that approximately 293 deaths will be observed at the IA, ie, 71% of information fraction (IF, ie, 293 out of the target 413 OS events). The study may be stopped at OS IA if the pre-specified superiority boundary is crossed."
              }
            }
          ],
          "final_database_lock": {
            "trigger_event": "All subjects have completed the study, all data is entered and clean, and all required analyses events have occurred.",
            "timeline_days_from_lplv": null,
            "prerequisites": [
              "All CRF pages completed",
              "All queries resolved",
              "SAE reconciliation completed",
              "External data reconciled",
              "Medical review completed"
            ],
            "signoff_required": [
              "data_management",
              "biostatistics",
              "medical_monitor"
            ],
            "provenance": {
              "section_number": "10.1.1",
              "page_number": 134,
              "text_snippet": "In all cases, the coordinating Investigator must be chosen before locking the database."
            }
          }
        },
        "data_transfers": {
          "instanceType": "DataTransfers",
          "central_lab": {
            "vendor_name": null,
            "transfer_frequency": "at_milestones",
            "transfer_method": "SFTP",
            "data_reconciliation": true,
            "provenance": {
              "section_number": "10.1.4",
              "page_number": 137,
              "text_snippet": "Data received from external sources such as central laboratories will be reconciled to the clinical database."
            }
          },
          "imaging": {
            "vendor_name": null,
            "data_collected": [
              "CT",
              "MRI",
              "Bone Scan",
              "18F-FDG PET/CT"
            ],
            "transfer_method": "DICOM",
            "provenance": {
              "section_number": "8.3",
              "page_number": 109,
              "text_snippet": "Imaging must include chest and abdomen CT or MRI scans, and brain CT or MRI scan at baseline (Screening) for all subjects... Bone scan (bone scintigraphy) or 18F-fluorodeoxyglucose positron emission tomography/CT is required at baseline."
            }
          },
          "epro": {
            "vendor_name": null,
            "transfer_frequency": "real_time",
            "instruments_collected": [
              "EORTC-QLQ-C30",
              "EORTC-QLQ-LC13",
              "EQ-5D-5L",
              "PRO-CTCAE"
            ],
            "provenance": {
              "section_number": "8.2",
              "page_number": 108,
              "text_snippet": "Patient-reported outcome (PRO) assessments will include:\n\u2022 The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)\n\u2022 The EORTC Quality of Life Questionnaire Lung Cancer-13 (EORTC-QLQ-LC13; except questions 36 and 37)\n\u2022 The EuroQol Questionnaire- 5 dimensions-5 levels (EQ-5D-5L)\n\u2022 The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) 1-3; 24; 28-29; 51; 74"
            }
          },
          "external_adjudication": {
            "adjudication_types": [
              "imaging",
              "endpoint"
            ],
            "export_frequency": "per_event",
            "blinding_maintained": true,
            "provenance": {
              "section_number": "10.1.5",
              "page_number": 137,
              "text_snippet": "Interstitial Lung Disease Adjudication Committee\nAn external ILD AC will be used for this study. Details on the membership, responsibilities, and working procedures of the external ILD AC will be described in its own charter, provided as a separate document. The ILD AC will adjudicate all cases of potential ILD/pneumonitis on an ongoing basis."
            }
          },
          "dsmb_exports": {
            "export_frequency": "per_meeting",
            "unblinded_access": true,
            "data_included": [
              "Safety data"
            ],
            "provenance": {
              "section_number": "10.1.6",
              "page_number": 138,
              "text_snippet": "Data Monitoring Committee\nAn independent data monitoring committee (DMC) will be created... The DMC will periodically review unblinded safety data in this study."
            }
          }
        },
        "data_archival": {
          "instanceType": "DataArchival",
          "retention_period_years": null,
          "retention_basis": "Retain until at least 2 years after the last approval of a marketing application in an ICH region or as required by local regulations.",
          "archival_format": [],
          "archival_location": "sponsor",
          "destruction_policy": "No study document should be destroyed without prior written agreement between the Sponsor and the Investigator.",
          "provenance": {
            "section_number": "10.1.7",
            "page_number": 139,
            "text_snippet": "All essential documentation will be retained by the Investigator until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2 years have lapsed since the formal discontinuation of clinical development of the investigational drug... No study document should be destroyed without prior written agreement between the Sponsor and the Investigator."
          }
        },
        "extraction_statistics": {
          "has_edc_specifications": true,
          "has_data_standards": true,
          "has_sdv_strategy": false,
          "has_database_lock_plan": true,
          "integration_count": 4,
          "crf_module_count": 12
        },
        "provenance": {
          "section_number": "10.1.4",
          "page_number": 136,
          "text_snippet": "10.1.4. Data Integrity and Quality Assurance"
        }
      }
    },
    "siteOperationsLogistics": {
      "moduleId": "site_operations_logistics",
      "instanceType": "SiteOperationsLogistics",
      "data": {
        "id": "DS1062-A-U301F-site-operations-logistics",
        "instanceType": "SiteOperationsLogistics",
        "name": "DS1062-A-U301F Site Operations & Logistics",
        "site_selection": {
          "instanceType": "SiteSelectionCriteria",
          "required_criteria": [],
          "preferred_criteria": [],
          "exclusionary_criteria": [],
          "geographic_requirements": {
            "countries": [],
            "regions": [
              "North America",
              "South America",
              "Europe",
              "Australia",
              "Asia"
            ],
            "site_count_target": 190,
            "language_requirements": [],
            "provenance": {
              "section_number": "4.1",
              "page_number": 64,
              "text_snippet": "The study will be conducted at approximately 190 study sites predominantly located in North America, South America, Europe, Australia, and Asia."
            }
          },
          "facility_requirements": {
            "patient_population_access": "Access to patients with advanced or metastatic non-small cell lung cancer (NSCLC).",
            "equipment_required": [
              "CT scanner",
              "MRI scanner",
              "ECHO/MUGA scan capability",
              "12-lead ECG machine",
              "Infusion center"
            ],
            "laboratory_capabilities": "Local laboratory for clinical laboratory tests (hematology, blood chemistry, urinalysis).",
            "pharmacy_capabilities": "Secure, limited-access storage area for study drug with temperature monitoring.",
            "storage_capabilities": "Ability to store study drug according to label specifications (e.g., temperature control, protection from light).",
            "provenance": {
              "section_number": "8.4.3",
              "page_number": 119,
              "text_snippet": "Clinical laboratory tests including hematology, blood chemistry, and pregnancy tests will be performed as per the Schedules of Events by the local laboratory (Table 1.1 and Table 1.2)."
            }
          },
          "experience_requirements": {
            "provenance": {
              "section_number": "2",
              "page_number": 2,
              "text_snippet": "INVESTIGATOR AGREEMENT"
            }
          },
          "provenance": {
            "section_number": "4.1",
            "page_number": 64,
            "text_snippet": "Overall Design"
          }
        },
        "regulatory_ethics": {
          "instanceType": "RegulatoryEthics",
          "regulatory_authorities": [
            {
              "id": "AUTH-001",
              "authority_name": "Food and Drug Administration (FDA)",
              "country_region": "USA",
              "submission_type": "IND",
              "submission_number": "136626",
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": null,
                "page_number": 1,
                "text_snippet": "IND 136626"
              }
            },
            {
              "id": "AUTH-002",
              "authority_name": "European Medicines Agency (EMA) region",
              "country_region": "European Union",
              "submission_type": "EudraCT",
              "submission_number": "2020-004643-80",
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": null,
                "page_number": 1,
                "text_snippet": "EudraCT NUMBER 2020-004643-80"
              }
            },
            {
              "id": "AUTH-003",
              "authority_name": "Japanese Ministry of Health, Labor and Welfare",
              "country_region": "JPN",
              "submission_type": null,
              "submission_number": null,
              "approval_status": null,
              "approval_date": null,
              "special_designations": [],
              "provenance": {
                "section_number": "10.1.1",
                "page_number": 134,
                "text_snippet": "Japanese Ministry of Health, Labor and Welfare Ordinance No. 28 (27 Mar 1997) and/or;"
              }
            }
          ],
          "ethics_committees": [
            {
              "id": "EC-001",
              "committee_type": "IRB/EC",
              "centralized_or_local": "local",
              "approval_requirements": "Written approval of protocol, IB, ICF, and other subject-facing materials is required prior to study start.",
              "approval_timeline": null,
              "continuing_review_frequency": "As per local regulations",
              "provenance": {
                "section_number": "10.1.1",
                "page_number": 134,
                "text_snippet": "The study protocol, the IB, available safety information, recruitment procedures (eg, advertisements), subject information and consent form, any subject written instructions to be given to the subject, information about payments and compensation available to the subjects, and documentation evidencing the Investigator\u2019s qualifications should be submitted to the independent IRB or EC for ethical review and approval according to local regulations, prior to the study start."
              }
            }
          ],
          "informed_consent": {
            "consent_type": "written",
            "languages_required": [
              "Local language(s) of the potential subject population"
            ],
            "reconsent_triggers": [
              "protocol_amendment",
              "new_safety_info",
              "revised subject information"
            ],
            "assent_required": null,
            "electronic_consent_allowed": null,
            "provenance": {
              "section_number": "10.1.2",
              "page_number": 135,
              "text_snippet": "If the subject information is revised, it must be re-approved by the EC/IRB. The Investigator should obtain written informed consent to continue participation with the revised written information even if subjects were already informed of the relevant information."
            }
          },
          "data_privacy": {
            "applicable_regulations": [
              "GDPR",
              "HIPAA"
            ],
            "data_transfer_requirements": null,
            "anonymization_requirements": "Subjects should be identified by a unique subject identification number on eCRFs and other documents submitted to the Sponsor.",
            "provenance": {
              "section_number": "10.1.3",
              "page_number": 136,
              "text_snippet": "For European study sites, the Sponsor will observe the rules laid down in the General Data Protection Regulation 2016/679/EU on the protection of individuals with regard to the processing of personal data and the free movement of such data.\nFor study sites in the US, an additional consent is required for the Health Insurance Portability and Accountability Act.\nOn the eCRFs or other documents submitted to the Sponsor or the CRO, subjects should be identified by a unique subject identification as"
            }
          },
          "provenance": {
            "section_number": "10.1",
            "page_number": 134,
            "text_snippet": "Appendix 1 Regulatory and Ethical Considerations"
          }
        },
        "site_personnel": {
          "instanceType": "SitePersonnel",
          "principal_investigator": {
            "qualifications_required": [
              "Qualified physician"
            ],
            "responsibilities": [
              "Conduct the study according to the protocol and ICH GCP.",
              "Ensure subject safety.",
              "Obtain informed consent.",
              "Maintain study documentation.",
              "Oversee delegated study duties."
            ],
            "delegation_restrictions": [],
            "time_commitment": null,
            "provenance": {
              "section_number": null,
              "page_number": 2,
              "text_snippet": "I agree to conduct this study according to this protocol and to comply with its requirements, subject to ethical and safety considerations and guidelines, and to conduct the study in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guideline for Good Clinical Practice (ICH E6[R2]), which has its foundations in the Declaration of Helsinki, and applicable regional regulatory requirements."
            }
          },
          "sub_investigators": {
            "minimum_number": null,
            "qualifications": [
              "Appropriately qualified"
            ],
            "delegated_duties": [
              "As delegated by the PI and documented on the Signature List."
            ],
            "provenance": {
              "section_number": "10.1.6",
              "page_number": 138,
              "text_snippet": "The Investigator will maintain a Signature List of appropriately qualified persons to whom he/she has delegated study duties. All persons authorized to obtain informed consent and make entries and/or corrections on eCRFs will be included on the Signature List."
            }
          },
          "coordinators": {
            "minimum_number": null,
            "responsibilities": [
              "As delegated by the PI and documented on the Signature List."
            ],
            "experience_required": null,
            "provenance": {
              "section_number": "10.1.6",
              "page_number": 138,
              "text_snippet": "The Investigator will maintain a Signature List of appropriately qualified persons to whom he/she has delegated study duties. All persons authorized to obtain informed consent and make entries and/or corrections on eCRFs will be included on the Signature List."
            }
          },
          "other_personnel": [
            {
              "id": "PERSONNEL-001",
              "role": "Pharmacist",
              "responsibilities": [
                "Responsible for study drug accountability, reconciliation, record maintenance, preparation, and dispensation."
              ],
              "provenance": {
                "section_number": "6.2.1",
                "page_number": 84,
                "text_snippet": "The pharmacist is responsible for study drug accountability, reconciliation and record maintenance (ie, Receipt of Shipment Form, dispensation/return record, and certificate of destruction/return receipt)."
              }
            }
          ],
          "provenance": {
            "section_number": null,
            "page_number": 2,
            "text_snippet": "INVESTIGATOR AGREEMENT"
          }
        },
        "training_requirements": {
          "instanceType": "TrainingRequirements",
          "protocol_training": {
            "required_for": [
              "PI",
              "All delegated study staff"
            ],
            "format": null,
            "duration": null,
            "assessment_required": null,
            "completion_deadline": "before performing study duties",
            "provenance": {
              "section_number": null,
              "page_number": 2,
              "text_snippet": "I have fully discussed the objectives of this study and the contents of this protocol with the Sponsor\u2019s representative."
            }
          },
          "gcp_training": {
            "required": true,
            "frequency": null,
            "certification_required": null,
            "accepted_providers": [],
            "provenance": {
              "section_number": "10.1.1",
              "page_number": 134,
              "text_snippet": "This study will be conducted in compliance with the protocol, the ethical principles that have their origin in the Declaration of Helsinki, the International Council for Harmonisation (ICH) consolidated Guideline E6 [R2] for Good Clinical Practice (GCP) (CPMP/ICH/135/95), and applicable regulatory requirement(s) including the following:"
            }
          },
          "specialized_training": [],
          "training_documentation": {
            "required": true,
            "documentation_method": "Maintenance of a Signature List of appropriately qualified persons to whom study duties have been delegated.",
            "provenance": {
              "section_number": "10.1.6",
              "page_number": 138,
              "text_snippet": "The Investigator will maintain a Signature List of appropriately qualified persons to whom he/she has delegated study duties."
            }
          },
          "provenance": {
            "section_number": "10.1.1",
            "page_number": 134,
            "text_snippet": "Compliance Statement, Ethics, and Regulatory Compliance"
          }
        },
        "monitoring_plan": {
          "instanceType": "MonitoringPlan",
          "monitoring_approach": "hybrid",
          "site_initiation_visit": {
            "required": null,
            "timing": null,
            "format": null,
            "activities": [],
            "provenance": {
              "section_number": "10.1.4",
              "page_number": 136,
              "text_snippet": "Monitoring and Inspections"
            }
          },
          "routine_monitoring": {
            "frequency": "Varies based on the activity at each study site.",
            "visit_type": "hybrid",
            "sdv_percentage": null,
            "sdv_scope": [
              "Adherence to protocol",
              "Data completeness, accuracy, and consistency",
              "Adherence to ICH GCP and local regulations"
            ],
            "remote_monitoring_activities": [
              "Review of study data remotely"
            ],
            "provenance": {
              "section_number": "10.1.4",
              "page_number": 136,
              "text_snippet": "The verification of adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to ICH GCP and local regulations on the conduct of clinical research will be accomplished through a combination of onsite visits by the monitor and review of study data remotely. The frequency of the monitoring visit will vary based on the activity at each study site."
            }
          },
          "triggered_monitoring": {
            "triggers": [],
            "response_timeline": null,
            "escalation_criteria": [],
            "provenance": {
              "section_number": "10.1.4",
              "page_number": 136,
              "text_snippet": "Monitoring and Inspections"
            }
          },
          "close_out_visit": {
            "required": true,
            "timing": "After all required documents and study supplies have been collected.",
            "format": "on_site",
            "activities": [
              "Final document collection",
              "Final drug accountability",
              "Ensuring all data is complete and signed off"
            ],
            "provenance": {
              "section_number": "10.1.10",
              "page_number": 140,
              "text_snippet": "A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed."
            }
          },
          "provenance": {
            "section_number": "10.1.4",
            "page_number": 136,
            "text_snippet": "Monitoring and Inspections"
          }
        },
        "site_activation_timeline": {
          "instanceType": "SiteActivationTimeline",
          "site_selection_phase": null,
          "feasibility_assessment": null,
          "contract_negotiation": null,
          "regulatory_submission": null,
          "ethics_approval": null,
          "site_training": null,
          "site_initiation_visit": null,
          "first_patient_ready": null,
          "critical_path_items": [],
          "provenance": {
            "section_number": "4.1",
            "page_number": 64,
            "text_snippet": "The study start date is the date when the first subject has signed an informed consent form (ICF). A subject is eligible to be randomized into the study when the Investigator or designee has obtained written informed consent, has confirmed all inclusion and exclusion criteria have been met by the subject, and all Screening procedures have been completed."
          }
        },
        "drug_supply_logistics": {
          "instanceType": "DrugSupplyLogistics",
          "packaging_labeling": {
            "blinding_requirements": "open_label",
            "label_languages": [
              "Local regulatory requirement"
            ],
            "temperature_indicators": null,
            "tamper_evident": null,
            "kit_design": null,
            "provenance": {
              "section_number": "6.3",
              "page_number": 85,
              "text_snippet": "This is an open-label study. No crossover between study treatment arms will be allowed."
            }
          },
          "storage_distribution": {
            "storage_temperature": "Docetaxel: Do not store above 25 \u00b0C. DS-1062a: As noted on the label.",
            "distribution_model": null,
            "cold_chain_required": null,
            "shelf_life_months": null,
            "shipping_conditions": null,
            "provenance": {
              "section_number": "6.2.2",
              "page_number": 84,
              "text_snippet": "Docetaxel supplies must be stored in a secure, limited-access storage area under the recommended storage conditions as noted on the label. Do not store above 25 \u00b0C. Store in the original package in order to protect from light. Do not freeze."
            }
          },
          "inventory_management": {
            "iwrs_rtsm_system": "Interactive Response Technology (IRT)",
            "kit_design": null,
            "resupply_triggers": null,
            "resupply_threshold_days": null,
            "expiry_management": null,
            "provenance": {
              "section_number": "6.2.1",
              "page_number": 84,
              "text_snippet": "The Receipt of Shipment Form should be faxed as instructed on the form unless receipt is controlled by Interactive Response Technology (IRT)."
            }
          },
          "dispensing_schedule": [
            {
              "id": "DISP-001",
              "visit_name": "Cycle X Day 1",
              "cycle_day": "Day 1",
              "kits_dispensed": [
                "DS-1062a or Docetaxel"
              ],
              "quantity_dispensed": "One dose per 21-day cycle",
              "titration_rules": null,
              "provenance": {
                "section_number": "6.1.1",
                "page_number": 81,
                "text_snippet": "One IV infusion every 3 weeks on Day 1 of each 21-day cycle."
              }
            }
          ],
          "drug_accountability": {
            "accountability_frequency": "Ongoing",
            "accountability_method": null,
            "documentation_requirements": "Receipt of Shipment Form, dispensation/return record, certificate of destruction/return receipt.",
            "discrepancy_handling": "Contact the Sponsor as soon as possible if there is a problem with the shipment.",
            "provenance": {
              "section_number": "6.2.1",
              "page_number": 84,
              "text_snippet": "The pharmacist is responsible for study drug accountability, reconciliation and record maintenance (ie, Receipt of Shipment Form, dispensation/return record, and certificate of destruction/return receipt)."
            }
          },
          "drug_return_destruction": {
            "return_required": true,
            "return_timing": "At the end of the study",
            "destruction_method": "return_to_sponsor",
            "destruction_documentation": "Certificate of destruction/return receipt",
            "environmental_requirements": null,
            "provenance": {
              "section_number": "6.2.1",
              "page_number": 84,
              "text_snippet": "At the end of the study, all unused DS-1062a will be returned or destroyed as per local laws or site policy and only after the CRO monitor has completed a final inventory."
            }
          },
          "dosing_error_handling": {
            "overdose_procedures": "Report to the Sponsor within 24 hours of awareness. Overdose is always considered a serious event.",
            "underdose_procedures": null,
            "missed_dose_procedures": "If study drug is delayed, missed doses will not be made up.",
            "dose_timing_windows": "Dosing must occur within 3 days of randomization.",
            "provenance": {
              "section_number": "8.4.1.1.1",
              "page_number": 115,
              "text_snippet": "All occurrences of overdose for DS-1062a or docetaxel must be reported to the Sponsor within 24 hours of awareness."
            }
          },
          "comparator_medications": [
            {
              "id": "COMP-001",
              "medication_name": "Docetaxel",
              "source": "sponsor_provided",
              "provenance": {
                "section_number": "6.2.2",
                "page_number": 84,
                "text_snippet": "Docetaxel is a commercially available product and will be supplied by the study Sponsor."
              }
            }
          ],
          "emergency_unblinding": {
            "unblinding_allowed": false,
            "unblinding_triggers": [],
            "unblinding_procedure": "Not applicable, this is an open-label study.",
            "who_can_unblind": [],
            "documentation_required": null,
            "provenance": {
              "section_number": "6.3",
              "page_number": 85,
              "text_snippet": "This is an open-label study."
            }
          },
          "provenance": {
            "section_number": "6",
            "page_number": 81,
            "text_snippet": "STUDY TREATMENT"
          }
        },
        "technology_systems": {
          "instanceType": "TechnologySystems",
          "edc_system": {
            "vendor_name": null,
            "system_capabilities": [
              "electronic_signature",
              "audit_trail"
            ],
            "integration_requirements": [],
            "language_requirements": [],
            "provenance": {
              "section_number": "10.1.4",
              "page_number": 137,
              "text_snippet": "An eCRF must be completed for each subject who signs an ICF and undergoes any Screening procedure. ... Instructions will be provided for the completion of the eCRF and any corrections made will be automatically documented via an \u201caudit trail.\u201d ... Upon completion of the subject\u2019s eCRF, it will be reviewed and signed off by the Investigator via the EDC system\u2019s electronic signature."
            }
          },
          "iwrs_rtsm": {
            "vendor_name": null,
            "functions": [
              "randomization"
            ],
            "integration_with_edc": null,
            "provenance": {
              "section_number": "8.2",
              "page_number": 108,
              "text_snippet": "Randomization will be performed by an IRT."
            }
          },
          "epro_devices": {
            "required": true,
            "device_type": "byod",
            "instruments_collected": [
              "EORTC-QLQ-C30",
              "EORTC-QLQ-LC13",
              "EQ-5D-5L",
              "PRO-CTCAE"
            ],
            "training_required": null,
            "provenance": {
              "section_number": "8.5",
              "page_number": 121,
              "text_snippet": "PROs will be directly reported by the subject. PROs will be collected electronically on site at baseline and at home thereafter. Subjects will be able to use apps on their own smartphones or personal electronic devices to access the electronic PRO questionnaires."
            }
          },
          "central_services": [
            {
              "id": "SVC-001",
              "service_type": "central_lab",
              "vendor_name": null,
              "data_flow": "Data will be reconciled to the clinical database.",
              "turnaround_time": null,
              "provenance": {
                "section_number": "8.6.2",
                "page_number": 123,
                "text_snippet": "Biomarker samples will be shipped to a central laboratory. Sample collection, preparation, handling, storage, and shipping instructions are provided in the Laboratory Manual."
              }
            },
            {
              "id": "SVC-002",
              "service_type": "central_imaging",
              "vendor_name": null,
              "data_flow": "Radiographic imaging scans will be sent to a central imaging vendor for BICR assessment.",
              "turnaround_time": null,
              "provenance": {
                "section_number": "8.3",
                "page_number": 110,
                "text_snippet": "BICR Radiographic Tumor Assessment\nRadiographic imaging scans will be sent to a central imaging vendor for BICR assessment."
              }
            },
            {
              "id": "SVC-003",
              "service_type": "central_ecg_reader",
              "vendor_name": null,
              "data_flow": "Electrocardiograms will be transmitted electronically to a central reader.",
              "turnaround_time": null,
              "provenance": {
                "section_number": "8.4.4",
                "page_number": 120,
                "text_snippet": "Electrocardiograms will be transmitted electronically to a central reader for determination of heart rate, PR interval, RR interval, QRS amplitude, QT interval, QTcF interval, and any other results."
              }
            }
          ],
          "provenance": {
            "section_number": "10.1.4",
            "page_number": 137,
            "text_snippet": "Data Collection"
          }
        },
        "equipment_facilities": {
          "instanceType": "EquipmentFacilities",
          "specialized_equipment": [
            {
              "id": "EQUIP-001",
              "equipment": "CT scanner",
              "required_or_preferred": "required",
              "specifications": "Spiral CT with <=5 mm cuts",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "8.3",
                "page_number": 109,
                "text_snippet": "Perform radiographic tumor assessments using spiral CT or MRI with \u22645 mm cuts unless another modality of disease assessment is necessary for the lesions."
              }
            },
            {
              "id": "EQUIP-002",
              "equipment": "MRI scanner",
              "required_or_preferred": "required",
              "specifications": "<=5 mm cuts",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "8.3",
                "page_number": 109,
                "text_snippet": "Perform radiographic tumor assessments using spiral CT or MRI with \u22645 mm cuts unless another modality of disease assessment is necessary for the lesions."
              }
            },
            {
              "id": "EQUIP-003",
              "equipment": "12-lead ECG machine",
              "required_or_preferred": "required",
              "specifications": "Digital transmission capable",
              "calibration_frequency": null,
              "provenance": {
                "section_number": "8.4.4",
                "page_number": 120,
                "text_snippet": "12-lead ECGs will be performed and recorded for every subject as per the Schedules of Events (Table 1.1 and Table 1.2)."
              }
            },
            {
              "id": "EQUIP-004",
              "equipment": "Echocardiogram (ECHO) or Multigated acquisition (MUGA) scan equipment",
              "required_or_preferred": "required",
              "specifications": null,
              "calibration_frequency": null,
              "provenance": {
                "section_number": "8.4.4",
                "page_number": 120,
                "text_snippet": "MUGA/ECHO must be performed as per the Schedules of Events (Table 1.1 and Table 1.2). Subjects must have an LVEF \u226550% to be eligible for the study."
              }
            }
          ],
          "facility_requirements": {
            "patient_space": "Area for IV infusion and post-infusion observation for at least 1 hour.",
            "storage_space": "Secure, limited-access, temperature-controlled storage for study drug.",
            "safety_equipment": null,
            "provenance": {
              "section_number": "6.1.1",
              "page_number": 81,
              "text_snippet": "Subjects should remain at the site for at least 1-hour post infusion of DS-1062a for close observation for possible allergic reaction."
            }
          },
          "provenance": {
            "section_number": "8",
            "page_number": 106,
            "text_snippet": "STUDY PROCEDURES"
          }
        },
        "vendor_coordination": [
          {
            "id": "VENDOR-001",
            "vendor_type": "CRO",
            "vendor_name": null,
            "services_provided": [
              "Monitoring",
              "Data management"
            ],
            "site_interface_required": true,
            "training_required": null,
            "contact_info": null,
            "provenance": {
              "section_number": "10.1.4",
              "page_number": 136,
              "text_snippet": "The CRO monitor and regulatory authority inspectors are responsible for contacting and visiting the Investigator for the purpose of inspecting the facilities and, upon request, inspecting the various records of the study (eCRFs, source data, and other pertinent documents)."
            }
          },
          {
            "id": "VENDOR-002",
            "vendor_type": "central_lab",
            "vendor_name": null,
            "services_provided": [
              "Biomarker sample analysis",
              "PK sample analysis",
              "COVID-19 testing"
            ],
            "site_interface_required": true,
            "training_required": null,
            "contact_info": null,
            "provenance": {
              "section_number": "8.6.2",
              "page_number": 123,
              "text_snippet": "Biomarker samples will be shipped to a central laboratory. Sample collection, preparation, handling, storage, and shipping instructions are provided in the Laboratory Manual."
            }
          },
          {
            "id": "VENDOR-003",
            "vendor_type": "central_imaging",
            "vendor_name": null,
            "services_provided": [
              "Blinded Independent Central Review (BICR) of radiographic scans"
            ],
            "site_interface_required": true,
            "training_required": null,
            "contact_info": null,
            "provenance": {
              "section_number": "8.3",
              "page_number": 110,
              "text_snippet": "BICR Radiographic Tumor Assessment\nRadiographic imaging scans will be sent to a central imaging vendor for BICR assessment."
            }
          },
          {
            "id": "VENDOR-004",
            "vendor_type": "central_ecg_reader",
            "vendor_name": null,
            "services_provided": [
              "Centralized reading of ECGs"
            ],
            "site_interface_required": true,
            "training_required": null,
            "contact_info": null,
            "provenance": {
              "section_number": "8.4.4",
              "page_number": 120,
              "text_snippet": "Electrocardiograms will be transmitted electronically to a central reader for determination of heart rate, PR interval, RR interval, QRS amplitude, QT interval, QTcF interval, and any other results."
            }
          }
        ],
        "extraction_statistics": {
          "has_site_selection_criteria": true,
          "has_regulatory_info": true,
          "has_personnel_requirements": true,
          "has_training_requirements": true,
          "has_monitoring_plan": true,
          "has_activation_timeline": false,
          "has_drug_supply_info": true,
          "has_technology_systems": true,
          "has_dispensing_schedule": true,
          "has_drug_accountability": true,
          "has_emergency_unblinding": true,
          "site_count_target": 190,
          "country_count": 0,
          "vendor_count": 4,
          "comparator_medication_count": 1
        },
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "CLINICAL STUDY PROTOCOL\nPHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS\nDOCETAXEL IN PREVIOUSLY TREATED ADVANCED\nOR METASTATIC NON-SMALL CELL LUNG CANCER\nWITH OR WITHOUT ACTIONABLE GENOMIC\nALTERATIONS (TROPION-LUNG01)"
        }
      }
    },
    "qualityManagement": {
      "moduleId": "quality_management",
      "instanceType": "QualityManagement",
      "data": {
        "id": "DS1062-A-U301F-quality-management",
        "instanceType": "QualityManagement",
        "name": "DS1062-A-U301F Quality Management",
        "ich_m11_section": "6.3",
        "monitoring": {
          "monitoring_approach": {
            "instanceType": "MonitoringApproach",
            "strategy": "hybrid",
            "rationale": "A combination of on-site and remote monitoring activities will be used to ensure subject safety, data integrity, and regulatory compliance, consistent with ICH E6(R2) principles. This approach allows for targeted on-site verification of critical data and processes, supplemented by frequent centralized review of data for trends and risk signals.",
            "regulatory_framework": [
              "ICH_E6_R2"
            ],
            "adaptive_monitoring": true,
            "centralized_monitoring_enabled": true,
            "centralized_monitoring_tools": [
              "EDC_data_review",
              "statistical_monitoring",
              "KRI_dashboard"
            ],
            "provenance": {
              "kind": "explicit",
              "explicit": {
                "section_number": "10.1.4",
                "page_number": 136,
                "text_snippet": "The verification of adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to ICH GCP and local regulations on the conduct of clinical research will be accomplished through a combination of onsite visits by the monitor and review of study data remotely. The frequency of the monitoring visit will vary based on the activity at each study site."
              }
            }
          },
          "sdv_strategy": {
            "instanceType": "SDVStrategy",
            "overall_approach": "risk_based",
            "default_sdv_percentage": 20,
            "critical_data_100_percent": [
              "informed_consent",
              "eligibility_criteria",
              "primary_endpoint",
              "SAEs",
              "withdrawal_reason"
            ],
            "sdv_reduction_criteria": {
              "enabled": true,
              "minimum_subjects_enrolled": 5,
              "error_rate_threshold_percent": 2,
              "reduced_sdv_percentage": 10,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not specify criteria for reducing SDV. These values are based on standard risk-based monitoring practices where SDV levels are adjusted based on site performance (e.g., low error rates after an initial number of subjects).",
                  "supporting_context": [
                    "Section 10.1.4 describes a hybrid monitoring approach, which is consistent with risk-based strategies."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "sdv_escalation_criteria": {
              "error_rate_threshold_percent": 5,
              "escalated_sdv_percentage": 100,
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not specify criteria for escalating SDV. These values are based on standard risk-based monitoring practices where high error rates would trigger an escalation to more intensive monitoring, potentially 100% SDV, to ensure data quality and subject safety.",
                  "supporting_context": [
                    "Section 10.1.4 states the monitor will ensure appropriate actions are taken for detected deviations."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "remote_sdv_enabled": true,
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol specifies a hybrid on-site and remote monitoring approach but does not detail the SDV strategy. The risk-based approach and specific percentages are inferred from standard industry practice for a Phase 3 oncology trial where critical data points are prioritized for verification.",
                "supporting_context": [
                  "Section 10.1.4: '...accomplished through a combination of onsite visits by the monitor and review of study data remotely.'"
                ],
                "confidence": "medium"
              }
            }
          },
          "monitoring_visits": {
            "instanceType": "MonitoringVisits",
            "site_initiation_visit": {
              "required": true,
              "timing": "Before first subject enrolled",
              "format": "on_site",
              "key_activities": [
                "protocol_training",
                "delegation_log_review",
                "EDC_training",
                "regulatory_binder_review",
                "IP_storage_verification"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not detail the Site Initiation Visit activities. These are standard, required activities for any clinical trial conducted under GCP to ensure a site is prepared to start enrollment, as implied by the requirement to follow GCP in Section 10.1.1.",
                  "supporting_context": [
                    "Section 10.1.1: 'This study will be conducted in compliance with the protocol...and applicable regulatory requirement(s)'",
                    "Section 10.1.6: Mentions maintenance of Signature List, regulatory documents, and inventory of study drug."
                  ],
                  "confidence": "high"
                }
              }
            },
            "routine_monitoring": {
              "on_site_visit_frequency": "risk_based_adaptive",
              "remote_monitoring_frequency": "monthly",
              "on_site_activities": [
                "100% review of informed consent forms",
                "Targeted SDV of critical data points",
                "Review of SAEs and protocol deviations",
                "Drug accountability reconciliation",
                "Review of investigator site file"
              ],
              "remote_activities": [
                "Centralized review of EDC data for trends and outliers",
                "Monitoring of KRIs and QTLs",
                "Query management and resolution tracking",
                "Review of visit compliance"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "10.1.4",
                  "page_number": 136,
                  "text_snippet": "The verification of adherence to the protocol; completeness, accuracy, and consistency of the data; and adherence to ICH GCP and local regulations on the conduct of clinical research will be accomplished through a combination of onsite visits by the monitor and review of study data remotely. The frequency of the monitoring visit will vary based on the activity at each study site."
                }
              }
            },
            "triggered_visits": [
              {
                "id": "trigger-001",
                "trigger_type": "KRI_threshold_breach",
                "response_timeline_hours": 72,
                "actions": [
                  "Remote contact with site to investigate root cause",
                  "Development of corrective action plan",
                  "Scheduling of on-site or remote targeted visit if issue persists"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not specify triggered visits based on KRI breaches. This is a standard component of a risk-based monitoring plan, where KRI alerts prompt timely follow-up to investigate and mitigate potential risks before they escalate.",
                    "supporting_context": [
                      "Section 10.1.4 implies a responsive monitoring approach: 'The monitor will communicate deviations...and will ensure that appropriate action(s)...is taken and documented.'"
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "id": "trigger-002",
                "trigger_type": "QTL_threshold_breach",
                "response_timeline_hours": 24,
                "actions": [
                  "Immediate escalation to study leadership",
                  "Initiation of formal root cause analysis",
                  "Implementation of study-wide CAPA"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol does not mention Quality Tolerance Limits (QTLs) or triggered visits. A QTL breach represents a significant risk to study integrity or subject safety, necessitating immediate, escalated action as a fundamental principle of risk-based quality management.",
                    "supporting_context": [
                      "The protocol's adherence to ICH GCP (Section 10.1.1) implies a quality management system that would respond to systemic errors affecting data integrity or subject safety."
                    ],
                    "confidence": "medium"
                  }
                }
              }
            ],
            "close_out_visit": {
              "timing": "after_LPLV",
              "timing_days_after_event": 60,
              "format": "on_site",
              "activities": [
                "Final review of investigator site file for completeness",
                "Final drug accountability and reconciliation",
                "Resolution of all outstanding data queries",
                "Ensuring all AEs/SAEs are reported and followed to resolution",
                "Review of data archiving requirements"
              ],
              "site_release_criteria": [
                "all_CRFs_complete",
                "all_queries_resolved",
                "final_drug_accountability_completed",
                "essential_documents_complete_and_filed"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "10.1.10",
                  "page_number": 140,
                  "text_snippet": "Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a study-site closure visit has been performed."
                }
              }
            },
            "provenance": {
              "kind": "explicit",
              "explicit": {
                "section_number": "10.1.4",
                "page_number": 136,
                "text_snippet": "Monitoring and Inspections"
              }
            }
          },
          "key_risk_indicators": [
            {
              "id": "KRI-001",
              "instanceType": "KeyRiskIndicator",
              "name": "Informed Consent Form Errors",
              "category": "protocol_compliance",
              "metric": "Percentage of subjects with errors in the ICF (e.g., missing signatures, incorrect dates).",
              "data_source": "EDC, Monitoring Reports",
              "review_frequency": "monthly",
              "threshold_green": "0%",
              "threshold_amber": ">0% to 2%",
              "threshold_red": ">2%",
              "action_amber": "Review specific errors with site staff and provide targeted retraining.",
              "action_red": "Immediate site call, perform root cause analysis, implement CAPA, and consider 100% review of all ICFs at site.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "10.1.2",
                  "page_number": 135,
                  "text_snippet": "The ICF should be signed and personally dated by the subject and by the person who conducted the informed consent discussion (not necessarily the Investigator)."
                }
              }
            },
            {
              "id": "KRI-002",
              "instanceType": "KeyRiskIndicator",
              "name": "Missed Tumor Assessments",
              "category": "data_integrity",
              "metric": "Percentage of scheduled tumor assessments (per RECIST 1.1) that are missed or performed outside the protocol-defined window.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": "<5%",
              "threshold_amber": "5-10%",
              "threshold_red": ">10%",
              "action_amber": "Contact site to understand reasons for missed assessments and reinforce scheduling requirements.",
              "action_red": "Escalate to project management, conduct site retraining on endpoint collection, assess impact on data usability.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "8.3",
                  "page_number": 109,
                  "text_snippet": "Antitumor activity will be assessed by Investigator at baseline (Screening) and every 6 weeks (\u00b17 days) from randomization independent of treatment cycle until radiographic disease progression..."
                }
              }
            },
            {
              "id": "KRI-003",
              "instanceType": "KeyRiskIndicator",
              "name": "SAE Reporting Timeliness",
              "category": "patient_safety",
              "metric": "Average number of business days from site awareness of an SAE to entry into the safety database.",
              "data_source": "Safety DB, EDC",
              "review_frequency": "weekly",
              "threshold_green": "<=1 day",
              "threshold_amber": ">1 to 2 days",
              "threshold_red": ">2 days",
              "action_amber": "Follow up with site on specific late reports to identify process delays.",
              "action_red": "Immediate site contact, retraining on SAE reporting process, and escalation to pharmacovigilance.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "8.4.1.1",
                  "page_number": 113,
                  "text_snippet": "The following types of events should be reported by the Investigator in the electronic data capture (EDC) within 24 hours of awareness: \u2022 SAEs (Section 10.5.2)."
                }
              }
            },
            {
              "id": "KRI-004",
              "instanceType": "KeyRiskIndicator",
              "name": "Major Protocol Deviation Rate",
              "category": "protocol_compliance",
              "metric": "Number of major protocol deviations per subject randomized at a site.",
              "data_source": "CTMS, Monitoring Reports",
              "review_frequency": "monthly",
              "threshold_green": "<0.1",
              "threshold_amber": "0.1 - 0.25",
              "threshold_red": ">0.25",
              "action_amber": "Review nature of deviations with site and discuss preventive measures.",
              "action_red": "Triggered monitoring visit to conduct root cause analysis and implement a formal CAPA.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "10.1.9",
                  "page_number": 140,
                  "text_snippet": "The Sponsor must be notified of all major deviations to the protocol (eg, inclusion/exclusion criteria, dosing, or missed study visits) and in accordance with the clinical study agreement between the parties on an expedited basis."
                }
              }
            },
            {
              "id": "KRI-005",
              "instanceType": "KeyRiskIndicator",
              "name": "Visit Compliance Rate",
              "category": "protocol_compliance",
              "metric": "Percentage of scheduled study visits completed within the protocol-specified window.",
              "data_source": "EDC",
              "review_frequency": "monthly",
              "threshold_green": ">=95%",
              "threshold_amber": "90-94.9%",
              "threshold_red": "<90%",
              "action_amber": "Investigate reasons for out-of-window visits with the site.",
              "action_red": "Discuss patient retention and scheduling challenges with the PI; evaluate for systemic site issues.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "1.3",
                  "page_number": 30,
                  "text_snippet": "Visit Window (Days)"
                }
              }
            },
            {
              "id": "KRI-006",
              "instanceType": "KeyRiskIndicator",
              "name": "ILD/Pneumonitis Reporting Rate",
              "category": "patient_safety",
              "metric": "Rate of reported potential ILD/pneumonitis cases (per subject-years) compared to expected rate.",
              "data_source": "Safety DB",
              "review_frequency": "monthly",
              "threshold_green": "Within expected range",
              "threshold_amber": "1.5x expected rate",
              "threshold_red": ">2x expected rate",
              "action_amber": "Review cases with medical monitor to ensure accurate reporting and assessment.",
              "action_red": "Escalate to safety committee, issue communication to all sites to reinforce awareness and detection guidelines.",
              "applies_to": "study_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "8.4.1.1",
                  "page_number": 113,
                  "text_snippet": "All potential ILD/pneumonitis cases should be reported within 24 hours, including both serious and non-serious potential ILD/pneumonitis cases (potential ILD/pneumonitis is described by the Event Adjudication Site Manual)."
                }
              }
            },
            {
              "id": "KRI-007",
              "instanceType": "KeyRiskIndicator",
              "name": "Eligibility Deviation Rate",
              "category": "protocol_compliance",
              "metric": "Percentage of randomized subjects found to have an eligibility deviation.",
              "data_source": "EDC, Monitoring Reports",
              "review_frequency": "monthly",
              "threshold_green": "0%",
              "threshold_amber": ">0% to 2%",
              "threshold_red": ">2%",
              "action_amber": "Review specific deviations to identify trends in misinterpretation of criteria.",
              "action_red": "Retrain site on eligibility criteria; consider revising IRT checklist if criteria are systematically missed.",
              "applies_to": "site_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "5.1",
                  "page_number": 73,
                  "text_snippet": "Subjects must meet all of the following criteria to be eligible for the study within 28 days before randomization into the study:"
                }
              }
            },
            {
              "id": "KRI-008",
              "instanceType": "KeyRiskIndicator",
              "name": "Screen Failure Rate",
              "category": "enrollment",
              "metric": "Percentage of subjects who sign consent but are not randomized.",
              "data_source": "CTMS, EDC",
              "review_frequency": "monthly",
              "threshold_green": "<40%",
              "threshold_amber": "40-60%",
              "threshold_red": ">60%",
              "action_amber": "Analyze screen failure reasons to identify potential recruitment challenges.",
              "action_red": "Discuss with site/region if specific criteria are disproportionately causing failures; evaluate pre-screening strategies.",
              "applies_to": "study_level",
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "5.3",
                  "page_number": 80,
                  "text_snippet": "For subjects who do not meet the criteria for participation in the study (screen failures), the reason for screen failure must be recorded in the Screening Log."
                }
              }
            }
          ],
          "quality_tolerance_limits": [
            {
              "id": "QTL-001",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Percentage of subjects with critical informed consent deviations (e.g., no consent, consent after start of procedures).",
              "category": "informed_consent",
              "acceptable_limit": "0%",
              "acceptable_limit_numeric": 0,
              "alert_threshold": "Any single occurrence",
              "alert_threshold_numeric": 1,
              "action_threshold": "Any single occurrence",
              "action_threshold_numeric": 1,
              "predefined_actions": [
                "Immediate investigation and root cause analysis",
                "CAPA initiation",
                "Reporting to IRB/EC and regulatory authorities as required",
                "Evaluation of subject's continuation in the study"
              ],
              "escalation_path": [
                "Project Lead",
                "Head of Clinical Operations",
                "Quality Assurance"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "10.1.2",
                  "page_number": 135,
                  "text_snippet": "In obtaining and documenting informed consent, the Investigator should comply with the applicable regulatory requirements, and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki."
                }
              }
            },
            {
              "id": "QTL-002",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Percentage of subjects randomized who do not meet key inclusion/exclusion criteria related to safety or primary endpoint interpretability.",
              "category": "eligibility",
              "acceptable_limit": "<= 1%",
              "acceptable_limit_numeric": 0.01,
              "alert_threshold": "> 1%",
              "alert_threshold_numeric": 0.01,
              "action_threshold": "> 2%",
              "action_threshold_numeric": 0.02,
              "predefined_actions": [
                "Conduct root cause analysis of eligibility deviations",
                "Implement study-wide retraining on eligibility criteria",
                "Revise screening and randomization procedures if necessary"
              ],
              "escalation_path": [
                "Medical Monitor",
                "Project Lead",
                "Steering Committee"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not define a specific QTL for eligibility. This limit is derived from ICH E6(R2) principles, where systemic failure to enroll the correct population is a critical quality issue that undermines study integrity. A low tolerance for such errors is standard.",
                  "supporting_context": [
                    "Section 5.1 and 5.2 define the strict inclusion and exclusion criteria, highlighting their importance."
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-003",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Percentage of subjects in the Full Analysis Set (FAS) with missing or unevaluable data for the primary endpoint (PFS by BICR).",
              "category": "data_integrity",
              "acceptable_limit": "<= 5%",
              "acceptable_limit_numeric": 0.05,
              "alert_threshold": "> 5%",
              "alert_threshold_numeric": 0.05,
              "action_threshold": "> 7.5%",
              "action_threshold_numeric": 0.075,
              "predefined_actions": [
                "Investigate reasons for missing endpoint data (e.g., missed scans, imaging quality)",
                "Implement corrective actions with sites and imaging vendor",
                "Assess impact on statistical power and study integrity"
              ],
              "escalation_path": [
                "Data Management Lead",
                "Biostatistics Lead",
                "Project Lead"
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not define a specific QTL for missing primary endpoint data. This limit is derived from statistical best practices, where a high percentage of missing primary endpoint data can severely compromise the statistical power and validity of the study's primary analysis.",
                  "supporting_context": [
                    "Section 3.1 identifies PFS as an independent primary endpoint.",
                    "Section 9.3 details the sample size calculation, which assumes a certain level of evaluable data."
                  ],
                  "confidence": "high"
                }
              }
            },
            {
              "id": "QTL-004",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Percentage of subjects who discontinue study drug due to toxicity who are subsequently lost to follow-up for survival assessment.",
              "category": "patient_safety",
              "acceptable_limit": "<= 5%",
              "acceptable_limit_numeric": 0.05,
              "alert_threshold": "> 5%",
              "alert_threshold_numeric": 0.05,
              "action_threshold": "> 10%",
              "action_threshold_numeric": 0.1,
              "predefined_actions": [
                "Analyze reasons for loss to follow-up",
                "Implement enhanced procedures for maintaining contact with discontinued subjects",
                "Assess potential for bias in the OS analysis"
              ],
              "escalation_path": [
                "Project Lead",
                "Biostatistics Lead",
                "Steering Committee"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "7.3",
                  "page_number": 105,
                  "text_snippet": "Knowledge of the vital status at study end in all subjects is crucial for the integrity of the study."
                }
              }
            },
            {
              "id": "QTL-005",
              "instanceType": "QualityToleranceLimit",
              "parameter": "Assignment of incorrect treatment arm at randomization.",
              "category": "protocol_compliance",
              "acceptable_limit": "0%",
              "acceptable_limit_numeric": 0,
              "alert_threshold": "Any single occurrence",
              "alert_threshold_numeric": 1,
              "action_threshold": "Any single occurrence",
              "action_threshold_numeric": 1,
              "predefined_actions": [
                "Immediate investigation of IRT system and site process failure",
                "CAPA to prevent recurrence",
                "Determine subject's disposition for safety and efficacy analyses per SAP"
              ],
              "escalation_path": [
                "IRT Vendor Manager",
                "Project Lead",
                "Head of Clinical Operations"
              ],
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "6.3",
                  "page_number": 85,
                  "text_snippet": "Eligible subjects will be randomized in a 1:1 ratio to DS-1062a 6.0 mg/kg or the control treatment, docetaxel. Randomization will be managed through an IRT for subjects meeting all eligibility criteria."
                }
              }
            }
          ],
          "findings_management": {
            "instanceType": "FindingsManagement",
            "finding_categories": [
              {
                "id": "finding-cat-001",
                "category": "critical",
                "definition": "A finding that adversely affects the rights, safety, or well-being of a subject, or the integrity of the study data. Requires immediate action.",
                "response_timeline_days": 1,
                "requires_capa": true,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol requires reporting of major deviations and SAEs within 24 hours, implying a 'critical' category for findings that pose an immediate risk to subject safety or data integrity, necessitating rapid response.",
                    "supporting_context": [
                      "Section 8.4.1.1: '...reported by the Investigator in the electronic data capture (EDC) within 24 hours of awareness: \u2022 SAEs...'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "id": "finding-cat-002",
                "category": "major",
                "definition": "A finding that could potentially affect subject safety or data integrity and indicates a significant departure from the protocol or GCP. Requires timely action.",
                "response_timeline_days": 15,
                "requires_capa": true,
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10.1.9",
                    "page_number": 140,
                    "text_snippet": "The Sponsor must be notified of all major deviations to the protocol (eg, inclusion/exclusion criteria, dosing, or missed study visits) and in accordance with the clinical study agreement between the parties on an expedited basis."
                  }
                }
              },
              {
                "id": "finding-cat-003",
                "category": "minor",
                "definition": "A finding that does not materially impact subject safety or data integrity but represents a deviation from the protocol or procedures. To be corrected in a timely manner.",
                "response_timeline_days": 30,
                "requires_capa": false,
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This category is inferred as the logical counterpart to 'major' deviations. Not all deviations are major; this category covers less significant departures from the protocol that still require documentation and correction but do not pose an immediate risk.",
                    "supporting_context": [
                      "Section 10.1.9: 'The Investigator, or person designated by the Investigator, should document and explain any deviation from the approved protocol.'"
                    ],
                    "confidence": "high"
                  }
                }
              }
            ],
            "capa_process": {
              "capa_triggers": [
                "critical_finding",
                "repeated_major_finding",
                "QTL_breach",
                "systemic_issue_identified_via_central_monitoring"
              ],
              "response_timeline_days": 30,
              "verification_required": true,
              "tracking_system": "Quality Management System",
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not describe a formal CAPA process. This is derived from standard GCP requirements (ICH E6 R2 Section 5.20) where sponsors must manage non-compliance, including root cause analysis and implementing corrective and preventive actions.",
                  "supporting_context": [
                    "Section 10.1.4: 'The monitor will communicate deviations...and will ensure that appropriate action(s) designed to prevent recurrence of the detected deviations is taken and documented.'"
                  ],
                  "confidence": "high"
                }
              }
            },
            "protocol_deviation_management": {
              "deviation_categories": [
                "major",
                "minor"
              ],
              "internal_reporting_timeline_days": 5,
              "irb_reporting_required": true,
              "irb_reporting_timeline_days": 15,
              "root_cause_analysis_required": true,
              "provenance": {
                "kind": "explicit",
                "explicit": {
                  "section_number": "10.1.9",
                  "page_number": 140,
                  "text_snippet": "The Sponsor must be notified of all major deviations to the protocol...on an expedited basis. The Investigator, or person designated by the Investigator, should document and explain any deviation from the approved protocol."
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The concept of 'Findings Management' is derived from the protocol's sections on monitoring and protocol deviations, which describe the process for identifying, documenting, and correcting issues found during the study.",
                "supporting_context": [
                  "Section 10.1.4 Monitoring and Inspections",
                  "Section 10.1.9 Protocol Deviations"
                ],
                "confidence": "high"
              }
            }
          },
          "monitoring_reports": {
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol does not specify the types or content of monitoring reports. This is a standard requirement under ICH GCP (E6 R2 5.18.6), where monitors are required to submit written reports to the sponsor after each visit or communication.",
                "supporting_context": [
                  "Section 10.1.4 implies reporting by stating the monitor will communicate deviations and ensure actions are documented."
                ],
                "confidence": "high"
              }
            }
          },
          "provenance": {
            "kind": "explicit",
            "explicit": {
              "section_number": "10.1.4",
              "page_number": 136,
              "text_snippet": "Monitoring and Inspections"
            }
          }
        },
        "rbqm": {
          "ract_register": {
            "critical_to_quality_factors": [
              {
                "ctq_id": "CTQ-001",
                "ctq_category": "Patient Safety",
                "factor": "Accurate and timely identification, management, and reporting of Interstitial Lung Disease (ILD)/pneumonitis.",
                "insight_type": "explicit",
                "clinical_reasoning": "ILD/pneumonitis is an important identified risk for DS-1062a with potential for severe or fatal outcomes. Failure to detect and manage it promptly poses a direct threat to subject safety.",
                "failure_mode": "Site staff fail to recognize early symptoms, delay necessary evaluations (e.g., HRCT), or do not adhere to protocol-specified dose modification/discontinuation guidelines.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 3,
                "risk_priority_number": 45,
                "affected_stakeholders": [
                  "Patient",
                  "Site",
                  "Sponsor"
                ],
                "preventive_controls": [
                  "Mandatory site training on ILD/pneumonitis identification and management protocol.",
                  "Providing sites with a symptom checklist for patients."
                ],
                "detective_controls": [
                  "Centralized monitoring of pulmonary-related adverse events and targeted questionnaires.",
                  "Independent ILD Adjudication Committee review of all potential cases."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "2.3",
                    "page_number": 57,
                    "text_snippet": "Based on cumulative review of safety data, important identified risks for DS-1062a are ILD/pneumonitis."
                  }
                }
              },
              {
                "ctq_id": "CTQ-002",
                "ctq_category": "Endpoint Integrity",
                "factor": "Consistent and accurate tumor assessments performed per RECIST v1.1 and study imaging manual for Blinded Independent Central Review (BICR).",
                "insight_type": "explicit",
                "clinical_reasoning": "Progression-Free Survival (PFS) by BICR is a primary endpoint. Inconsistent or poor-quality imaging invalidates the assessment of progression, compromising the ability to evaluate the primary study objective.",
                "failure_mode": "Sites use incorrect imaging techniques, fail to perform scans within the specified window, or submit incomplete/unreadable images to the central vendor, leading to unevaluable timepoints.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 2,
                "risk_priority_number": 30,
                "affected_stakeholders": [
                  "Sponsor",
                  "Regulatory Authorities"
                ],
                "preventive_controls": [
                  "Detailed Imaging Manual provided to all sites.",
                  "SIV training on imaging requirements.",
                  "Central imaging vendor performs quality check on initial scans from each site."
                ],
                "detective_controls": [
                  "Ongoing quality checks of submitted scans by the central imaging vendor.",
                  "Centralized monitoring of missed scan visits."
                ],
                "mitigation_hierarchy_level": "Engineering",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "4.1",
                    "page_number": 64,
                    "text_snippet": "PFS as assessed by BICR per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) and OS are the 2 independent primary endpoints of the study."
                  }
                }
              },
              {
                "ctq_id": "CTQ-003",
                "ctq_category": "GCP Compliance",
                "factor": "Ensuring every subject provides legally effective informed consent prior to any study-specific procedures.",
                "insight_type": "explicit",
                "clinical_reasoning": "Informed consent is the ethical and legal foundation of clinical research. Failure to obtain it correctly violates GCP, subject rights, and renders all collected data unusable.",
                "failure_mode": "Site performs study procedures before consent is signed/dated, uses an outdated version of the ICF, or fails to properly document the consent process.",
                "severity_score": 5,
                "probability_score": 2,
                "detectability_score": 1,
                "risk_priority_number": 10,
                "affected_stakeholders": [
                  "Patient",
                  "Site",
                  "Sponsor",
                  "IRB_IEC"
                ],
                "preventive_controls": [
                  "Thorough training on the consent process at SIV.",
                  "Use of an eligibility checklist that includes confirmation of consent."
                ],
                "detective_controls": [
                  "100% SDV of informed consent forms at the first monitoring visit for each subject."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10.1.2",
                    "page_number": 135,
                    "text_snippet": "In obtaining and documenting informed consent, the Investigator should comply with the applicable regulatory requirements, and should adhere to GCP and to the ethical principles that have their origin in the Declaration of Helsinki."
                  }
                }
              },
              {
                "ctq_id": "CTQ-004",
                "ctq_category": "Patient Safety",
                "factor": "Correct application of dose modification guidelines for DS-1062a and docetaxel-related toxicities.",
                "insight_type": "explicit",
                "clinical_reasoning": "The protocol provides specific rules for dose delays, reductions, and discontinuations based on toxicity grade. Failure to follow these rules can lead to unnecessary harm to subjects or premature discontinuation of a potentially beneficial treatment.",
                "failure_mode": "Investigator does not reduce dose as required for a Grade 3 toxicity, or delays a dose for longer than permitted, leading to increased risk or protocol deviation.",
                "severity_score": 4,
                "probability_score": 3,
                "detectability_score": 2,
                "risk_priority_number": 24,
                "affected_stakeholders": [
                  "Patient",
                  "Site"
                ],
                "preventive_controls": [
                  "Clear dose modification tables in the protocol.",
                  "Site training on toxicity management guidelines."
                ],
                "detective_controls": [
                  "Centralized review of lab data and AE data for events that should trigger dose modifications.",
                  "Targeted SDV of dosing records."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-004"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.5",
                    "page_number": 85,
                    "text_snippet": "All dose modifications (ie, infusion interruptions, dose delays, re-initiation, dose reduction, and/or treatment discontinuation) should be based on the worst preceding toxicity NCI-CTCAE v5.0."
                  }
                }
              },
              {
                "ctq_id": "CTQ-005",
                "ctq_category": "Endpoint Integrity",
                "factor": "Complete and accurate collection of survival status for all subjects until the end of the study.",
                "insight_type": "inferred",
                "clinical_reasoning": "Overall Survival (OS) is a primary endpoint. Missing survival data, especially if the missingness is not random, can introduce significant bias into the analysis and compromise the study's ability to assess the treatment effect on survival.",
                "failure_mode": "Sites lose contact with subjects after they discontinue treatment, failing to obtain date and cause of death. This leads to a high rate of censoring in the OS analysis.",
                "severity_score": 5,
                "probability_score": 3,
                "detectability_score": 3,
                "risk_priority_number": 45,
                "affected_stakeholders": [
                  "Sponsor",
                  "Regulatory Authorities"
                ],
                "preventive_controls": [
                  "Clear procedures for long-term survival follow-up defined in the protocol.",
                  "Obtaining secondary contact information from subjects at enrollment."
                ],
                "detective_controls": [
                  "Centralized monitoring of subject status and follow-up contact schedule.",
                  "Periodic checks against public records where permissible."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-005"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "7.3",
                    "page_number": 105,
                    "text_snippet": "Knowledge of the vital status at study end in all subjects is crucial for the integrity of the study."
                  }
                }
              },
              {
                "ctq_id": "CTQ-006",
                "ctq_category": "Operational Feasibility",
                "factor": "Accurate enrollment of subjects with or without actionable genomic alterations (AGAs) according to complex prior therapy requirements.",
                "insight_type": "inferred",
                "clinical_reasoning": "The study has distinct, complex eligibility pathways for subjects with and without AGAs. Enrolling subjects in the wrong cohort undermines the scientific validity of subgroup analyses and the overall interpretability of the results.",
                "failure_mode": "Sites misinterpret the number or type of prior therapies required for a specific cohort, or rely on incomplete genomic testing results, leading to enrollment of ineligible subjects.",
                "severity_score": 4,
                "probability_score": 4,
                "detectability_score": 2,
                "risk_priority_number": 32,
                "affected_stakeholders": [
                  "Sponsor",
                  "Site"
                ],
                "preventive_controls": [
                  "Detailed flowcharts and training materials for eligibility assessment.",
                  "Mandatory use of a comprehensive eligibility checklist prior to randomization."
                ],
                "detective_controls": [
                  "100% SDV of eligibility criteria, including source documentation for prior therapies and genomic reports.",
                  "Centralized review of screening data."
                ],
                "mitigation_hierarchy_level": "Administrative",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.1",
                    "page_number": 74,
                    "text_snippet": "Subject must meet the following prior therapy requirements: Subjects without AGA must meet ONE of the following prior therapy requirements... Subjects with AGA must meet the following prior therapy requirements..."
                  }
                }
              }
            ],
            "emergent_systemic_risks": [
              {
                "risk_id": "ESR-001",
                "risk_type": "cross_domain",
                "risk_description": "Misclassification of subjects' Actionable Genomic Alteration (AGA) status due to variability in local lab testing standards and incomplete testing for all required genes (EGFR, ALK, ROS1, etc.).",
                "discovery_reasoning": "The protocol relies on local testing for genomic status, which introduces variability. This risk emerges from the interaction between study design (stratification) and operational execution (site procedures).",
                "affected_domains": [
                  "Eligibility",
                  "Study Design",
                  "Data Quality"
                ],
                "trigger_conditions": "Sites with less experience in comprehensive genomic profiling or in regions with limited access to next-generation sequencing.",
                "probability": "Possible",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Primary Efficacy",
                  "Subgroup Analysis Integrity"
                ],
                "quantitative_estimate": "Potential for 5-10% mis-stratification rate.",
                "preventive_redesign": "Implement central laboratory confirmation for key genomic alterations for all subjects.",
                "monitoring_approach": "Monitor rates of AGA vs. non-AGA enrollment by country/site to detect unexpected distributions. Review source documentation for genomic reports.",
                "contingency_plan": "Conduct sensitivity analyses to assess the impact of potential mis-stratification on study results. Re-classify subjects if definitive data becomes available.",
                "linked_ctq_ids": [
                  "CTQ-006"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.1",
                    "page_number": 73,
                    "text_snippet": "If test results for EGFR and ALK are not available, subjects are required to undergo testing performed locally for these genomic alterations."
                  }
                }
              },
              {
                "risk_id": "ESR-002",
                "risk_type": "interaction_effect",
                "risk_description": "Diagnostic confusion between drug-induced ILD/pneumonitis and respiratory infections like COVID-19, leading to delayed or inappropriate treatment for either condition.",
                "discovery_reasoning": "The protocol acknowledges the risk of COVID-19. This risk emerges from the interaction of a known drug safety risk (ILD) with an external, environmental factor (pandemic respiratory virus) that presents with similar symptoms.",
                "affected_domains": [
                  "Safety",
                  "Data Collection"
                ],
                "trigger_conditions": "Subject presents with cough, dyspnea, or fever.",
                "probability": "Likely",
                "impact_severity": "Catastrophic",
                "affected_objectives": [
                  "Patient Safety"
                ],
                "quantitative_estimate": "Could impact 10-15% of subjects experiencing respiratory symptoms.",
                "preventive_redesign": "N/A - Cannot redesign out an external factor.",
                "monitoring_approach": "Track all respiratory AEs and ensure protocol-required workups (including COVID-19 testing and HRCT) are performed promptly. Use ILD Adjudication Committee.",
                "contingency_plan": "Issue study-wide guidance on the differential diagnosis process. Ensure medical monitors are readily available for consultation with sites.",
                "linked_ctq_ids": [
                  "CTQ-001"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "2.3.1",
                    "page_number": 58,
                    "text_snippet": "With the emergence of the Coronavirus disease 2019 (COVID-19) comes an increased safety risk for all subjects. As a result of the potential impact of COVID-19 on the lung, the Sponsor has developed a monitoring plan to limit and manage the potential risk of COVID-19..."
                  }
                }
              },
              {
                "risk_id": "ESR-003",
                "risk_type": "temporal",
                "risk_description": "Over the study's long duration (~43 months), the standard of care for previously treated NSCLC may evolve, making docetaxel a less relevant comparator and confounding the OS endpoint due to heterogeneous and more effective subsequent therapies.",
                "discovery_reasoning": "The oncology landscape changes rapidly. This risk emerges over time as external medical practice advances independently of the trial.",
                "affected_domains": [
                  "Study Design",
                  "Endpoint Integrity"
                ],
                "trigger_conditions": "Approval of new, highly effective therapies for the study population during the trial's follow-up phase.",
                "probability": "Almost Certain",
                "impact_severity": "Major",
                "affected_objectives": [
                  "Overall Survival Endpoint"
                ],
                "quantitative_estimate": "Potential for significant crossover-like effect, diluting OS hazard ratio by 10-20%.",
                "preventive_redesign": "Use of PFS as a co-primary endpoint helps mitigate confounding of OS.",
                "monitoring_approach": "Systematically collect data on all subsequent anti-cancer therapies for all subjects.",
                "contingency_plan": "Pre-specify statistical analyses to adjust for the impact of subsequent therapies (e.g., two-stage models, rank-preserving structural failure time models).",
                "linked_ctq_ids": [
                  "CTQ-005"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "4.1.4",
                    "page_number": 69,
                    "text_snippet": "The anticipated total duration of the study is approximately 43 months."
                  }
                }
              },
              {
                "risk_id": "ESR-004",
                "risk_type": "second_order",
                "risk_description": "High incidence of Grade 1-2 oral mucositis/stomatitis, while not severe, leads to poor quality of life and nutritional status, causing a higher-than-expected rate of dose reductions and discontinuations for 'tolerability' reasons, which are not the primary dose-limiting toxicities.",
                "discovery_reasoning": "Stomatitis is a known frequent TEAE. The second-order effect is the cumulative impact of a non-critical AE on overall treatment adherence and subject well-being.",
                "affected_domains": [
                  "Safety",
                  "Data Quality"
                ],
                "trigger_conditions": "Subjects in cycles 2-4 who have experienced persistent low-grade stomatitis.",
                "probability": "Likely",
                "impact_severity": "Moderate",
                "affected_objectives": [
                  "Treatment Exposure",
                  "PRO data"
                ],
                "quantitative_estimate": "May contribute to 10% more dose modifications than anticipated.",
                "preventive_redesign": "Strengthen protocol guidance on prophylactic oral care protocols (OCP) and make them mandatory.",
                "monitoring_approach": "Track rates of dose modifications linked to stomatitis/mucositis. Monitor PRO data related to oral symptoms.",
                "contingency_plan": "Issue a study newsletter to all sites reinforcing the importance of proactive management of oral mucositis and available supportive care options.",
                "linked_ctq_ids": [
                  "CTQ-004"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "6.2.1",
                    "page_number": 83,
                    "text_snippet": "For prevention of oral mucositis/stomatitis, subjects are advised to initiate a daily oral care protocol (OCP) before study intervention initiation and maintain it throughout the study."
                  }
                }
              }
            ],
            "strategic_risk_indicators": [
              {
                "kri_id": "SKRI-001",
                "kri_type": "leading_indicator",
                "category": "Risk Velocity",
                "metric": "Rate of site-initiated queries to the medical monitor regarding eligibility criteria for prior lines of therapy.",
                "rationale": "A high rate of queries indicates widespread confusion about the complex eligibility rules. This is a leading indicator that predicts a future increase in enrollment errors and major protocol deviations if not addressed.",
                "predictive_value": "Predicts an increase in the rate of major protocol deviations related to eligibility in the subsequent 1-2 months.",
                "calculation_formula": "(Number of eligibility queries from sites in a period) / (Number of subjects screened in that period)",
                "data_sources": [
                  "Medical Monitoring Log",
                  "CTMS"
                ],
                "frequency": "Monthly",
                "thresholds": {
                  "green": {
                    "range": "<5%",
                    "interpretation": "Sites understand eligibility criteria."
                  },
                  "amber": {
                    "range": "5-10%",
                    "interpretation": "Emerging confusion at some sites.",
                    "escalation": "Project Manager"
                  },
                  "red": {
                    "range": ">10%",
                    "interpretation": "Systemic misunderstanding of eligibility.",
                    "escalation": "Steering Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-006"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This is a strategic, leading indicator not explicitly defined in the protocol. It is derived from the identified risk of misinterpreting complex eligibility criteria (Section 5.1) and represents a proactive method to monitor and mitigate that risk before it leads to deviations.",
                    "supporting_context": [
                      "Section 5.1 details the complex prior therapy requirements for AGA and non-AGA cohorts."
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "kri_id": "SKRI-002",
                "kri_type": "leading_indicator",
                "category": "Quality Trajectory",
                "metric": "Median time from onset of respiratory symptoms (cough, dyspnea) to completion of required ILD workup (HRCT scan).",
                "rationale": "This metric tracks the operational efficiency of the safety process for the study's most critical risk. An increasing trend is a leading indicator of process decay or site burden, predicting a higher likelihood of delayed diagnosis and management of ILD.",
                "predictive_value": "Predicts an increased risk of severe outcomes (Grade 3+ ILD) due to delayed intervention.",
                "calculation_formula": "Median (Date of HRCT - Date of symptom onset) for all subjects with a workup in a rolling 3-month period.",
                "data_sources": [
                  "EDC",
                  "Safety DB"
                ],
                "frequency": "Monthly",
                "thresholds": {
                  "green": {
                    "range": "<= 7 days",
                    "interpretation": "Prompt safety evaluation."
                  },
                  "amber": {
                    "range": "8-14 days",
                    "interpretation": "Potential delays in safety workup.",
                    "escalation": "Medical Monitor Lead"
                  },
                  "red": {
                    "range": ">14 days",
                    "interpretation": "Unacceptable delay in critical safety process.",
                    "escalation": "Safety Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-001"
                ],
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "8.4.1.2",
                    "page_number": 115,
                    "text_snippet": "If the AE is suspected to be ILD/pneumonitis, treatment with study drug should be delayed pending further evaluations. Evaluations should include high-resolution CT..."
                  }
                }
              },
              {
                "kri_id": "SKRI-003",
                "kri_type": "leading_indicator",
                "category": "Operational Health",
                "metric": "Percentage of subjects requiring a dose reduction for any toxicity within the first two cycles of treatment.",
                "rationale": "A high rate of early dose reductions, even for non-severe toxicities, is a leading indicator of overall drug tolerability in the real-world study population. It predicts challenges with maintaining dose intensity and long-term treatment adherence.",
                "predictive_value": "Predicts overall rates of treatment discontinuation and total drug exposure over the life of the study.",
                "calculation_formula": "(Number of subjects with a dose reduction in C1 or C2) / (Total subjects who completed C2)",
                "data_sources": [
                  "EDC"
                ],
                "frequency": "Quarterly",
                "thresholds": {
                  "green": {
                    "range": "<15%",
                    "interpretation": "Tolerability is as expected."
                  },
                  "amber": {
                    "range": "15-25%",
                    "interpretation": "Tolerability may be worse than anticipated.",
                    "escalation": "Medical Monitor"
                  },
                  "red": {
                    "range": ">25%",
                    "interpretation": "Significant tolerability concerns.",
                    "escalation": "Safety Committee, Steering Committee"
                  }
                },
                "linked_ctq_ids": [
                  "CTQ-004"
                ],
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This indicator is not in the protocol. It is derived from the known safety profile and dose modification rules (Section 6.5). Monitoring early dose reductions provides a leading indicator of overall treatment tolerability and potential challenges with maintaining dose intensity throughout the study.",
                    "supporting_context": [
                      "Section 6.5.1 provides guidelines for dose modification and reduction for DS-1062a."
                    ],
                    "confidence": "high"
                  }
                }
              }
            ],
            "strategic_summary": {
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "A strategic summary is not present in the protocol. It is an output of a comprehensive risk assessment process, which is implied by the protocol's adherence to modern GCP standards but not explicitly detailed within this document.",
                  "supporting_context": [
                    "The entire RBQM section is derived from the risks and processes described throughout the protocol."
                  ],
                  "confidence": "medium"
                }
              }
            }
          },
          "risk_governance": {
            "risk_assessment_matrix": {
              "scoring_methodology": {
                "probability_scale": {
                  "1": "Rare (<5%)",
                  "2": "Unlikely (5-20%)",
                  "3": "Possible (20-50%)",
                  "4": "Likely (50-80%)",
                  "5": "Almost Certain (>80%)"
                },
                "impact_scale": {
                  "1": "Negligible",
                  "2": "Minor",
                  "3": "Moderate",
                  "4": "Major",
                  "5": "Catastrophic"
                },
                "risk_levels": {
                  "1-4": "Low",
                  "5-9": "Medium",
                  "10-14": "High",
                  "15-25": "Critical"
                }
              },
              "identified_risks": [
                {
                  "risk_id": "RISK-001",
                  "risk_category": "Safety",
                  "risk_description": "Delayed detection and management of drug-induced ILD/pneumonitis, leading to severe patient outcomes.",
                  "risk_owner": "Sponsor Medical Monitor",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "risk_reduction_percentage": 33,
                  "linked_ctq_id": "CTQ-001",
                  "linked_mitigation_ids": [
                    "MIT-001",
                    "MIT-002"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "8.4.1.2",
                      "page_number": 115,
                      "text_snippet": "ILD/pneumonitis is considered an important identified risk based on a comprehensive cumulative review of the available safety data from the clinical development program..."
                    }
                  }
                },
                {
                  "risk_id": "RISK-002",
                  "risk_category": "Endpoints",
                  "risk_description": "Inconsistent tumor imaging (technique, timing) across sites leads to high variability and unevaluable scans for the primary PFS endpoint by BICR.",
                  "risk_owner": "Clinical Operations Lead",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 5,
                    "score": 20,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-002",
                  "linked_mitigation_ids": [
                    "MIT-003"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "8.3",
                      "page_number": 109,
                      "text_snippet": "The same imaging technique (CT or MRI) used to characterize each identified and reported lesion at baseline will be used in the subsequent tumor assessments."
                    }
                  }
                },
                {
                  "risk_id": "RISK-003",
                  "risk_category": "Subject Population",
                  "risk_description": "Enrollment of ineligible subjects due to misinterpretation of complex prior therapy and genomic alteration criteria.",
                  "risk_owner": "Site Investigator",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 4,
                    "score": 16,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 4,
                    "score": 8,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-006",
                  "linked_mitigation_ids": [
                    "MIT-004",
                    "MIT-005"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.1",
                      "page_number": 74,
                      "text_snippet": "Subject must meet the following prior therapy requirements..."
                    }
                  }
                },
                {
                  "risk_id": "RISK-004",
                  "risk_category": "IMP",
                  "risk_description": "Incorrect application of dose modification rules for managing toxicities, leading to patient safety events or premature discontinuation.",
                  "risk_owner": "Site Investigator",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 4,
                    "score": 12,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 4,
                    "score": 8,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 33,
                  "linked_ctq_id": "CTQ-004",
                  "linked_mitigation_ids": [
                    "MIT-006"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "6.5.1",
                      "page_number": 86,
                      "text_snippet": "Specific criteria for DS-1062a infusion interruptions, dose delays, re-initiation, dose reduction, and/or discontinuation in case of TEAEs that are considered related to the use of DS-1062a by the Investigator are presented in Table 6.4..."
                    }
                  }
                },
                {
                  "risk_id": "RISK-005",
                  "risk_category": "Data Collection",
                  "risk_description": "High rate of loss to follow-up for survival status after treatment discontinuation, introducing bias to the OS primary endpoint.",
                  "risk_owner": "Clinical Operations Lead",
                  "inherent_risk": {
                    "probability": 3,
                    "impact": 5,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 2,
                    "impact": 5,
                    "score": 10,
                    "level": "High"
                  },
                  "risk_reduction_percentage": 33,
                  "linked_ctq_id": "CTQ-005",
                  "linked_mitigation_ids": [
                    "MIT-007"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "7.3",
                      "page_number": 105,
                      "text_snippet": "A subject will be considered lost to follow-up if s/he fails to return for 2 consecutive scheduled visits per the Schedules of Events and is unable to be contacted by the study site staff."
                    }
                  }
                },
                {
                  "risk_id": "RISK-006",
                  "risk_category": "Operational",
                  "risk_description": "Slow enrollment due to high screen failure rate from restrictive eligibility criteria, jeopardizing study timelines.",
                  "risk_owner": "Project Manager",
                  "inherent_risk": {
                    "probability": 4,
                    "impact": 3,
                    "score": 12,
                    "level": "High"
                  },
                  "residual_risk": {
                    "probability": 3,
                    "impact": 3,
                    "score": 9,
                    "level": "Medium"
                  },
                  "risk_reduction_percentage": 25,
                  "linked_ctq_id": null,
                  "linked_mitigation_ids": [
                    "MIT-008"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "5.3",
                      "page_number": 80,
                      "text_snippet": "For subjects who do not meet the criteria for participation in the study (screen failures), the reason for screen failure must be recorded in the Screening Log."
                    }
                  }
                },
                {
                  "risk_id": "RISK-007",
                  "risk_category": "Geography",
                  "risk_description": "Significant regional differences in subsequent lines of therapy post-progression confound the OS analysis.",
                  "risk_owner": "Biostatistics Lead",
                  "inherent_risk": {
                    "probability": 5,
                    "impact": 3,
                    "score": 15,
                    "level": "Critical"
                  },
                  "residual_risk": {
                    "probability": 5,
                    "impact": 2,
                    "score": 10,
                    "level": "High"
                  },
                  "risk_reduction_percentage": 33,
                  "linked_ctq_id": "CTQ-005",
                  "linked_mitigation_ids": [
                    "MIT-009"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "4.1.1",
                      "page_number": 64,
                      "text_snippet": "...stratified by...geographical region (United States [US]/Japan/Western Europe versus rest of world [ROW])."
                    }
                  }
                },
                {
                  "risk_id": "RISK-008",
                  "risk_category": "Technology",
                  "risk_description": "IRT system mis-stratifies a subject due to incorrect data entry at the site, leading to randomization imbalance.",
                  "risk_owner": "Site Staff",
                  "inherent_risk": {
                    "probability": 2,
                    "impact": 4,
                    "score": 8,
                    "level": "Medium"
                  },
                  "residual_risk": {
                    "probability": 1,
                    "impact": 4,
                    "score": 4,
                    "level": "Low"
                  },
                  "risk_reduction_percentage": 50,
                  "linked_ctq_id": "CTQ-006",
                  "linked_mitigation_ids": [
                    "MIT-010"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "8.2",
                      "page_number": 108,
                      "text_snippet": "Randomization will be performed by an IRT. Randomization will be stratified by documented actionable genomic alteration (present versus absent), histology (squamous versus nonsquamous), most immediate prior therapy included anti-PD-1/anti-PD-L1 immunotherapy (yes versus no) and geographical region..."
                    }
                  }
                }
              ],
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not contain a formal risk assessment matrix. The identified risks and their scoring are derived from the key challenges, safety concerns, and complex procedures described throughout the protocol, such as the ILD risk, complex eligibility, and primary endpoint definitions.",
                  "supporting_context": [
                    "Section 2.3 Benefit and Risk Assessment",
                    "Section 3 Objectives, Outcome Measures, and Endpoints",
                    "Section 5 Study Population"
                  ],
                  "confidence": "high"
                }
              }
            },
            "mitigation_strategies": [
              {
                "mitigation_id": "MIT-001",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "control_type": "Preventive",
                "control_category": "Training",
                "strategy_description": "Mandatory, role-based training for all investigators and site staff on the identification, workup, and management of ILD/pneumonitis per protocol guidelines.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Review of training records; knowledge assessment quiz.",
                "verification_frequency": "Prior to site activation",
                "resource_requirements": "Development of training materials, learning management system.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol mandates adherence to specific ILD management guidelines (Table 6.4). Training is the standard preventive control to ensure site staff understand and can execute these critical safety procedures, as required by GCP.",
                    "supporting_context": [
                      "Table 6.4 details the management guidelines for ILD/pneumonitis."
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "mitigation_id": "MIT-002",
                "linked_risk_ids": [
                  "RISK-001"
                ],
                "control_type": "Detective",
                "control_category": "Oversight",
                "strategy_description": "Establishment of an independent ILD Adjudication Committee to review all potential cases of ILD/pneumonitis for consistent and accurate assessment.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "High",
                "verification_method": "Review of committee charter and meeting minutes.",
                "verification_frequency": "Ongoing",
                "resource_requirements": "External clinical experts, committee coordination staff.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10.1.5",
                    "page_number": 137,
                    "text_snippet": "An external ILD AC will be used for this study. ... The ILD AC will adjudicate all cases of potential ILD/pneumonitis on an ongoing basis."
                  }
                }
              },
              {
                "mitigation_id": "MIT-003",
                "linked_risk_ids": [
                  "RISK-002"
                ],
                "control_type": "Preventive",
                "control_category": "Protocol Design",
                "strategy_description": "Use of a central imaging vendor and a detailed Imaging Manual to standardize acquisition parameters and procedures for all tumor assessment scans.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor/CRO",
                "effectiveness_rating": "High",
                "verification_method": "Confirmation of Imaging Manual distribution; review of vendor QC reports.",
                "verification_frequency": "Ongoing",
                "resource_requirements": "Central imaging vendor costs.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "8.3",
                    "page_number": 110,
                    "text_snippet": "Radiographic imaging scans will be sent to a central imaging vendor for BICR assessment. ... For further instructions, refer to the Imaging Site Manual which will be provided to the site."
                  }
                }
              },
              {
                "mitigation_id": "MIT-004",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "control_type": "Preventive",
                "control_category": "Trial Processes",
                "strategy_description": "Implementation of a mandatory, detailed electronic eligibility checklist within the IRT system that must be completed before a randomization number is issued.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Sponsor/IRT Vendor",
                "effectiveness_rating": "High",
                "verification_method": "User acceptance testing of the IRT system.",
                "verification_frequency": "Prior to go-live",
                "resource_requirements": "IRT programming and validation.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "The protocol specifies that randomization will be managed through an IRT for subjects meeting all eligibility criteria. An electronic checklist is a standard technical control within an IRT to prevent randomization of ineligible subjects.",
                    "supporting_context": [
                      "Section 6.3: 'Randomization will be managed through an IRT for subjects meeting all eligibility criteria.'"
                    ],
                    "confidence": "high"
                  }
                }
              },
              {
                "mitigation_id": "MIT-005",
                "linked_risk_ids": [
                  "RISK-003"
                ],
                "control_type": "Detective",
                "control_category": "Monitoring",
                "strategy_description": "100% source data verification of all eligibility criteria for the first 3-5 subjects enrolled at each site, and ongoing risk-based SDV thereafter.",
                "implementation_phase": "Conduct",
                "responsible_party": "CRO/Monitor",
                "effectiveness_rating": "Medium",
                "verification_method": "Review of monitoring reports.",
                "verification_frequency": "Per monitoring schedule",
                "resource_requirements": "Monitor time and effort.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This is a standard monitoring practice for mitigating the high risk of eligibility errors, especially early in a study. While not explicitly stated, it is a component of the risk-based monitoring approach mentioned in Section 10.1.4.",
                    "supporting_context": [
                      "Section 10.1.4 describes the monitor's responsibility for verifying data and adherence to protocol."
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "mitigation_id": "MIT-006",
                "linked_risk_ids": [
                  "RISK-004"
                ],
                "control_type": "Detective",
                "control_category": "Centralized Monitoring",
                "strategy_description": "Centralized data review of AE and lab data to flag any events that should have triggered a dose modification per protocol, for follow-up by the monitor.",
                "implementation_phase": "Conduct",
                "responsible_party": "Sponsor/CRO Data Analytics Team",
                "effectiveness_rating": "Medium",
                "verification_method": "Review of centralized monitoring outputs and action items.",
                "verification_frequency": "Weekly",
                "resource_requirements": "Central monitor/data analyst time.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This mitigation is a standard application of centralized monitoring. The protocol's commitment to a hybrid monitoring approach (Section 10.1.4) implies the use of such centralized data review techniques to proactively identify risks like non-adherence to dose modification rules.",
                    "supporting_context": [
                      "Section 10.1.4: '...review of study data remotely.'",
                      "Section 6.5 details the specific rules that would be programmed for this review."
                    ],
                    "confidence": "medium"
                  }
                }
              },
              {
                "mitigation_id": "MIT-007",
                "linked_risk_ids": [
                  "RISK-005"
                ],
                "control_type": "Preventive",
                "control_category": "Trial Processes",
                "strategy_description": "Implement a robust survival follow-up process, including obtaining secondary contact information at consent and defining multiple contact attempt methods.",
                "implementation_phase": "Study Startup",
                "responsible_party": "Site/CRO",
                "effectiveness_rating": "Medium",
                "verification_method": "Review of site training on follow-up procedures.",
                "verification_frequency": "During SIV and routine monitoring",
                "resource_requirements": "Site staff time for follow-up calls.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "7.3",
                    "page_number": 105,
                    "text_snippet": "Before a subject is deemed lost to follow-up, the Investigator or designee will make every effort to regain contact with the subject (where possible, 3 telephone calls, texts, or emails, and if necessary, a certified letter to the subject\u2019s last known mailing address or local equivalent methods)."
                  }
                }
              },
              {
                "mitigation_id": "MIT-008",
                "linked_risk_ids": [
                  "RISK-006"
                ],
                "control_type": "Corrective",
                "control_category": "Recruitment",
                "strategy_description": "Regularly review screen failure reasons at a study level to identify problematic criteria. If a specific criterion is a major barrier, consider a protocol amendment if scientifically justifiable.",
                "implementation_phase": "Conduct",
                "responsible_party": "Sponsor",
                "effectiveness_rating": "Medium",
                "verification_method": "Review of enrollment meeting minutes.",
                "verification_frequency": "Monthly",
                "resource_requirements": "Data analysis and medical/scientific review time.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "5.3",
                    "page_number": 80,
                    "text_snippet": "For subjects who do not meet the criteria for participation in the study (screen failures), the reason for screen failure must be recorded in the Screening Log."
                  }
                }
              },
              {
                "mitigation_id": "MIT-009",
                "linked_risk_ids": [
                  "RISK-007"
                ],
                "control_type": "Detective",
                "control_category": "Data Collection",
                "strategy_description": "Systematically collect detailed data on all subsequent anti-cancer therapies received by subjects in both arms of the study.",
                "implementation_phase": "Conduct",
                "responsible_party": "Site/Data Management",
                "effectiveness_rating": "High",
                "verification_method": "Review of EDC completion rates for subsequent therapy forms.",
                "verification_frequency": "Quarterly",
                "resource_requirements": "EDC form design, site data entry time.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "8.3",
                    "page_number": 110,
                    "text_snippet": "Subsequent anticancer treatments, radiation therapy received, and surgeries performed since the EOT must be monitored and recorded in the eCRF until EOS."
                  }
                }
              },
              {
                "mitigation_id": "MIT-010",
                "linked_risk_ids": [
                  "RISK-008"
                ],
                "control_type": "Preventive",
                "control_category": "Technology",
                "strategy_description": "IRT system design includes checks and confirmations for stratification parameters before randomization is finalized.",
                "implementation_phase": "Study Startup",
                "responsible_party": "IRT Vendor",
                "effectiveness_rating": "High",
                "verification_method": "Review of UAT scripts and results.",
                "verification_frequency": "Prior to go-live",
                "resource_requirements": "IRT programming.",
                "provenance": {
                  "kind": "derived",
                  "derived": {
                    "reasoning": "This is a standard design feature for an IRT system used for a stratified trial. The protocol requires stratification (Section 8.2), and built-in checks are the primary technological control to ensure the stratification is executed correctly.",
                    "supporting_context": [
                      "Section 8.2: 'Randomization will be stratified by documented actionable genomic alteration...'"
                    ],
                    "confidence": "high"
                  }
                }
              }
            ],
            "safety_signal_detection": {
              "statistical_methods": [
                {
                  "method_id": "SSD-001",
                  "method_name": "AE Incidence Monitoring",
                  "method_description": "Regular, periodic review of adverse event frequencies, severities, and seriousness by system organ class and preferred term, comparing treatment arms.",
                  "application": "General safety surveillance for unexpected events or imbalances.",
                  "data_requirements": [
                    "Coded AE data from EDC",
                    "Treatment exposure data"
                  ],
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "9.5.2",
                      "page_number": 131,
                      "text_snippet": "Safety analyses in general will be descriptive and will be presented in tabular format with the appropriate summary statistics. ... The TEAEs will be summarized using MedDRA system organ class (SOC) and preferred term."
                    }
                  }
                }
              ],
              "stopping_rules": [
                {
                  "rule_id": "STOP-001",
                  "rule_type": "Safety",
                  "condition": "Statistically significant and clinically meaningful increase in mortality or irreversible morbidity in the investigational arm compared to the control arm.",
                  "threshold": "Defined in DMC charter, based on statistical analysis of safety data.",
                  "action": "DMC recommendation to pause or terminate the study.",
                  "decision_authority": "DMC",
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "10.1.5",
                      "page_number": 138,
                      "text_snippet": "An independent data monitoring committee (DMC) will be created to further protect the rights, safety, and well-being of subjects who will be participating in this study by monitoring the progress and results."
                    }
                  }
                },
                {
                  "rule_id": "STOP-002",
                  "rule_type": "Efficacy",
                  "condition": "DS-1062a demonstrates superiority for Overall Survival at the interim analysis.",
                  "threshold": "O'Brien-Fleming stopping boundary is crossed.",
                  "action": "DMC may recommend stopping the study early for success.",
                  "decision_authority": "DMC",
                  "provenance": {
                    "kind": "explicit",
                    "explicit": {
                      "section_number": "9.6",
                      "page_number": 133,
                      "text_snippet": "OS will also be analyzed at the primary analysis of PFS (OS IA). The overall 2-sided alpha is to be controlled at 0.042 for the interim OS analysis and final OS analysis using the Lan-DeMets alpha spending function with an O\u2019Brien-Fleming stopping boundary. ... The study may be stopped at OS IA if the pre-specified superiority boundary is crossed."
                    }
                  }
                }
              ],
              "dsmb_interface": {
                "dsmb_required": true,
                "meeting_frequency": "Periodically",
                "review_scope": [
                  "Safety",
                  "Efficacy",
                  "Study Conduct"
                ],
                "unblinding_criteria": "The DMC will review unblinded safety and efficacy data at pre-specified intervals as defined in the DMC charter.",
                "provenance": {
                  "kind": "explicit",
                  "explicit": {
                    "section_number": "10.1.5",
                    "page_number": 138,
                    "text_snippet": "The DMC will periodically review unblinded safety data in this study. The details about the reviews of the study data and other DMC processes will be described in the DMC charter."
                  }
                }
              }
            },
            "issue_management_cascade": {
              "provenance": {
                "kind": "derived",
                "derived": {
                  "reasoning": "The protocol does not specify an issue management cascade. This is a standard operational process within a quality management system, derived from the need to have clear escalation pathways for risks and issues identified during monitoring, as implied by GCP.",
                  "supporting_context": [
                    "Section 10.1.4 implies issue management by stating the monitor will ensure appropriate actions are taken for deviations."
                  ],
                  "confidence": "medium"
                }
              }
            },
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The concept of 'Risk Governance' is not explicitly named, but its components are described throughout the protocol. This includes the establishment of a DMC (10.1.5), safety reporting rules (8.4), and monitoring (10.1.4), which collectively form the governance structure for managing study risks.",
                "supporting_context": [
                  "Section 10.1.5 Committees",
                  "Section 8.4 Safety Assessments",
                  "Section 10.1.4 Monitoring and Inspections"
                ],
                "confidence": "high"
              }
            }
          },
          "technology_config": {
            "provenance": {
              "kind": "derived",
              "derived": {
                "reasoning": "The protocol mentions specific technologies like EDC and IRT but does not detail their configuration for RBQM. This is inferred as a necessary implementation step for executing the described monitoring and randomization strategies.",
                "supporting_context": [
                  "Section 6.3 mentions IRT for randomization.",
                  "Section 10.1.4 mentions eCRFs and the EDC system."
                ],
                "confidence": "medium"
              }
            }
          },
          "provenance": {
            "kind": "derived",
            "derived": {
              "reasoning": "The term 'RBQM' is not used, but the principles are evident. The protocol describes a risk-based approach through its focus on critical risks (ILD), use of a DMC, centralized/remote monitoring, and specific management plans for key safety events, aligning with ICH E6(R2) quality management principles.",
              "supporting_context": [
                "Section 2.3 Benefit and Risk Assessment",
                "Section 10.1.4 Monitoring and Inspections",
                "Section 10.1.5 Committees"
              ],
              "confidence": "high"
            }
          }
        },
        "extraction_statistics": {
          "has_monitoring_approach": true,
          "has_sdv_strategy": true,
          "has_monitoring_visits": true,
          "kri_count": 8,
          "qtl_count": 5,
          "ctq_count": 6,
          "emergent_risk_count": 4,
          "mitigation_strategy_count": 10,
          "identified_risks_count": 8,
          "has_ract_register": true,
          "has_risk_governance": true
        },
        "provenance": {
          "kind": "derived",
          "derived": {
            "reasoning": "The overall quality management plan is not described in a single section. It is synthesized from multiple sections covering monitoring, safety assessment, data handling, and committees, which collectively define the study's approach to ensuring quality.",
            "supporting_context": [
              "Section 8.4 Safety Assessments",
              "Section 10.1.4 Data Integrity and Quality Assurance",
              "Section 10.1.5 Committees"
            ],
            "confidence": "high"
          }
        }
      }
    },
    "withdrawalProcedures": {
      "moduleId": "withdrawal_procedures",
      "instanceType": "WithdrawalProcedures",
      "data": {
        "id": "WP-001",
        "instanceType": "WithdrawalProcedures",
        "name": "Withdrawal and Discontinuation Procedures",
        "description": "Procedural specifications for subject withdrawal and discontinuation",
        "discontinuation_types": [
          {
            "id": "DT-001",
            "type_name": {
              "code": "TREATMENT_DISCONTINUATION",
              "decode": "Treatment Discontinuation"
            },
            "definition": "This refers to withdrawal from treatment with DS-1062a or docetaxel, which is NOT the same thing as a complete withdrawal from the study. The subject will remain in the study (ie, continue with study visits and assessments, including survival follow-up).",
            "allows_continued_followup": true,
            "provenance": {
              "section_number": "7.1",
              "page_number": 102,
              "text_snippet": "Withdrawal by subject (to discontinue study treatment)\n\u2212 Note: this section only refers to withdrawal from treatment with DS-1062a or docetaxel, which is NOT the same thing as a complete withdrawal from the study. Discuss with the subject that they will remain in the study (ie, continue with study visits and assessments, including survival follow-up)."
            }
          },
          {
            "id": "DT-002",
            "type_name": {
              "code": "STUDY_WITHDRAWAL",
              "decode": "Study Withdrawal"
            },
            "definition": "Indicates that the subject withdraws consent and refuses to undergo any further study procedures. In such cases, subjects will be asked to be followed for long-term survival only.",
            "allows_continued_followup": false,
            "provenance": {
              "section_number": "7.2",
              "page_number": 104,
              "text_snippet": "Withdrawal by subject (discontinuation from the study)\n\u2212 NOTE: this indicates that the subject withdraws consent and refuses to undergo any further study procedures. In such cases, subjects will be asked to be followed for long-term survival only (eg, study personnel contacting the subject by telephone)."
            }
          }
        ],
        "consent_withdrawal": {
          "right_to_withdraw": "Subjects may discontinue from the study for any of the following reasons: Withdrawal by subject (discontinuation from the study).",
          "withdrawal_process": "If the subject refuses all potential methods of follow up, the Investigator will document this as a withdrawal of consent (from the interventional portion and follow-up). The Investigator will complete and report the observations as thoroughly as possible up to the date of withdrawal.",
          "data_handling_options": [
            {
              "option": {
                "code": "RETAIN_ALL",
                "decode": "Retain all collected data"
              },
              "description": "Any disclosure of future information is also withdrawn; the Sponsor may retain and continue to use any data collected before such a withdrawal of consent."
            }
          ],
          "sample_handling": "The subject may request destruction of any samples taken and not tested, and the Investigator must document this in the site study records.",
          "consequences": "Not explicitly stated, but withdrawal is at the subject's discretion without penalty.",
          "provenance": {
            "section_number": "7.2",
            "page_number": 105,
            "text_snippet": "If a subject is withdrawn from both the interventional and follow-up portions of the study:\n\u2022 The Investigator will complete and report the observations as thoroughly as possible up to the date of withdrawal, including the date of last dose, date of last contact, and the reason for withdrawal.\n\u2022 Any disclosure of future information is also withdrawn; the Sponsor may retain and continue to use any data collected before such a withdrawal of consent.\n\u2022 The subject may request destruction of any"
          }
        },
        "discontinuation_visit": {
          "timing": "An End of Treatment (EOT) evaluation should be performed as described in the Schedule of Events.",
          "timing_days_from_last_dose": 7,
          "required_assessments": [
            {
              "id": "ASS-001",
              "assessment_type": {
                "code": "VITAL_SIGNS",
                "decode": "Vital Signs"
              },
              "assessment_name": "Vital Signs",
              "mandatory": true
            },
            {
              "id": "ASS-002",
              "assessment_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "assessment_name": "SpO2",
              "mandatory": true
            },
            {
              "id": "ASS-003",
              "assessment_type": {
                "code": "PHYSICAL_EXAM",
                "decode": "Physical Exam"
              },
              "assessment_name": "Physical Examination and ECOG PS",
              "mandatory": true
            },
            {
              "id": "ASS-004",
              "assessment_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "assessment_name": "Weight",
              "mandatory": true
            },
            {
              "id": "ASS-005",
              "assessment_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "assessment_name": "Ophthalmologic Assessment",
              "mandatory": true
            },
            {
              "id": "ASS-006",
              "assessment_type": {
                "code": "ECG",
                "decode": "Electrocardiogram"
              },
              "assessment_name": "12-Lead ECG",
              "mandatory": true
            },
            {
              "id": "ASS-007",
              "assessment_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "assessment_name": "ECHO/MUGA (LVEF)",
              "mandatory": false
            },
            {
              "id": "ASS-008",
              "assessment_type": {
                "code": "LABORATORY",
                "decode": "Laboratory"
              },
              "assessment_name": "Hematology, Clinical Chemistry, Urinalysis, Pregnancy Test",
              "mandatory": true
            },
            {
              "id": "ASS-009",
              "assessment_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "assessment_name": "COVID-19 Sample",
              "mandatory": true
            },
            {
              "id": "ASS-010",
              "assessment_type": {
                "code": "OTHER",
                "decode": "Other"
              },
              "assessment_name": "ADA Sample",
              "mandatory": true
            },
            {
              "id": "ASS-011",
              "assessment_type": {
                "code": "IMAGING",
                "decode": "Imaging"
              },
              "assessment_name": "Tumor Response and Lung Disease Assessment",
              "mandatory": true
            },
            {
              "id": "ASS-012",
              "assessment_type": {
                "code": "AE_REVIEW",
                "decode": "Adverse Event Review"
              },
              "assessment_name": "Non-serious AEs and SAEs",
              "mandatory": true
            },
            {
              "id": "ASS-013",
              "assessment_type": {
                "code": "QUESTIONNAIRE",
                "decode": "Questionnaire"
              },
              "assessment_name": "PRO Assessments (EORTC-QLQ-C30, EORTC-QLQ-LC13, EQ-5D-5L, PRO-CTCAE)",
              "mandatory": true
            }
          ],
          "documentation_requirements": [
            "The reason(s) for discontinuation and the last dose date should be documented in the subject\u2019s medical record and eCRF."
          ],
          "provenance": {
            "section_number": "7.1",
            "page_number": 103,
            "text_snippet": "If a subject is discontinued from the study drug:\n... \n\u2022 An EOT evaluation should be performed as described in the Schedule of Events (Table 1.2)."
          }
        },
        "post_discontinuation_followup": {
          "safety_followup": {
            "duration_days": 28,
            "duration_description": "A safety follow-up evaluation should be performed approximately 28 days (+7 days) after the last dose of study drug.",
            "assessments": [
              "Vital Signs",
              "SpO2",
              "Physical Examination and ECOG PS",
              "Weight",
              "Ophthalmologic Assessment",
              "12-Lead ECG",
              "Hematology",
              "Clinical Chemistry",
              "Pregnancy Test",
              "ADA Sample",
              "SAEs"
            ],
            "contact_method": {
              "code": "IN_PERSON",
              "decode": "In-person visit"
            }
          },
          "survival_followup": {
            "required": true,
            "frequency": "Every 3 months",
            "duration": "Until End of Study (EOS)",
            "information_collected": [
              "Survival status",
              "Cause of death",
              "Subsequent anticancer treatment"
            ]
          },
          "ae_followup": {
            "ongoing_ae_followup": true,
            "followup_until": "All SAEs will be followed until resolution, stabilization, the event is otherwise explained, or the subject is lost to follow up. All AESIs must be followed until either event resolution, end of study, study termination, withdrawal of consent, or subject death."
          },
          "provenance": {
            "section_number": "7.1",
            "page_number": 103,
            "text_snippet": "\u2022 A safety follow-up evaluation should be performed approximately 28 days (+7 days) after the last dose of study drug as described in the Schedule of Events (Table 1.2).\n\u2022 If subject has not discontinued due to disease progression, continue tumor assessments until disease progression, death, lost to follow-up, or withdrawal of consent, and survival as described in the Schedule of Events (Table 1.2).\n\u2022 LTSFU evaluations will be performed to assess survival as described in the Schedule of Events"
          }
        },
        "lost_to_followup": {
          "definition": "A subject will be considered lost to follow-up if s/he fails to return for 2 consecutive scheduled visits per the Schedules of Events and is unable to be contacted by the study site staff.",
          "missed_visits_threshold": 2,
          "contact_attempts_required": 3,
          "contact_methods": [
            {
              "code": "PHONE",
              "decode": "Telephone call"
            },
            {
              "code": "EMAIL",
              "decode": "Email"
            },
            {
              "code": "LETTER",
              "decode": "Certified letter"
            }
          ],
          "documentation_required": [
            "These contact attempts should be documented."
          ],
          "provenance": {
            "section_number": "7.3",
            "page_number": 105,
            "text_snippet": "A subject will be considered lost to follow-up if s/he fails to return for 2 consecutive scheduled visits per the Schedules of Events and is unable to be contacted by the study site staff. Before a subject is deemed lost to follow-up, the Investigator or designee will make every effort to regain contact with the subject (where possible, 3 telephone calls, texts, or emails, and if necessary, a certified letter to the subject\u2019s last known mailing address or local equivalent methods)."
          }
        },
        "replacement_strategy": {
          "allows_replacement": false,
          "replacement_conditions": [],
          "timing_cutoff": null,
          "randomization_handling": null,
          "stratification_maintenance": null,
          "provenance": {
            "section_number": "5.3",
            "page_number": 80,
            "text_snippet": "Subjects who have dropped out of the study will not be replaced."
          }
        },
        "administrative_withdrawal": {
          "reasons": [
            {
              "id": "AWR-001",
              "reason_type": {
                "code": "STUDY_TERMINATION",
                "decode": "Study Termination"
              },
              "description": "Study termination by Sponsor."
            },
            {
              "id": "AWR-002",
              "reason_type": {
                "code": "INVESTIGATOR_DECISION",
                "decode": "Investigator Decision"
              },
              "description": "Physician decision."
            },
            {
              "id": "AWR-003",
              "reason_type": {
                "code": "PROTOCOL_VIOLATION",
                "decode": "Protocol Violation"
              },
              "description": "Only protocol deviations that are deemed significant by the Investigator, with or without consultation with the Sponsor, may lead to permanent study drug discontinuation."
            },
            {
              "id": "AWR-004",
              "reason_type": {
                "code": "SITE_CLOSURE",
                "decode": "Site Closure"
              },
              "description": "Reasons for early site closure include failure to comply with protocol, inadequate recruitment, or discontinuation of study intervention development."
            }
          ],
          "notification_requirements": "In the event of early termination of the study, the Sponsor will consider providing DS-1062a to subjects who benefit from treatment according to legal regulations in the corresponding countries.",
          "irb_notification": true,
          "provenance": {
            "section_number": "7.1",
            "page_number": 102,
            "text_snippet": "Reasons for treatment discontinuation include:\n\u2022 Death\n\u2022 Adverse event\n\u2022 Disease progression\n\u2022 Clinical progression\n\u2022 Withdrawal by subject (to discontinue study treatment)\n\u2022 Physician decision\n\u2022 Lost to follow up (see Section 7.3 for details on when a subject is considered Lost to Follow-up)\n\u2022 Pregnancy\n\u2022 Protocol deviation (Note: Only protocol deviations that are deemed significant by the Investigator, with or without consultation with the Sponsor, may lead to permanent study drug"
          }
        },
        "data_retention": {
          "retention_period_years": null,
          "retention_policy": "The Sponsor may retain and continue to use any data collected before a withdrawal of consent. Essential documentation will be retained by the Investigator until at least 2 years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region.",
          "analysis_populations": [
            {
              "population": {
                "code": "SAFETY",
                "decode": "Safety Population"
              },
              "inclusion_criteria": "The Safety Analysis Set will include all randomized subjects who received at least 1 dose of study drug."
            },
            {
              "population": {
                "code": "ITT",
                "decode": "Intent-to-Treat"
              },
              "inclusion_criteria": "The Full Analysis Set (FAS) will include all subjects who have been randomized to the study. Following the Intent-to-Treat principle, subjects will be analyzed according to the treatment and strata they have been assigned to during the randomization process."
            }
          ],
          "provenance": {
            "section_number": "9.4",
            "page_number": 127,
            "text_snippet": "The Safety Analysis Set will include all randomized subjects who received at least 1 dose of study drug. Subjects will be analyzed according to the study treatment received, where treatment received is the randomized study drug if the subject took at least 1 dose of the randomized study drug; otherwise, the first treatment received will be used."
          }
        },
        "retention_strategies": {
          "prevention_measures": [
            "If a subject does not agree to continue to come to the study site, then a modified follow-up must be arranged. Options include: Study personnel contacting the subject by telephone; contacting an alternative person (e.g., family member); accessing and reviewing the subject\u2019s medical information from alternative sources (e.g., doctor\u2019s notes)."
          ],
          "incentives": [],
          "re_consent_procedures": "If the subject information is revised, it must be re-approved by the EC/IRB. The Investigator should obtain written informed consent to continue participation with the revised written information even if subjects were already informed of the relevant information.",
          "provenance": {
            "section_number": "7.1",
            "page_number": 104,
            "text_snippet": "Modified Follow-up Options\nThe following modified follow-up options can be offered to the subject who does not agree to study visits at the study site. If a subject does not come back to the study site, every effort should be made to contact the subject to gain required information, such as the approaches listed below.\n\u2022 Study personnel contacting the subject by telephone.\n\u2022 Study personnel contacting an alternative person (eg, family member, spouse, partner, legal representative, physician, or"
          }
        },
        "provenance": {
          "section_number": "7",
          "page_number": 102,
          "text_snippet": "7. STUDY DRUG DISCONTINUATION AND DISCONTINUATION FROM THE STUDY"
        }
      }
    },
    "imagingCentralReading": {
      "moduleId": "imaging_central_reading",
      "instanceType": "ImagingCentralReading",
      "data": {
        "id": "DS1062-A-U301F-imaging-central-reading",
        "instanceType": "ImagingCentralReading",
        "name": "DS1062-A-U301F Imaging & Central Reading",
        "description": "Tumor assessment and imaging specifications for the TROPION-Lung01 study.",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "CLINICAL STUDY PROTOCOL\nPHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)"
        },
        "response_criteria": {
          "primary_criteria": "RECIST",
          "criteria_version": "1.1",
          "secondary_criteria": [],
          "modifications": "Confirmatory measurement for CR or PR is not required in this study.",
          "provenance": {
            "section_number": "10.4",
            "page_number": 144,
            "text_snippet": "Appendix 4: Response Evaluation Criteria in Solid Tumors (Version 1.1.)\nAssessment of tumor responses will be performed according to revised RECIST v1.1 guidelines. Some of these definitions and criteria are highlighted below."
          },
          "modificationsProvenance": {
            "section_number": "10.4",
            "page_number": 149,
            "text_snippet": "The BOR is the best response recorded from the start of the study treatment until the EOT. Confirmatory measurement for CR or PR is not required in this study."
          }
        },
        "imaging_modalities": [
          {
            "modality_id": "IMG-001",
            "modality_type": "CT",
            "body_regions": [
              "chest",
              "abdomen",
              "pelvis",
              "brain",
              "other sites of disease"
            ],
            "contrast_required": true,
            "contrast_type": "IV contrast unless contraindicated",
            "slice_thickness": "\u22645mm",
            "technical_requirements": "Spiral CT is preferred. The same imaging technique used at baseline must be used for subsequent assessments.",
            "preferred_modality": true,
            "provenance": {
              "section_number": "8.3",
              "page_number": 109,
              "text_snippet": "Imaging must include chest and abdomen CT or MRI scans, and brain CT or MRI scan at baseline (Screening) for all subjects... The CT scans should be performed with contrast agents unless contraindicated for medical reasons... Perform radiographic tumor assessments using spiral CT or MRI with \u22645 mm cuts unless another modality of disease assessment is necessary for the lesions."
            }
          },
          {
            "modality_id": "IMG-002",
            "modality_type": "MRI",
            "body_regions": [
              "chest",
              "abdomen",
              "pelvis",
              "brain",
              "other sites of disease"
            ],
            "contrast_required": true,
            "contrast_type": "Gadolinium-based contrast unless contraindicated",
            "slice_thickness": "\u22645mm",
            "technical_requirements": "The same imaging technique used at baseline must be used for subsequent assessments.",
            "preferred_modality": false,
            "provenance": {
              "section_number": "8.3",
              "page_number": 109,
              "text_snippet": "Imaging must include chest and abdomen CT or MRI scans, and brain CT or MRI scan at baseline (Screening) for all subjects... Perform radiographic tumor assessments using spiral CT or MRI with \u22645 mm cuts unless another modality of disease assessment is necessary for the lesions. The same imaging technique (CT or MRI) used to characterize each identified and reported lesion at baseline will be used in the subsequent tumor assessments."
            }
          },
          {
            "modality_id": "IMG-003",
            "modality_type": "Bone Scan",
            "body_regions": [
              "whole body"
            ],
            "contrast_required": false,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "Bone scintigraphy. Used for assessment of bone metastases.",
            "preferred_modality": false,
            "provenance": {
              "section_number": "8.3",
              "page_number": 109,
              "text_snippet": "Bone scan (bone scintigraphy) or 18F-fluorodeoxyglucose positron emission tomography/CT is required at baseline. If bone metastases are present at baseline, subjects should have bone scan (bone scintigraphy) or 18 FDG PET/CT or CT/MRI every 6 weeks (\u00b17 days) from randomization."
            }
          },
          {
            "modality_id": "IMG-004",
            "modality_type": "PET/CT",
            "body_regions": [
              "whole body"
            ],
            "contrast_required": false,
            "contrast_type": null,
            "slice_thickness": null,
            "technical_requirements": "18F-fluorodeoxyglucose (18F-FDG) PET/CT. Used for assessment of bone metastases.",
            "preferred_modality": false,
            "provenance": {
              "section_number": "8.3",
              "page_number": 109,
              "text_snippet": "Bone scan (bone scintigraphy) or 18F-fluorodeoxyglucose positron emission tomography/CT is required at baseline. If bone metastases are present at baseline, subjects should have bone scan (bone scintigraphy) or 18 FDG PET/CT or CT/MRI every 6 weeks (\u00b17 days) from randomization."
            }
          }
        ],
        "assessment_schedule": {
          "baseline_window": "Within 28 days prior to randomization.",
          "on_treatment_frequency": "Every 6 weeks (\u00b17 days) from randomization.",
          "first_assessment_timing": "Week 6 (\u00b17 days) from randomization.",
          "post_treatment_schedule": "Tumor assessments continue every 6 weeks (\u00b17 days) for subjects who discontinue treatment for reasons other than radiographic disease progression, until progression, death, lost to follow-up, or withdrawal of consent.",
          "confirmatory_scan_required": false,
          "confirmatory_scan_window": null,
          "assessment_timepoints": [
            "Screening (Baseline)",
            "Every 6 weeks (\u00b17 days) until Investigator-assessed radiographic disease progression",
            "One additional tumor assessment 6 weeks (\u00b17 days) after Investigator-assessed progression (if BICR has not yet determined progression)"
          ],
          "provenance": {
            "section_number": "8.3",
            "page_number": 109,
            "text_snippet": "Antitumor activity will be assessed by Investigator at baseline (Screening) and every 6 weeks (\u00b17 days) from randomization independent of treatment cycle until radiographic disease progression, death, lost to follow up, or withdrawal of consent regardless of discontinuation of study treatment or initiation of new anticancer therapy (Table 1.1 and Table 1.2). ... Baseline tumor assessment must be performed within 28 days prior to randomization."
          }
        },
        "lesion_requirements": {
          "measurable_disease_definition": "Tumor lesions must be accurately measured in at least 1 dimension with a minimum size of 10 mm by CT scan, 10 mm by caliper, or 20 mm by chest X-ray. Malignant lymph nodes must be \u226515 mm in the short axis.",
          "target_lesion_minimum_size": "\u226510 mm longest diameter",
          "lymph_node_criteria": "\u226515 mm in short axis",
          "max_target_lesions": 5,
          "max_target_lesions_per_organ": 2,
          "non_target_lesion_definition": "All other lesions (or sites of disease) including pathological lymph nodes with short axis \u226510 mm but <15 mm.",
          "non_measurable_disease": [
            "leptomeningeal disease",
            "ascites",
            "pleural or pericardial effusion",
            "inflammatory breast disease",
            "lymphangitic involvement of skin or lung",
            "abdominal masses/organomegaly not measurable by imaging",
            "blastic bone lesions"
          ],
          "provenance": {
            "section_number": "10.4",
            "page_number": 145,
            "text_snippet": "Tumor lesions: Must be accurately measured in at least 1 dimension (longest diameter in the plane of measurement is to be recorded) with a minimum size of: 10 mm by CT scan... 10 mm caliper measurement... 20 mm by chest X-ray. Measurable malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node must be \u226515 mm in the short axis when assessed by CT scan..."
          },
          "max_target_lesionsProvenance": {
            "section_number": "10.4",
            "page_number": 146,
            "text_snippet": "When more than 1 measurable lesion is present at baseline all lesions, up to a total of 2 lesions per organ and a maximum of 5 lesions total representative of all involved organs should be identified as target lesions (TLs) and will be recorded and measured at baseline"
          },
          "non_measurable_diseaseProvenance": {
            "section_number": "10.4",
            "page_number": 145,
            "text_snippet": "Lesions considered truly non-measurable include leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal masses/abdominal organomegaly identified by physical examination that is not measurable by reproducible imaging techniques."
          }
        },
        "response_categories": [
          {
            "category_code": "CR",
            "category_name": "Complete Response",
            "definition": "Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.",
            "target_lesion_criteria": "Disappearance of all target lesions.",
            "non_target_lesion_criteria": "Disappearance of all non-target lesions and normalization of tumor marker level.",
            "new_lesion_criteria": "No new lesions.",
            "provenance": {
              "section_number": "10.4",
              "page_number": 147,
              "text_snippet": "Complete Response (CR): Disappearance of all TLs. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm."
            }
          },
          {
            "category_code": "PR",
            "category_name": "Partial Response",
            "definition": "At least a 30% decrease in the Sum of Diameters (SoD) of target lesions, taking as reference the baseline SoD.",
            "target_lesion_criteria": "\u226530% decrease in SoD of target lesions.",
            "non_target_lesion_criteria": "Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.",
            "new_lesion_criteria": "No new lesions.",
            "provenance": {
              "section_number": "10.4",
              "page_number": 147,
              "text_snippet": "Partial Response (PR): At least a 30% decrease in the SoD of TLs, taking as reference the baseline SoD."
            }
          },
          {
            "category_code": "SD",
            "category_name": "Stable Disease",
            "definition": "Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SoD while on study.",
            "target_lesion_criteria": "Neither PR nor PD criteria met.",
            "non_target_lesion_criteria": "Persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.",
            "new_lesion_criteria": "No new lesions.",
            "provenance": {
              "section_number": "10.4",
              "page_number": 147,
              "text_snippet": "Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SoD while on study."
            }
          },
          {
            "category_code": "PD",
            "category_name": "Progressive Disease",
            "definition": "At least a 20% increase in the SoD of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of 1 or more new lesions is also considered progression. Unequivocal progression of existing non-target lesions is also progression.",
            "target_lesion_criteria": "\u226520% increase in SoD of target lesions (with \u22655mm absolute increase).",
            "non_target_lesion_criteria": "Unequivocal progression of existing non-target lesions.",
            "new_lesion_criteria": "Appearance of one or more new lesions.",
            "provenance": {
              "section_number": "10.4",
              "page_number": 147,
              "text_snippet": "PD: At least a 20% increase in the SoD of TLs, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: The appearance of 1 or more new lesions is also considered progression)."
            }
          },
          {
            "category_code": "NE",
            "category_name": "Not Evaluable",
            "definition": "When no imaging/measurement is done at all at a particular time point, or if only a subset of lesion measurements is made that does not allow for a conclusive response assessment.",
            "target_lesion_criteria": null,
            "non_target_lesion_criteria": null,
            "new_lesion_criteria": null,
            "provenance": {
              "section_number": "10.4",
              "page_number": 150,
              "text_snippet": "Missing Assessments and In-evaluable Designation\nWhen no imaging/measurement is done at all at a particular time point, the subject is not evaluable (NE) at that time point."
            }
          }
        ],
        "central_reading": {
          "bicr_required": true,
          "bicr_purpose": "Primary analysis of Progression-Free Survival (PFS).",
          "reading_methodology": null,
          "reader_qualifications": null,
          "blinding_requirements": "Results of BICR assessment will not be shared with the site or Investigator.",
          "adjudication_process": null,
          "vendor_name": "A central imaging vendor",
          "turnaround_time": null,
          "provenance": {
            "section_number": "8.3",
            "page_number": 110,
            "text_snippet": "BICR Radiographic Tumor Assessment\nRadiographic imaging scans will be sent to a central imaging vendor for BICR assessment... The results of BICR assessment of the subject scans will not be shared with the site or Investigator... The results of BICR-assessed tumor response will be used for the primary analysis of PFS in this study (see Section 3)."
          }
        },
        "image_submission": {
          "submission_method": "Electronic transfer to a central imaging vendor.",
          "format_requirements": null,
          "anonymization_requirements": null,
          "submission_timeline": "After each tumor assessment visit.",
          "quality_requirements": null,
          "provenance": {
            "section_number": "8.3",
            "page_number": 110,
            "text_snippet": "Radiographic imaging scans will be sent to a central imaging vendor for BICR assessment. Sites will send subject scans to the central imaging vendor after each tumor assessment visit."
          }
        },
        "special_assessments": [
          {
            "assessment_id": "SPEC-001",
            "assessment_name": "Brain Imaging",
            "purpose": "To assess for and monitor CNS metastases.",
            "methodology": "CT or MRI",
            "schedule": "Mandatory for all subjects at baseline. For subjects with brain metastases at baseline, imaging is required every 6 weeks (\u00b17 days).",
            "provenance": {
              "section_number": "8.3",
              "page_number": 109,
              "text_snippet": "Imaging must include chest and abdomen CT or MRI scans, and brain CT or MRI scan at baseline (Screening) for all subjects. Subjects with brain metastases at baseline should have brain MRI or CT scan performed every 6 weeks (\u00b17 days) from randomization. Additional brain imaging may be performed as needed clinically."
            }
          },
          {
            "assessment_id": "SPEC-002",
            "assessment_name": "Bone Imaging",
            "purpose": "To assess for and monitor bone metastases.",
            "methodology": "Bone scan (scintigraphy), 18F-FDG PET/CT, or CT/MRI.",
            "schedule": "Required at baseline. For subjects with bone metastases at baseline, imaging is required every 6 weeks (\u00b17 days). Otherwise, follow-up is only required if new bone metastases are suspected.",
            "provenance": {
              "section_number": "8.3",
              "page_number": 109,
              "text_snippet": "Bone scan (bone scintigraphy) or 18F-fluorodeoxyglucose positron emission tomography/CT is required at baseline. If bone metastases are present at baseline, subjects should have bone scan (bone scintigraphy) or 18 FDG PET/CT or CT/MRI every 6 weeks (\u00b17 days) from randomization. Otherwise, follow-up bone imaging is required only if new bone metastases are suspected."
            }
          }
        ],
        "immune_related_criteria": {
          "irecist_used": false,
          "pseudoprogression_handling": null,
          "confirmation_requirements": null,
          "treatment_beyond_progression": null,
          "provenance": {
            "section_number": "10.4",
            "page_number": 144,
            "text_snippet": "Appendix 4: Response Evaluation Criteria in Solid Tumors (Version 1.1.)\nAssessment of tumor responses will be performed according to revised RECIST v1.1 guidelines. Some of these definitions and criteria are highlighted below."
          }
        },
        "extraction_statistics": {
          "has_response_criteria": true,
          "has_bicr": true,
          "has_immune_criteria": false,
          "modality_count": 4,
          "response_category_count": 5
        }
      }
    },
    "pkpdSampling": {
      "moduleId": "pkpd_sampling",
      "instanceType": "PKPDSampling",
      "data": {
        "id": "DS1062-A-U301F-pkpd-sampling",
        "instanceType": "PKPDSampling",
        "name": "DS1062-A-U301F PK/PD Sampling",
        "description": "Pharmacokinetic and pharmacodynamic sampling requirements for the TROPION-LUNG01 study.",
        "provenance": {
          "section_number": null,
          "page_number": 1,
          "text_snippet": "CLINICAL STUDY PROTOCOL\nPHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)"
        },
        "pk_sampling": {
          "pk_sampling_required": true,
          "pk_sampling_purpose": "To assess the PK of DS-1062a. Plasma concentrations and PK parameters of DS-1062a, total anti-TROP2 antibody, and MAAA-1181a will be evaluated.",
          "provenance": {
            "section_number": "8.5",
            "page_number": 121,
            "text_snippet": "Pharmacokinetic Assessments\nBlood samples for PK analyses of DS-1062a will be obtained from subjects receiving DS-1062a based on the Schedules of Events (Table 1.1 and Table 1.2) at time points outlined in Table 8.1."
          },
          "analytes": [
            {
              "analyte_id": "ANALYTE-001",
              "analyte_name": "DS-1062a",
              "analyte_type": "parent_drug",
              "matrix": "plasma",
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "Plasma concentration-time profiles of the 3 analytes (DS-1062a ADC, total anti-TROP2 antibody, and MAAA-1181a) will be established from blood PK samples collected from Cycle 1 Day 1 to Cycle 8 Day 1 for the following cohorts:"
              }
            },
            {
              "analyte_id": "ANALYTE-002",
              "analyte_name": "total anti-TROP2 antibody",
              "analyte_type": "other",
              "matrix": "plasma",
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "Plasma concentration-time profiles of the 3 analytes (DS-1062a ADC, total anti-TROP2 antibody, and MAAA-1181a) will be established from blood PK samples collected from Cycle 1 Day 1 to Cycle 8 Day 1 for the following cohorts:"
              }
            },
            {
              "analyte_id": "ANALYTE-003",
              "analyte_name": "MAAA-1181a",
              "analyte_type": "metabolite",
              "matrix": "plasma",
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "Plasma concentration-time profiles of the 3 analytes (DS-1062a ADC, total anti-TROP2 antibody, and MAAA-1181a) will be established from blood PK samples collected from Cycle 1 Day 1 to Cycle 8 Day 1 for the following cohorts:"
              }
            }
          ],
          "sampling_schedule": [
            {
              "schedule_id": "SCHED-PK-FULL",
              "cohort": "Full Sampling Pharmacokinetic Cohort (approx. 20 subjects receiving to-be-marketed material)",
              "provenance": {
                "section_number": "8.1",
                "page_number": 122,
                "text_snippet": "Table 8.1: Pharmacokinetic Sampling Collection\nFull Sampling Pharmacokinetic Cohort (only for 20 subjects receiving to-be-marketed material)"
              },
              "visits": [
                {
                  "visit_name": "Cycle 1, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 30 minutes after end of infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "nominal_time": "3 hours",
                      "window": "\u00b115 minutes after infusion start"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "nominal_time": "5 hours",
                      "window": "\u00b115 minutes after infusion start"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "nominal_time": "7 hours",
                      "window": "\u00b115 minutes after infusion start"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 1, Day 2",
                  "timepoints": [
                    {
                      "timepoint_name": "Post-dose",
                      "nominal_time": "24 hours",
                      "window": "\u00b12 hours after Day 1 infusion start"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 1, Day 4",
                  "timepoints": [
                    {
                      "timepoint_name": "Post-dose",
                      "nominal_time": "3 days",
                      "window": "\u00b11 day after Day 1 infusion start"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 1, Day 8",
                  "timepoints": [
                    {
                      "timepoint_name": "Post-dose",
                      "nominal_time": "7 days",
                      "window": "\u00b11 day after Day 1 infusion start"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 1, Day 15",
                  "timepoints": [
                    {
                      "timepoint_name": "Post-dose",
                      "nominal_time": "14 days",
                      "window": "\u00b11 day after Day 1 infusion start"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 2, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 1 hour after end of infusion"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 3, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 1 hour after end of infusion"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 4, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 1 hour after end of infusion"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 6, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 1 hour after end of infusion"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 8, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 1 hour after end of infusion"
                    }
                  ]
                }
              ]
            },
            {
              "schedule_id": "SCHED-PK-SPARSE",
              "cohort": "Sparse Sampling Pharmacokinetic Cohort (all other subjects receiving DS-1062a)",
              "provenance": {
                "section_number": "8.1",
                "page_number": 122,
                "text_snippet": "Table 8.1: Pharmacokinetic Sampling Collection\nSparse Sampling Pharmacokinetic Cohort"
              },
              "visits": [
                {
                  "visit_name": "Cycle 1, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 1 hour after end of infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "nominal_time": "5 hours",
                      "window": "\u00b11 hour after infusion start"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 2, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 30 minutes after end of infusion"
                    }
                  ]
                },
                {
                  "visit_name": "Cycle 3, Day 1",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    }
                  ]
                },
                {
                  "visit_name": "Cycles 4, 6, 8",
                  "note": "Sparse PK sampling only for C4, C6, and C8 only. No PK sampling after C8.",
                  "timepoints": [
                    {
                      "timepoint_name": "Pre-dose",
                      "window": "Within 8 hours before infusion"
                    },
                    {
                      "timepoint_name": "Post-dose",
                      "window": "Within 1 hour after end of infusion"
                    }
                  ]
                }
              ]
            },
            {
              "schedule_id": "SCHED-PK-UNSCHEDULED",
              "cohort": "All subjects",
              "provenance": {
                "section_number": "8.5",
                "page_number": 121,
                "text_snippet": "In addition, a blood sample for PK will be collected as soon as ILD/pneumonitis is suspected in a subject."
              },
              "visits": [
                {
                  "visit_name": "Suspected ILD/pneumonitis",
                  "provenance": {
                    "section_number": "6.4",
                    "page_number": 90,
                    "text_snippet": "One blood sample collection for PK analysis as soon as ILD/pneumonitis is suspected, if feasible"
                  },
                  "timepoints": [
                    {
                      "timepoint_name": "Unscheduled",
                      "window": "As soon as ILD/pneumonitis is suspected, if feasible"
                    }
                  ]
                }
              ]
            }
          ]
        },
        "pk_parameters": {
          "primary_parameters": [
            "Cmax",
            "Tmax",
            "AUClast",
            "AUCtau"
          ],
          "secondary_parameters": [
            "AUCinf",
            "t1/2",
            "CL",
            "Vss",
            "Vz",
            "Kel"
          ],
          "calculation_method": "non-compartmental analysis",
          "provenance": {
            "section_number": "9.5.3",
            "page_number": 132,
            "text_snippet": "The following PK parameters will be calculated for each subject in the full PK sampling cohort using non-compartmental analysis of concentration time data of DS-1062a, total anti-TROP2 antibody, and MAAA-1181a: maximum plasma concentration, time to reach maximum plasma concentration, area under the plasma concentration-time curve up to the last quantifiable time, area under the plasma concentration-time curve during dosing interval, and if data permit, area under the plasma concentration-time"
          }
        },
        "population_pk": {
          "pop_pk_planned": true,
          "modeling_approach": "Population PK and exposure-response (ER) analyses will be performed.",
          "covariates": [
            "body weight",
            "other intrinsic covariates",
            "extrinsic covariates"
          ],
          "objectives": "To characterize the relationships of dose, exposure, efficacy, and safety endpoints. The effects of intrinsic and extrinsic covariates on PK and ER relationship will be evaluated.",
          "provenance": {
            "section_number": "9.5.3",
            "page_number": 133,
            "text_snippet": "Population PK and exposure-response (ER) analyses will be performed to characterize the relationships of dose, exposure, efficacy, and safety endpoints. The effects of intrinsic (eg, body weight) and extrinsic covariates on PK and ER relationship will be evaluated. The results of the population PK and ER analyses will be reported separately from the CSR."
          }
        },
        "pd_assessments": {
          "pd_assessments_required": true,
          "provenance": {
            "section_number": "8.6",
            "page_number": 122,
            "text_snippet": "8.6. Biomarker and Pharmacodynamic Assessments"
          },
          "pd_biomarkers": [
            {
              "biomarker_id": "BIOMARKER-001",
              "biomarker_name": "Cell-free DNA (cfDNA)",
              "biomarker_type": "exploratory",
              "matrix": "Blood",
              "sampling_schedule": "Cycle 1 Day 1 (pre-dose), Cycle 2 Day 1, Cycle 3 Day 1, and at time of suspected ILD onset.",
              "purpose": "To assess changes in tumor mutations or other genomic alterations in response to treatment.",
              "provenance": {
                "section_number": "8.6.1",
                "page_number": 123,
                "text_snippet": "Cell-free DNA from blood samples collected during the study to assess changes in tumor mutations or other genomic alterations in response to treatment will be analyzed with the intent of monitoring the biological or antitumor impact of treatment with DS-1062a or control therapy, docetaxel."
              }
            },
            {
              "biomarker_id": "BIOMARKER-002",
              "biomarker_name": "Biomarkers predictive of ILD",
              "biomarker_type": "exploratory_safety",
              "matrix": "Plasma and serum",
              "sampling_schedule": "Collected at time of suspected ILD onset.",
              "purpose": "To assess biomarkers predictive of ILD.",
              "provenance": {
                "section_number": "8.6.1",
                "page_number": 123,
                "text_snippet": "Plasma and serum will be collected at the time points specified in the Schedules of Events (Table 1.1 and Table 1.2) and at the time of suspected ILD onset. Samples may be analyzed to assess biomarkers predictive of ILD."
              }
            },
            {
              "biomarker_id": "BIOMARKER-003",
              "biomarker_name": "TROP2 expression",
              "biomarker_type": "exploratory",
              "matrix": "Tumor tissue",
              "assay_method": "Immunohistochemistry",
              "sampling_schedule": "Pre-treatment biopsy during Screening.",
              "purpose": "To investigate the effect of DS-1062a at the molecular and cellular level.",
              "provenance": {
                "section_number": "8.6.4",
                "page_number": 124,
                "text_snippet": "TROP2 Immunohistochemistry Analysis\nTROP2 expression levels may be measured using an immunohistochemistry assay on all tumor biopsy samples collected during this study. Results from the TROP2 testing of the tumor biopsy samples will not be used to determine eligibility for the study."
              }
            },
            {
              "biomarker_id": "BIOMARKER-004",
              "biomarker_name": "Pharmacogenomic (Inherited Genetic) Analysis",
              "biomarker_type": "exploratory",
              "matrix": "Blood",
              "sampling_schedule": "Scheduled for Cycle 1 Day 1 pre-dose but may be collected at any time after the first dose.",
              "purpose": "To analyze for genes involved in absorption, metabolism, elimination, safety, and efficacy of the study drug, or drug-related signaling pathways, or safety related to the study drug, such as ILD.",
              "provenance": {
                "section_number": "8.6.5",
                "page_number": 124,
                "text_snippet": "Pharmacogenomic (Inherited Genetic) Analysis\nA single blood sample for pharmacogenetic analysis will be collected from each subject. The pharmacogenomic blood sample will be scheduled for Cycle 1 Day 1 pre-dose (see Table 1.1) but may be collected at any time after the first dose of DS-1062a... Pharmacogenomic samples may be analyzed for genes involved in absorption, metabolism, elimination, safety, and efficacy of the study drug..."
              }
            },
            {
              "biomarker_id": "BIOMARKER-005",
              "biomarker_name": "Liquid biopsy",
              "biomarker_type": "exploratory",
              "matrix": "Blood",
              "sampling_schedule": "Cycle 1 Day 1 (pre-dose)",
              "purpose": "To identify subjects who are likely to derive clinical benefit.",
              "provenance": {
                "section_number": "8.6.1",
                "page_number": 123,
                "text_snippet": "A blood sample will be collected at the time point specified in the Schedules of Events to serve as a liquid biopsy to identify subjects who are likely to derive clinical benefit (Table 1.1)."
              }
            }
          ]
        },
        "immunogenicity": {
          "ada_testing_required": true,
          "ada_assay_type": "The ADA testing will be performed using a validated ADA assay following tiered assay steps including Screening, confirmatory as well as titer determination.",
          "provenance": {
            "section_number": "8.6.6",
            "page_number": 125,
            "text_snippet": "Immunogenicity\nBlood samples for plasma antidrug antibody (ADA) analyses will be collected from subjects receiving DS-1062a at the time points specified in the Schedules of Events (Table 1.1 and Table 1.2)."
          },
          "sampling_schedule": [
            "Screening",
            "Cycle 1 Day 8",
            "Cycle 2 Day 1",
            "Cycle 3 Day 1",
            "Every 2 cycles from C4 to C8 (ie, C4, C6, C8)",
            "Every 4 cycles from C8 to EOT (ie, C12, C16, etc.)",
            "28-Day Safety Follow-up",
            "Long-Term Survival Follow-up"
          ],
          "tiered_approach": "Screening, confirmatory, titer determination, neutralizing antibody assay.",
          "impact_on_pk": "Plasma concentrations of DS-1062a, total anti-TROP2 antibody, and MAAA-1181a may also be measured using the same ADA samples for purpose of ADA assessment."
        },
        "sample_handling": {
          "processing_requirements": "Instructions for the collection and handling of biological samples will be included in the Laboratory Manual.",
          "provenance": {
            "section_number": "8.6",
            "page_number": 122,
            "text_snippet": "Instructions for the collection and handling of biological samples will be included in the Laboratory Manual. The actual date and time (24-hour clock time) of each sample collection should be recorded."
          }
        },
        "special_populations": {
          "hepatic_impairment": "Subjects with significant hepatic impairment are excluded. Specific AST, ALT, and bilirubin levels are defined in inclusion/exclusion criteria. No dedicated PK cohort for hepatic impairment is planned.",
          "renal_impairment": "Subjects must have Creatinine clearance \u226530 mL/min. No dedicated PK cohort for renal impairment is planned.",
          "pediatric": "Study includes adults \u226518 years only.",
          "elderly": "No specific PK considerations or dedicated cohorts for elderly subjects are mentioned.",
          "provenance": {
            "section_number": "5.1",
            "page_number": 73,
            "text_snippet": "The study population includes adult subjects with advanced or metastatic NSCLC with or without actionable genomic alterations, as per the inclusion and exclusion criteria described below."
          }
        },
        "extraction_statistics": {
          "has_pk_sampling": true,
          "has_pd_assessments": true,
          "has_immunogenicity": true,
          "has_population_pk": true,
          "analyte_count": 3,
          "biomarker_count": 5
        }
      }
    }
  },
  "provenanceSummary": {
    "totalPagesReferenced": 120,
    "pageRange": [
      1,
      158
    ],
    "sectionPageCounts": {
      "studyMetadata": 10,
      "studyDesign": 15,
      "endpointsEstimandsSAP": 16,
      "adverseEvents": 13,
      "safetyDecisionPoints": 15,
      "concomitantMedications": 10,
      "biospecimenHandling": 11,
      "laboratorySpecifications": 24,
      "informedConsent": 32,
      "proSpecifications": 10,
      "dataManagement": 20,
      "siteOperationsLogistics": 21,
      "qualityManagement": 24,
      "withdrawalProcedures": 6,
      "imagingCentralReading": 9,
      "pkpdSampling": 10
    },
    "pageToSections": {
      "1": [
        "studyMetadata",
        "endpointsEstimandsSAP",
        "informedConsent",
        "siteOperationsLogistics",
        "imagingCentralReading",
        "pkpdSampling"
      ],
      "2": [
        "siteOperationsLogistics"
      ],
      "3": [
        "studyMetadata"
      ],
      "15": [
        "studyMetadata",
        "informedConsent"
      ],
      "16": [
        "endpointsEstimandsSAP"
      ],
      "17": [
        "endpointsEstimandsSAP",
        "proSpecifications"
      ],
      "18": [
        "endpointsEstimandsSAP"
      ],
      "19": [
        "endpointsEstimandsSAP",
        "proSpecifications"
      ],
      "22": [
        "studyMetadata"
      ],
      "24": [
        "studyMetadata",
        "laboratorySpecifications"
      ],
      "25": [
        "laboratorySpecifications"
      ],
      "29": [
        "studyDesign"
      ],
      "30": [
        "informedConsent",
        "dataManagement",
        "qualityManagement"
      ],
      "31": [
        "informedConsent",
        "dataManagement"
      ],
      "32": [
        "laboratorySpecifications",
        "informedConsent",
        "dataManagement"
      ],
      "33": [
        "laboratorySpecifications",
        "informedConsent"
      ],
      "34": [
        "biospecimenHandling",
        "informedConsent"
      ],
      "35": [
        "biospecimenHandling",
        "informedConsent"
      ],
      "36": [
        "informedConsent",
        "dataManagement"
      ],
      "37": [
        "dataManagement"
      ],
      "38": [
        "biospecimenHandling",
        "informedConsent"
      ],
      "39": [
        "informedConsent",
        "dataManagement"
      ],
      "41": [
        "concomitantMedications"
      ],
      "42": [
        "informedConsent",
        "dataManagement"
      ],
      "44": [
        "laboratorySpecifications"
      ],
      "45": [
        "biospecimenHandling"
      ],
      "49": [
        "biospecimenHandling"
      ],
      "51": [
        "proSpecifications",
        "dataManagement"
      ],
      "52": [
        "proSpecifications"
      ],
      "54": [
        "studyDesign",
        "informedConsent"
      ],
      "55": [
        "adverseEvents",
        "informedConsent"
      ],
      "57": [
        "informedConsent",
        "qualityManagement"
      ],
      "58": [
        "qualityManagement"
      ],
      "59": [
        "endpointsEstimandsSAP",
        "dataManagement"
      ],
      "64": [
        "studyMetadata",
        "studyDesign",
        "endpointsEstimandsSAP",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "65": [
        "studyDesign"
      ],
      "66": [
        "studyDesign",
        "endpointsEstimandsSAP"
      ],
      "67": [
        "endpointsEstimandsSAP"
      ],
      "68": [
        "studyDesign"
      ],
      "69": [
        "studyMetadata",
        "qualityManagement"
      ],
      "73": [
        "studyMetadata",
        "qualityManagement",
        "pkpdSampling"
      ],
      "74": [
        "qualityManagement"
      ],
      "75": [
        "studyMetadata",
        "informedConsent"
      ],
      "76": [
        "concomitantMedications"
      ],
      "77": [
        "studyMetadata",
        "concomitantMedications",
        "informedConsent"
      ],
      "78": [
        "concomitantMedications"
      ],
      "79": [
        "laboratorySpecifications"
      ],
      "80": [
        "qualityManagement",
        "withdrawalProcedures"
      ],
      "81": [
        "informedConsent",
        "siteOperationsLogistics"
      ],
      "82": [
        "concomitantMedications"
      ],
      "83": [
        "concomitantMedications",
        "qualityManagement"
      ],
      "84": [
        "siteOperationsLogistics"
      ],
      "85": [
        "studyDesign",
        "safetyDecisionPoints",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "86": [
        "studyDesign",
        "safetyDecisionPoints",
        "qualityManagement"
      ],
      "88": [
        "safetyDecisionPoints"
      ],
      "89": [
        "studyDesign",
        "safetyDecisionPoints",
        "laboratorySpecifications",
        "informedConsent"
      ],
      "90": [
        "safetyDecisionPoints",
        "laboratorySpecifications",
        "pkpdSampling"
      ],
      "91": [
        "studyDesign",
        "safetyDecisionPoints"
      ],
      "92": [
        "safetyDecisionPoints"
      ],
      "93": [
        "studyDesign",
        "safetyDecisionPoints",
        "laboratorySpecifications"
      ],
      "94": [
        "safetyDecisionPoints",
        "laboratorySpecifications"
      ],
      "95": [
        "studyDesign",
        "safetyDecisionPoints",
        "concomitantMedications",
        "laboratorySpecifications"
      ],
      "96": [
        "studyDesign",
        "safetyDecisionPoints"
      ],
      "97": [
        "studyDesign",
        "safetyDecisionPoints"
      ],
      "98": [
        "studyDesign",
        "safetyDecisionPoints"
      ],
      "99": [
        "concomitantMedications",
        "dataManagement"
      ],
      "100": [
        "concomitantMedications"
      ],
      "101": [
        "concomitantMedications"
      ],
      "102": [
        "informedConsent",
        "withdrawalProcedures"
      ],
      "103": [
        "informedConsent",
        "withdrawalProcedures"
      ],
      "104": [
        "informedConsent",
        "withdrawalProcedures"
      ],
      "105": [
        "qualityManagement",
        "withdrawalProcedures"
      ],
      "106": [
        "biospecimenHandling",
        "siteOperationsLogistics"
      ],
      "107": [
        "laboratorySpecifications"
      ],
      "108": [
        "informedConsent",
        "proSpecifications",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "109": [
        "proSpecifications",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement",
        "imagingCentralReading"
      ],
      "110": [
        "laboratorySpecifications",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement",
        "imagingCentralReading"
      ],
      "111": [
        "endpointsEstimandsSAP",
        "adverseEvents"
      ],
      "113": [
        "adverseEvents",
        "laboratorySpecifications",
        "qualityManagement"
      ],
      "114": [
        "informedConsent"
      ],
      "115": [
        "adverseEvents",
        "informedConsent",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "116": [
        "adverseEvents",
        "informedConsent"
      ],
      "117": [
        "adverseEvents",
        "informedConsent"
      ],
      "118": [
        "laboratorySpecifications"
      ],
      "119": [
        "laboratorySpecifications",
        "siteOperationsLogistics"
      ],
      "120": [
        "safetyDecisionPoints",
        "proSpecifications",
        "siteOperationsLogistics"
      ],
      "121": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "proSpecifications",
        "dataManagement",
        "siteOperationsLogistics",
        "pkpdSampling"
      ],
      "122": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "pkpdSampling"
      ],
      "123": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "siteOperationsLogistics",
        "pkpdSampling"
      ],
      "124": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "pkpdSampling"
      ],
      "125": [
        "biospecimenHandling",
        "laboratorySpecifications",
        "informedConsent",
        "pkpdSampling"
      ],
      "126": [
        "endpointsEstimandsSAP"
      ],
      "127": [
        "endpointsEstimandsSAP",
        "withdrawalProcedures"
      ],
      "128": [
        "endpointsEstimandsSAP"
      ],
      "129": [
        "endpointsEstimandsSAP",
        "proSpecifications"
      ],
      "130": [
        "endpointsEstimandsSAP"
      ],
      "131": [
        "endpointsEstimandsSAP",
        "adverseEvents",
        "qualityManagement"
      ],
      "132": [
        "pkpdSampling"
      ],
      "133": [
        "dataManagement",
        "qualityManagement",
        "pkpdSampling"
      ],
      "134": [
        "dataManagement",
        "siteOperationsLogistics"
      ],
      "135": [
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "136": [
        "informedConsent",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "137": [
        "adverseEvents",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "138": [
        "adverseEvents",
        "dataManagement",
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "139": [
        "informedConsent",
        "dataManagement"
      ],
      "140": [
        "siteOperationsLogistics",
        "qualityManagement"
      ],
      "141": [
        "laboratorySpecifications"
      ],
      "142": [
        "laboratorySpecifications"
      ],
      "144": [
        "imagingCentralReading"
      ],
      "145": [
        "imagingCentralReading"
      ],
      "146": [
        "imagingCentralReading"
      ],
      "147": [
        "imagingCentralReading"
      ],
      "149": [
        "imagingCentralReading"
      ],
      "150": [
        "imagingCentralReading"
      ],
      "152": [
        "adverseEvents"
      ],
      "153": [
        "adverseEvents"
      ],
      "154": [
        "adverseEvents",
        "proSpecifications"
      ],
      "155": [
        "adverseEvents"
      ],
      "157": [
        "safetyDecisionPoints"
      ],
      "158": [
        "laboratorySpecifications"
      ]
    }
  }
}